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Is Silver the Ultimate Antimicrobial Bullet?
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The use of metal compounds as antimicrobial agents has been around since antiquity, only
to be replaced by the introduction of organic antibiotics and antiseptics in the mid-20th century.
The discovery of penicillin by Alexander Fleming in 1928 began the era of antibiotics. Unfortunately,
this time is rapidly coming to an end, as antibiotic resistance is now the norm for most pathogen
strains. We now accept that we have entered the Antibiotic Resistance Era, where the World Health
Organization considers antibiotic resistance one of the biggest threats to global health, food security
and development today. Their 2017 report confirms the world is running out of useful antibiotics [1].
Since the turn of the century, interest into alternatives to antibiotics has seen an explosion of attention
into inorganic antimicrobial agents including metal-based antimicrobials [2].
Beyond its malleable and aesthetic qualities, silver has been used since antiquity to control
infection. For example, ancient mariners would toss silver coins into the drinking water barrel on
ships to prevent fouling. Nowadays, silver and silver nanoparticles (AgNPs) are widely used in
healthcare, food industry, cosmetic industry, coatings to surface materials and in textiles. Most of
these applications are targeting for infection control or treatment, however, in textiles the antimicrobial
properties are exploited for odor control.
Considerable efforts have been made towards understanding the molecular mechanism(s) of
action of silver [3,4]. The rules for efficacy of metals as antimicrobials are poorly understood but
may follow some fundamental chemical rules (discussed in [5]). In the case of silver, there are likely
multiple targets, both direct and indirect, leading various cellular systems to be affected [6]. Regardless
of the efficacy, bacteria can develop resistance to metal-based antimicrobials [7], with a silver resistance
determinant identified as early as 1975, primarily through an efflux mechanism as well as others
(reviewed in [8]).
With a few exceptions, the articles of this special issue of ‘Silver-based antimicrobials’ focus on
AgNPs or nanomaterials, which reflects field-wide research trends. Different AgNP synthesis methods
or formulations that are in combination with other antimicrobials are of interest. The various methods,
either biological or chemical-physical, produce different types of AgNPs. The articles here and the
review of patents from Sim et al., [9] reflects an explosion of such exploratory activity towards potential
industrial and health care applications. It is becoming clear that the different formulations of AgNPs
that lead to differences in their size, shape, structure and their release of Ag atoms lead to very different
antimicrobial activities. This body of work suggests the possibility of tuning silver’s antimicrobial
activity towards specific strains. Research to date suggests AgNPs to be very effective antimicrobial
silver bullets.
As we research the mechanisms of toxicity and resistance of silver, as well as how to prepare
novel AgNP formulations, we must keep in mind how we intend to use silver in order to preserve
its efficacy. It is prudent to consider stewardship and sustainability at the start before misuse runs
rampant. However, given the present overuse of silver in textiles, are we already too late?
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Abstract: The therapeutic arsenal against bacterial infections is rapidly shrinking, as drug resistance
spreads and pharmaceutical industry are struggling to produce new antibiotics. In this review we
cover the efficacy of silver as an antibacterial agent. In particular we recall experimental evidences
pointing to the multiple targets of silver, including DNA, proteins and small molecules, and we
review the arguments for and against the hypothesis that silver acts by enhancing oxidative stress.
We also review the recent use of silver as an adjuvant for antibiotics. Specifically, we discuss the state
of our current understanding on the potentiating action of silver ions on aminoglycoside antibiotics.
Keywords: silver; antibiotics; adjuvant; combinatorial; metal; ROS
1. Introduction
The antibacterial effect of silver ions (Ag+) has been known for centuries as ancient Greek used
silver for stomach pains or wound healing. According to Mijnendonckx et al. [1], “silver was perhaps
the most important antimicrobial compound before the introduction of antibiotics”. Currently, it is
used on surfaces in hospitals to reduce nosocomial disease. It is also widely used in water cleaning
systems such as hospital hot water circuits, swimming pool and potable water delivery systems.
And as Simon Silver repeatedly recalled it, silver can even be found within Japanese Jintan pills meant
“to cure from nausea, vomiting, hangover, bad breath and sunstroke among others” [1]. More recently,
a series of initiatives aimed at fighting multidrug resistant bacteria elected combinatorial strategies
as a way of potentiating drug efficiency [2]. Likewise, silver ions were identified as a highly efficient
potent of antibiotics of different classes [3,4]. Last, silver nanoparticles (AgNP) rank currently among
the most widely commercialised nanomaterial used in medical, bactericidal and electrical products [5].
Despite this old and broad use, the mechanism underlying antimicrobial activity of silver ions is not
fully understood.
In this Review, we will first describe the multiple cases of silver ions being used as biocides.
We will then give a broad overview of the many situations wherein combining silver and antibiotics
yielded to enhanced antibacterial efficiency. Last, the molecular mechanism allowing silver to
potentiate aminoglycoside toxicity will be discussed. Strategies based upon silver nanostructures, as
well as their synthesis, toxicity and efficiency, will not be covered in the present review and interested
readers can find examples of such studies in References [6–8].
2. Molecular Basis of Silver Toxicity toward Microbes
Silver antibacterial activity has been studied for a long period of time [9]. Silver ions were
proposed to target macromolecules and their associated alteration was predicted to be the cause of
silver mediated toxicity (Figure 1). Yet, although some consistent trend emerged from this bulk of
studies, several discrepancies remained.
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Figure 1. Pleiotropic molecular basis of antimicrobial effects of silver. Silver targets different
macromolecules in bacteria. Here are depicted modifications observed in silver-treated bacteria
such as DNA condensation, membrane alteration and protein damages. In this latter case, several
situations were reported wherein silver ions interacted with thiol group, destabilised Fe-S clusters or
substituted to metals in metalloproteins.
2.1. Silver Ions Target DNA
Silver ions are strong nucleic acids binders and form several complexes with DNA or RNA.
They interact preferentially with bases rather than the negatively charged backbone of DNA.
Thermodynamic experiments showed that silver ions formed homo-base pairs with a higher affinity
with guanine, which could potentially lead to pyrimidine dimerization. At a high concentration,
silver ions were observed to interact with adenine [10]. Microscopy analysis of silver treated bacteria
showed a dense electron-light region assigned as condensed DNA in the centre of the cells. While all
of these in vitro observations support the hypothesis that silver could lead to DNA modification prone
to mutation or replication inhibition, actual contribution of DNA-silver adducts formation to silver
antimicrobial toxicity remains to be assessed in vivo.
2.2. Silver Ions Target Proteins
A silver target on which everybody agrees is the sulfhydryl group, which results in the formation
of S-silver bond [11]. Sulfhydryl groups belong to lateral chains of Cys residues. Cys residue
frequently served as ligand for metal and/or cofactors in metalloproteins, including those forming
respiratory chains. Accordingly, silver ions were found to alter respiration of E. coli [9,12] and it
was thought that proton motive force (PMF) collapse due to respiration inhibition constituted the
basis of silver toxicity [13]. However, subsequent work revealed that silver had additional targets
besides respiration [14]. For instance, in Vibrio cholerae, proton leakage, which could be a consequence
of PMF collapse, was observed even in the absence of the NADH-ubiquinone oxidoreductase [13].
This suggested that silver had multiple protein targets in the membrane. Recently, Xu and Imlay
investigated the toxicity of different soft metals in E. coli and identified Fe-S cluster containing proteins
as primary targets of silver [15]. Importantly, NADH dehydrogenase I activity, a main component of the
aerobic respiratory electron transfer chain, was untouched by silver treatment. Instead dehydratases
like fumarase A appeared as preferred targets. The 4Fe4S cluster from fumarase was degraded to
3Fe4S cluster that could be reactivated by exogenous Fe2+ under reducing conditions. The reason for
the apparent specificity of silver ions for Fe-S cluster from dehydratases likely stems from the exposed
nature of their solvent and the lability of the catalytic Fe atom.
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Other candidate targets include thiol containing cytoplasmic proteins. For instance, OxyR,
the H2O2-sensing transcriptional activator, was reported to be inactivated in silver-exposed E. coli
strains [3]. The authors argued that silver antagonises disulphide bond formation within OxyR
monomer, which is required for activating transcription.
Last, one should keep in mind that the high thiophilicity of silver ions could allow them to
substitute for any SH-liganded metal. For instance, it is conceivable that silver acts upon Fe-S
cluster by substituting for labile Fe atom, which would apply to the dehydratase situation depicted
above. Alternatively, silver could substitute for zinc ions in, for instance, zinc-finger proteins. Overall,
these substitutions could lead to massive protein mis-metallation, loss of function and associated
defects. It is noteworthy that cytosolic dense granules were observed in silver treated E. coli cells;
such granules were interpreted as being constituted of misfolded protein aggregates [3].
2.3. Silver Mediated Membrane Alteration
Transmission electronic microscopy (TEM) observation of silver treated E. coli revealed
morphological and structural changes of the cell envelope. Moreover, use of propidium iodine
showed an enhanced permeability of the cell envelope [3]. In a separate study, TEM revealed an
enlargement of the periplasmic space in E. coli, suggesting the shrinking of the inner membrane and
its detachment from the cell wall. Interestingly a gram-positive bacterium, Staphylococcus aureus,
which exhibits a thicker cell envelope underwent similar morphological changes than E. coli, albeit to a
lesser extent, suggesting a stronger resistance to silver ions [16].
2.4. Are Silver Ions Producing ROS?
There is much debate on whether silver, which is not a redox active metal, induces ROS formation,
and if it is the case, how this happens. To determine whether silver ions induce ROS, Park et al.
used a soxS-lacZ reporter strain. After exposure to silver nitrate, induction of soxS was observed.
As soxS expression being under the control of SoxR, it was deduced that superoxide radicals had
been produced by the presence of silver ions. However, no soxR control mutant was tested and the
actual signal SoxR is responding to remains a matter of debate. In particular, it has been proposed
that SoxR senses the ratio NAD(P)H/NAD(P) [17]. Were silver ions to impair respiration, this ratio
would be modified and SoxR activated without the need for superoxide production. Importantly OxyR
activation was not observed, supporting the notion that no H2O2 accumulated in the presence of silver
ions. Using 3′-p-hydroxyphenyl fluorescein (HPF), a dye, Morones et al. observed hydroxyl radicals
production in silver treated E. coli cells [3]. Surprisingly, overproduction of superoxide dismutase
(SOD), predicted to enhance hydroxyl radical production via the Fenton reaction, was found to reduce
HPF-estimated hydroxyl radical. Moreover, detection of hydroxyl radicals by Morones et al. [3]
somehow did not fit with the lack of H2O2 enhanced production and lack of OxyR induction
reported by Park et al. [18]. If ROS were instrumental in conveying silver toxicity, a prediction
is that anaerobically grown cultures should be less sensitive to silver ions. This issue was investigated
in several studies but unfortunately conflicting observations were reported and it is so far impossible
to draw a firm conclusion from the literature (see [1]). Last, a very recent transcriptomic analysis of
E. coli exposed to silver ions failed to identify anti-ROS defence genes induction, while dysregulation
of silver transport and detoxification (copA, cueO, mgtA, nhaR), stress response genes (dnaK, dnaJ, pspA,
oxidoreductase genes), methionine biosynthesis (metA, metR), membrane homeostasis (fadL), and cell
wall integrity (lpxA, arnA, ycfS, ycbB) were identified [19]. Hence, experimental evidences for silver
ions to induce ROS production remain scant and open to discussion.
On the other hand, if one admits that silver ions are perturbing iron homeostasis as well as
destabilizing Fe-S clusters, it seems quite likely that eventually this will indirectly lead to ROS
production (Figure 2). Indeed, because Fe-S proteins are central to respiration, this latter is expected
to be perturbed and this could provoke electron leakage and associated ROS production. Also,
destabilization of Fe-S clusters is expected to release free iron, which should fuel in the Fenton reaction.
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Last, silver ions by binding to thiols will preclude endogenous anti-ROS defences such as free cysteine
and glutathione, two compounds with ROS-scavenging properties.
Hence it seems indeed a safe prediction that silver ions will favour ROS production, yet the
causal chain linking silver, a non-redox soft metal, and ROS production remains to be established and
described in precise molecular terms.
Figure 2. Searching for the causal link between silver ions and ROS production. Silver is a non-redox
active metal that cannot directly produce ROS. Some experimental evidences however pointed to
the enhanced production of ROS in the presence of silver ions. Depicted here are possible indirect
ways silver ions could participate to ROS production: Perturbation of respiratory electron transfer
chain, Fenton chemistry following destabilization of Fe-S clusters, or displacement of iron, inhibition of
anti-ROS defences by thiol-silver bond formation.
3. Silver Enhances Antibacterial Activity of Antibiotics
In 2007, Morones et al. investigated the capacity of silver ions to synergise antibiotics [3].
They reported that silver potentiates bactericidal antibiotics both in laboratory growth conditions and
animal models. The three major classes of bactericidal antibiotics in E. coli were tested, i.e., ß-lactams
(ampicillin), which target cell-wall synthesis, quinolones (ofloxacin), which target DNA replication and
repair, aminoglycosides (gentamicin) that are ribosome binders known to cause protein mistranslation.
All of these drugs were tested at a concentration close or inferior to the MIC values, and in the presence
of sublethal concentrations of silver. In all of these cases, a significantly enhanced antimicrobial activity
was observed. A more precise analysis revealed that the highest synergistic effect was found when
combining gentamicin and silver as viability dropped 2 logs. In the case of ampicilin and ofloxacin,
presence of silver decreased viability 1 log at the maximum. After showing that mice tolerated the
silver concentration used (3–6 mg/kg), the authors reported that silver potentiated both the gentamicin
activity in a urinary tract infection mouse model, and the vancomycin activity in a mouse peritonitis
infection mouse model.
The potentiating activity of silver on antibiotic toxicity in E. coli K12 was further investigated by
Herisse et al. [4]. An extended set of bactericidal and bacteriostatic antibiotics including tetracycline
and chloramphenicol were tested [4]. According to changes in MIC values, silver was found to be
6
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most potent with aminoglycosides (gentamicin, kanamycin, tobramycin, streptomycin) as MIC value
decreased by more than 10-fold. A reduction in the MIC value of 2-fold was noted with spectinomycin,
a bacteriostatic antibiotic related to aminoglycoside and also with tetracycline. Moreover, they reported
a slight potentiating effect (less than 20%) when silver was used in conjunction with quinolone (nalidixic
acid and norfloxacin) or with chloramphenicol [4].
Another study showed that silver enhances the toxicity of the selenazol drug ebselen,
a competitive inhibitor of bacterial thioredoxin reductase activity against clinically multidrug-resistant
Gram-negative bacteria (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomnas aeruginosa,
Enterobacter cloacae, Escherichia coli) [20]. Potentiating effects were observed both in laboratory growth
conditions and mice peritonitis model (6 mg/kg). Similarly, Wan and collaborators in a study on
AgNP showed that ionic nitrate silver acts synergistically with polymixin B and rifampicin to combat
carbapenem-resistant A. baumannii obtained from clinical patients. Interestingly, AgNP and AgNO3
showed the same potentiating effect with both antibiotics, but cytotoxicity of AgNP was lower than
that of AgNO3 [21]. Silver was also reported to potentiate polymixin B and a series of antimicrobial
peptides to combat gram-negative bacteria [22].
Many antibiotics that are effective against planktonic cells turned out to be ineffective against
biofilms. Combination of silver with tobramycin combated biofilm of E. coli and Pseudomonas aeruginosa
as a 3-fold enhancement of antimicrobial efficiency was observed [23]. A similar potentiating effect of
silver (6 mg/kg) with gentamicin was noted in combating biofilm formed on a catheter located into a
mouse model [3].
Last, silver made antibiotics effective against resistant bacteria. Indeed, silver was able to sensitise
E. coli to the Gram-positive-specific antibiotic vancomycin and the highly tolerant anaerobic pathogen
Clostridium difficile became sensitive to aminoglycoside [3,4]. Moreover, silver could restore antibiotic
susceptibility to a tetracycline resistant E. coli mutant [3].
We wish to underline that the use of silver as an adjuvant might also be of interest to treat persister
cells, a subpopulation of isogenic bacteria that become highly tolerant to antibiotics [3]. All these data
are grouped in Table 1.
Table 1. Antibacterial activity of silver ions in combination with antibiotics.
Antibiotics Organism Culture Condition Effects References





E. coli Laboratory medium
10-fold increase in antimicrobial





E. coli Laboratory medium.Animal models
100-fold increase in antimicrobial
activity. MIC value decreased
more than 10-fold
[3,4]
C. difficile Laboratory medium MIC value decreased 4-fold [4]
Tobramycin E. coli.,P. aeruginosa Laboratory medium
MIC value decreased 10-fold





Streptomycin E. coli Laboratory medium
MIC value decreased more than
10-fold [4]
Spectinomycin E. coli Laboratory medium MIC value decreased 2-fold [4]
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Table 1. Cont.
Antibiotics Organism Culture Condition Effects References
Vancomycin E. coli Laboratory medium.Animal models
10-fold increase in antimicrobial
activity [3]





E. cloacae, E. coli
Laboratory medium.
Animal models 10-fold increase in MIC value [20]
Polymixin B E. coli Laboratory medium MIC value decreased 5- to 10-fold [21,22]
Rifampicin A. baumannii Laboratory medium MIC value decreased 5-10 fold [21]
Tetracycline E. coli (TetR) Laboratory medium MIC value decreased 2-fold [3]
4. Molecular Mechanism in the Aminoglycoside/Silver Synergy
Of all antibiotics tested, aminoglycosides (gentamicin, tobramycin, kanamycin, streptomycin)
benefited the most from silver ions as adjuvants (Figure 3). The molecular basis of the synergistic effect
between silver and aminoglycoside has been investigated in two separated studies, which we discuss
below [3,4]. However, we shall first recall how aminoglycosides are predicted to kill bacteria, and in
particular how they are uptaken by E. coli.
Figure 3. Silver potentiates antibiotics toxicity. The capacity of silver ions to enhance the toxicity of
antibiotics from different family is represented. The size of the arrows line reflects the extent of the
synergistic effect.
Aminoglycosides, first discovered in the 1940s, are the antibiotics most commonly used
worldwide, due to their high efficacy and low cost [24]. Aminoglycosides are a group of
bactericidal antibiotics that target the 30S ribosomal subunit and induce amino acid mis-incorporation.
Aminoglycoside need to be transported through the cytoplasmic membrane to reach their target.
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These transport systems are energised via proton motive force (PMF)-dependent pathways [25].
Moreover a so-called feed-forward loop model postulates the occurrence of a two-steps
process: Aminoglycosides would cross quite inefficiently the cytoplasmic membrane prior to hit
membrane-bound ribosome (EDP-I), resulting in aborted translated products, which would go into the
membrane due to their hydrophobic characters, and destabilise further the membrane, allowing for
enhanced entry of aminoglycoside (EDP-II) [26].
Herisse et al. showed that silver enhances aminoglycoside toxicity by acting independently of PMF
as it by-passes the EDP-I PMF-dependent step of the aminoglycoside entry process. Silver by-passed
the antagonist effect of the PMF dissipating action of the carbonyl cyanide-m-chlorophenylhydrazone
(CCCP), an uncoupler H+ ionophore [4]. Moreover, silver restored aminoglycoside uptake by strains
exhibiting a reduced PMF level such as mutants lacking complex I and II (Δnuo Δsdh) or Fe-S
cluster biosynthesis (ΔiscUA) [4]. In contrast, the silver-potentiating effect of aminoglycoside toxicity
remained dependent on translation, the EDP-II proteins translation-dependent step [4]. Indeed,
adding chloramphenicol, a bacteriostatic antibiotic inhibiting translation, prevented silver from
potentiating aminoglycoside toxicity. It was proposed that silver destabilises the membrane in a
protein translation-dependent pathway, allowing aminoglycoside to get access to the cytosol more
efficiently. This implied that membrane disturbance induced by silver is not sufficient for massive
aminoglycoside uptake and needs additional contribution from mis-localised aborted polypeptides.
By acting directly on ribosomes, silver could release aborted translated products that would eventually
go to the membrane and cause an EDP-II like step (Figure 4). This agrees with a proposal by Morones
et al. [3] who envisioned that silver produced misfolded proteins would be directed towards the inner
membrane and destabilised it. An argument supporting this view was that enhanced silver resistance
of a secG mutant impaired in protein translocation [3]. Hence, irrespective of the origin and cause of
increased level of misfolded proteins, both studies pointed out to an enhanced permeability of the cell
envelope. This is consistent with morphological and structural changes observed by TEM studies of
silver treated cells (see above).
Figure 4. A molecular mechanism model for aminoglycoside and silver synergy. Silver enhances
aminoglycoside toxicity by enhancing their uptake. Silver could destabilise the membrane either
directly by altering intrinsic membrane proteins or indirectly by acting on ribosomes, which would
produce misfolded aborted polypeptides that would eventually go to the inner membrane. Increased
permeability of membrane would provoke massive aminoglycoside uptake.
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In contrast, the contribution of ROS to silver toxicity was more controversial. Morones et al.
postulated that silver ions enhance gentamicin toxicity via the capacity of silver to produce ROS [3].
However the enhanced production of ROS in the presence of the combination (silver+gentamicin)
was not tested. Moreover, the actual production of ROS following silver addition is highly debatable
as summarised above. Last, Herisse et al. directly addressed the question of the contribution of
ROS to the silver potentiating effect and collected only negative evidences: (i) silver potentiated
gentamicin toxicity even in anaerobic conditions; (ii) mutants altered in anti-ROS activities like the
strains lacking superoxide dismutases (ΔsodA ΔsodB) or the H2O2-stress responding master regulator
(ΔoxyR) exhibited similar sensitivity to silver potentiating effect as the wild type E. coli [4].
5. Conclusions
In this review we listed numerous cases in which silver ions were reported to exhibit efficient
antibacterial activity. We also reviewed the emerging trend of using silver ions as adjuvants for
potentiating antibiotic toxicity. It is compelling that after so many years, the actual reason silver
kills bacteria is still eluding us. In fact, it is likely that silver ions act upon multiple different
targets, from macromolecules to free amino-acid like cysteine or small molecule such as glutathion,
and therefore renders it difficult, if not impossible, to trace the actual cause of death of a silver treated
bacterium. Nevertheless, some pressing issues remain: Is silver destabilising protein components of
respiratory chains? Does silver have any deleterious (mutagenic?) effect on genome integrity? What is
the actual structural state of a silver-destabilised membrane? What is the link, if any, between silver
and ROS production?
There is little doubt that new efforts should be dedicated towards the understanding of the action
of silver such that this very ancient antibacterial metal can be further exploited within the context
of the multiple antibiotic resistance crisis. Interest for such a potential path is reinforced by the fact
that pharmacological, toxicological and pharmacokinetic modelling studies indicated that human
health risks associated with silver exposure were low [27,28]. From a broader perspective, recently,
we advocated the need to take into account iron in its influence on antibiotic sensitivity [29]. It is
known that most metals can have antibacterial activities at high concentration, such as bismuth, cobalt,
copper and cadmium, to cite a few [15,30–32]. Aiming at characterising and further exploiting their
biocide activity might be a rewarding goal.
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Abstract: Urgent need for innovative and effective antibacterial coatings in different fields
seems to have triggered the development of numerous strategies for the production of such
materials. As shown in this short overview, plasma based techniques arouse considerable attention
that is connected with the possibility to use these techniques for the production of advanced
antibacterial Ag/plasma polymer coatings with tailor-made functional properties. In addition,
the plasma-based deposition is believed to be well-suited for the production of novel multi-functional
or stimuli-responsive antibacterial films.
Keywords: non-equilibrium plasma; silver; antibacterial coatings; plasma polymers; nanocomposites
1. Introduction
As shown in numerous recent reviews, road-maps, and “white” papers [1–7], non-equilibrium
plasmas may be successfully used in various fields, such as from the automotive or aerospace industry
to waste and pollution control, or from the production of advanced functional biomaterials to the
design of smart textiles. The tremendous boom that plasma-based technologies experienced in the last
few decades is mainly given by their unique features. These comprise a relatively low-temperature
nature of the processes that employ plasma, allowing processing of heat-sensitive materials, including
polymers, to treat or coat virtually any material without compromising the bulk properties of
treated objects or high versatility in terms of materials that may be deposited by plasma-based
techniques (e.g., metals, metal-oxides, plasma polymers). In contrast to techniques that utilize chemical
synthesis, plasma processes are dry with no or limited use of solvents or potentially harmful chemical
substances, making them, in many cases, a highly valuable “green” alternative to “wet” chemical
methods. Enormous advancement in the use of plasma technologies was also enabled by recent
progress in plasma science and technology, especially in the case of atmospheric pressure discharges,
as well as by close collaborations of plasma physicists with chemists, biologists, and medical doctors.
This broadened the range of possible applications of non-equilibrium plasmas that nowadays include
sterilization/decontamination of surfaces [8–13], plasma medicine [14–17], agriculture [18–22], or as it
will be discussed in this review, the production of antibacterial coatings [23–25].
In order to highlight the state-of-the-art plasma-based strategies for the deposition of
silver-containing antibacterial coatings, the article is organized as follows: In Section 2, different
approaches that may be used for the suppression of bacteria adhesion or biofilms formation will be
briefly summarized, with emphasis given to Ag-containing nanocomposites. Different plasma-based
strategies that were developed for the production of Ag/plasma polymer nanocomposites will be
presented in Section 3. Finally, Section 4 will cover the challenges and future perspectives of the plasma
deposition of antibacterial coatings.
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2. Antibacterial Coatings
Preventing the bacterial colonization of surfaces is a key requirement to limit the spread of
infections. Although this is important in various fields (e.g., the textile industry, food packaging
production, or space missions [26–30]), most of the attention is devoted to surfaces used in medicine
and healthcare services. Here, the presence of bacteria on medical instruments, tools, accessories etc.
may have catastrophic consequences. Although many of the factors leading to bacterial infection can be
easily avoided by appropriate hygiene procedures in the hospitals, it is impossible to completely avoid
bacterial infections. For example, this is true in the case of medical implants. It is well known that
planktonic bacteria present in body fluids may adhere to the implant surface in vivo, multiply, and start
to form complex and highly resistant communities, such as biofilms, where bacteria can survive for
extended periods of time. The biofilms may then act as persistent reservoirs for pathogens which may
trigger infections. This, in turn, often necessitates re-operation and replacement of the infected implant
that not only increases costs, but represents serious risk—especially for elderly patients. A promising
strategy for reducing the occurrence of such undesirable events is to avoid the initial attachment of
bacteria to the implant’s surface. Generally, this can be done by following two strategies [31].
The first one is based on coating implants with non-fouling thin films, i.e. films that are capable
of resisting protein adsorption or bacteria adhesion. The typical examples of such materials are poly
(ethylene glycol) (PEG) derivatives or zwitterionic polymers, that have proved to be able to reduce or
inhibit bio-fouling [32–36]. However, it has to be stressed that in most of the in vivo experiments,
surfaces led only to the delay of biofilm formation and restricted longer-term stability and performance.
Furthermore, non-fouling coatings are prone to damage during their handling.
The second way in which to combat biofilm formation is by the production of surfaces
that actively kill bacteria. This may be achieved either by contact-killing, or by release-based
strategies. The contact-killing of adhered bacteria is achieved either by antimicrobial compounds
covalently anchoring to the material surface. Examples include quaternary ammonium compounds,
cationic peptides, or enzymes [23,37,38], or the design of biomimetic nanostructured coatings with
high-aspect-ratio surface topographies that exhibit biocidal efficacy [39,40]. In the case of release-based
coatings, antibacterial action is connected with the gradual leaching of antibacterial agents from
the coatings into the surrounding media. The antimicrobial agents may either be organic or
inorganic [23,31,41]. Regardless of the antibacterial agent used, its local delivery at a specific site
ensures a high local dose without exceeding the systemic toxicity. Because of this, various techniques
for the production of such antibacterial coatings were developed, including plasma-based ones that
utilized organic antibiotics [42,43].
However, despite the success of these approaches, silver-based materials have been receiving
increasing attention since the 1960s. This was caused by ongoing reports on the development of the
resistance of certain bacteria to commonly used antibiotics (e.g., [44–50]). Even though this is also the
case for silver, where reports exist which indicate the occurrence of silver-resistant bacteria [51,52],
the development of bacterial resistance towards Ag is highly improbable due to the multiple possible
pathways that may lead to bacterial damage by silver nanoparticles (NPs). The exact mechanism of the
antibacterial action of Ag NPs is still not fully understood, and is a frequent topic of discussion and
controversy. Ag NPs may either induce the formation of reactive oxygen species (ROS) or may release
in aqueous media, such as highly bioactive silver ions. The ROS and Ag+ ions produced subsequently
interact with DNA or the thiol groups of molecules present in the cytoplasm, cell membrane, and inner
membrane of mitochondria, that may result in changes in permeability, disturbance of respiration,
leakage of intracellular content, inhibition of protein synthesis and function, and cell apoptosis or
necrosis [52–55].
Naturally, the silver NPs and released silver ions may interact not only with bacteria, but also
with tissue cells. Fortunately, the health risks associated with systemic absorption of Ag+ ions are
rather low [56]. Nevertheless, in order to avoid any undesirable side-effects connected with silver
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release, its dosage has to be carefully controlled and regulated, which is one of the key challenges
connected with the application of silver-based antibacterial nanocomposites.
3. Antibacterial Ag/Plasma Polymer Nanocomposites
Numerous studies have been devoted to the functionalization of surfaces (mostly polymeric ones)
by antibacterial nanosilver (e.g., [57–62]). However, a limitation of the proposed methods was the
poor adhesion of silver to substrates, which often led to the washing-out of Ag NPs from the substrate,
which came with unacceptable pollution of the environment. Although it was demonstrated by
different groups that this effect may be substantially suppressed by plasma activation/functionalization
of substrate materials prior to the silver deposition (e.g., [63–68]), in many cases the stability of Ag
layers still remained questionable. Because of this, alternative strategies based on the embedding of
Ag NPs into a supporting matrix were suggested. From these points of view, plasma polymers are
considered to be highly promising matrix materials, i.e. macromolecular solids that are created when
an organic vapour or precursor passes through a plasma [69–74]. In contrast to conventional polymers,
plasma polymers have a random and irregular structure with higher degrees of crosslinking, and a
branched structure. Despite their complex structure, plasma polymers offer certain advantages- they
can be deposited in the form of conformal, pin-hole free thin films on any substrate material with
well-controlled thicknesses at a nanometre scale. Furthermore, their properties that can be tuned by a
wide range of operational conditions (e.g., applied power, precursor/working gas mixture, pressure)
span from soft to hard polymers, from bio-fouling to non-fouling, or from films that are stable, swelling,
or dissolvable in aqueous media. The use of plasma polymers thus may not only improve the fixation
on Ag NPs and avoid their release to surrounding media, but, due to the high flexibility of plasma
polymers in terms of their physico-chemical and bio-adhesive properties, also tailor their antibacterial
or bio-fouling performance. In the following two subsections, different approaches that were tested,
with the aim of producing Ag/plasma polymer nanocomposites, will be summarized.
3.1. Layered Nanocomposites
Sandwich or multi-layer structures (see Figure 1) represent the first family of antibacterial
Ag/plasma polymer nanocomposites. Such coatings typically consist of Ag NPs overcoated with a
thin top layer of plasma polymer (typically from several nanometers to tens of nanometers) that fixes
Ag NPs on a substrate material and acts as a diffusion barrier for leaching Ag+ ions. Ag NPs may be
deposited on a substrate either by immersion into a colloidal solution of Ag NPs followed by drying,
salt reduction, or physical methods, such as evaporation, magnetron sputtering, or the use of gas
aggregation sources (GAS) of silver NPs (see Figure 2). The physical methods of Ag NPs deposition
are highly advantageous, as they limit the possible uncontrolled aggregation of Ag NPs on surfaces,
ensure high purity of silver NPs, and may be easily combined with other low-pressure deposition
techniques used for plasma polymer matrix deposition. In order to facilitate the adhesion of Ag NPs
onto a substrate additional bottom layer (often plasma polymer film) is used as an interface between
the substrate and Ag NPs.
 
Figure 1. Common structure of (a) sandwich and (b) multi-layered Ag-based nanocomposites.
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Figure 2. Schematic representation of possible strategies for coating substrates with Ag NPs.
(a) Immersion into a colloidal solution of Ag NPs, followed by drying (e.g., [63,67,75]). (b) Salt reduction.
Substrates are commonly exposed to silver nitrate solution. AgNO3 is, in the second step, reduced by
an appropriate reducing agent (e.g., sodium citrate, sodium borohydride, or even H2 plasma) [76–79].
(c) Direct current (DC) magnetron sputtering. In this low-pressure vacuum-based plasma deposition
technique, a silver target mounted onto a DC magnetron is subjected to a flux of highly energetic
ions produced in the plasma bulk. This leads to the emission of silver atoms that condense on a
substrate located in the deposition chamber. Depending on the deposition conditions (magnetron
current, pressure, deposition time, etc.) various silver nanostructures are formed that range from
individual separated nanoislands to interconnected Ag networks (e.g., [59,80–87]. (d) Deposition of Ag
NPs by means of a gas aggregation source equipped with a silver target. Gas aggregation sources based
on magnetron sputtering were introduced by Haberland et al. [88] and since then were successfully
applied for the fabrication of different kinds of nanoparticles (for more information, readers should
refer to the instance to monography [89] or recent review articles [90–93]). In contrast to sputter
deposition, silver nanoparticles are already formed in a volume of the aggregation chamber as a result
of gas-phase nucleation of sputtered atoms, which is followed by the coagulation or coalescence of
growing nanoparticles. As shown by our group, the fact that NPs are formed in the gas-phase means
their properties are not dependent on the substrate material, which makes it possible to independently
control the size and number of deposited NPs [94,95].
In most cases, low pressure deposition systems (plasma-enhanced chemical vapor deposition
or magnetron sputtering, see Figure 3a,b) were selected for the deposition of the base and top layers.
The choice of overcoat material and its thickness strongly influenced the antibacterial action of
the resulting coatings. For instance, the Kiel group, in their detailed study using Ag NPs that
were sandwiched in between RF sputtered polytetrafluoroethylene (PTFE) and a layer of either
plasma-sputtered PTFE, plasma-polymerized hexamethyldisiloxane (ppHMDSO), or SiOx films prepared
by plasma polymerization of HMDSO with admixed oxygen, proved that the release of silver ions and
also the antibacterial efficacy of produced coatings strongly depended on the overcoat material [96,97],
and the highest Ag+ release and bacteria-killing rates were observed for SiOx films. Similar conclusions
were drawn by Kuzminova et al. [98], who used multi-layer structures with alternating layers of
ppHMDSO or SiOx and Ag NPs prepared by the PE-CVD and GAS system. Better antibacterial behavior
of an SiOx-like matrix was ascribed to the different wettability of ppHMDSO and SiOx—whereas
ppHMDSO is hydrophobic and thus acts as a barrier for water penetration into the depth of the
coatings, SiOx films are hydrophilic and more water permeable. This was confirmed by Blanchard
et al. [99] who studied water penetration into ppHMDSO and SiOx thin films by means of neutron
reflectometry. However, recent results of Kylian et al. [100] showed that even for highly hydrophobic
C:F top layers (water contact angles of prepared coatings up to 165◦), a strong antibacterial character
of the coatings may still be observed when only a thin C:F layer (10 nm) is used. Such a result suggests
that coating wettability is not the only parameter, and that the morphology of the coatings—especially
the presence of crevices and defects in the overcoat layer which make Ag NPs accessible by water—has
to be considered as well. In addition, the release of antibacterial Ag+ responsible for antibacterial
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action of produced coatings was found to be strongly linked with the number of silver NPs in the
coatings, as well as with the thickness of the top barrier layer. This allows for the fabrication of the
coatings with either a burst-release of silver ions, or a slow but temporally stable leaching of Ag+ ions.
Although the low-pressure deposition systems were traditionally used for the production of
plasma polymer overcoats, the possibility to also use atmospheric pressure deposition systems was
suggested by Deng et al. [101,102]. These authors used an atmospheric pressure plasma jet operated
in a mixture of N2/O2/tetramethyldisiloxane (TMDSO) to produce a barrier layer deposited on top of
PET fabrics coated with Ag NPs. It was demonstrated that the antibacterial effect of such prepared
fabrics on P. aeruginosa, S. aureus, C. albicans and E. coli may be varied by the thickness of the top
layer. Furthermore, the top layer was confirmed to enhance the stability of antibacterial effect, and no
variation of antibacterial action was observed after 10 washing cycles [101].
 
Figure 3. Schematic representation of possible plasma-based strategies for the overcoating of Ag
NPs. (a) Plasma-enhanced chemical vapor deposition (PE-CVD). In this method, organic vapours or
precursors are introduced into the plasma, where they are activated and fragmented. Formed radicals
that condense on a substrate subsequently undergo free radical chain growth polymerization (for more
details, please refer to the monographies [69,71,72] or reviews [2,24,74]). (b) RF magnetron sputtering
of a polymeric target. In this case, starting material is supplied in the form of a solid-state polymeric
target that is attached onto a magnetron. Atoms, molecules, and molecular fragments sputtered from
the polymeric target consequently participate in plasma polymerisation, as in the PE-CVD. In contrast
to sputtering of metallic targets, polymers are not conductive, meaning that RF power has to be applied.
Magnetron sputtering was employed for the production of a wide range of plasma polymers, including
C:H, C:H:N:O, or C:F ones (e.g., [103–109]). (c) Atmospheric pressure plasma jets. These systems are
based on PE-CVD process, but the gaseous or liquid precursors are introduced to the plasma ignited at
atmospheric pressure. Different configurations of atmospheric pressure plasma jets were demonstrated
to be suitable for the deposition of various plasma polymer films (e.g., [110–118]).
3.2. Direct Embedment of Ag NPs into Plasma Polymer Matrix
As shown in the previous section, layered silver-containing structures are highly effective at
killing bacteria. However, the deposition procedure involves multiple steps, which is, from a
technological point of view, a limiting factor. Consequently, alternative approaches for Ag-based
nanocomposite production were developed, in which Ag nanoparticles are incorporated directly
into the growing plasma polymer matrix. One of the first attempts toward this direction were
reported by Favia et al. [119] and Sardella et al. [120]. These authors prepared conformal coatings
with silver NPs embedded in a polyethylene oxide-like (PEO-like) matrix, using PE-CVD from RF
glow discharges fed with Ar, and diethylglycol-dimethyl-ether (DEGME) with simultaneous sputtering
from the Ag RF electrode in an asymmetric parallel-plate configuration (see Figure 4a). Due to the
reactor asymmetry, negative DC self-bias developed on the smaller Ag electrode, which led to the
bombardment of the Ag target by highly energetic ions inducing silver sputtering. Emitted Ag atoms
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impinged upon the plasma polymer surface, which grew simultaneously by plasma polymerization.
Ag atoms, due to their limited diffusion in a cross-linked matrix, subsequently formed stable metal
nanoparticles through an aggregation process. The properties of the resulting nanocomposites (Ag
filling factor, size of Ag NPs, and PEO-like character of the matrix) were controlled by operational
parameters (power, pressure, and Ar flow). Based on the disk diffusion test that was performed
with S. epidermidis, it was reported that the inhibition area correlated with the Ag content in the
coatings. Similar approaches using simultaneous plasma polymerization and Ag sputtering was since
then employed by other research groups, which utilized different precursors/working gas mixtures.
Prepared nanocomposites were tested towards both Gramm-negative and Gramm-positive bacteria
(for a summary of results, please refer to Table 1). Furthermore, it was found that Ag/HMDSO
nanocomposites with properly-tuned silver content may not only kill bacteria, but also drastically
reduce microbial adhesion [121,122].
 
Figure 4. Different approaches for the production of Ag/plasma polymer nanocomposites:
(a) Simultaneous sputtering and plasma polymerization, (b) deposition from two independent
magnetrons, and (c) a combination of a gas aggregation source and plasma polymerization.
The great advantage of simultaneous sputtering and plasma polymerization is that it is a
single-step process. However, as the sputtering and plasma polymerization are fully coupled, it is
not possible to independently tailor the size of Ag NPs and their amount in the films and matrix
properties. In order to overcome this limitation, another procedure that is based on co-sputtering
from two independent magnetron sources may be used (see Figure 4b). The volume fraction of silver
in a matrix material is, in this case, controlled by the power applied to the individual magnetrons.
This approach, which is also applicable for the production of inorganic Ag containing antibacterial
nanocomposites (e.g., Ag/silica [123], Ag/hydroxyapatite [124], or Ag/TiO2 [125]), was used for
the fabrication of Ag/C:F antibacterial films by Zaporojtchenko et al. [126]. It was reported that the
nanocomposites produced steadily supplied silver ions for a long period of time (reported values
were for 300 days) and exhibited antibacterial effects towards S. epidermidis, S. aureus, and P. aeruginosa.
Moreover, an addition of a small amount of Au (1%) was found to substantially increase the release
rate of silver ions (by one order of magnitude) [126]. This effect is explained by the formation of
18
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galvanically-coupled Ag and Au NPs, because in the galvanic pair, silver is more active than gold,
and the presence of gold enhances Ag+ ion formation.
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Another strategy that makes it possible to completely decouple the deposition of Ag NPs and the
plasma polymer matrix is based on the use of gas aggregation sources [134,135]. This approach was
recently used by Vaidulych et al. [133] for the deposition of Ag/a-C:H nanocomposites. In order to
produce hard coatings, the substrates were placed on a RF electrode, used for a-C:H matrix deposition,
perpendicularly to the direction of a beam of Ag NPs produced by the GAS system (Figure 4c). As it
was shown in a previous study focusing on Cu/a-C:H nanocomposites [136], the volume fraction
of metallic NPs in a-C:H matrix and connected antibacterial efficiency may be tuned either by the
current applied onto the DC magnetron in the gas aggregation source, or by changing the duty
cycle of RF power used for the matrix deposition. Furthermore, it was reported that antibacterial
action of Ag/a-C:H coatings may be enhanced by the partial etching of nanocomposites by plasma
treatment performed in the same deposition chamber resulting in partial removal of a carbonaceous
layer from the outermost surface of produced nanocomposites, thus making Ag NPs more accessible
for water [133].
A completely different one-step process applicable for the deposition of Ag/plasma polymer
antibacterial films was proposed by Zimmerman et al. [137], Beier et al. [138], and Gerullis et al. [139].
These authors used an atmospheric pressure plasma chemical vapor deposition technique, in which a
HMDSO precursor was introduced into the atmospheric pressure plasma, together with silver nitrate
by a modified jet nozzle (Figure 5a). A strong antibacterial effect of nanocomposites produced in this
way on E. coli was shown even after 10,000 washing cycles [138]. Atmospheric pressure deposition was
finally also tested by Deng et al. [140], where they directly introduced Ag NPs (100 nm size) instead
of silver nitrate into the feed gas (N2 with admixing of O2 and TMDSO) (Figure 5b). According to
the reported results, prepared coatings exhibited strong antibacterial effects against Gramm-negative
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E. coli, and a modest effect on Gram-positive S. aureus. A similar approach was recently employed by
Ligouri et al. [141] for the production of plasma-polymerized polyacrylic acid with embedded Ag NPs.
Disk diffusion tests with E. coli confirmed the antibacterial efficacy of fabricated coatings.
 
Figure 5. Schematic representation of atmospheric pressure plasma systems for the deposition of
Ag/plasma polymer nanocomposites. (a) Plasma jet with injection of silver nitrate solution, and (b)
plasma jet fed with suspension of Ag NPs.
4. Perspectives and Challenges
Plasma-based techniques have been shown to present itself as an interesting option for the
production of antibacterial Ag-based coatings. In addition, plasma-based deposition technologies are
well-suited for the production of novel antibacterial coatings with enhanced functionality. This refers
not only to the possibility to produce coatings with a multi-approach character that may combine
the antibacterial action of Ag NPs with the non-fouling nature of a polymeric matrix (e.g., PEO-like
plasma polymers, Figure 6a), silver/plasma polymer nanocomposites with covalently immobilized
bactericidal substances (Figure 6b), or surface nanotopography (Figure 6c), but also coatings with (i) a
temporally non-monotonous release of silver ions, (ii) so-called multi-release coatings that employ two
or more antibacterial agents, or even (iii) thin films with Ag+ release induced by an external stimuli,
i.e., coatings that were suggested to facilitate prevention of bacterial infections (e.g., [31]).
 
Figure 6. Ag-based multi-functional coatings with (a) non-fouling character, (b) Ag/plasma polymer
nanocomposites with covalently immobilized antibacterial agents, or (c) a nanostructured plasma
polymer top layer.
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Regarding coatings with non-monotonous kinetics in the release of silver ions, two approaches
are under investigation. The first one is based on the possibility to tune Ag+ release by the thickness of
the barrier top layer (Figure 7). In this case, different parts of Ag NPs containing films may be coated
by plasma polymer films with different thicknesses. Zones with thin top layers will ensure burst
release, whereas zones coated with thicker films will be characterized by the delayed and prolonged
leaching of a smaller amount of Ag+. The same is expected to be achieved by the second approach that
is based on multi-layer coatings, or the coatings with a depth gradient in the number of embedded
NPs. Such materials should fulfill the requirement of long-lasting (several months of) antibacterial
action needed to prevent infections on implants.
 
Figure 7. Scheme of Ag/plasma polymer coating with non-monotonous kinetics of release of silver ions.
In the case of multi-release coatings, different antibacterial agents (e.g., silver and copper NPs or
Ag NPs and antibiotics) with different release kinetics and/or bactericidal effects can be combined.
Such coatings should significantly reduce the induction of bacterial resistance and guarantee synergic
antibacterial action, thus enhancing antibacterial efficiency. Possible structures under consideration
include silver-containing plasma polymer films impregnated with antibiotics (Figure 8a), sandwiched
structures with different metallic NPs with antibacterial character (Figure 8b), or multi-layered coatings
prepared by a step-by-step deposition, in which individual layers will be loaded with different
antibacterial agents (Figure 8c).
Figure 8. Different architectures suggested for multi-release coatings.
Plasma-based deposition techniques may also be utilized for producing coatings with
stimuli-responsive behavior. These materials benefit from the ability of some materials to undergo
volume or structural changes when exposed to a particular trigger. This property may be utilized for
controlling the release of antibacterial agents, including silver ions, from the coatings “on demand”.
The first example of Ag/plasma polymer nanocomposites with this ability was reported by Kulaga
et al. [142]. These authors coated polypropylene surgical mesh with a layer of plasma-polymerized
maleic anhydride (MA), impregnated with silver NPs and coated by a barrier layer (plasma polymerized
MA) that blocked the spontaneous release of silver from the coatings. Tailored release of silver ions
was then achieved by mechanical stimulation of the coatings that led to the formation of cracks in
the barrier layer. Moreover, plasma polymerization may also be used for the production of other
types of stimuli-responsive plasma polymers where changes in the temperature or pH acts as a trigger.
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For instance, Pan et al. [143], Spridon et al. [144], Chen et al. [145], and Moreno-Couranjou et al. [146]
synthetized thermo-responsive plasma-polymerized poly(N-isopropylacrylamide) or N-vinylcaprolactam
films. Muzammil et al. [147] reported on the pH-responsive coatings prepared by the plasma
co-polymerization of acrylic acid and octafluorocyclobutane. Although none of the already developed
stimuli-responsive plasma polymers were used for the fabrication of Ag-containing nanocomposites,
this option still shows a great deal of promise.
Finally, it has to be mentioned that despite the substantial and undisputable progress in the field
of antibacterial Ag/plasma polymer coatings and the large amount of suggested and tested approaches
that were briefly summarized in this review, to date the use of such materials still remains very
limited. This is partly due to the lack of clinical studies, as well as the not yet standardized methods
applied for evaluating the antibacterial effects of produced coatings. The latter relates both to the
choice of bacteria or procedures used for the quantification of antibacterial effects that makes it almost
impossible to compare results reached by different groups. Because of this, there is a clear demand to
propose/develop standardized, reliable, and high throughput validation methodologies for testing
produced antibacterial coatings, which applies not only to the coatings produced by plasma-based
methods but to other methods as well. In addition, all the experiments focused on determining
the antibacterial effects of produced Ag/plasma polymer coatings were performed in vitro. It is
well-known that under the more relevant in vivo conditions the performance of produced coatings
may be largely altered, e.g., by the possible accumulation of dead bacteria or proteins on surfaces of
produced coatings. Furthermore, other issues relate to factors which are often overlooked, such as
wear resistance, long-term stability, the ability of Ag/plasma polymer nanocomposites to withstand
common sterilization procedures, or, in the case of implanted materials, to integrate well with a
host tissue. However, the use of plasma-based techniques—most likely in combination with other
approaches—still presents itself as a vivid and auspicious option for the production of highly effective
antibacterial coatings.
5. Conclusions
There has been enormous progress in silver/plasma polymer nanocomposite antibacterial coatings
in the last two decades. As shown in this paper, numerous strategies have already been tested or are
under consideration for the effective production of such materials. However, despite promising results,
the field of Ag/plasma polymer antibacterial coatings still faces many challenges, meaning that better
understanding and control of bactericide activity of the prepared coatings, as well as the development
of new manufacturing procedures, are needed.
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Kylián, O.; Straňák, V. Plasma polymerized C:H:N:O thin films for controlled release of antibiotic substances.
Plasma Process. Polym. 2018, 15. [CrossRef]
44. Daschner, F.; Langmaack, H.; Wiedemann, B. Antibiotic resistance in intensive care unit areas. Infect. Control
1983, 4, 382–387. [CrossRef] [PubMed]
45. Neu, H.C. The crisis in antibiotic resistance. Science 1992, 257, 1064–1073. [CrossRef] [PubMed]
46. Albrich, W.C.; Angstwurm, M.; Bader, L.; Gärtner, R. Drug resistance in intensive care units. Infection 1999,
27, S19–S23. [CrossRef] [PubMed]
47. Hanberger, H.; Diekema, D.; Fluit, A.; Jones, R.; Struelens, M.; Spencer, R.; Wolff, M. Surveillance of antibiotic
resistance in European ICUs. J. Hosp. Infect. 2001, 48, 161–176. [CrossRef] [PubMed]
48. Loeffler, J.M.; Garbino, J.; Lew, D.; Harbarth, S.; Rohner, P. Antibiotic consumption, bacterial resistance and
their correlation in a swiss university hospital and its adult intensive care units. Scand. J. Infect. Dis. 2003,
35, 843–850. [CrossRef] [PubMed]
49. Levy, S.B.; Marshall, B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat. Med.
2004, 10, S122–S129. [CrossRef] [PubMed]
50. Hsueh, P.-R.; Chen, W.-H.; Luh, K.-T. Relationships between antimicrobial use and antimicrobial resistance
in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan.
Int. J. Antimicrob. Agents 2005, 26, 463–472. [CrossRef] [PubMed]
24
Antibiotics 2018, 7, 78
51. Silver, S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS
Microbiol. Rev. 2003, 27, 341–353. [CrossRef]
52. Mijnendonckx, K.; Leys, N.; Mahillon, J.; Silver, S.; Van Houdt, R. Antimicrobial silver: Uses, toxicity and
potential for resistance. BioMetals 2013, 26, 609–621. [CrossRef] [PubMed]
53. Chernousova, S.; Epple, M. Silver as antibacterial agent: Ion, nanoparticle, and metal. Angew. Chem. Int. Ed.
2013, 52, 1636–1653. [CrossRef] [PubMed]
54. Durán, N.; Durán, M.; de Jesus, M.B.; Seabra, A.B.; Fávaro, W.J.; Nakazato, G. Silver nanoparticles: A new
view on mechanistic aspects on antimicrobial activity. Nanomedicine 2016, 12, 789–799. [CrossRef] [PubMed]
55. Wei, L.; Lu, J.; Xu, H.; Patel, A.; Chen, Z.-S.; Chen, G. Silver nanoparticles: synthesis, properties, and
therapeutic applications. Drug Discov. Today 2015, 20, 595–601. [CrossRef] [PubMed]
56. Lansdown, A.B.G. A Pharmacological and toxicological profile of silver as an antimicrobial agent in medical
devices. Adv. Pharmacol. Sci. 2010, 2010, 1–16. [CrossRef] [PubMed]
57. Scholz, J.; Nocke, G.; Hollstein, F.; Weissbach, A. Investigations on fabrics coated with precious metals using
the magnetron sputter technique with regard to their anti-microbial properties. Surf. Coatings Technol. 2005,
192, 252–256. [CrossRef]
58. Sant, S.B.; Gill, K.S.; Burrell, R.E. Nanostructure, dissolution and morphology characteristics of microcidal
silver films deposited by magnetron sputtering. Acta Biomater. 2007, 3, 341–350. [CrossRef] [PubMed]
59. Mejía, M.I.; Restrepo, G.; Marín, J.M.; Sanjines, R.; Pulgarín, C.; Mielczarski, E.; Mielczarski, J.; Kiwi, J.
Magnetron-sputtered ag surfaces. New evidence for the nature of the Ag ions intervening in bacterial
inactivation. ACS Appl. Mater. Interfaces 2010, 2, 230–235. [CrossRef] [PubMed]
60. Jiang, S.X.; Qin, W.F.; Guo, R.H.; Zhang, L. Surface functionalization of nanostructured silver-coated polyester
fabric by magnetron sputtering. Surf. Coat. Technol. 2010, 204, 3662–3667. [CrossRef]
61. Baghriche, O.; Ruales, C.; Sanjines, R.; Pulgarin, C.; Zertal, A.; Stolitchnov, I.; Kiwi, J. Ag-surfaces sputtered
by DC and pulsed DC-magnetron sputtering effective in bacterial inactivation: Testing and characterization.
Surf. Coat. Technol. 2012, 206, 2410–2416. [CrossRef]
62. Baghriche, O.; Zertal, A.; Ehiasarian, A.P.; Sanjines, R.; Pulgarin, C.; Kusiak-Nejman, E.; Morawski, A.W.;
Kiwi, J. Advantages of highly ionized pulse plasma magnetron sputtering (HIPIMS) of silver for improved
E. coli inactivation. Thin Solid Films 2012, 520, 3567–3573. [CrossRef]
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Abstract: The emergence of bacterial resistance to available antimicrobials has prompted the search
for novel antibacterial compounds to overcome this public health problem. Metal-based complexes
have been much less explored than organic compounds as antimicrobials, leading to investigations of
the antimicrobial properties of selected complexes in which silver may occupy the frontline due to
its use as medicine since ancient times. Like silver, camphor has also long been used for medicinal
purposes. However, in both cases, limited information exists concerning the mechanisms of their
antimicrobial action. This work reviews the present knowledge of the antimicrobial properties of
camphor-derived silver complexes, focusing on recent research on the synthesis and antimicrobial
properties of complexes based on silver and camphor imines. Selected examples of the structure and
antimicrobial activity relationships of ligands studied so far are presented, showing the potential of
silver camphorimine complexes as novel antimicrobials.
Keywords: silver; camphor derivatives; silver camphorimine complexes; antimicrobial activity
1. Introduction
The discovery and use of antimicrobials is a landmark of modern medicine. Most of the
antimicrobials currently in use were developed last century, between the 1940s and 1960s [1,2].
These “magic bullets” have since then saved millions of human lives. However, bacterial resistance to
multiple antimicrobials has increased worldwide over the last decades, mainly due to their misuse
and abuse. Antibiotic resistance poses a serious threat to infection treatment, and thus a significant
pressure on health systems, and is considered a major menace to human health [3,4]. A particular
group of bacteria, referred to as the ESKAPE group (comprising Enterococcus faecium, Staphyloccus
aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter species)
has emerged worldwide, with an increasing prevalence in hospitals and resistance to antibiotics [5,6].
Despite this emergence of resistance, the number of new antimicrobials reaching the market has
been declining since the 1990s [7]. Multiple factors, including low investment return and regulatory
requirements, are the major reasons [8] for the exodus of pharmaceutical and biotechnological
companies from antimicrobial research and development.
Due to the new and emergent risks posed by bacterial resistance, the World Health Organization
(WHO, February 2017) [9] has appealed for the investment of publicly funded agencies and the private
sector in the research and development of new antibiotics. Motivated by the urgent need for new and
effectively active antimicrobials, we have initiated the investigation of the antimicrobial activity of
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silver camphorimine complexes. Silver and camphor are medicines empirically used since ancient
times, although the mechanisms underlying their antimicrobial activities remain to be fully understood.
2. The Antimicrobial Properties of Silver
Silver (Ag0) vessels were used in ancient times not only for aesthetic reasons but because they
preserved the quality of water. Although microbes were unknown, the consequences of microbial
contaminations were well known, and silver was a great help to control them. Aware of that,
Hippocrates (the father of medicine, 5th to 4th centuries BC) prescribed silver preparations against
infections. Later, the Romans extended the medicinal use to silver nitrate (AgNO3, Figure 1), and during
the Medieval Period, it continued to be used for the treatment of skin wounds and ulcers [10,11]. Silver
sulfadiazine (Figure 1) came later and is still in use to treat infections associated with burns [12,13].
 
 
Silver nitrate Silver sulfadiazine 
Figure 1. Examples of silver compounds with antibacterial properties.
Nowadays, silver metal and silver nanoparticles are used for medical device coatings and the
reduction of bacterial adhesion to the surfaces of implants as gels or films [14,15]. Silver composites
are used as antimicrobials against Gram-positive and/or Gram-negative bacteria [16–18]. Therapeutic
and antiseptic applications of silver and silver derivatives actually extend to the control of surgical
infections [19], a domain of increasing concern.
Despite the recognized antimicrobial activity of silver salts (e.g., silver nitrate, silver sulfadiazine)
and silver particles, the pharmacological uses of silver derivatives have been restricted mostly to
external uses in creams and dressings due to toxicity concerns. Recent studies showed that silver
nitrate and silver nanoparticles have no significant toxicity, although AgNO3 accumulates more than
silver nanoparticles in the organs of rats [20].
Notwithstanding years of use, only recently has some information been gathered on the molecular
mechanisms underlying the antimicrobial properties of silver. Proteins have been pointed out as the
major targets of silver ions, which can react with thiol groups, inactivating membrane-associated
enzymes (e.g., those involved in electron transfer and energy generation) as the Na+-translocating
NADH:ubiquinone oxidoreductase [21]. For instance, the addition of AgNO3 to Escherichia coli has
been shown to lead to proton motive force collapse and subsequent cell death [22].
Using reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Ansari et al. [23]
investigated changes in E. coli lipopolysaccharide (LPS) and L-α-phosphatidyl-ethanolamine (PE) upon
exposure to silver nanoparticles. These authors showed that the LPS O-antigen was involved in the
interaction with silver nanoparticles through hydrogen bonding. In addition, the silver nanoparticles
induced the break of the phosphodiester bond of PE, forming phosphate monoesters and resulting in a
highly disordered alkyl chain, most probably causing the destruction of the membrane and cell leaking.
Dibrov et al. [24] reported that low concentrations of silver ions induce massive proton leakage
and loss of cell viability in Vibrio cholerae, suggesting that the antimicrobial activity of Ag+ results
from its unspecific action on membrane proteins and/or the Ag+-modified phospholipid bilayer.
Consistently, the increase in d/cis ratios of unsaturated membrane fatty acids were reported upon
exposure to silver species [25], most probably affecting membrane fluidity and culminating with
membrane integrity loss [23,26]. A proteomics study carried out with Pseudomonas aeruginosa revealed
that treatment with silver nanoparticles led to the identification of 59 proteins related to membrane
functions and intracellular oxygen reactive species generation, and 5 silver-binding proteins were
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found by proteomics [27]. Feng and colleagues [28] showed that, upon exposure to silver ions, E.
coli and S. aureus lost the ability to replicate DNA, suggesting that the nucleoid is another bacterial
structure targeted by silver ions.
A few studies have also used electron microscopy techniques to inspect the effects of silver
nanoparticles on bacterial cell morphology. An example is the work by Huang et al. [29], who
used transmission electron microscopy (TEM) and scanning electron microscopy (SEM) to study the
antimicrobial mechanisms of catechol-functional chitosan silver nanoparticles on the Gram-positive
S. aureus and the Gram-negative E. coli. These authors suggest that the silver nanoparticles killed S.
aureus through disruption of the cell wall and the consequent membrane damage and cytoplasmic
content leak out. In the case of the Gram-negative E. coli, the antimicrobial mechanisms involved the
adsorption of the silver nanoparticles to the surface of surface bacterial cells, interaction with the outer
membrane, and damage of its permeability. This change in permeability was suggested to allow the
silver ions to enter into the cytoplasm, interfering with cellular functioning.
Silver nanoparticles have also been reported as active against a wide range of multidrug-resistant
(MDR) bacteria, including the Gram-positive S. aureus, S. epidermidis, Streptococcus mutans, Enterococcus
faecalis, and Bacillus subtilis, and the Gram-negative E. coli, V. cholerae, P. aeruginosa, Klebsiella pneumoniae,
and Salmonella typhi [30].
3. The Biological Properties of Camphor
(1R)-(+)-camphor (Figure 2) is a natural product (also produced by synthetic means) with
very ancient applications as an insect repellent, muscular relaxant, and anesthetic [31,32] and is
currently used as a cough suppressant and decongestant according to conditions established by
the Food and Drug Administration. Recent studies show that camphor derivatives may also have
relevant antimicrobial [33], antiviral [34,35], and/or cytotoxic properties [36], being also used as
photoinitiators [37] or neuro-blocking agents [38]. However, in contrast with some knowledge of silver
antibacterial mechanisms, such knowledge is inexistent in the case of camphor or camphor derivatives.
  
Camphor Camphorsulfonic acid 
Figure 2. Molecular structures of camphor and camphorsulfonic acid.
The wide range of pharmacological applications of camphor has fostered studies on the properties
of camphor derivatives and camphor complexes. Camphor derivatives can be obtained by the
introduction of suitable substituents on the camphor molecule (e.g., imine or carboxylic groups),
keeping the camphor skeleton intact. Camphor imines, camphor carboxylates, camphor sulfonimines,
and camphor sulfonamides (derived from camphorsulfonic acid, Figure 2) are among the camphor
derivatives with suitable coordinating properties, some of which (e.g., camphor sulfonamides) display
therapeutic properties [39].
Such as for silver and silver derivatives, not much information is available on the molecular
mechanisms underlying the antimicrobial activity of camphor derivatives. Recent computer
simulations of interactions with the viral surface hemagglutinin (HA) glycoprotein suggest that
camphor derivatives inhibit HA activity by binding to hydrophobic sites of the protein [40]. Apparently,
camphor imines are able to effectively block conformational rearrangements of HA, required for
membrane fusion during virus entry in host cells.
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4. Silver Camphorimine Complexes
In complexes, the characteristics of the metal and the ligands combine in a cooperative way
to generate compounds with distinct and frequently improved properties relative to the precursor
species. Complexes have a wide variety of applications in catalysis, medicine, and the materials
industry. Furthermore, properties of complexes can be tuned towards specific applications by varying
the metal and ligands. The catalytic properties of silver complexes have been explored to promote
organic transformations and bio-conjugation [41]. In the last decade, the evaluation of the biological
properties of silver complexes has garnered considerable attention, in particular, fostering their use as
antimicrobials or anticancer agents [1,4,42–47]. The therapeutic uses of silver complexes include silver
sulfadiazine for treatment of infections associated with burns.
The core of the silver camphor imine complexes, the biological properties of which we have been
studying, is formed by silver nitrate (AgNO3) that binds one or two camphor ligands per metal atom.
Data obtained by X-rays show that nitrate acts as a bidentate ligand and that the camphor ligand binds
the silver atom through the imine nitrogen atom. The complexes arrange according to monomeric (type
1, Figure 3) or polymeric (type 2, Figure 3) structures. The polymeric arrangement was typically found
in imine and bicamphor imine complexes of general formula [Ag(NO3)L]n [33], while the monomeric
arrangement was found in camphor sulphonylimine ([Ag(NO3)L2]) [43] complexes (Figure 3).
 
Type 1 Type 2 
Figure 3. Structural arrangements corroborated by X-ray analysis in Ag(I)-camphor-derived complexes.
The synthesis of the Ag(I) camphor complexes includes the preparation of suitable camphor compounds
to be used as ligands, since just a few imine functionalized camphor derivatives are commercially
available (e.g., camphor oxime and camphor sulphonylimine). (1R)-(+)-camphor is the starting material
for the camphor compounds of type A1–A5 (Figure 4).
(1S)-(+)-10-camphorsulfonic acid is the precursor for the tricyclic camphor sulfonylimine
derivatives of types B1 and B2 (Figure 5) within a process that involves the sequential
formation of chloride and amine derivatives prior to ring closure and oxidation to obtain
3-oxo-camphorsulfonylimine, which is then condensed with amines or hydrazines to afford camphor
sulfonylimines of types B1 and B2 (Figure 5).
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Figure 4. Camphor derivatives of the imine type: Y-aromatic or aliphatic; R1 = H, Me, Ph; R2 = H, Me,
Ph, among others; Z = phenyl; biphenyl, linear alkane. For preparative details see references (i)—[48];
(ii)—[42]; (iii)—[49,50]; (iv)—[42,51]; (v)—[42,52].
Figure 5. Camphorsulfonic acid derivatives of the camphorsulfonimine type.
A wide variety of amines (YNH2) and hydrazines (NR1R2NNH2) can be used to tune the electronic
and steric characteristics of the imine group at position 3 (see Figure 5 for labelling) of the camphor
skeleton. Thus, the design and synthesis of camphor Ag(I) complexes can be driven to control electronic
and steric parameters towards the aimed objectives.
The camphor imine complexes, the antimicrobial properties of which were studied by us [42],
were obtained in acetonitrile by the reaction of silver nitrate with the suitable camphor ligand
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(L) under metal-to-ligand ratios directed to mononuclear (Equation (1)) or polymeric complexes
(Equation (2)). Strict control of the experimental conditions (exposure to light and reaction time) is
necessary depending on the electronic characteristics of the camphor ligands to inhibit Ag(I) reduction,
the formation of silver nanoparticles (AgNPs) (Equation (3)), and products of oxidation of the camphor
derivatives (e.g., camphorquinone).
AgNO3 + 2 L → [Ag(N O3)(L)2 ] (1)
AgNO3 + L → [Ag(N O3)(L) ] (2)
AgNO3 + 2 L → AgNPs + camphorquinone + other products (3)
Studies carried out so far evidence that all silver camphor imine complexes display biological
activity that, according to the structural and electronic characteristics of the ligands, favors antibacterial,
antifungal, and/or anticancer activity [33–35]. In some cases, antibacterial, antifungal, and cytotoxic
activity combine in the same complex [42,44]. Such performance is highly relevant to cancer treatments
because opportunistic fungi and bacteria might develop when body defenses diminish due to the use
of anticancer drugs.
5. Antibacterial Activity
To date, several silver camphor complexes have been synthesized and characterized, and their
antibacterial activity towards Gram-positive (S. aureus) and Gram-negative bacteria (E. coli, P. aeruginosa,
Burkholderia contaminans) has been screened using the Kirby–Bauer disk diffusion method and
quantified based on the determination of minimal inhibitory concentrations (MIC) by microdilution
assay standard methods [45]. E. coli, S. aureus, and P. aeruginosa strains were chosen because these
species belong to the ESKAPE group. B. contaminans is a member of the Burkholderia cepacia complex
(Bcc), a group of Gram-negative bacteria capable of causing life-threatening respiratory infections,
of particular severity among cystic fibrosis patients [46,47,53,54]. Bcc bacteria are intrinsically resistant
to multiple antimicrobials, rendering their eradication difficult to achieve [55]. Photographs in Figure 6
illustrate results from disk diffusion and MIC assays, obtained with complex 1 (see Table 1) for E. coli
ATCC25922 and S. aureus Newman.
 
Figure 6. Photographs illustrating results from the assessment of complex 1 antibacterial activity
towards E. coli ATCC25922 or S. aureus Newman by the disk diffusion method and MIC determination
by broth microdilution assays. Circular growth inhibition zones are visible in plates spotted with
50 or 30 μg of the complex. The numbers below the wells indicate the respective complex 1 final
concentration, in μg/mL. Photographs (not at the same scale) taken after 24 h of incubation at 37 ◦C.
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Table 1. Minimal inhibitory concentration (MIC) values calculated for complexes [Ag(NO3)L],
in μg/mL, towards the bacterial strains Staphylococcus aureus Newman, E scherichia coli ATCC25922,
Pseudomonas aeruginosa 477, and Burkholderia contaminans IST408. Data taken from previous publications
[42–44].
Ligand (L) Complex S. aureus E. coli P. aeruginosa B. contaminans
1 66 ± 5 50 ± 1 56 ± 4 79 ± 4
2 183 ± 3 65 ± 2 121 ± 2 144 ± 1
3 73 ± 2 20 ± 1 19 ± 4 36 ± 3
4 <100 <100 86 ± 7 <100
AgNO3 (Control) - 73 47 39 74
MIC values of a selection of silver camphor imine complexes towards E. coli, S. aureus, P. aeruginosa,
and B. contaminans are shown in Table 1. The examples aim to highlight the profound effects of the
presence, position, and number of aryl groups in the antibacterial activity of the silver camphor
imine complexes. These selected examples also evidence that structural differences in the complexes
due to para (complex 3) or meta (complex 2) substituents in the aromatic ring drive significant
variations in the MIC values for the strains tested, not only between Gram-positive and Gram-negative
strains but also within the Gram-negative strains. From the set of bicamphor complexes in Table 1,
[Ag(NO3)(OC10H14N)2(p-C6H4)] (3, ligand of type A3, Figure 4) displays the highest antibacterial
activity against Gram-negative strains, followed by complex 1 with a type A5 ligand (Figure 4). In both
cases, electron delocalization throughout the camphor ligand may not be innocent since it affects the
electron density at the silver center and consequently the electron transfer processes in which the silver
ion may be involved. The MIC values for complexes 1, 3, and 4 show that one aromatic group between
the two camphor moieties (3) increased the antimicrobial activity towards the Gram-negative strains,
while two sequential aromatic groups in between the camphor moieties (4) resulted in a general loss
of antibacterial activity (Table 1). Comparing the biological activity of complexes 2 and 3 (selected to
illustrate the effects of the geometry of the ligand in the MIC values according to a relevant effect of
geometry and/or electron delocalization on activity), a marked decrease in activity is observed upon
replacement of a para (3) by a meta (2)-substituted aromatic spacer (Table 1).
A step forward in this work considers the design of new camphor ligands and the synthesis of
silver and eventually other metal complexes to investigate the effects of electron density, electron
delocalization, distinct geometries, and substituents at the camphor skeleton on the antibacterial
activity. The identification of the complexes’ bacterial targets is expected to enable the design of
suitable ligands to tailor complexes with enhanced antimicrobial activity and allow rationalization of
the mechanisms.
A major concern when developing novel antimicrobials is the emergence of resistant strains.
Preliminary unpublished work from our team indicates that the frequency of spontaneous emergence
of resistance for E. coli ATCC25922, P. aeruginosa 477, B. contaminans IST408, and S. aureus Newman is
lower than 4 × 10−10. These data were obtained after spreading approximately 109 CFUs of each strain
onto the surface of Mueller-Hinton solid medium containing twice the estimated MIC concentration of
complex 3 and enumerating the CFUs after five days of incubation at 37 ◦C. Another issue that still
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needs to be addressed is the toxicity of the silver camphorimine complexes to humans and animals
when envisaging their use in human and veterinary medicine.
6. Conclusions
Camphor and silver derivatives have been used since ancient times as medicines. Although
their combination in complexes and the search for their antimicrobial activities only started
recently, there is no application of silver camphor imine complexes in medicine, pharmacy, or
industry. The results obtained until now show that some silver camphor imine complexes combine
antimicrobial activity against bacteria and fungi with cytotoxic activity [42–44]. This feature is highly
relevant since opportunistic bacteria and fungi usually develop during cancer treatments due to the
immunosuppressive effects of anticancer drugs.
The insights already made into the antimicrobial properties of some silver camphor imine
complexes show they have moderate to high antibacterial activity, depending on the characteristics of
the ligands. Such information fosters further enhancement of the ligands to optimize the antibacterial
properties of the camphor imine complexes. Meanwhile, synthetic strategies to synthesize, characterize,
and evaluate the antimicrobial properties of silver camphor imine complexes were developed and
described in the present minireview. Detailed knowledge of the bacterial targets of these compounds
is still missing, and therefore, future work will focus on the unveiling of the molecular targets and
mechanisms underlying their antimicrobial activity. To address these issues, studies will focus on the
use of transcriptomic approaches to gain clues regarding the bacterial gene expression responses to
exposure to inhibitory concentrations of silver camphor imine complexes. It will be also necessary
to use more classical biochemical approaches to identify the bacterial targets of these complexes.
The comprehensive knowledge of the molecular details of the antimicrobial activity of silver camphor
imine complexes is expected to enable the exploitation of structure and activity relationships to tailor
complexes with enhanced antimicrobial activity.
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Abstract: This paper sets out to determine whether silver nanoparticles conjugation enhance
the antibacterial efficacy of clinically approved drugs. Silver conjugated Cephradine and
Vildagliptin were synthesized and thoroughly characterized by ultraviolet visible spectrophotometry
(UV-vis), Fourier transform infrared (FT-IR) spectroscopic methods, atomic force microscopy
(AFM), and dynamic light scattering (DLS) analysis. Using antibacterial assays, the effects
of drugs alone and drugs-conjugated with silver nanoparticles were tested against a variety
of Gram-negative and Gram-positive bacteria including neuropathogenic Escherichia coli K1,
Pseudomonas aeruginosa, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA),
Bacillus cereus and Streptococcus pyogenes. Cytopathogenicity assays were performed to determine
whether pretreatment of bacteria with drugs inhibit bacterial-mediated host cell cytotoxicity.
The UV-vis spectra of both silver-drug nanoconjugates showed a characteristic surface plasmon
resonance band in the range of 400–450 nm. AFM further confirmed the morphology of
nanoparticles and revealed the formation of spherical nanoparticles with size distribution of
30–80 nm. FT-IR analysis demonstrated the involvement of Hydroxyl groups in both drugs in
the stabilization of silver nanoparticles. Antibacterial assays showed that silver nanoparticle
conjugation enhanced antibacterial potential of both Cephradine and Vildagliptin compared to the
drugs alone. Pretreatment of bacteria with drugs inhibited E. coli K1-mediated host cell cytotoxicity.
In summary, conjugation with silver nanoparticle enhanced antibacterial effects of clinically approved
Cephradine. These findings suggest that modifying and/or repurposing clinically approved drugs
using nanotechnology is a feasible approach in our search for effective antibacterial molecules.
Keywords: Cephradine; Vildagliptin; nanoparticles; antibacterial; nanotechnology
1. Introduction
Infectious diseases are a significant burden on public health, driven largely by socio-economic,
environmental and ecological factors [1]. About 15 million of 57 million annual deaths worldwide are
estimated to be caused by infectious diseases, principally due to bacterial pathogens [1]. The burden of
morbidity and mortality falls most heavily on people in developing countries [2]. Drug-resistant
microbes are a major factor causing microbial re-emergence [3]. Among numerous bacteria,
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus species, Klebsiella pneumoniae
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are important human pathogens contributing to urinary tract infections, neonatal meningitis,
gastroenteritis, wound and skin diseases, food poisoning and nosocomial infections [4–10]. The overuse
of antibiotics has contributed to bacterial acquisition of drug resistance resulting in reduced efficacy of
available drugs.
During the past decade, nanomedicine has shown great potential due to effectiveness of various
nanoconjugates against pathogenic microbes [11]. Nanomaterials have been frequently used as effective
coatings to prevent bacterial adhesion to surfaces as well as bactericidal agents [12]. He et al., showed
the development of self-defensive and antibacterial adhesion surface coating based on bilayer hydrogel
which can promote cell adhesion and proliferation [13,14]. Polymers-based antibacterial agents are
also an important class of nanomaterials. Yuan et al. reported various types of hydroxyl-rich cationic
derivatives of star-like poly (glycidyl methacrylate) as broad-spectrum antibacterial and antifouling
surface coating agents [15]. Antibacterial activity of low molecular weight cationic polymers is
shown to affect the membrane permeability and disruption against a broad range of bacteria [16].
In another report, a salivary statherin protein inspired poly(amidoamine) dendrimer is shown to exhibit
antibacterial effects as effective coating on hydroxyapatite [17,18]. Similarly, dendrons have been shown
as a clicking tool for generating nonleaching antibacterial materials [19]. Metal nanoparticles have
been studied extensively because of their unique physicochemical characteristics including catalytic
activity, optical properties, electronic properties, antimicrobial activity, and magnetic properties [20].
Among these, silver nanoparticles (AgNPs) have shown growth inhibitory as well as bactericidal
effects [21]. The high surface area of AgNPs leads to high antimicrobial activity as compared with
the silver metal [22]. With the limited discovery of novel antibacterial agents, a feasible approach is
to modify clinically approved drugs to enhance their efficacy and/or drug repurposing to expedite
discovery of effective formulation of antibacterial agents.
Cephradine (relative molecular mass 349.406 g mol−1) is a first generation cephalosporins
antibiotic drug that is widely used in the treatment of bacterial infections of the urinary and the
respiratory tract, as well as ear, skin and soft tissues. It is used against both Gram-positive and
Gram-negative bacteria. Its mode of action is inhibition of bacterial cell wall synthesis [23,24].
Vildagliptin (relative molecular mass 303.399 g mol−1) is an antidiabetic drug, which is a small
molecule and inhibits dipeptidyl peptidase-4 (DPP4). Vildagliptin has been shown to stimulate insulin
secretion and inhibit glucagon secretion in a glucose-dependent manner [25–27]. Here we tested
whether conjugation of AgNPs can enhance efficacy of the clinically approved drug, Cephradine.
2. Materials and Methods
2.1. Bacterial Cultures
The cultures of six bacterial isolates including neuropathogenic Escherichia coli K1 (a cerebrospinal
fluid isolate from a meningitis patient; 018:K1:H7), strain E44, was used in the present study
(Malaysian Type Culture Collection 710859), and methicillin-resistant Staphylococcus aureus (MRSA)
was used as described previously (Malaysian Type Culture Collection 381123). The MRSA strain
was originally derived from the blood cultures, obtained from the Luton & Dunstable Hospital NHS
Foundation Trust, Luton, England, UK. Pseudomonas aeruginosa, Klebsiella pneumoniae, Bacillus cereus
and Streptococcus pyogenes were obtained from the Microbiology Research Laboratory at Sunway
University. Stock cultures were refreshed by subculturing every 15 days on nutrient agar plates and
were maintained at 4 ◦C.
2.2. Synthesis of AgNPs Coated with Drugs
Cephradine conjugated silver nanoparticles (Ceph-AgNPs) were synthesized. Briefly, 5 mL
(0.1 mM) Cephradine aqueous solution was reacted with 5 mL (0.1 mM) silver nitrate aqueous
solution, and the reaction mixture was magnetically stirred for 10 min. Twenty μL of 5 mM
freshly prepared Sodium borohydride aqueous solution (NaBH4) was added in the above stirring
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reaction mixture. The color of solution turned yellow-brown from transparent upon addition of
a reducing agent indicating the reduction of silver ions and the formation of Ceph-AgNPs [28,29].
For Vildagliptin-conjugated silver nanoparticles (Vgt-AgNPs), a similar procedure was repeated by
optimizing different volume ratio (v/v) of silver solution and drugs. Stable Vgt-AgNPs were obtained
at respective v/v of silver to drug at 1:1. The amount of drug loaded on the nanoparticles was also
measured. Nanoparticles were centrifuged at 12,000× g for 1 h, supernatant was collected, freeze-dried,
and the unloaded drugs was determined by weighing. The results are expressed as the percentage of
the drug amount contained in 100 mg of the dried nanoparticle. The percentage of drug loading on
nanoparticles was found to be 52% and 68% for Ceph-AgNPs and Vgt-AgNPs, respectively.
2.3. Characterization of AgNPs-Coated Drugs
After successful synthesis of nanoconjugates, Ceph-AgNPs and Vgt-AgNPs were subjected to
complete analysis via ultraviolet-visible spectrophotometry (UV-vis), Fourier transformation infrared
(FT-IR), atomic force microscopy (AFM), and dynamic light scattering (DLS) as described previously [28,29].
2.4. Bactericidal Assay
Antibacterial potential of AgNPs, Ceph and Ceph-AgNPs was determined by using bactericidal
assay [30]. Briefly, bacterial cultures were adjusted to optical density (OD) of 0.22 at 595 nm using a
spectrophotometer (OD595 = 0.22) which corresponds to 108 colony-forming units per mL (C.F.U. mL−1).
An inoculum of 10 μL of above bacteria culture (equivalent to approximately 106 C.F.U.) was incubated
with various concentrations of either Ceph-AgNPs, and Vgt-AgNPs in 1.5 mL centrifuge tubes at 37 ◦C
for 2 h. For negative controls untreated bacterial culture were incubated with phosphate buffer saline
(PBS). Vildagliptin and Cephradine alone were used as additional controls, while bacteria incubated
with 100 μg mL−1 of gentamicin were used as positive control. Next, bacteria were serially diluted
and 10 μL of each dilution was plated on nutrient agar plates. These plates were incubated at 37 ◦C
overnight, followed by viable bacterial C.F.U. count.
2.5. Cytopathogenicity Assay
Cytopathogenicity assays were performed as described previously [31]. Briefly, E. coli K1 were
incubated with various concentrations of Cephradine, Vildagliptin, and their nanoconjugates for 2 h
at 37 ◦C. Next, all test samples were incubated with confluent HeLa monolayers in supplemented
medium. Plates were incubated at 37 ◦C for 24 h in a 5% CO2 incubator and observed for cytotoxic
effects. At the end of this incubation period, the supernatants were collected and cytopathogenicity
was detected by measuring lactate dehydrogenase (LDH) release (Cytotoxicity Detection kit) as follows:
% cytotoxicity = (sample value − control value)/total LDH release − control value) × 100. Control
values were obtained from host cells incubated in RPMI-1640 medium alone. Total LDH release was
determined from HeLa cells treated with 1% Triton X-100 for 30 min at 37 ◦C. The basis of this assay
is that cell supernatant containing LDH catalyzes the conversion of lactate to pyruvate, generating
reduced form of nicotinamide adenine dinucleotide (NADH) and H+. In the second step, the catalyst
(diaphorase, solution from kit) transfers H and H+ from NADH and H+ to the tetrazolium salt
p-iodo-nitrotetrazolium violet (INT), which is reduced to formazan (dye), and absorbance is read at
490 nm.
3. Results
3.1. Characterization of Cephradine and Vildagliptin Coated Silver Nanoparticles
The UV-vis spectra of both silver-drug nanoconjugates showed characteristic surface plasmon
resonance band in the range of 400–450 nm. AFM images were recorded to ascertain the morphology of
these nanoparticles. The representative topographical images of Ceph-AgNPs and Vgt-AgNPs revealed
the formation of spherical nanoparticles (Figure 1a,b). The size distribution of drugs nanoconjugates
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was determined by DLS (Figure 1c,d). Vgt-AgNPs was found to be a mixture of small and large particle
size ranging from 2, 7, and 90 nm with an average size of 33 nm, as compared to Ceph-AgNPs (average
size 85 nm). FT-IR analysis demonstrated the involvement of hydroxyl groups in both drugs in the
stabilization of silver nanoparticles (Figure 2).
Figure 1. Representative images of atomic force microscopy (AFM) of Ceph-AgNPs (a); Vgt-AgNPs (b);
AFM topographs were recorded on Agilent 5500 instrument used in tapping mode with silicon nitride
cantilever. Ceph-AgNPs were found to be 85 nm (c); whereas, Vgt-AgNPs with the size distribution of
33 nm as measured by DLS (d). Both nanoparticles were spherical and polydisperesed.
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Figure 2. Representative spectra of FT-IR of Ceph-AgNPs (a); Vgt-AgNPs (b); shows the presence of
hydroxyl, lactam, carboxylic acid and amino groups. However, while compared with drugs alone (c,d),
hydroxyl groups peaks showed a shift in wave number which indicates the interaction with silver
nanoparticles. Spectra were recorded at Bruker Vector 22 instrument using Potassium bromide (KBr)
disc method.
3.2. Cephradine and Vildagliptine Conjugated with AgNPs Exhibited Increased Bactericidal Effects against
E. coli K1 and MRSA Compared with AgNPs and Drugs Alone
Bactericidal assay was performed to determine the effects of drugs conjugated with AgNPs
and drugs alone on E. coli K1 and MRSA. The concentrations of samples were adjusted to achieve
MIC50 (minimum inhibitory concentration to kill 50% bacteria), which can be observed in MRSA and
S. pyogense, and in the rest of bacteria MIC90 (minimum inhibitory concentration to kill 90% bacteria)
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is observed at tested concentrations. The results revealed that both drugs conjugated with AgNPs
exhibited significant bactericidal effects (p < 0.05 using t-test, two-tailed distribution). In addition,
treatment with bare AgNPs alone had limited effects on E. coli K1 and MRSA (Figure 3). Notably,
Ceph-AgNPs showed significant bactericidal effects at 5 and 10 μM compared with drugs alone
(p < 0.05). Vildagliptin alone did not show significant bactericidal effects at 5 or 10 μM, while, at 5 and
10 μM, Vgt-AgNPs, bacteria were significantly reduced (from 7.3 × 107 to 5.4 × 105) and (from 8.6 × 107
to 4.8 × 105) respectively for Gram-negative E. coli K1, and (from 1.0 × 107 to 4.3 × 106) (from 9.3 × 106
to 2.3 × 106) at 5 and 10 μM for Gram-positive MRSA (Figure 3).
Figure 3. E. coli K1 (a); MRSA (b); colonies were determined following incubation with drugs alone,
Ag alone, AgNPs conjugated with drugs. Briefly, 1 × 106 E. coli K1, MRSA colonies were incubated
with drugs and controls at 37 ◦C for 24 h. Next, colonies were accounted. Both drug-conjugated AgNPs
exhibited significant bactericidal effects (p < 0.05 using t-test, two-tailed distribution, as indicated by
asterisk). The results are the mean ± standard error of three independent experiments performed
in duplicate.
3.3. Cephradine and Vildagliptine Conjugated with AgNPs Exhibited Increased Bactericidal Effects against
P. aeruginosa, K. pneumoniae, B. cereus, S. pyogenes Compared with the Drugs Alone
The results revealed that drugs conjugated with AgNPs exhibited significant bactericidal effects
at 1- and 2-μM concentration against P. aeruginosa, K. pneumoniae, B. cereus, S. pyogenes (p < 0.05 using
T test and two-tailed distribution). However, at 1 μM and 2 μM concentration, the treatment with
AgNPs alone had similar effects on the number of bacteria. Notably, Ceph-AgNPs and Vgt-AgNPs
showed significant effects at 1 μM and 2 μM compared with the drugs alone (Figure 4).
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Figure 4. P. aeruginosa (a); K. pneumoniae (b); B. cereus (c); S. pyogenes (d). Bacterial colonies were
determined following incubation with Cephradine and Vildagliptine. Briefly, 1 × 106 bacteria
were incubated with drugs and controls at 37 ◦C for 24 h. Both drugs—conjugated AgNPs and
Ag-NPS—alone exhibited significant bactericidal effects (p < 0.05 using t-test, two-tailed distribution,
as indicated by asterisk), while as there was no significant effects of drugs alone. The results are the
mean ± standard error of three independent experiments performed in duplicate.
3.4. Silver Nanoparticle-Conjugated Drugs Inhibited E. coli K1-Mediated Host Cell Cytotoxicity
To determine whether AgNP-conjugated drugs inhibited bacteria-mediated host cell cytotoxicity,
assays were performed by incubating 106 E. coli K1 with HeLa cells for 24 h. E. coli K1 alone produced
60% host cell death. On the other hand, bacteria pretreated with AgNPs as well as Ceph-AgNPs and
Vgt-AgNPs caused minimal host cell damage and host cell cytotoxicity was reduced to less than 15%
(Figure 5). These findings also showed that Ceph-AgNPs and Vgt-AgNPs alone had minimal host
cell cytotoxicity.
Figure 5. Cytopathogenicity assays were performed using E. coli K1 as described in materials and
methods. Briefly, bacteria were incubated with test samples for 2 h before putting on HeLa cells
monolayer with and without different drugs (10 μM), Cephradine (Ceph) and Vildagliptine (Vgt). Cells
were then incubated for 24 h on standard conditions. Untreated bacteria, and bacteria treated with
gentamicin were also treated with cells to evaluate their effects on cells cytotoxicity. Triton-X was used
to lyse cells before determination of lactate dehydrogenase (LDH) release as marker of cell damage.
LDH was determined by using Roche applied sciences LDH kit supplemented with enzyme and buffer.
The % cytotoxicity was calculated by formula: % cytotoxicity = (sample value − control value)/total
LDH release − control value) × 100. The results are representative of at least three independent
experiments performed in duplicates. Asterisk indicates p < 0.05 using t-test, two-tailed distribution.
4. Discussion
The lack of development and approval of new and effective antibacterials as well as growing MDR
microbes presents a major challenge in our ability to counter bacterial infections [31]. Nanotechnology
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offers great promise in the field of biomedicines, especially diagnosis and drug delivery. It offers
opportunities for therapeutic agent delivery to specific cells and receptors. Nanomaterial-based
drug delivery systems have the potential to improve pharmacokinetics and pharmacodynamics of
the drugs [32]. The small size of nanoparticles provides them a greater surface area for maximum
drug loading as well as high accessibility for specific targets. Recently, various drug-conjugated
nanoparticles are being developed against infections caused by resistant microbes [33]. The most
common metal carriers for nanoparticle-based drug delivery systems include gold, silver, and iron
oxide due to their inertness and biocompatibility [33].
Though the mode of action of silver nanoparticles on the bacteria has been suggested to affect
morphological and structural changes in the bacterial cells, the large surface area, provides better
uptake by microorganisms [34]. Hence, silver nanoparticles have the ability to anchor to the bacterial
cell wall and subsequently penetrate it, thereby causing structural changes leading to increased
permeability of the cell membrane and cell death. In addition, the formation of free radicals by the
silver nanoparticles have the ability to damage the cell membrane and make it porous resulting in
bacterial cell death [35]. The bacterial membrane contains sulfur-containing proteins and the AgNPs
interact with these proteins in the cell as well as with the phosphorus containing compounds. When
AgNPs enter the bacterial cell, it forms a low molecular weight region in the center of the bacteria to
which the bacteria conglomerates thus protecting the DNA from silver ions. Also, it generates reactive
oxygen species, which are produced to attack the respiratory chain, cell division, and finally leading to
cell death [36].
Silver conjugated Cephradine (mode of action involves binding and inactivation penicillin binding
proteins leading to inhibition of peptidoglycan layer and causing cell lysis) and Vildagliptin (DPP4
inhibitor) were synthesized by reducing silver nitrate with sodium borohydride in the presence
of drugs. These nanodrug conjugates were characterized by UV-visible spectrophotometry, FT-IR
spectroscopy, and AFM. Cephradine and Vildagliptin successfully stabilized AgNPs and displayed
surface plasmon resonance band in the range of 400–450 nm. FT-IR analysis showed the interaction of
hydroxyl groups of drugs with silver nanoparticles for stabilization. Hence, the mode of stabilization
is anticipated to be noncovalent interactions. Ceph-AgNPs and Vgt-AgNPs both were found to be
spherical in shape and lie in a range of size distribution from 30–80 nm. Ceph-AgNPs were larger as
compared to Vgt-AgNPs.
After characterization, these nanoparticles were subjected to antibacterial assays. Ceph-AgNPs
and Vgt-AgNPs showed significant bactericidal effects against Gram-negative E. coli K1, P. aeruginosa,
K. pneumonia and Gram-positive MRSA, B. cereus, and S. pyogenes. Nevertheless, these findings
show tremendous potential in the development of new antibacterial formulations. As discussed
previously, Cephradine is a cephalosporin first-generation antibiotic, which is not very effective against
a number of bacteria because the different resistance mechanisms varied from the variation of the
penicillin-binding protein, production of β-lactamase, existence of β-lactamase genes on plasmids or
on bacterial chromosomes, and efflux pump mechanisms. For instance, MRSA produces abnormal
penicillin binding protein 2A, which has low methicillin affinity (mediated through the mecA gene),
which is carried on the staphylococcal cassette chromosome mec (SCCmec) by horizontal gene transfer
and this results in resistance to Cephradine as an antibiotic [37]. Ceph-AgNPs provide a change
in susceptibility of the drug along with, presumably, enhanced bioavailability. On the other hand,
Vildagliptin (dipeptidyl peptidase-4 inhibitor) and its silver nanoparticles showed some promising
effects as an antibacterial. Furthermore, these nanoparticles significantly and selectively reduced the
pathogen-mediated host cell cytotoxicity caused by Gram-negative bacteria.
Drug-loaded nanoparticles enter in the bacteria by endocytosis showing either specific
or non-specific type of interactions with cell membrane [38]. The positive charge of AgNPs
interacts with lipopolysaccharides of Gram-negative bacteria with more affinity than the cellular
wall of Gram-positive bacteria, that possess few sites for interactions, then releases the drugs
intracellularly [38]. In previous reports, cephalosporin conjugated with AgNPs also showed
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enhancement in the antibacterial potency of Ceftriaxone and Cefixime against E. coli and S. pyogenes,
respectively [39,40]. In conclusion, Cephradine and Vildagliptin showed bactericidal effects against
the six tested bacteria in this study, but their conjugation with AgNPs enhanced their antibacterial
efficacy. Moreover, Ceph-AgNPs and Vgt-AgNPs also significantly reduced the host cells cytotoxicity.
The exact mechanism of action of these nanoparticles is not precisely understood and it is the subject
of future studies along with testing their potential in vivo.
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Abstract: The increase in the prevalence of bacterial resistance to antibiotics has become one of the
main health problems worldwide, thus threatening the era of antibiotics most frequently used in the
treatment of infections. The need to develop new therapeutic strategies against multidrug resistant
microorganisms, such as the combination of selected antimicrobials, can be considered as a suitable
alternative. The in vitro activities of two groups of conventional antimicrobial agents alone and in
combination with silver nanoparticles (AgNPs) were investigated against a set of ten multidrug
resistant clinical isolate and two references strains by MIC assays and checkerboard testing, as well as
their cytotoxicity, which was evaluated on human fibroblasts by MTT assay at the same concentration
of the antimicrobial agents alone and in combination. Interesting results were achieved when the
AgNPs and their combinations were characterized by Dynamic Light Scattering (DLS), Zeta Potential,
Transmission Electron Microscopy (TEM), UV–visible spectroscopy and Fourier Transforms Infrared
(FTIR) spectroscopy. The in vitro activities of ampicillin, in combination with AgNPs, against the
12 microorganisms showed one Synergy, seven Partial Synergy and four Additive effects, while the
results with amikacin and AgNPs showed three Synergy, eight Partial Synergy and one Additive
effects. The cytotoxic effect at these concentrations presented a statistically significant decrease of
their cytotoxicity (p < 0.05). These results indicate that infections caused by multidrug resistant
microorganisms could be treated using a synergistic combination of antimicrobial drugs and AgNPs.
Further studies are necessary to evaluate the specific mechanisms of action, which could help predict
undesirable off-target interactions, suggest ways of regulating a drug’s activity, and identify novel
therapeutic agents in this health problem.
Keywords: antimicrobial activity; biofilm; urinary infection; silver nanoparticles; bacterial resistance
1. Introduction
Urinary tract infections (UTIs) are defined as inflammatory processes related to the invasion
and multiplication of microorganisms that occur at any level of the urinary tract, including urethral
(urethritis), bladder (cystitis), ureters (ureteritis) and kidney infections (pyelonephritis) [1].
Approximately between 150 and 250 million cases of UTIs occur each year worldwide [2]. In 2011,
more than 8 million cases were reported in the U.S. [1], of which 93,300 were acquired in intensive care
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units [3]. Recently, the epidemiological bulletin of the Ministry of Health reported in 2016 a total of
4,023,432 cases of UTIs in Mexico, of which 76.68% were in women and only 23.31% in men.
Gram-negative intestinal bacteria are the most common etiology agents of UTIs, where
uropathogenic Escherichia coli (UPEC) is the major microorganism isolate, which is a member of
the Enterobacteriacea family [4]. Other commonly associated pathogens include Klebsiella sp. and
Proteus mirabilis, both of which are characterized by their urease enzyme and Gram-positive bacteria
such as Staphylococcus saprophyticus and Enterococcus faecalis [5].
Urinary Tract Infections Associated with Catheters (CAUTI) are one of the most frequent
explanations of nosocomial infections [6]. Patients with urinary catheters show an increment of
bacteriuria in relation to duration of catheterization [7], however, the most important factor is
the biofilm formation along the catheter surface [7,8]. A biofilm is a resistance mechanism that
consists in a self-organized community of microorganisms embedded in a matrix of extracellular
polymeric substances synthesized by themselves [9]. Many bacterial species show growth in the
form of biofilms, which gives them various advantages [10]. Some of the benefits are metabolic
cooperation (nutrients) [11], horizontal gene transfer [12], protection against environmental stresses,
lower susceptibility to antimicrobial agents [13,14] and prevention of host defense mechanisms
(immune system) [15]. The most common organisms that contaminate the urinary catheter and
develop biofilms are strains of Escherichia coli, Pseudomonas aeruginosa, Enterococcus, Proteus mirabilis,
Klebsiella pneumoniae and coagulase-negative staphylococci [10,16].
The antibiotic resistance of bacteria is a global health problem that is continually expanding, and
is recognized as a medical problem that increases morbidity and mortality rates, which implies length
of hospital stays as well as cost and bad prognosis [17,18]. In fact, the speed at which bacteria are
establishing resistance to current antibiotics is faster than the development of new molecules with
antimicrobial features. Unfortunately, it is very difficult to identify new bacterial targets that can be
used to develop new classes of antimicrobial agents that are safe and effective.
In this context, nanotechnology opens new possibilities, allowing new solutions with old resources.
Nanoscale materials such as silver nanoparticles (AgNPs) have emerged as novel agents due to
their unique physicochemical properties and remarkable antimicrobial activities that confer a great
advantage for the development of alternative products against, for example, multi-drug resistant
microorganisms [19,20]. Due to the above, it has been proposed to implement the use of AgNPs on
different devices for medical use. One of the strategies is the modification of surfaces of the devices to
inhibit the formation of bacterial biofilms [21].
Recently, several studies have indicated that AgNPs can enhance the effect of antibiotics against
susceptible and resistant bacteria, [22] as a well as decrease bacterial adhesion in the early stages
of biofilm formation. In 2016, Rajendran and et al., impregnated urinary catheters with antibiotics
(amikacin and nitrofurantoin) and a synergistic combination of antibiotics and AgNPs (synthesized by
a biological method) in order to evaluate antibiofilm activity. The authors reported that the synergistic
combination showed a 90% inhibition of bacterial adhesion, whereas functionalization with antibiotics
showed only 25% inhibition [23].
Some authors have reported that AgNPs have toxic effects on mammalian cells; for example,
impairment of normal mitochondrial function, increased membrane permeability and generation of
reactive oxygen species [24,25].
In this study, the synergistic activity of AgNPs was evaluated with conventional antibiotics
against Gram-positive and Gram-negative multi-drug resistant isolates from clinical samples. Results
presented here show that AgNPs, in combination with antibiotics, increase the antimicrobial effect in
an additive or synergistic manner. Furthermore, MTT assays suggest that at low concentrations the
AgNPs and their combinations do not present cytotoxic effects in eukaryotic cells.
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2. Results and Discussion
2.1. Synthesis and Characterization of AgNPs
TEM micrograph revealed that the AgNPs were of spherical and pseudospherical shapes (Figure 1).
Based on the particle size distribution histogram evaluated from the corresponding TEM micrograph
(n = 100), the mean (±SD) size of AgNPs 8.57 ± 1.17 nm was calculated. The mean size for the
combination of AgNPs with ampicillin (AgNPs + AMP) was 4.01 ± 0.80 nm and for the combination
of AgNPs with amikacin (AgNPs + AMK) was 6.03 ± 0.87 nm (Table 1).
The particle size distributions of AgNPs + AMP and AgNPs + AMK were also evaluated in
Dulbecco’s Modified Eagle Medium (DMEM).
Figure 1. Morphological characterization of silver nanoparticles and their combinations with
antibiotics. Transmission electron micrographs showing the formation of spherical and pseudospherical
nanoparticles. (a) AgNPs; (a’) AgNPs in DMEM; (b) AgNPs + AMP; (b’) AgNPs + AMP in DMEM;
(c) AgNPs + AMK; (c’) AgNPs + AMK in DMEM. Insets: Particle size distribution histogram. DMEM:
Dulbecco’s Modified Eagle Medium. AMP: Ampicillin. AMK: Amikacin.
AgNPs synthesized in aqueous solution and their combinations with antibiotics were characterized by
DLS (Table 1). The results of the dialyzed AgNPs showed a narrow size distribution with a hydrodynamic
diameter of (±SD) 8.23 nm± 0.91 nm and a zeta potential value of−40.80 mV± 9.54 mV. The combination of
AgNPs + AMP also showed a narrow size distribution with a hydrodynamic diameter of 4.69 nm ± 0.51 nm.
This decrease in size was attributed to the fact that ampicillin favors the homogeneous dispersion of the
nanoparticles and gives it a greater stability when it obtains a zeta potential value of −51.00 mV ± 20.20 mV.
The results of combination of AgNPs + AMK showed a narrow distribution of sizes with a hydrodynamic
diameter of 947.90 nm ± 65.30 nm and a value of −21.10 mV ± 4.63 mV for zeta potential. The increase
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of size of the nanoparticles are attributed to the addition of amikacin, which favors agglomeration of the
AgNPs and causes an increase in the zeta potential, which translates in less stable nanoparticles.
The hydrodynamic diameters and zeta potentials of AgNPs and their combinations were also
evaluated in DMEM.
















AgNPs 8.23 ± 0.91 39.25 ± 6.42 −40.80 ± 9.54 −16.20 ± 0.0 8.57 ± 1.17 25.08 ± 2.74
AgNPs + AMP 4.69 ± 0.51 26.25 ± 5.55 −51.00 ± 20.20 −15.60 ± 0.0 4.01 ± 0.80 24.17 ± 16.29
AgNPs + AMK 947.90 ± 65.30 222.50 ± 47.10 −21.10 ± 4.63 −18.10 ± 7.56 6.03 ± 0.87 6.14 ± 0.99
Data are expressed as mean and standard deviation. DLS: Dynamic Light Scattering. TEM: Transmission Electron
Microscopy. DMEM: Dulbecco’s Modified Eagle Medium. AMP: Ampicillin. AMK: Amikacin.
The UV–visible spectrum revealed a peak at a wavelength of 412 nm for AgNPs whereas in the
combination AgNPs + AMP, the peak was observed at 410 nm and in the combination AgNPs + AMK,
the peak appeared at a wavelength of 450 nm (Figure 2). These peaks correspond to the excitation
of the surface plasmon of AgNPs. The plasmonic resonance depends on several parameters, like the
nature, size and geometry of the nanoparticles and the physical properties of the medium in which the
nanoparticles are dispersed. In the case of AgNPs, the plasmon peak appears at a wavelength around
400 nm [26].
Figure 2. UV–visible absorption spectra of silver nanoparticles and their combinations with antibiotics.
UV–visible spectrum showed the maximum absorbance at (a) 412 nm for AgNPs, (b) 410 nm for AgNPs
+ AMP and (c) 450 nm for AgNPs + AMK. AMP: Ampicillin. AMK: Amikacin.
In this study, gallic acid was used as a reducing and stabilizing agent, a molecule with a carboxylic
group and rich in hydroxyl functional groups. Yoosaf et al. proposed that AgNPs are stabilized by
gallic acid through electrostatic interactions through their oxidized carboxylic group and the afore-cited
hydroxyl groups were capable of forming hydrogen bonds [27].
To study the possible interactions between antibiotics and the surface of the AgNPs, FTIR was
performed (Figure 3). FTIR is useful for determining the chemical composition of antibiotics involved
in the coating of AgNPs. The observed intense bands were compared with standard values to identify
the functional groups. The FTIR spectra of the antibiotics (Figure 3a,b) changed greatly upon the
combination with AgNPs (AgNPs + AMP and AgNPs + AMK), as displayed in Figure 3a’,b’. Ampicillin
is a molecule that has carbonyl and amine functional groups, while amikacin is a molecule rich in
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hydroxyl and amine groups. In the case of ampicillin, the band at 1759 cm−1 disappeared completely
(Figure 3a’), which suggests that the antibiotic interacts with the AgNPs through its carbonyl group
(C=O). Furthermore, the peak of the primary amine at 3380 cm−1 (Figure 3a) shifted to 3130 cm−1
(Figure 3a’) after the combination with nanoparticles, indicating that the amine functional group was
involved in the interaction with the surface of the AgNPs. Therefore, the spectrum of the amikacin
showed that the bands at 1626 cm−1 corresponding to a carbonyl group and 3400 cm−1 for a primary
amine disappeared completely (Figure 3b’) after being combined with the nanoparticles. Those results
of the FTIR suggest that the functional groups of the antibiotics could be involved in the interaction
by hydrogen bonds with gallic acid [28,29]. The results showed in Figure 3 are in concordance with
the previous results of the Hua Deng et al., 2016, who carried out UV–Vis and Raman spectroscopy
studies reveal that amikacin can form complexes with AgNPs, while ampicillin do not [30]. The authors
reported that no Raman enhancement is observed when AgNPs are combined with ampicillin at any
test concentrations. This implies that the antibiotics do not strongly interact with AgNPs to replace the
stabilizer molecules on the surface of AgNPs. Moreover, they infer that the combinations of antibiotics
and AgNPs have different ways to develop antimicrobial activities.
Figure 3. FTIR spectra of the antibiotics and their combinations with silver nanoparticles. (a) AMP:
Ampicillin; (a’) AgNPs + AMP; (b) AMK: Amikacin; (b’) AgNPs + AMK. Insets: AMP and
AMK structure.
2.2. Samples and Bacterial Strains
The multidrug resistance clinical strains used for this experiment were isolated from the urine
of patients with CAUTI; microbiological analysis showed that the clinical pathogenic strains isolated
were in accordance with the main etiologic agents causing CAUTI; these results are in accordance
with previously results reported when the UTI were evaluated on hospitalized patients in Kolkata,
an eastern region of India, as well as in studies where complicate and non-complicate UTI were
studied [4,31].
2.3. Antimicrobial Test
A set of ten clinical pathogenic strains resistant to antibiotics associated with CAUTI were
evaluated, of which two corresponded to Gram-positive strains and the rest to Gram-negative strains.
The results showed that all clinical isolates (E. faecium, S. aureus, A. baumannii, E. cloacae, three different
isolates of E. coli, K. pneumoniae, M. morgannii and P. aeruginosa) showed a MIC to AgNPs between
4 and 16 μg/mL. The bacterial strains showed MIC values of 4–128 μg/mL for amikacin and all
Gram-negative strains were resistant to ampicillin.
2.4. Checkerboard Synergy
Table 2 shows the MIC archived with the ten multidrug resistance clinical strains grown in Mueller
Hinton Broth with amikacin and ampicillin, both in the absence of AgNPs and when present; when the
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bacteria were incubated with the combination of AgNPs and antibiotic (AgNPs + AMK and AgNPs
+ AMP), the ampicillin and amikacin MICs decreased drastically for all strains. The combination
of AgNPs + AMK reduce the MIC by 2 to 32-fold. By contrast, with the combination of AgNPs +
AMP reduce the MIC just with S. aureus and E. cloacae by 1- and 4-fold respectively; with the other
microorganisms, the MICs were reduced by 16- and 32-fold. These results show a better antimicrobial
activity of the combination of AgNPs + AMP, which could be explained by the interaction between
the AgNPs and ampicillin and, therefore, arrangement of the molecules in a new compound, which
could work in both ways, like independent chemical entities or a new compound; more experiments
are needed to explain the role and proportion of each one of them.







ChangeAgNPs AMK AgNPs + AMK * AMP AgNPs + AMP *
Gram-positive
Enterococcus faecium 8 128 4 32 128 8 16
Staphylococcus aureus 8 4 2 2 4 4 1
Gram-negative
Acinetobacter baumannii 16 128 4 32 128 8 16
Enterobacter cloacae 16 16 8 2 128 32 4
Escherichia coli (501) ** 8 64 4 16 128 8 16
Escherichia coli (508) ** 8 4 1 4 128 8 16
Escherichia coli (515) ** 8 32 8 4 128 8 16
Klebsiella pneumoniae 4 4 2 2 128 4 32
Morganella morganii 8 8 4 2 128 8 16
Pseudomonas aeruginosa 4 32 4 8 128 4 32
* Minimum Inhibitory Concentration (MIC) represents the concentration of antibiotic (amikacin or ampicillin)
present in the combination. AMK: Amikacin. AMP: Ampicillin. ** The numbers in parentheses indicate that E. coli
corresponds to a different clinical sample.
The synergistic effects of AgNPs and conventional antibiotics were evaluated by determination
of the Fractional Inhibitory Concentration (FIC) index (Figure 4). Synergistic interactions of AgNPs
and amikacin were observed against Acinetobacter baumannii, Escherichia coli (508) and E. coli (ATCC
25922). Synergistic interactions of AgNPs and ampicillin were found only against Acinetobacter
baumannii. Other combinational activities of AgNPs and antibiotics were considered as partially
synergistic interactions. These synergistic activities of AgNPs in combination with conventional
antibiotics suggest that it may be possible to reduce the viability of bacterial strains at lower antibiotic
concentrations (Table 3).
 
Figure 4. Example of checkerboard testing. Blue circles denote the MIC of antimicrobial agents (alone)
and blue line denote the FIC (combination of both). MIC: Minimum Inhibitory Concentration. FIC:
Fractional Inhibitory Concentration.
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AgNPs + AMK AgNPs + AMP
Gram-positive
Staphylococcus aureus (ATCC 25923) 1.06 (AD) 1.03 (AD)
Enterococcus faecium 0.53 (PS) 0.56 (PS)
Staphylococcus aureus 0.63 (PS) 1.25 (AD)
Gram-negative
Escherichia coli (ATCC 25922) 0.31 (S) 1.50 (AD)
Acinetobacter baumannii 0.28 (S) 0.31 (S)
Enterobacter cloacae 0.75 (PS) 1.25 (AD)
Escherichia coli (501) ** 0.56 (PS) 0.56 (PS)
Escherichia coli (508) ** 0.31 (S) 0.56 (PS)
Escherichia coli (515) ** 0.75 (PS) 0.56 (PS)
Klebsiella pneumoniae 0.75 (PS) 0.53 (PS)
Morganella morganii 0.75 (PS) 0.56 (PS)
Pseudomonas aeruginosa 0.63 (PS) 0.53 (PS)
FIC: Fractional Inhibitory Concentration. AMK: Amikacin. AMP: Ampicillin. ATCC: American Type Culture
Collection. The FIC index was interpreted as follows: FIC ≤ 0.5, Synergy (S); 0.5 ≤ FIC < 1, Partial Synergy (PS);
FIC = 1, Additive (AD); 2 ≤ FIC < 4, Indifferent (I); FIC > 4, Antagonism (AN) [32,33]. ** The numbers in parentheses
indicate that E. coli corresponds to a different clinical sample.
2.5. Cytotoxicity of AgNPs
The cytotoxicity of AgNPs and antibiotics was evaluated separately and in combination by
the MTT assay. AgNPs were tested at concentrations of 0.25, 1, 4, 16, 64 and 128 μg/mL in human
fibroblasts. The percentages of living and dead cells were determined after 24 h of being exposed
in contact with the AgNPs. AgNPs concentrations less than 4 μg/mL showed a cytotoxic effect that
resulted in a death rate of 13.8% or less. However, concentrations greater than 64 μg/mL caused
significant cell death of approximately 67%. In addition, antibiotics (ampicillin and amikacin) were
tested at concentrations of 64, 32, 8, 2, 0.5 and 0.125 μg/mL in human fibroblasts. It was found that the
viability percentage for each of the concentrations of ampicillin was greater than 80% and for amikacin
greater than 76%. To evaluate the cytotoxic effects of the combination of AgNPs and conventional
antibiotics, ten combinations of different concentrations (AgNPs μg/mL + antibiotic μg/mL: 128 + 64;
64 + 32; 32 + 16; etc.) were tested. It was found that there is no statistically significant difference
between the two treatments (AgNPs + AMP and AgNPs + AMK) with respect to cell viability when
the two-way ANOVA was performed (p < 0.05). However, combinations of 128 μgAgNPs/mL + 64 μg
of antibiotic/mL and 64 μgAgNPs/mL + 32 μg of antibiotic/mL caused a statistically significant
decrease in cell viability when compared with the rest of the combinations tested (p < 0.05) evidenced
by the reduction of the mitochondrial activity. On the other hand, it is important to highlight that
when AgNPs were combined with antibiotics, at concentrations equal to or less than 8 μg AgNPs/mL
showed a viability percentage between 90–95% (Figure 5).
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Figure 5. Viability of cells treated with combinations of silver nanoparticles and antibiotics. To measure
cytotoxicity, fibroblasts were treated with increasing concentrations of AgNPs + AMP (red) or AgNPs +
AMK (blue) (n = 3). Twenty-four hours after of addition of treatment cell viability was determined
using MTT. Results are expressed as mean and standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001
by two-way ANOVA. Control: DMEM. AB: Antibiotic = Amikacin (AMK) or Ampicillin (AMP).
Interesting results were archived when two specific multi-resistant strains, E. faecium with
resistance to vancomycin and A. baumannii with resistance to meropenem, were tested and both
showed, with the combination of AgNPs + AMK, a reduction of the MIC by 32-fold, as well as with
the combination of AgNPs + AMP of the MIC by 16-fold. In both cases, the cytotoxicity to fibroblasts,
of the concentrations of AgNPs + Antibiotic which showed a reduction of MIC, showed a reduction
with statistical significance (Table 4).
Table 4. Viability of fibroblasts treated with silver nanoparticles, antibiotics and their combinations
using concentrations corresponding to the MIC value.
Clinical Strains
Viability of Fibroblasts (%)
AgNPs AMK AgNPs + AMK AMP AgNPs + AMP
E. faecium >80 ≈55 >90 >90 85–95
A. baumannii 72 ≈55 >90 >90 85–95
MIC: Minimum Inhibitory Concentration. AMK: Amikacin. AMP: Ampicillin.
3. Materials and Methods
3.1. Synthesis of AgNPs
For the synthesis of nanoparticles, AgNO3 (0.01 M) was used as a metallic precursor and gallic
acid (0.1 g) was used as a reducer and stabilizer agent. NaOH (3 M) was used for pH regulation.
AgNPs were synthesized by dissolving 0.0169 g of AgNO3 in 90 mL of deionized water and this
solution was placed in a 250 mL reaction vessel. A total of 0.01 g gallic acid was dissolved in 10 mL of
deionized water and was added to the AgNO3 solution with magnetic stirring. After the addition of
gallic acid, the pH value of the solution was adjusted using a solution of NaOH 3 M. At the end of the
synthesis, approximately 100 mL of nanoparticles were obtained with a pH of 12.66, of which 50 mL
were dialyzed for 48 h on a 12 kDa nitrocellulose membrane.
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3.2. Characterization of AgNPs
AgNPs were characterized by Dynamic Light Scattering (DLS), the hydrodynamic diameter and
zeta potential were determined using a Malvern Zetasizer Nano ZS (Malvern Panalytical, Malvern,
United Kingdom) operating with a He-Ne laser at a wavelength of 633 nm and a detection angle
of 90◦. Samples were analyzed for 60 s at 25 ◦C. To confirm the shape, each sample was diluted
with deionized water and 50 μL of each suspension was placed on a copper wire for Transmission
Electron Microscopy (TEM). All samples were analyzed by Transmission Electron Microscopy (JEOL
JEM-1230, Tokyo, Japan) at an acceleration voltage of 100 kV. Afterwards, AgNPs were characterized by
UV-visible spectroscopy using an S2000 UV-Vis spectrophotometer from OceanOptics Inc. (Dunedin,
FL, USA). The functional groups present in the antibiotics were identified by Fourier Transform Infrared
Spectroscopy (Shimadzu, IRaffinity-1, Osaka, Japan). A certain amount of nanopowder was collocated
in the equipment and the spectrum was taken in the range of 400–4000 cm−1 with a resolution of
2 cm−1 and 200 times scanning using the attenuated total reflection (ATR) method.
3.3. Preparation and Characterization of Combinations of AgNPs with Antibiotics
To study the effect of ampicillin and amikacin on the size, shape and stability of the
AgNPs, an aqueous solution containing a 1:1 ratio of antibiotic (128 μg/mL) and nanoparticles
(128 μg/mL) was prepared for each antibiotic. These solutions were characterized by TEM, DLS,
zeta potential and UV-visible spectroscopy. On the other hand, the chemical interaction between
the AgNPs and antibiotics was carried out by FTIR, we prepared an aqueous solution containing
higher concentrations of antimicrobials (500 μg/mL), the combinations preserved the ratio of 1:1.
Subsequently, these solutions were centrifuged, keeping only the precipitate, which was left to dry for
24 h at room temperature.
3.4. Patients
The study protocol and the letter of informed consent were approved by the local Hospital’s
Ethics and Science Committee with the number 102-16.
The study included urine samples from patients with urinary catheters treated at the local Hospital.
Patients were selected in basis to NOM-045-SSA2-2005. For the purposes of this study, only samples of
patients older than 15 years, of any genus, whose culture had a bacterial count greater than or equal to
50,000 CFU/mL were selected, and also with an antimicrobial resistance profile.
3.5. Microbiological Analysis
3.5.1. Sample Collection and Bacterial Culture
Urine samples were collected in 5 mL syringes using the probe puncture technique under aseptic
conditions by trained personnel. Microbiological analysis was performed according to the established
criteria by the American Society for Microbiology (ASM) for urine samples. A count greater than or
equal to 50 colonies (equivalent to 50,000 CFU/mL) was considered as the cutoff point for diagnosing
infection. Plaques without development at 24-h incubation were discarded and indicated absence of
urinary tract infection.
3.5.2. Identification and Antimicrobial Susceptibility Profile of Clinical Strains
The identification and antimicrobial susceptibility of the microorganisms isolated were
determined by VITEK2 equipment. From a pure culture grown for 24 h, an inoculum was transferred
to a test tube with 3 mL of solution sterile saline (0.45% to 0.5% NaCl aqueous solution, pH 4.5
to 7.0). Subsequently, the turbidity was adjusted to 0.50–0.63 units of the McFarland scale with
the densitometer. The bacterial suspension was placed inside the cassette. The identification and
susceptibility cards were placed in the nearby slot, inserting the transfer tube into the test tube with
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the corresponding suspension. The cassette was placed with the samples in the VITEK2 system.
The resistance profiles are shown in Table S1.
3.5.3. Conservation of Strains
The conservation of the strains was carried out by the freeze conservation method. Glycerol was
used as the cryoprotective agent. The samples were stored at −20 ◦C.
3.6. Antimicrobial Test
The Minimum Inhibitory Concentration (MIC) was determined by broth microdilution assay in
accordance with the procedures recommended by the Clinical and Laboratory Standards Institute
(CLSI) [34]. MICs were determined by incubating the microorganisms in 96-well microplates for 24 h at
37 ◦C. Microorganisms were exposed to serial dilutions of the antimicrobial agent (AgNPs, ampicillin
and amikacin), and the end points were determined when no turbidity in the well was observed.
The standardization of the method was made based on the criteria established by the CLSI. The strains
used were Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922. The antibiotics used
were oxacillin (64 μg/mL) and ceftazidime (32 μg/mL). The assay was performed in duplicate for four
days. The results of the standardization of the MIC are shown in Table S2.
3.7. Checkerboard Synergy
The MIC of each antimicrobial substance alone or in combination was determined by a broth
microdilution method in accordance with CLSI standards. The assay was performed in 96-well
microtiter plates, a two-fold dilution of the antibiotic was distributed into each well to obtain a
varying concentration of 128, 64, 32, 16, 8, 4, 2, 1, 05, 0.25 and 0.125 μg/mL in the wells of the
first row, while those of the AgNPs were similarly distributed among the first column (128 to
1 μg/mL). The AgNPs dilutions were started from the columns to the right and the antibiotic dilutions
were started from the first row downwards. Thus, each of the wells held a unique combination of
concentrations of AgNPs and the antibiotic. The broth microdilution plates were inoculated with each
test microorganism to yield the appropriate density (105 CFU/mL) in 100 μL Mueller–Hinton broth
and incubated at the optimum temperature and time of growth conditions (37 ◦C/24 h). The MIC was
determined as the least dilution without any turbidity. The MICs of single antimicrobial A and B (MICA
and MICB) and in combination were determined. The ten multidrug resistant clinical strains were
exposed to serial dilutions of the antimicrobial agents. Subsequently, we calculated the proportion:
MICAntibiotic alone/MICAntibiotic in combination (fold-change) to describe the number of times that MIC
decreased from an initial to final value.
3.8. Cytotoxicity of AgNPs
To evaluate the toxicity of AgNPs in combination with antibiotics, human fibroblasts (baby
foreskin) were used. Cells were dispensed in 96-well microplates at a density of 5000 cells per well in
DMEM supplemented with 1% fetal bovine serum (FBS) for 24 h at 37 ◦C. After 24 h the cells were
incubated with the established concentrations of AgNPs and antibiotics for 24 h at 37 ◦C. Treatment
was withdrawn and 100 μL MTT (3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(0.5 mg/mL) was added in DMEM without FBS for 4 h at 37 ◦C for the formation of formazan crystals.
MTT was removed from the wells and 100 μL of DMSO was added to read absorbance in a Synergy
H1 microplate reader with Gen 5 software (Biotek Instruments, Winooski, VT, USA) at a wavelength of
595 nm. As a positive control, cells were treated with hydrogen peroxide and as a negative control,
they were only treated with medium. The assay was performed in triplicate.
64
Antibiotics 2018, 7, 50
3.9. Statistical Analysis
Each assay was repeated three times. Data are presented as mean ± standard deviation (SD).
The comparison between the effects of the two sources of variation was made using the two-way
analysis of variance (ANOVA). The analysis was performed with the statistical software SPSS 23.0
(IBM, New York, NY, USA). A value of p < 0.05 was considered significant.
4. Conclusions
These results indicate that infections due to multidrug resistant microorganisms could be treated
by the use of a synergistic combination of antimicrobial drugs and AgNPs. Further studies are
necessary to evaluate the specific mechanisms of action, which could help predict undesirable off-target
interactions, suggest ways of regulating a drug’s activity, and identify novel therapeutics to this
health problem.
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Table S1: Resistance profile of the set of clinical strains, Table S2: Standardization of the method MIC.
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Appendix FIC Calculation
One strategy used to overcome the resistance mechanism of the microorganisms is the use of
the combination of drugs. The way to measure their effectiveness is through the calculation of the
Fractional Inhibitory Concentration (FIC) index.
The FIC index was calculated as follows:
FIC of AgNPs = MICAgNPs in combination/MICAgNPs alone
FIC of Antibiotic = MICAntibiotic in combination/MICAntibiotic alone
FIC index = FIC of AgNPs + FIC of Antibiotic
The FIC index was interpreted as follows: FIC < 0.5, Synergy (S); 0.5 ≤ FIC <1, Partial Synergy
(PS); FIC = 1, Additive (AD); 2 ≤ FIC < 4, Indifferent (I); FIC > 4, Antagonism (AN).
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Abstract: Elevated levels of silver in the environment are anticipated with an increase in silver
nanoparticle (AgNP) production and use in consumer products. To potentially reduce the burden of
silver ion release from conventional solid core AgNPs, a lignin-core particle doped with silver ions
and surface-stabilized with a polycationic electrolyte layer was engineered. Our objective was to
determine whether any of the formulation components elicit toxicological responses using embryonic
zebrafish. Ionic silver and free surface stabilizer were the most toxic constituents, although when
associated separately or together with the lignin core particles, the toxicity of the formulations
decreased significantly. The overall toxicity of lignin formulations containing silver was similar to
other studies on a silver mass basis, and led to a significantly higher prevalence of uninflated swim
bladder and yolk sac edema. Comparative analysis of dialyzed samples which had leached their
loosely bound Ag+, showed a significant increase in mortality immediately after dialysis, in addition
to eliciting significant increases in types of sublethal responses relative to the freshly prepared
non-dialyzed samples. ICP-OES/MS analysis indicated that silver ion release from the particle into
solution was continuous, and the rate of release differed when the surface stabilizer was not present.
Overall, our study indicates that the lignin core is an effective alternative to conventional solid core
AgNPs for potentially reducing the burden of silver released into the environment from a variety of
consumer products.
Keywords: nanotechnology; environmentally-friendly; pesticide; antimicrobial; zebrafish
1. Introduction
Silver nanoparticles (AgNPs) are an effective antimicrobial agent and the most widely
commercialized engineered nanomaterial, incorporated into half of all reported consumer and medical
products in the Nanotechnology Consumer Products Inventory [1]. Prominent examples include
cosmetics, clothing, shoes, detergents, water filters, phones, laptops, and toys [2–4]. AgNP use has
risen steadily in the past decade (~52 new consumer products per year), and global production is
estimated based on surveys of European producers to be between 12–1216 tons per year by 2020,
assuming the number of products on the market continues to increase at the current rate [5,6]. With the
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increasing production and use of AgNPs, the fate and the subsequent release of silver in nanomaterial
and ionic form into the environment are of concern.
Research indicates that AgNPs can enter aqueous environments from discharges at the
point of production, by erosion from household products, and from disposal of silver-containing
products [7–11]. These studies have prompted the investigation of AgNP interactions in the
environment [12], particularly aquatic systems, to determine which general intrinsic and extrinsic
properties are important in determining fate [9,13–15]. Extrinsic properties include environmental
factors and processes that can impact the fate of the particles in aquatic systems, such as pH,
temperature, ionic strength of the water, and natural organic matter, as well as processes like
sedimentation, deposition, dissolution, agglomeration, and/or particle sulfidation [16–19]. Intrinsic
factors address inherent particle characteristics, such as size, shape, chemical composition, surface
structure, and surface charge [12,20–23]. Extrinsic factors can interact with intrinsic features
of nanoparticles to alter particle behavior with concomitant effects on properties, such as the
bioavailability of AgNPs to living organisms; thus, a more comprehensive understanding is
needed [13,24].
AgNPs are known to be toxic to many aquatic organisms, including algae, bacteria, invertebrates,
and fish [2]. Several mechanisms of action have been proposed, mainly attributing the toxicity of
AgNPs to silver ions released from the nanoparticle. However, nanoparticle-specific mechanisms
are also being investigated, with data suggesting that mechanistic differences exist compared to
dissolved silver [5,25]. Silver ion specific mechanisms include interactions with thiols and electron
donor groups, which can impact enzymes and DNA, which makes them unavailable for cellular
processes [26–28], denaturing of DNA and RNA, which ultimately affects protein synthesis [29,30],
and production of superoxide radicals and other reactive oxygen species via reactions with oxygen [29].
Particle-specific mechanisms have been suggested that focus on the ability of AgNPs to cause cell
membrane damage, leading to disruption in the ion efflux system in cells [31,32], as well as by
intracellular ion release elicited by the acidic conditions of the lysosomal cellular compartment where
particles are internalized (Trojan horse effect) [33]. Since multiple aquatic organisms may be at risk
due to an increased prevalence of silver in the environment, it is important to consider ways to reduce
the environmental silver burden related to AgNP production and use.
By applying the principles of green chemistry during nanomaterial design and synthesis,
harmful effects to the environment can be limited while maintaining the desired antimicrobial
activity [34]. In order to reduce silver ion release into the environment, a silver-doped lignin
nanoparticle was engineered, which is anticipated to have lower environmental impacts upon release
into the environment [35]. During the synthesis of these particles, we replaced the silver core with
lignin, which was chosen as it is a natural biodegradable biopolymer [36]. Similar synthesized lignin
nanoparticles have been shown to have no impact on algae and yeast survival, suggesting they have
a high level of biocompatibility [37]. The lignin is easily precipitated into nanosized particles using
environmentally-friendly solvents, and the resulting nanoparticles can be infused with up to ten times
lower (Ag+) than silver core nanoparticles, and still maintain the same antimicrobial efficacy [35]. The
particles are then surface-functionalized with a polycationic electrolyte layer to stabilize the particle,
as well as to provide additional antimicrobial impact. The lignin nanoparticles exhibit both high and
low affinity binding regions for silver ions, and these differing affinities, as well as the electrostatic
barrier provided by the surface stabilizer, impact the rate of silver ion release to the surrounding
solution [35,36]. It is expected that the low affinity binding sites will primarily release the majority of
the weakly bound silver in the first 24 h [35]; however, we also wanted to investigate the long-term
release from the high affinity binding sites, so two of the formulated samples were dialyzed to remove
the weakly bound silver. When compared to their non-dialyzed counterparts, this allowed us to
determine whether there are any differences in toxicological responses after the release of the loosely
bound silver ions to quantify the potential environmental risks of these particles.
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Our aim was to elucidate which aspects of the formulation contribute most to the toxicity of
the formulation, and to discover whether these nanoparticles exhibit any toxicity after dialysis,
which intended to simulate post-consumer use. We hypothesized that (1) released silver ions from
the lignin particle and the surface stabilizer are the main contributors to the aquatic toxicity of these
nanoparticles; and (2) once the particles have been dialyzed to remove the ionic silver from the
low affinity lignin-binding sites, there would be a reduction in toxicity of the formulated particles.
To test these hypotheses, we utilized the embryonic zebrafish assay, which is a widely-used model
for toxicity testing as it provides a suite of developmental endpoints that are critical to the survival of
the organism [38,39]. Zebrafish also develop quickly and are optically transparent, which allows for
easy observations of phenotypic responses [38]. Additionally, they share similar homology to humans,
so observed effects of chemical stressors from this assay can potentially be extrapolated to human
physiological responses [40].
2. Materials and Methods
2.1. Materials and Characterization
Reference component solutions of silver nitrate (AgNO3) salt (CAS# 7761-88-8,
Fisher Scientific, Hampton, NH, USA) at 50 mg/L of Ag+ dissolved in ultrapure water and
poly (diallyldimethylammonium chloride) (PDAC, MW 100,000–200,000, CAS# 26062-79-3,
Sigma Aldrich, St. Louis, MO, USA) at 200 mg/L in ultrapure water were prepared and refrigerated
at 4 ◦C until use. The lignin (Indulin AT) for the nanoparticle core was extracted from biomass
as a by-product of kraft pulping processes [36,41]. The Indulin AT lignin powder (lot MB05) and
supporting documentation were obtained from MeadWestVaco, SC. The size range of the particles
after synthesis with the pH-drop flash precipitation method (Figure S1c) was 84 ± 5 nm in ultrapure
water [35]. PDAC was chosen to provide a cationic surface charge to the particles, such that they would
be attracted to the negatively charged bacterial cell membranes. Stock nanomaterial suspensions
of the lignin nanoparticle (NP), the silver functionalized lignin nanoparticle (NP + Ag), the silver
functionalized particle with the cationic PDAC surface (NP + Ag + PDAC), and the lignin nanoparticle
with PDAC alone (NP + PDAC) were prepared as previously described, and tested for antimicrobial
efficacy, as is reported in previous publications [35,36]. Stock concentrations of each component
were as follows: 500 mg/L lignin nanoparticle, 5 mg/L Ag+, and 200 mg/L PDAC. All stock
materials were stored in distilled water at 4 ◦C until use. Seven-fold dilutions of stock nanomaterial
suspensions were performed with fishwater to prepare the varied exposure solutions. Fishwater was
prepared by dissolving 260 mg/L Instant Ocean salts (Aquatic Ecosystems, Apopka, FL, USA) in
reverse osmosis water and adjusting pH to 7.2 ± 0.2 using ~0.1 g sodium bicarbonate (conductivity
480–600 μS/cm) [39]. Experimental materials were stored under the same conditions as the reference
materials. The NP + Ag and NP + PDAC formulations were solely used for comparative purposes,
whereas the NP + Ag + PDAC is the proposed complete product formulation.
The samples to be dialyzed (NP + Ag and NP + Ag + PDAC) were placed in deionized water for
24 h which included a Slide-A-Lyzer MINI Dialysis Device (Thermo Scientific, Waltham, MA, USA)
with a 10 K molecular weight cutoff membrane to remove dissolved silver from solution prior to
dilution and testing. A second sample of NP + Ag was also dialyzed and allowed to age for 5 months
prior to testing. Thus, the dialyzed samples included NP + Ag Aged, NP + Ag Fresh, and NP + Ag
+ PDAC Fresh, with the “Fresh” and “Aged” designations referring to when the sample was tested
relative to when it was dialyzed.
The hydrodynamic diameter (HDD) and the zeta potential of each formulation that contained
particles were measured in triplicate using a Zetasizer Nano ZS (Malvern Instruments Ltd.,
Worcestershire, UK) at 26.8 ◦C after dilution with fishwater to 50 mg/L. Aliquots (1 mL) were stored
in an incubator under the same conditions as the embryonic zebrafish, until ready for analysis.
Measurements were made over a five-day period, which also included an initial measurement (Day 0)
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which correlates with the exposure time of the experiment. Metadata associated with the zeta potential
measurements can be found in Table S1.
2.2. Embryonic Zebrafish Assay
Exposure solutions of reference and nanomaterial suspensions were dispensed into 96-well plates,
with each row having 12 wells of a given concentration of test material. Each well was filled with 200 μL
of test solution and one of the eight rows on the plate was reserved for fishwater alone as a control.
Adult zebrafish (Danio rerio) were maintained at the Sinnhuber Aquatic Research Laboratory (SARL)
at Oregon State University, Corvallis, OR, USA. Embryos received from SARL were approximately
6–8 h post-fertilization (hpf) and were inspected under a dissecting microscope to ensure viability and
developmental stage, then placed individually into wells of a 96-well plate. The chorionic membrane
surrounding the zebrafish was preserved. Two replicate exposures were conducted over two weeks for
each material, which allowed us to have a total sample size of 24 fish per concentration, per material.
After plating, the exposure wells were covered with Parafilm to reduce evaporation, and embryos
were incubated at 26.8 ◦C under a 14:10 light/dark photoperiod.
2.3. Toxicological Evaluations of Embryonic Zebrafish
Fish were observed at 24 hpf and 120 hpf for mortality, as well as a suite of developmental,
morphological, and physiological abnormalities. At 24 hpf, embryos were evaluated for
mortality, presence of spontaneous movement, delayed developmental progression, and notochord
malformations. At 120 hpf, mortality was evaluated in conjunction with malformations of the snout,
brain, pectoral and caudal fin, eye, jaw, otic structures, axis, trunk, somites, swim bladder, and body
pigmentation. In addition, physiological and behavioral endpoints evaluated at 120 hpf include
the presence of pericardial or yolk sac edema, impaired circulation and active touch response [39].
Hatching success was measured between 48 and 120 hpf, with embryos that hatched between 48 and 72
hpf being considered normal, and any individuals hatching after 72 hpf were considered delayed [42].
All endpoints were reported as either absent or present. Representative images of control fish and
any individuals that displayed developmental abnormalities at 24 and 120 hpf were taken with
an Olympus SZX10 microscope (Tokyo, Japan) fitted with an Olympus SC100 high resolution digital
color camera (Olympus Corporation, Center Valley, PA, USA), and representative images are included
in the Supplementary Materials (Figure S1). All experiments were performed in compliance with
national care and use guidelines, and approved by the Institutional Animal Care and Use Committee
(IACUC) at Oregon State University (ACUP #4764).
2.4. Measurement of Dissolved Silver and Particle-Associated Silver
Both the concentration of dissolved silver released from the nanoparticles and the silver
associated with the particle itself were quantified by inductively coupled plasma-optical emission
spectroscopy or mass spectrometry (ICP-OES or ICP-MS). To quantify silver content in solution,
acid digestion of particles was performed using established methods [18,43]. Triplicate 0.5 mL
samples of stock suspensions were centrifuged at 13,000× g for 10 min in a 3 kDa centrifugal filter
(VWR, Radnor, PA, USA) with a polyethersulfone (PES) membrane, to separate the lignin particles
from the filtrate. A total of 0.45 mL of filtrate sample was collected, diluted 10-fold with ultrapure
water, and adjusted with 70% trace-metal grade HNO3 to a final concentration of 3% HNO3. For the
lignin particle digestion, 0.1 mL of stock solution was digested in the same manner as the filtrate
samples, without the centrifugation step. All samples were digested in Teflon tubes at 200 ◦C with
3 mL 70% trace-metal grade HNO3. The acid was allowed to completely evaporate, and the process
was repeated three times. Final digested samples were dissolved in 5 mL of 3% HNO3 prior to
ICP-OES/MS analysis. The silver ICP standard was purchased from RICCA Chemical Company
(Ricca Chemical Company, Arlington, TX, USA) and diluted to six concentrations spanning the
expected concentrations. All samples, including standards, were analyzed in triplicate with ICP-OES
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(Teledyne Leeman Labs, Hudson, NH, USA) for silver content, except the filtrate from the NP + Ag
+ PDAC sample, which was analyzed by ICP-MS (Thermo-Fisher, Waltham, MA, USA) to provide
a lower level of detection (≥5 μg/L).
2.5. Statistical Analyses
All statistical analyses were conducted with SigmaPlot version 13.0 (Systat Software, San Jose,
CA, USA), unless otherwise noted, and all differences were considered significant at p ≤ 0.05.
For measurements of zeta potential and HDD, significant differences were determined with repeated
measures analysis of variance (ANOVA) and Tukey’s post hoc analysis. Two-way ANOVA was
conducted to ensure that there was no significant difference in mortality between replicate exposure
plates prior to pooling of the data. Concentration–response curves were generated with the
Environmental Protection Agency’s Toxicity Relationship Analysis Program (EPA TRAP v. 1.30,
March 2015). EPA TRAP was also used to calculate the concentration at which fifty percent of exposed
zebrafish perished (LC50) for each material, and the Litchfield/Wilcoxon formula was utilized for LC50
comparisons between treatments [44]. Significant sublethal endpoints were determined by Fisher’s
Exact Test, by comparing the control (fishwater alone) response to each concentration response tested.
To determine whether there were significant differences in the concentration of silver associated with
the particle versus the filtrate in the ICP analysis, a paired t-test was utilized.
3. Results and Discussion
3.1. Particle Characterization
Average zeta potential and HDD for the formulated particles in fishwater were measured over
a five-day period. As expected, the zeta potential of the formulated particles varied with the presence
of the surface stabilizer with the lignin NP alone, and the NP + Ag, both having negative zeta potentials
in fishwater (−24.6 and −29.0 mV, respectively), while the particles with the cationic surface stabilizer
had positive zeta potentials with and without silver ions present (28.1 and 25.5 mV respectively.
Over the five day incubation in fishwater, only relatively minor changes in particle zeta potential were
identified (Figure S2a). Zeta potentials for the dialyzed particles in fishwater were similarly consistent
over time, and correlated well with their non-dialyzed counterparts (Figure S2b).
The initial HDD of the various particle formulations in fishwater were similar to the 84 nm
primary particle size ranging from 80 to 95 nm, depending on the particle type (Figure S2c). Most of
the formulated particles had consistent HDDs over time, however, the NP + Ag sample had the
largest increase in size, reaching 124 nm by the end of the five day incubation. The dialyzed NP + Ag
samples (both freshly dialyzed and aged dialyzed samples) had much more consistent HDD than the
non-dialyzed counterparts (Figure S2d). These data suggest that the rapid loss of silver ions from the
non-dialyzed components to the solution can lead to some particle swelling, however, the surface
stabilizer effectively stabilized the particles from agglomeration.
3.2. Analysis of Dissolved Silver and Particle-Associated Silver
The concentration of silver in solution and the silver associated with the particles was quantified
for the five nanoparticle samples that included silver. Figure 1 shows the concentration of silver
present in the particle and in the solution which, when combined, matches the nominal concentration
provided for each material. In all cases, the silver associated with the particle was greater than
the silver present in solution (1.62 to 132 times greater. The full formulation (NP + Ag + PDAC)
contains approximately 11 times more silver associated with the particle than the dialyzed full
formulation (NP + Ag + PDAC Fresh). Additionally, the age of the NP + Ag sample played a role in
silver distribution, as the older formulation contained approximately 10 times more silver in the filtrate
than the particle.
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Figure 1. Concentration of silver associated with the filtrate and the particle as determined by ICP
analysis. “Fresh” and “Aged” designations relate to the amount of time since the samples were
dialyzed. All samples were analyzed via ICP-OES, except for the filtrate in the NP + Ag + PDAC
sample, which was analyzed with ICP-MS.
Previous analyses of similar particles by Richter and colleagues [35] found that the concentration
of silver associated with the particle after dialysis was approximately 18%; however, in this study,
we found much higher concentrations associated with the particle (61.7–99.2%). This may have been
due to variance between batches of the lignin nanoparticle stock solutions, as well as the differences in
digestion techniques. Although the dialysis process is effective at releasing the loosely bound silver
from the particles, the electrostatic barrier in the samples that contained PDAC may have impacted
the rate at which silver was released. The full formulation had the lowest release of dissolved silver,
although there was significantly more silver released from the freshly dialyzed full formulation sample,
suggesting that PDAC may retard the release of ionic silver by repulsive electrostatic interactions.
Additionally, through previous characterization of the lignin particle functional groups by Richter
and colleagues [35,36], there is a higher proportion of organically-bound sulfur compared to other
lignin types (nine times that of high-purity lignin), which would likely provide strong binding sites for
dissolved silver [45].
3.3. Comparative Analysis of Formulation Toxicity
No significant differences were found between replicate exposure plates; therefore, replicates
were pooled to increase the sample size to 24 fish per concentration, per material. To encompass all
possible comparisons, but for clarity in interpreting the data, two groupings were made, which parallel
our hypotheses. These two groupings are formulation comparisons and dialyzed sample comparisons.
Concentration-response curves for the two groupings are illustrated in the SI (Figure S3). Additionally,
a modeled concentration-response curve was generated for the reference material silver nitrate, which is
included in the SI (Figure S4).
3.3.1. Formulation Components
As represented in Figure 2a, the lignin core nanoparticle (NP) itself was the least toxic component
(LC50 = 323 mg/L), and when the NP was combined with the other aspects of the formulation,
LC50 values decreased significantly in all cases (NP + Ag LC50 = 164 mg/L, NP + PDAC LC50 = 33 mg/L,
NP + Ag + PDAC LC50 = 32 mg/L). The presence of silver in the full formulation (NP + Ag + PDAC)
did not change the overall toxicity relative to NP + PDAC. Additionally, when PDAC was present
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in the formulation (NP + PDAC or NP + Ag + PDAC), a significant increase in mortality events
occurred. PDAC and Ag+ alone were the two most toxic constituents, with LC50′s of 5.39 mg/L and
1.53 mg/L, respectively.
Figure 2. LC50′s for nanoparticles and components (a) and dialyzed samples (b) with standard error
of two experimental replicates with 12 embryos exposed at each concentration in each replicate test
(24 embryos per concentration total). Significant differences between LC50 values are indicated with
a change in letter above the bar.
The estimated LC50 for Ag+ is greater than many published literature values for zebrafish [46–50],
however, exposure time and conditions differ in these studies, which may explain the observed
differences in toxicity. Our zebrafish embryos were exposed at 8 hpf with the chorion intact, whereas
some of the referenced studies did not expose the fish until after hatching, or even as adults.
Th chorionic membrane can modulate silver toxicity by sequestering ions to prevent them from entering
the perivitelline fluid [51], and removing the chorion has been shown to increase toxic responses [40,51].
It is likely that the presence of the chorion may have played a large role in modulating silver toxicity,
but the exposure media may have also played a role as well.
The hardness of our prepared fishwater may have altered the toxicity of silver nitrate, as well
as nanoparticle-containing formulations to the embryonic zebrafish. Based on dissolved magnesium
and calcium concentrations, our fishwater is categorized as soft water (<60 mg/L CaCO3), whereas
many of the above studies utilize moderately hard to hard water when exposing their zebrafish
(up to 148 mg/L CaCO3). It has been reported that LC50′s tend to be higher in the presence of dissolved
organic matter, which has the greatest effect on silver toxicity, followed by Cl−, Na+, and Ca2+ [52].
This is based on the coalescence effect, which leads to complexation and/or formation of nanoparticle
agglomerates and/or aggregates, which can decrease apparent toxicity by minimizing particle uptake
by the organism [53]. As our fishwater was categorized as soft water (low concentrations of Na+ and
Ca2+), we then determined the concentration of chloride ions present, as silver ion bioavailability can
be impacted due to complexation and subsequent precipitation of silver chloride [24,47].
In the Instant Ocean salt formulation used to make the fishwater, the majority of the cations are
paired with chloride, and we determined the chloride concentration in our fishwater to be 142 mg/L,
which is approximately 55% of the dissolved ion content. It is possible that when the fishwater was
used to dilute the silver-containing treatments, the silver complexed with the chloride and precipitated
out of solution, which may have led to a greater LC50 value. To determine whether precipitation
was a significant factor, we utilized Visual MINTEQ (v.3.1) for each silver-containing formulation.
We used the filtrate concentrations from the ICP data for each of the formulations that contained silver,
and determined that nearly all of the dissolved silver (98.2–99.8%) would complex with the chloride
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present in the fishwater to form a precipitate of silver chloride, except the NP + Ag + PDAC sample,
as the concentration of Ag+ in solution was very low. However, as the exposures occurred over a five
day period, and the movement of silver from the particle to the surrounding solution is a dynamic
process, dissolved silver could have still been bioavailable to the zebrafish.
Considering our nanoparticle and silver combination formulations, comparisons to published
LC50 values for conventional silver core AgNPs differ significantly. Reported AgNP LC50′s for fish
generally range between 0.05 and 20 mg/L [2,54]. Variations in reported LC50 values may relate
to differences in the type of exposure, exposure time, age of the fish, the presence of the chorionic
membrane, the use of bare or coated nanoparticles, and/or differences in exposure media. A study
completed by Bar-Ilan and colleagues [55] matched our exposure conditions most consistently, and had
reported LC50′s within the range above, although the LC50′s differed from our findings. They exposed
embryonic zebrafish to different sizes of colloidal AgNPs (3–100 nm), and found a range of LC50′s,
from 10.1 to 14.7 mg/L. Although the sizes of the particles, length and timing of the exposure, and
retention of the chorionic membrane is consistent with our experiment, our LC50′s were an order of
magnitude less toxic based on total particle mass (for example, the measured LC50 for the NP + Ag
formulation was 164 mg/L). Thus, the silver doped lignin nanoparticles have a lower mass-based
toxicity than solid core AgNPs, while maintaining a similar antimicrobial efficacy [35]. The difference
may be due to the use of the lignin particle, which was shown via ICP-OES/MS analysis to retain
bound silver, probably due to the higher binding affinity sites (Figure 1). It should be noted that there
was a 100:1 ratio of lignin to Ag+ in the nanoparticles, so the amount of silver in each particle was
only a hundredth of the mass of the total particle, making our LC50 values, based on silver content
alone, similar to those measured for solid core AgNPs reported in other studies. Therefore, potential
exposure to silver ions would be reduced in the presence of the lignin particles, leading to an apparent
increase in the LC50. This suggests that by replacing the silver core typical of conventional AgNPs,
the concentration of silver released to the environment may be reduced, which was one of the goals of
formulating the nanoparticle with a lignin core.
PDAC alone was the second most toxic component tested, and formulations that contained PDAC
were significantly more toxic than formulations that did not contain PDAC (Figure 2a). Although PDAC
is a high charge density cationic polymer commonly used as a flocculant/coagulant in wastewater
treatment, it is also cited as a cytotoxin that interacts with cell membranes to elicit cell damage,
and eventually necrosis [56,57]. Our results correspond with this literature finding, as embryos
that were exposed to PDAC alone progressively blackened and disintegrated, starting at 5.75 mg/L.
Other formulations that contained PDAC did not elicit this response, perhaps because the PDAC is
electrostatically associated with the lignin particle, or was “complexed”. Free, or “non-complexed”
PDAC, can interact with blood components, such as erythrocytes and plasma proteins, cell membranes,
and extracellular matrix proteins, leading to undesired side effects not seen with complexed
polycations [58]. Our experimental observations support this, as we see that the uncomplexed PDAC
sample is indeed more toxic than any formulation that contains a nanoparticle–PDAC complex
(Figure 2a). Additionally, research suggests polycationic polymers like PDAC can disrupt the lipid
bilayer, with larger polymers leading to the formation of holes in the lipid membrane that increased
membrane permeability [59,60]. Given that information, it is possible that PDAC made the fish more
susceptible to both dissolved and particle-bound silver as a result of changes in membrane permeability.
The positively charged PDAC-coated particles (SI, Figure S2) may have also been attracted to the
negatively-charged membranes of the zebrafish, which could have increased the exposure to silver
associated with the particle.
3.3.2. Dialyzed Formulations
The purpose of dialyzing the samples was to simulate post-consumer use of the nanoparticle by
purging the surrounding solution of excess silver ions. In the LC50 comparisons of dialyzed materials,
two results can be observed (Figure 2b). First, there was no difference in LC50 between the dialyzed
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complete formulation (NP + Ag + PDAC Fresh) and its non-dialyzed counterpart (NP + Ag + PDAC).
This may be due to similar nominal concentrations of silver, as calculated by adding the silver
associated with the particle and silver present in the filtrate (Figure 1). Second, the NP + Ag samples
showed a significant decrease in toxicity post-dialysis, with LC50 values increasing immediately after
dialysis (NP + Ag Fresh, LC50 = 222 mg/L), however, the dialyzed aged sample had a similar toxicity
to the non-dialyzed sample (NP + Ag LC50 = 164 mg/L and NP + Ag Aged LC50 = 184 mg/L). Perhaps
over time, the higher affinity binding sites on the lignin release more silver into solution compared to
the freshly dialyzed sample, leading to the slight decrease in the aged LC50 (Figure 1).
3.4. Analysis of Sublethal Endpoints
There were several endpoints that were significant (p ≤ 0.05), which included morphological
abnormalities, including uninflated swim bladder and snout malformations, developmental endpoints,
such as delay in hatching and delayed developmental progression, and physiological anomalies,
such as impaired circulation, yolk sac edema, and pericardial edema (Figure 3a–f). Exposure to the
silver nitrate at concentrations similar to the amount of silver in the NPs did not cause any significant
malformations in the embryos. Overall, there was a significant increase in the types of sublethal
responses observed in the dialyzed samples compared to the non-dialyzed samples. The dialyzed
samples, particularly the aged sample, had proportionally less silver associated with the particle than
the non-dialyzed samples (Figure 1), which could explain the increase in sublethal impacts, as well as
the lack of sublethal endpoints for NP + Ag + PDAC (Figure 3).
Swim bladder malformations occurred when silver or PDAC were included in the particle
formulation; however, this did not occur when silver and PDAC were both present in the particle
formulation (NP + Ag + PDAC), except when freshly dialyzed (Figure 3e). Exposure to silver ions
during embryonic zebrafish development has been described as impacting cholinergic signaling,
which is important in swim bladder formation [61]. Swim bladder malformations were not significant
in the NP + Ag + PDAC sample, likely due to high ratio of silver associated with the particle as
compared to the filtrate (Figure 1).
Malformations of the snout were only significant in the freshly dialyzed full formulation
(Figure 3e). Although others have reported silver nanoparticles causing snout malformations [54],
we do not see this malformation in silver nitrate (Figure S5) or any other formulation containing silver,
suggesting some other mechanisms of malformation may be involved. Perhaps the presence of all three
formulation components may have contributed to the prevalence of snout malformations, in addition
to the increased concentration of silver in the filtrate, as it exceeded the other treatments by a factor of
six (Figure 1), except for the aged dialyzed particle (NP + Ag Aged).
Yolk sac edema was present in all fish exposed to formulations containing silver, and impaired
circulation was significant in both freshly dialyzed formulations (Figure 3d,e). Significant pericardial
edema responses were only noted in the NP + Ag and NP + Ag + PDAC Fresh formulations. Similarly,
several other studies have reported that as a result of silver nanoparticle exposure, pericardial
edema, yolk sac edema, and impaired circulation are prevalent in the early developmental stages of
zebrafish [62–65]. As the development of the circulatory system and the formation of the heart typically
occur between 21 and 24 hpf in zebrafish embryos [42,64], it is likely that the release of dissolved
silver from the nanoparticles resulted in these endpoints being prevalent, however, particle-specific
responses cannot be ruled out. The chorion has been reported to modulate metal toxicity [51], but there
has been recent evidence that nanoparticles (30–72 nm) can move through the chorionic membrane
pores and distribute to numerous parts of the fish, including the brain, heart, yolk, and blood [66].
Should the distribution of silver include the yolk and heart, edemas would be expected to occur due
to disturbances in osmoregulation [55,62,63,67]. Once these developmental pathways are disturbed
during early development, normal embryogenesis can be impacted, resulting in numerous defects [68].
In addition, silver nanoparticles may agglomerate in exposure media, which can alter oxygen exchange
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through chorionic pores, affecting oxygen tension and osmotic balance, which could then result in
edemas similar to those observed in our study [66].
Figure 3. Types of developmental and morphological abnormalities observed in 120 hpf zebrafish
embryos exposed to various formulations of the nanoparticles including (a) NP + PDAC; (b) NP +
Ag; (c) NP + Ag + PDAC; (d) NP + Ag Dialyzed (Fresh); (e) NP + Ag + PDAC Dialyzed (Fresh) and
(f) NP + Ag Dialyzed (Aged). Asterisk represents significant increase relative to unexposed (control)
fish embryos at p ≤ 0.05.
Pericardial edema coupled with impaired circulation following AgNP exposure has been shown
to be concentration dependent [63], with an increase in prevalence from 10–100 mg/L. This was the
trend we observed in our study, although our study saw increases up to 125 mg/L with a maximum
of 17% responding. The most reasonable explanation for the slight difference in observations may be
due to differences between solid silver nanoparticles with surface stabilizers, and the lignin-coated
particles with specific silver binding sites on the particle core. Polyvinyl alcohol was used as the
surface coating in Asharani and colleagues [63], which may have altered the dynamics of silver ion
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release relative to our samples. Our samples contained PDAC as a surface stabilizer, which provides
an electrostatic barrier that could impede silver ion release, which we did see in our samples (Figure 1);
however, when freshly dialyzed, PDAC had limited impact on silver ion release, suggesting solution
equilibrium may be controlled by PDAC. Additionally, although there was silver present in the filtrate
of the freshly dialyzed samples, the lignin core bound the majority of the silver, probably due to the
higher affinity silver ion binding sites being utilized.
Significant delay in hatching and delayed developmental progression were the two developmental
abnormalities observed in our study following exposure to silver salts (Figure S5) and high
concentrations of the bare lignin nanoparticles (Figure S6), respectively. As delayed developmental
progression was found following exposure to relatively high concentrations of the bare lignin
nanoparticle and no other samples, the bare particle may interact with necessary ions in the solution,
making them limited for supporting embryo development at concentrations of 350 mg/L and higher
(Figure S6). This is further supported by the finding that this process does not occur when the particle
is functionalized with silver, PDAC, or both, as the binding sites on the lignin particle are already
occupied. Silver nitrate was the only material tested that led to a delay in hatching. A delay in hatching
is primarily caused by deactivation of the ZHE1 enzyme, which prevents chorionic degradation [69].
Lin and colleagues have shown that dissolved metals can interfere with ZHE1, and although silver
was included in their assay, it did not lead to a significant decrease in ZHE1 activity [69]. Asharani and
colleagues exposed zebrafish to Ag+ at 2.14 mg/L, and observed a delay in hatching at 4% compared
to controls, but this was not significant [62]. Approximately 50% of our surviving fish exhibited a delay
in hatching compared to controls following exposure to silver salts, however, this was not seen in
lignin nanoparticle formulations containing silver.
4. Conclusions
The results of this study provide several insights into a nanoparticle engineered to be
an environmentally friendly alternative to solid silver core nanoparticles. Our data shows that the
use of lignin as the nanoparticle core could be a viable alternative, as it did not pose a significant
toxicological hazard to our test organism. Since our reported toxicity was similar to other findings
when compared on the basis of silver content, the toxicity of silver-enabled nanoparticles may be
predictable, based on the silver concentration of the particle. Ionic silver and PDAC alone were
the most toxic components of the formulation, which may be attributed to their higher diffusivity
and propensity to interact with cell membranes relative to silver and/or PDAC associated with the
particle. The inclusion of PDAC not only adds antimicrobial activity to the particle, but also seems to
delay the release of silver ions, so in situations where time release of antimicrobial agents is desired,
stabilizing the particles with PDAC may be warranted. This data also encourages further development
of similar nanomaterials to minimize their impact on the environment, as well as testing the current
particle under environmentally relevant conditions to evaluate toxicity. One way of reducing the
environmental impact of these engineered nanomaterials is to design them in a way to minimize the
release of soluble components, or to replace these components with less toxic ingredients. We are
presently investigating the use of an alternative nanoparticle coating which is biologically derived,
that may have the potential to be less toxic in comparison to PDAC.
5. Associated Content
Supplemental Information Is Available for This Publication
Representative images of zebrafish with and without significant developmental impacts; Average
zeta potential and hydrodynamic diameter measurements for particle-containing formulations over
a five day period; Metadata associated with zeta potential measurements; Concentration-response
curves for formulation components and dialyzed materials based on zebrafish mortality at 120 hpf;
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Modeled concentration-response curve for the reference material silver nitrate based on zebrafish
mortality at 120 hpf; Visual MINTEQ output for all silver-containing formulations.
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Figure S1: Representative images of zebrafish with and without significant developmental impacts, Figure S2:
Average zeta potential and hydrodynamic diameter (HDD) of particle formulations over a five day period in
fishwater. Figure S1a,b are average zeta potential measurements for the formulation components (a) and the
dialyzed formulations (b), and Figure S1c,d are the average HDD measurements for the formulation components
(c) and the dialyzed formulations (d), Figure S3: Concentration-response comparisons for formulation components
(a) and dialyzed materials (b) based on zebrafish mortality at 120 hpf (a) Significant differences (p ≤ 0.05) existed
between materials in the formulation component treatments. The lignin particle exhibited the lowest toxicity,
followed by silver, and PDAC. (b) No significant differences (p > 0.05) existed in the dialyzed sample treatments.
Comparisons included the two full formulations (NP + Ag + PDAC) and the three NP + Ag formulations,
Figure S4: Concentration–response curve for silver nitrate based on zebrafish mortality at 120 hpf, Figure S5:
Frequency of delayed hatching in zebrafish embryos exposed to Ag+ as silver nitrate in fishwater. Asterisk
represents significant increase (p ≤ 0.05) relative to unexposed (control) fish embryos, Figure S6: Frequency of
delayed developmental progression in zebrafish embryos exposed to lignin nanoparticles in fishwater. Asterisk
represents significant increase (p ≤ 0.05) relative to unexposed (control), Table S1: Metadata associated with zeta
potential measurements.
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Abstract: Phytophthora cinnamomi, responsible for “root rot” or “dieback” plant disease, causes
a significant amount of economic and environmental impact. In this work, the fungicide action of
nanocomposites based on silver nanoparticles and polyphenol inclusion compounds, which feature
enhanced bioavailability and water solubility, was assayed for the control of this soil-borne water
mold. Inclusion compounds were prepared by an aqueous two-phase system separation method
through extraction, either in an hydroalcoholic solution with chitosan oligomers (COS) or in a choline
chloride:urea:glycerol deep eutectic solvent (DES). The new inclusion compounds were synthesized
from stevioside and various polyphenols (gallic acid, silymarin, ferulic acid and curcumin), in a [6:1]
ratio in the COS medium and in a [3:1] ratio in the DES medium, respectively. Their in vitro response
against Phytophthora cinnamomi isolate MYC43 (at concentrations of 125, 250 and 500 μg·mL−1) was
tested, which found a significant mycelial growth inhibition, particularly high for the composites
prepared using DES. Therefore, these nanocomposites hold promise as an alternative to fosetyl-Al
and metalaxyl conventional systemic fungicides.
Keywords: antifungal; chitosan oligomers; composites; deep eutectic solvents; phenolic compounds;
Phytophthora cinnamomi; root rot; silver nanoparticles
1. Introduction
Nanotechnology has shown remarkable applications in biomedicine, diagnosis and antibacterial
treatments, and is now transforming the agricultural sector, particularly with the development of
novel nanopesticides and nanofertilizers [1]. The increase in the frequency of resistant or tolerant
pathogenic agents, which has in turn led to an excessive application of pesticides, has resulted in
an increase in the presence of residues in food products, which may pose a major risk to health.
The design and testing of safe, effective and environmentally sustainable formulations based on
nanoemulsions, nanocomposites and nanoparticles to control agricultural pests and pathogens has
become a burgeoning field of research in the past few years.
Silver, which has long been used as a disinfectant for pathogenic microorganisms [2], has become
one of the best exponents of this transition. Silver nanoparticles (AgNPs), which feature antibacterial,
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antifungal and antitumor activities [3–5], are one of the most popular active ingredients employed
to enhance the efficacy of plant protection products. Furthermore, they can be prepared through
green synthesis procedures with the aid of plant extracts [6], which act as reducing and stabilizing
agents. Polyol components, polysaccharides, and water-soluble heterocycles (such as those from
Stevia rebaudiana [7], Curcuma longa [8], Pongamia pinnata [9], Gliricidia sepium [10], Eucalyptus
hybrida [11], or Quercus brantii [12]) have been reported to lead to a synergistic effect in the resulting
phytonanocomposites [13–15].
Nonetheless, bioactive compounds from plants (that include phenolic acids, flavonoids,
curcuminoids, coumarins, quinones, tannins and lignans), in spite of having a wide range of
activities, generally suffer from a number of drawbacks derived from their inherent physicochemical
characteristics (poor water solubility, low bioavailability, chemical instability, photodegradation,
rapid metabolism and short half-life) [16], which limit their applications. To stabilize them and
improve their bioavailability, one well-known approach is to use biopolymers, such as chitin, chitosan,
starch, and cellulose, or other macromolecular systems [17]. Binary composites based on chitosan
with polyphenols (e.g., gallic acid or curcumin [18–20]) and ternary composites that also include
AgNPs [21,22] with a broadened bio-activity have been reported in the literature.
Other approaches to improve solubility are based on forming inclusion compounds with terpene
glycosides (such as rubusoside, stevioside, rebaudioside, or steviol monoside) or cyclodextrins,
which result in an enhancement of the solubility of polyphenols [23,24], or on using deep eutectic
solvents (DES). DES are an excellent extraction medium for phenolic compounds [25] and may be used
in combination with inclusion compounds [26] or with chitosan [27,28].
Phytophthora cinnamomi is a pathogen with over 1000 host species, transmitted by the soil and
which causes rotting of the roots of many horticultural and forestry crops [29]. P. cinnamomi can
collapse, which cause sudden death of plants and a decrease in fruit yield and size. The infection by
P. cinnamomi can also occur together with other species of Phytophthora, mainly P. cambivora, P. cryptogea,
P. citricola and P. cactorum. Its eradication by means of fungicides is expensive and causes damage
to the environment, and fumigation is not always effective for deeper roots [30,31]. Consequently,
the European Union is promoting the development of new natural bioactive compounds to replace
conventional systemic fungicides, such as the organophosphorus compound fosetyl-Al or acylalanines
such as metalaxyl.
It has been shown, in vitro, that AgNPs synthesized using aqueous plant extracts have had
antifungal effect on Phytophthora pathogens [32], and so do chitosan [33], the binary combinations
of the two [34] and their ternary combinations with propolis [35]. Nonetheless, to the best of the
authors’ knowledge, no studies have explored the use of composites of AgNPs with polyphenol
inclusion compounds, combined either with chitosan oligomers (COS) or with DES, for the control of
P. cinnamomi or any other oomycetes.
In the present study, four polyphenols (gallic acid, silymarin, ferulic acid and curcumin) were
assessed for the microwave-assisted formation of the new inclusion compounds with stevioside.
AgNPs were subsequently incorporated into the composites [36]. Two types of host matrices
were tested, namely COS in a hydroalcoholic solution, and a DES based on a choline chloride
and urea solution (1:2 v/v) in glycerol, evaluating in vitro their response against P. cinnamomi at
different concentrations.
2. Results
The antifungal activity of the different treatments in aforementioned two preparation media (COS
in hydroalcoholic solution and DES) against P. cinnamomi (isolate MYC43) was studied in vitro by
monitoring the radial growth of the mycelium (Figures 1 and 2).
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Figure 1. Phytophthora cinnamomi growth inhibition assays with the nanocomposites based on
the chitosan oligomers in hydroalcoholic solution preparation medium. From left to right: Control
(no treatment) and treatments with AgNPs combined with gallic acid, silymarin, ferulic acid and
curcumin inclusion compounds. From top to bottom: 125 μg·mL−1, 250 μg·mL−1, and 500 μg·mL−1
concentrations. Only one repetition per treatment is shown.
Figure 2. P. cinnamomi growth inhibition assays with the nanocomposites based on the deep eutectic
solvent preparation medium. From left to right: Control (no treatment) and treatments with AgNPs
combined with gallic acid, silymarin, ferulic acid and curcumin inclusion compounds. From top to
bottom: 125 μg·mL−1, 250 μg·mL−1 and 500 μg·mL−1 concentrations. Only one repetition per treatment
is shown. The blue background in the control and curcumin-treated samples is due to the blue color of
the paper on which the plates were on.
As shown in Figure 3, the increase in the concentration of the inclusion complexes from 125 μg·mL−1
to 500 μg·mL−1 resulted in a reduction in the radial growth of the mycelium in all cases. It may be observed
that 100% mycelial growth inhibition occurred with the COS medium at the highest concentration of
500 μg·mL−1 for the composites with gallic acid, ferulic acid and curcumin (but not for silymarin). On the
other hand, at lower concentrations (125 and 250 μg·mL−1), silymarin and ferulic acid-based treatments
were more effective than those based on gallic acid and curcumin.
As regards the nanocomposites with a DES preparation medium, total inhibitory activities
were attained for the composites based on the four polyphenols under study concentrations of 250,
and 500 μg·mL−1. Further, at the lowest concentration of 125 μg·mL−1, the antifungal performance of
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the composites in the DES medium was close to 90% for all polyphenols. Thus, the product efficacies
were clearly higher than those of the composites based on the hydroalcoholic solution of COS.
Upon comparison with the treatments without phenolic inclusion compounds, it could be
observed that the AgNPs-only treatment attained a lower inhibition than the composites for the
COS medium, with mycelium growth even at the highest dose. On the other hand, the DES-based
AgNPs-only treatment performed noticeably better than its COS counterpart, albeit it did not
completely inhibit growth at a concentration of 250 mg·mL−1 (whereas all the composites did).
Therefore, an enhanced fungal growth control activity of the ternary mixtures was evidenced.
Figure 3. Radial growth values of P. cinnamomi in the presence of the composites, which consisted of
different polyphenol inclusion compounds and silver nanoparticles at different concentrations, either
in a chitosan hydroalcoholic solution (COS) or in a deep eutectic solvent (DES). A control (no treatment)
and two treatments with AgNPs (in COS and DES) without the inclusion compounds are shown for
comparison purposes. Error bars represent the standard deviation across three replicates.
The results from the sensitivity tests for P. cinnamomi may also be expressed with the help of
EC50 and EC90 indicators (Table 1). The sensitivity of the isolate mainly varied as a function of the
preparation media, but also according to the phenolic compound used. In line with the discussion
presented above, P. cinnamomi (MYC43) was found to be remarkably more sensitive to the treatments
prepared in DES, with EC50 values ranging from 0.1 to 8.9 μg·mL−1 and EC90 values between 77.9 and
184.3 μg·mL−1. For comparison purposes, for the COS in hydroalcoholic solution medium treatments
the EC50 values ranged from 171.6 to 279.9 μg·mL−1 and those of EC90 from 450.4 to 963.7 μg·mL−1.
Table 1. Effective concentrations that inhibited mycelial growth by 50% and 90% (EC50 and
EC90, respectively).
Treatment EC50 (μg·mL−1) EC90 (μg·mL−1)
COS AgNPs 458.4 1192.8
COS Gallic acid 261.3 455.6
COS Silymarin 261.8 963.7
COS Ferulic acid 171.6 450.4
COS Curcumin 279.9 487.4
DES AgNPs 13.3 253.3
DES Gallic acid 0.1 77.9
DES Silymarin 0.6 107.8
DES Ferulic acid 0.6 107.8
DES Curcumin 8.9 184.3
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The highest sensitivity of the P. cinnamomi isolate (MYC43) corresponded to the inclusion
compound with gallic acid in DES (EC50 = 0.1 μg·mL−1), followed by the inclusion compounds
with silymarin and ferulic acid, and finally by the one with curcumin, with EC50 values of 0.6, 0.6 and
8.9 μg·mL−1, respectively.
3. Discussion
With a view to comparing the efficacy of the proposed nanocomposites verses other phenolic-based
products against Phytophthora spp. discussed in the literature, it should be noted that Kim et al. [37]
reported strong fungicidal activities of Curcuma longa L. rhizome-derived curcumin in ethyl acetate and
hexane fractions against P. infestans with 100% and 84% control values at a concentration of 1000 μg·mL−1.
Apart from the higher concentrations used in those experiments as compared to the ones presented herein,
it should be noted that a contribution of the pronounced cytotoxic activities of the solvents could not
be excluded.
Pompimon et al. [38] assessed the anti-P. capsici activity of C. longa in acetone fraction, finding
an inhibition of mycelial growth of ca. 90% at a concentration of 300 μg·mL−1, higher than the EC90 of
184 μg·mL−1 of the curcumin-based treatment in DES media reported in this study.
The nanocomposites of the four polyphenols in DES medium would also be more active than,
for instance, cuminic acid, which featured an EC50 value against mycelial growth of P. capsici of
19.7 μg· mL−1 (which in turn was lower than the EC50 value of other benzoic acid derivatives
in previous reports) [39]. Other natural compounds, such as furanocoumarins (e.g., psoralen or
isopsoralen) would require concentrations of 500 μg·mL−1 to attain 82–84% disease control against
P. infestans [40].
An EC50 value of amphopolycarboxyglycinate-stabilized AgNPs against P. infestans of 3.1 μg·mL−1
was reported by Krutyakov et al. [41], i.e., a 30 and 6 times higher concentration than those obtained for the
AgNPs combined with gallic acid, silymarin and ferulic acid inclusion compounds in DES, respectively.
Banik and Pérez-de-Luque [42] found that the integration of copper nanoparticles (CuNPs) with
non-nano copper like copper oxychloride, both at a 50 μg·mL−1 concentration, resulted in a 76% growth
inhibition in vitro of the oomycete P. cinnamomi as compared to the control. Since in comparative
assays between NPs the concentrations of AgNPs are usually 10 times higher than those CuNPs [43,44],
the equivalent concentration of AgNPs to attain aforementioned effects should be 500 ca. μg·mL−1,
four times higher than that required by the DES treatments to attain a comparable mycelial growth
inhibition (ca. 90%).
Chitosan has also been assayed against P. infestans [33], finding that concentrations of 500 μg· mL−1
would be required to fully inhibit mycelial growth, similar to those of the COS-based nanocomposites
with gallic acid, ferulic acid and curcumin in this study. On the other hand, N-(6-carboxyl
cyclohex-3-ene carbonyl) chitosan with different degrees of substitution achieved an EC50 of
298 μg·mL−1 for P. infestans [45], better than the ones for the COS composites based on the three
aforementioned polyphenols (in the 450–490 μg·mL−1 range).
The overall efficacy of the reported nanocomposites should be referred to the combination of the
properties afforded by each of its constituents and their synergies.
According to Kim et al. [46], nanosilver may exert an antifungal activity by disrupting the
structure of the cell membrane and inhibiting the normal budding process due to the destruction of the
membrane integrity. Silver nanoparticles antifungal action may also result from the release of silver
ions into the intracellular matrix of the pathogen [47]. Reports on the mechanism of inhibitory action
of silver ions on microorganisms have shown that upon treatment with Ag+, DNA loses its ability to
replicate, resulting in inactivated expression of ribosomal subunit proteins, as well as certain other
cellular proteins and enzymes essential to ATP production. It has also been hypothesized that Ag+
would affect the function of membrane-bound enzymes, such as those in the respiratory chain [4].
Apropos of the role of the stevioside, the improvement in the solubility and bioavailability of the
polyphenolic compounds should be ascribed to the formation of a nanocomposite structure comprising
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a transglycosylated compound, which includes the insoluble compounds. Transglycosylated materials
have been reported to self-associate into particular micelle-like structures with a core-shell-like
architecture, in which the hydrophobic skeleton is segregated from the aqueous exterior to form
a novel drug-loading core, surrounded by a hydrophilic shell of sugar groups [48]. For instance,
Kadota, Okamoto, Sato, Onoue, Otsu and Tozuka [24] found a 13000× increase in curcumin solubility
when the tri-component system curcumin/α-glucosyl stevia/polyvinylpyrrolidone was used.
In relation to the phenolic compounds, they have been reported to have toxic activities against
fungi involved in the deterioration of agricultural products by interfering with the development of
mycelia [49]. They affect membrane functions such as electron transport, nutrition, enzyme activity,
protein and nucleic acid synthesis, and they interact with membrane proteins, causing disruption of
the structures and functionality. For instance, curcumin’s efficacy would be influenced by its lipophilic
nature, which leads to an adequate transmembrane permeability [16]. Its antifungal mechanism has
been ascribed to the disruption of plasma membrane integrity, causing leakage of potassium ion from
the cytosol and change in membrane potential [50]. On the other hand, gallic acid would exhibit both
antioxidant as well as pro-oxidant characteristics, displaying a dual-edge sword behavior, which turns
it into an efficient apoptosis inducing agent [51].
Regarding the inhibition mode of chitosan, three mechanisms have been proposed [52]:
(1) Its positive charge can interact with negatively charged phospholipid components of fungi
membrane, increasing its permeability and causing the leakage of cellular contents, which subsequently
leads to cell death; (2) it can act as a chelating agent by binding to trace elements, causing the essential
nutrients unavailable for normal growth of fungi; and (3) it may be able to penetrate the cell wall of
fungi and bind to its DNA, inhibiting the synthesis of mRNA and, thus, affecting the production of
essential proteins and enzymes.
As far as DES are concerned, they would act as a plasticizer, affecting the apparent viscosity of
the solutions and enhancing water vapor permeability, water solubility and water sorption capability,
as reported by Almeida, Magalhães, Souza and Gonçalves [27]. Nonetheless, it worth noting that,
while choline chloride and urea show no inhibition as individual materials, their final product as
ChCl:U DES has been reported to show inhibition towards Candida cylindracea [53]. This behavior
could be due to the synergistic effect of forming DES [54] and can be used to prove that occasionally
DES have a higher toxicological behavior than its original components.
The antimicrobial activity of DES is still not fully understood [55]. Some reports have noted that
DES would increase the permeability of the lipid membrane of eukaryotic cells [56,57], as chitosan
does. Since the mechanism for COS and DES would tentatively be similar, the differences in the
performance of the composites presented herein in terms of fungal growth control should then be
ascribed to differences in their ability to solubilize a wide range of solutes (e.g., components in the
fungal cell membrane), pH, osmolality or chelation of membrane-bound divalent cations [58].
Since one of the possible mechanisms of action of silver requires that the silver ions enter the
fungal cell for efficient killing, the enhancement of permeability driven by COS, DES and polyphenols
would support that their interaction should be synergistic rather than simply additive.
From our work, the best results of mycelial growth inhibition at the lowest concentration
(125 mg·mL−1) in DES (GI 91.5%), attained for the composite based on gallic acid, may be ascribed to
the fact that gallic acid is extremely well absorbed, and very soluble in water as compared with other
polyphenols [51]. Moreover, the introduction of the hydroxyl group on the cation in the chloride of choline
salt has also been reported to significantly improve the extraction capacity of ionic liquids for gallic acid [59].
4. Materials and Methods
4.1. Reagents
Stevioside standard was purchased from Wako (Osaka, Japan). Gallic acid, silymarin, ferulic
acid, curcumin, choline chloride, urea, glycerol, and silver nanoparticles (40 nm particle size
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(TEM), 0.02 mg·mL−1 in aqueous buffer, with sodium citrate as a stabilizer) were purchased from
Sigma-Aldrich/Merck KGaA (Darmstadt, Germany).
Chitosan oligomers were obtained from medium molecular weight chitosan (supplied by
Hangzhou Simit Chemical Technology Co., Ltd., Hangzhou, China), dissolving 10 g in 500 mL of
acetic acid (1%) under constant stirring at 60 ◦C. Once dissolved, hydrogen peroxide (0.3 mol·L−1) was
added for the degradation of the polymer chains, obtaining oligomers of less than 2000 Da [60].
Liquefaction of the choline chloride and urea (1:2 v/v) eutectic mixture occurred at 80 ◦C under
stirring in a hot-plate magnetic stirrer for 10 min, in good agreement with Biswas et al. [61].
4.2. Microwave-Assisted Preparation of the Polyphenol Inclusion Compounds
The aqueous biphasic system separation technique was used for the formation of the inclusion
compounds. This technology is a liquid-liquid extraction system for bioseparation and is frequently
used to process all types of biotechnological materials, such as proteins, enzymes, phytochemicals,
nucleic acids and pigments [62]. In the case under study, the inclusion complexes formed with
stevioside were recovered from the upper part of the reactor.
4.3. Chitosan Oligomers (COS)-Based Composites
In each of the four jars with screw caps, 1 g of chitosan oligomers of 2000 Da (COS), 0.06 g of
stevioside and 0.01 g of one of the polyphenols (either gallic acid, silymarin, ferulic acid or curcumin)
were added to 40 mL of hydroalcoholic solution (1:1 v/v distilled water and ethanol), followed by
treatment in a microwave (Milestone Ethos-One, Sorisole, BG, Italy) at 80 ◦C for 20 min under stirring.
The resulting solutions were centrifuged at 2500 rpm and stored at 4 ◦C. For the incorporation of
the silver nanoparticles to the nanocomposite, 0.1 mL of commercial AgNPs (0.02 mg·mL−1) were
added dropwise to 0.9 mL of the previously centrifuged microwave fractions, and the final solution
(with pH 7.5) was stirred at room temperature.
4.4. Deep Eutectic Solvent-Based Composites
To prepare the DES-based composites, 20 mL of choline chloride and urea (1:2 v/v) DES and 10 mL
of glycerol were added to each of the four jars with screw caps, together with 0.03 g of stevioside and
0.01 g of the respective polyphenol (gallic acid, silymarin, ferulic acid or curcumin). The mixture was
heated at 80 ◦C in the microwave, under stirring, for 20 min. Then, 0.1 mL of AgNPs (0.02 mg·mL−1)
were added dropwise to 0.9 mL of the microwave fractions (previously centrifuged at 2500 rpm).
The mixture, with pH 7.5, was subjected to vigorous stirring for 5 min at room temperature.
4.5. Silver Nanoparticles-Only Treatments
Two additional treatments consisting of 0.1 mL of AgNPs (0.02 mg·mL−1) added dropwise
to 0.9 mL of the dispersion medium (either COS or DES), without the polyphenol inclusion
compounds, were prepared for control purposes. The mixtures were vigorously stirred for 5 min at
room temperature.
4.6. Characterization of the Nanocomposites
The structure and properties of the nanocomposites obtained through the synthetic procedures
described above were characterized using Fourier-Transform Infrared spectroscopy (FTIR), scanning
electron microscopy (SEM) and transmission electron microscopy (TEM). Results were recently
reported in patent P201731489 [36].
4.7. Fungal Isolates and Growth Conditions
The fungal species used in the experiment was Phytophthora cinnamomi isolate MYC43, supplied by
Centro de Investigaciones Científicas y Tecnológicas de Extremadura—Instituto del Corcho, la Madera
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y el Carbón Vegetal, Spain. The isolate was maintained in potato-dextrose-agar (PDA) slant tubes,
supplied by Merck Millipore (Darmstadt, Germany), stored at 4 ◦C.
4.8. Efficacy of the Nanocomposites for the Control of Phytophthora cinnamomi
Agar disks (8 mm in diameter) were cut from the margin of a 7-day-old colony growing on PDA
and were transferred to a PDA medium supplemented with the nanocomposites at final concentrations
of 125 μg·mL−1, 250 μg·mL−1 and 500 μg·mL−1. Three replicates were performed for each treatment.
For each active ingredient and concentration, inhibition of radial mycelial growth (mm) compared
with the untreated control was evaluated after 7 days of incubation at 24 ◦C, in the dark. The relative
growth inhibition (%) of each treatment compared to untreated control was calculated as follows:
Growth inhibition (%) = [(dc − dt)/dc] × 100, where dc stands for the average diameter of the fungal
colony in the control and dt is the average diameter of the treated colony [63]. Results were expressed
as effective concentrations EC50 and EC90 (i.e., the concentrations which reduced growth inhibition by
50% and 90%) by regressing the inhibition of radial mycelial growth values (% control) against the
values of the antifungal nanocomposite concentrations.
5. Conclusions
Composites consisting of silver nanoparticles and polyphenol inclusion compounds were
synthesized using two preparation media, one based on chitosan oligomers in an hydroalcoholic
solution and the other based on a deep eutectic solvent. Both types of composites showed
an increase in the water solubility of the polyphenols and in the in vitro antifungal activity against
Phytophthora cinnamomi (MYC43 isolate). Nonetheless, the DES-based samples efficacy was remarkably
higher than that of their counterparts with a chitosan oligomers-based matrix: Complete inhibition
of mycelial growth was attained at concentrations of 250 and 500 μg·mL−1, and even at the lowest
dose of 125 μg·mL−1, they resulted in a 90% growth inhibition. As regards the impact of the choice
of the different polyphenols, for the DES-based treatments, the highest sensitivity of P. cinnamomi
corresponded to the composite with gallic acid (EC50 = 0.1 μg·mL−1), followed by those with silymarin
and ferulic acid, and finally by the one with curcumin, with EC50 values of 0.6, 0.6 and 8.9 μg·mL−1,
respectively. This may be ascribed to the fact that gallic acid is extremely well absorbed, and very
soluble in water as compared with other polyphenols. The reported activities for the composites were
remarkably higher than those reported for Phytophthora spp. using AgNPs, chitosan or polyphenols
separately. This points to the possibility of a successful application of these nanocomposites in
agriculture, with the aim of reducing the use of toxic and expensive conventional systemic fungicides.
Further research on the ability of the prepared nanocomposites to inhibit growth of P. cinnamomi in
the context of a plant infection model and on the basic mechanism involved, fungistatic or fungicidal,
is underway.
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Abstract: Previously, we demonstrated that silver nanoparticle-dispersed silane-based coating could
inhibit biofilm formation in conditions where seawater was used as a bacterial source and circulated
in a closed laboratory biofilm reactor. However, it is still unclear whether the microbiome of a biofilm
of silver nanoparticle-dispersed silane-based coating samples (Ag) differs from that of a biofilm of
non-dispersed silane-based coating samples (Non-Ag). This study aimed to perform a microbiome
analysis of the biofilms grown on the aforementioned coatings using a next-generation sequencing
(NGS) technique. For this, a biofilm formation test was conducted by allowing seawater to flow
through a closed laboratory biofilm reactor; subsequently, DNAs extracted from the biofilms of Ag
and Non-Ag were used to prepare 16S rRNA amplicon libraries to analyze the microbiomes by NGS.
Results of the operational taxonomy unit indicated that the biofilms of Non-Ag and Ag comprised
one and no phyla of archaea, respectively, whereas Proteobacteria was the dominant phylum for both
biofilms. Additionally, in both biofilms, Non-Ag and Ag, Marinomonas was the primary bacterial
group involved in early stage biofilm formation, whereas Anaerospora was primarily involved in
late-stage biofilm formation. These results indicate that silver nanoparticles will be unrelated to the
bacterial composition of biofilms on the surface of silane-based coatings, while they control biofilm
formation there.
Keywords: biofilm; microbiomes; silver nanoparticles; silane-based coating; Marinomonas; Anaerospora
1. Introduction
A ship’s engine room has a plumbing system that includes a power unit, steam pipes,
heat exchangers and fuel pipes. Generally, seawater is used in the ship’s cooling system; however,
this can lead to biofouling. Biofouling is a series of bioprocesses where material surfaces are
initially covered by conditioning films of non-organic polymers, followed by biofilm formation by
microorganisms, such as bacteria and archaea, and then by macroorganisms, such as algae and
balanoids, which adhere to the surface [1]. Biofouling reduces the efficiency of heat exchange in the
cooling system, and it may at times result in the destruction of heat exchange pipes [2–4]. The key
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stage in biofouling is biofilm formation. Biofilms are composed of bacteria and their extracellular
polymeric substrates and can cause microbially-influenced corrosion (MIC) of steel [5,6].
Previously, we demonstrated that a combination of silver nanoparticles and silane-based coating
inhibited biofilm formation on the surface of pipes of water cooling systems that used seawater as
a coolant [7]. However, the microbiome composition of biofilms is still unknown. In this study,
we utilized a next-generation sequencing (NGS) technique to study microbiomes of biofilms on steels
with silver nanoparticles-dispersed silane-based coating.
2. Materials and Methods
2.1. Specimens
A carbon steel JIS SS400 plate (Sakai Netsu-Giken, Tsu, Japan) was cut into coupons of an area
of 10 × 20 mm2 (thickness, 1 mm) using a shearing machine (Komatsu Industries, Kanazawa, Japan).
Each coupon was washed with acetone and then dried for 24 h in a desiccator before initiating the
coating process. Silane-based coating solution was prepared as previously described [7]. Subsequently,
silver nanoparticles (diameter, 100 nm; Sigma–Aldrich, St. Louis, MO, USA) were added to the
silane-based coating solution. Next, the coating solution was filtered through a nylon mesh #110 (NBC
Meshtec Inc., Hino, Japan) to remove any residues or impurities. The filtered Ag solution was then
sprayed onto the surface of each SS400 coupon, which were subsequently incubated at 20 ◦C for 24 h.
2.2. Sampling Seawater
Seawater was collected in a sterile glass bottle (1 L, AGC Techno Glass, Haibara-gun, Japan) at
a depth of 2 m on 7 November 2016. The sampling location was 1.6 km offshore in Ise Bay, Japan
(34◦31.20′ N, 136◦48.36′ E). The seawater-filled bottle was covered using double-layered aluminum foil
and stored in a refrigerator (4 ◦C–8 ◦C) until use.
2.3. Biofilm Formation Test
A laboratory biofilm reactor (LBR) comprising two polycarbonate columns (Sanplatec Corporation,
Osaka, Japan), a three-necked, glass culture bottle and a peristaltic pump was used (Figure 1).
All coupons were fixed in acryl holders (Sanplatec Corporation) using acryl screw pins (Sanplatec
Corporation) with their coated surfaces facing upward. These holders were then placed in LBR
columns, which were connected to silicone tubes (As One, Osaka, Japan). The silicone tubes were
connected to the three-necked, glass culture bottle. After the assembly was sterilized using an autoclave
(Tomy Seiko, Tokyo, Japan) at 121 ◦C for 15 min, the stored seawater (500 mL) was transferred to the
sterile three-necked, glass culture bottle and was circulated by the peristaltic pump at a speed of dial
10 (Thermo Fisher Scientific, Waltham, MA, USA) at 20 ◦C for 139 h.
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Figure 1. The closed laboratory biofilm reactor. 1: peristaltic pump; 2: culture bottle; 3: column;
4: sample holder. The seawater was circulated in a counterclockwise direction.
2.4. DNA Extraction from Seawater and Biofilms
A PowerSoil® DNA isolation kit (MO BIO Laboratories, Carlsbad, CA, USA) was used for DNA
extraction, both from the biofilms on the surface of each coupon and from microbes in the seawater.
Stored seawater was filtered through a 0.1-μm polyethersulfone filter (Sartorius Japan, Tokyo, Japan).
After filtration, the sediment on the filter was collected in PowerSoil® Bead tubes (MO BIO Laboratories).
Biofilms on the surface of each coupon were scratched using a sterile spatula, and the scratched biofilms
were collected in PowerSoil® Bead tubes. Then, 60 μL of Solution C1 was added to each tube, which was
then inverted several times, secured to a bead crusher (TITEC, Koshigaya, Japan), vortexed at 4600 rpm
for 1 min and placed on ice. Vortexing and cooling was repeated nine more times. Any DNA present
in tubes was then purified according to a previously reported procedure [7]. The concentration of
the purified DNA solution was measured using the Qubit fluorometer (Thermo Fisher Scientific) and
a dsDNA high sensitivity (HS) assay kit (Thermo Fisher Scientific).
2.5. 16S rRNA Gene-Based Bacterial Community Analysis
Bacterial and archaebacterial 16S rRNA genes were partially amplified using 16S rRNA V4 region
primers: 515f (5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCCAG-CMGCCGCGGTAA-3′)
and 806r (5′-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-GGACTACHVGGGTWTCTAAT-3′).
The first sampled polymerase chain reaction (PCR) solution (total volume, 20 μL) comprised
2.0 μL of PCR buffer (TaKaRa BIO, Kusatsu, Japan), 1 U of ExTaq (TaKaRa BIO), 0.5 μM of
primers (515f and 806r each), 0.2 mM of dNTP mixture, 2.0 μL of purified DNA sample and
12.2 μL of deionized distilled water (TaKaRa BIO). For PCR, the samples were initially subjected
to 94 ◦C for 2 min, followed by 94 ◦C for 30 s, 50 ◦C for 30 s and 72 ◦C for 30 s (25 cycles)
and finally by 72 ◦C for 5 min using a thermal cycler (TaKaRa BIO). At the tagging PCR
step, each PCR amplicon was tagged for MiSeq Illumina sequencing using Index2 (a unique
8-bp sequence) and Index1 (5′-TCCTCTAC-3′), which was separately inserted into the 2ndF
(5′-AATGATACGGCGACCACCGAGATCTACAC-Index2-ACACTCTTTCCCTACACGACGC-3′) and
2ndR primer (5′-CAAGCAGAAGACGGCATACGAGAT-Indexl-GTGACTGGAGTTCAGACGTGTG-3′).
The tagging PCR solution (total volume, 20 μL) comprised 2 μL of the first PCR amplicon, 1 U of
ExTaq, 2.0 μL of PCR buffer, 0.2 mM of dNTP mixture, 0.5 μM of 2ndF primer, 0.5 μM of 2ndR primer
and deionized distilled water. The tagging PCR conditions were as follows: the initial step involved
a treatment at 94 ◦C for 2 min; followed by a treatment at 94 ◦C for 30 s, 60 ◦C for 30 s and 72 ◦C for
30 s (8 cycles); and a final step of 72 ◦C for 5 min using a thermal cycler (TaKaRa BIO). After reaction
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completion, the concentration of all tagged PCR products was measured using a dsDNA HS assay kit
and Qubit fluorometer. The quality of all tagged PCR products was assessed using a High Sensitivity
NGS Fragment Analysis Kit (Advanced Analytical Technology, Ames, IA, USA) and Fragment Analyzer
(Advanced Analytical Technology). Finally, all tagged PCR products were pooled in one tube, and NGS
was performed using the MiSeq system (Illumina, San Diego, CA, USA). The 16S rRNA gene library
was pre-processed and analyzed using a combination of USEARCH [8,9], bioinformatics software
package QIIME [10] and FASTX-Toolkit [11], a fast processing tool. Complete tag-matching sequences
were extracted from forward- and reverse-sequence raw data files using the fastq_barcode_splitter.pl
script, and then, the primer sequences were removed. Extracted sequences were trimmed, and specific
sequences, which had a quality score of <20 and length of <40 bp, were discarded using sickle
tools [12]. Trimmed forward and reverse sequences with a merged length of 260 bases, reading length
of 230 bases and minimum overlap size of 10 bases were merged using the FLASH software [13,14].
Next, merged sequences were filtered from 246 bases to 260 bases, then chimeric sequences were
checked using the identify_chimeric_seqs.py script and uchime algorithm of USEARCH against
reference sequences of 97% operational taxonomic units (OTU) using the Greengenes database [15].
After removing chimeric sequences from the merged sequences, non-chimeric sequences were
clustered based on 97% identity, and an OTU table was created using the pick_de_novo_otus.py script.
The Greengenes database was used for taxonomically assigning the bacteria. Raw data files have been
deposited in the NCBI Sequence Read Archive and are awaiting an accession number.
3. Results and Discussions
We compared the microbiomes of stored seawater samples (Seawater), of biofilms on the surface
of non-dispersed silane-based coating samples (Non-Ag) and of biofilms on the surface of silver
nanoparticle-dispersed silane-based coating samples (Ag). At the phylum level, three archaea were
detected in Seawater; two archaea were detected on the biofilms of Non-Ag; and no archaea were
detected on the biofilms of Ag (Table 1). Crenarchaeota contains hyperthermophilic and acidophilic
bacteria [16], whereas Euryarchaeota contains methanogens and halophiles [17]. The content of
archaea in Seawater was approximately 2%, whereas that of archaea on the biofilms of Non-Ag was
approximately 0.1%. The outstanding difference in the microbiomes of biofilms of Non-Ag compared
with that of biofilms of Ag was that no archaea were observed on the biofilms on Ag. These results
indicate that marine archaea do not prefer silane-based coating surfaces for attachment and growth;
moreover, silver nanoparticles will enhance the effect of silane-based coating killing archaea.
Table 1. Percentage abundance of operational taxonomic units of archaea.
Seawater-1 Seawater-2 Non-Ag-1 Non-Ag-2 Ag-1 Ag-2 Phyla
0.58 0.54 0.12 0.00 0 0 Crenarchaeota
1.20 1.90 0 0 0 0 Euryarchaeota
0.02 0.03 0 0.11 0 0 Parvarchaeota
In all samples, the most common bacterial phylum identified was Proteobacteria (#6 in Figure 2),
and over 90% of all organisms identified on the biofilms of Non-Ag and Ag belonged to this phylum.
This result showed one possibility that MIC may occur in either Non-Ag or Ag because Proteobacteria
comprises many MIC-related bacteria such as Pseudomonas, sulfate-reducing bacteria, Acidithiobacillus
and Gallionella. Meanwhile, the proportion of Actinobacteria (#1 in Figure 2), Bacteroidetes (#2 in
Figure 2), Cyanobacteria (#4 in Figure 2) and Planctomycetes (#5 in Figure 2) had markedly reduced
on the biofilms of Non-Ag and Ag compared with Seawater. Huttunen-Saarivirta et al. reported
significantly higher biofilm formation on Grade EN 1.4162 stainless steel than that on five other
common stainless steels [18]. Moreover, Actinobacteria and Proteobacteria were the main phyla on
the biofilms of EN 1.4162 and those of five other common stainless steels. However, the biofouling
tendency differed from the corrosion behavior among these six stainless steels [18]. Yu et al. reported
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that Proteobacteria, Actinobacteria and Bacteroidetes were detected on the biofilms formed on several
types of water-distribution pipes and that a plastic-based pipe was suitable for water distribution due
to its low biofilm-forming potential and microbial diversity [19]. Considering these reports, both Ag
and Non-Ag will have low potential to form biofilms.
Figure 2. Main bacterial phyla detected in the seawater (Seawater), biofilms of silane-based coating
samples (Non-Ag) and biofilms of silver nanoparticles-dispersed silane-based coating samples (Ag).
Unassigned and archaeal OTUs were removed. When all samples showed phyla with an abundance
of <0.1%, the phyla were excluded from the bacterial percentages. 1: Actinobacteria; 2: Bacteroidetes;
3: Chloroflexi; 4: Cyanobacteria; 5: Planctomycetes; 6: Proteobacteria; 7: SAR406; 8: SBR1093;
9: Verrucomicrobia; 10: ZB3.
At the order level, for Seawater, there were three major bacterial orders: Flavobacteriales of
Bacteroidetes (OTU, 14% and 19%, #2 in Figure 3), Rhodobacterales of Alphaproteobacteria (OTU,
14% and 18%, #9 in Figure 3) and Oceanospirillales of Gammaproteobacteria (OTU, 13% and 15%,
#16 in Figure 3), respectively. Conversely, biofilms of Non-Ag and Ag had two major bacterial orders:
Rhodobacterales, which comprised approximately 50% of the microbiomes, and Oceanospirillales,
which comprised approximately 25% of the microbiomes. Bacteroidetes are well known as a main
marine bacterial group present across many oceans. They play a vital role in degrading organic
compounds in the ocean [20]. In this study, all Seawater, Non-Ag and Ag contained Flavobacteriales
of Bacteroidetes; they mainly occupied 14–19% in Seawater; however, Non-Ag and Ag had a low
proportion of this order of 1–3%, which means Flavobacteriales had difficulty proliferating on the
surface of Non-Ag and Ag. Therefore, the biofilm formation conditions provided by Non-Ag and
Ag would not be suitable for Flavobacteriales growth. The order Rhodobacterales contains the
family Rhodobacteraceae, whose members are key biofilm formers at the initial stage of biofilm
formation in seawater [21]. Besides, Alteromonadales (#15 in Figure 3) and Oceanospirillales have
been reported in young biofilms and with potential tolerance toward polysaccharide biodegradation
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and carbohydrate metabolism in biofilms [22]. In this study, the biofilms of Ag and Non-Ag were rich
in Rhodobacterales and Oceanospirillales, indicating an early, not matured, stage of these biofilms.
However, Rhodospirillales, whose members are known as marine biocorrosion bacteria [22], was only
detected in Seawater (OTU, 0.6% and 0.9%). Additionally, higher proportions of Vibrionales (#18
in Figure 3), which include Vibrio, were detected on the biofilms of Non-Ag (OTU, 8.8% and 11.2%)
and Ag (OTU, 5.0% and 10.2%) compared with those in Seawater (OTU, 0.5%). The members of
Vibrio are considered to be corrosion-protective bacteria [22]. These results indicate the possibility
that biofilms of Non-Ag and Ag did not contain MIC-related bacteria. As discussed in the previous
section, Proteobacteria comprises many MIC-related bacteria, but OTUs of the order level show that
the members of Proteobacteria identified on the biofilms of Non-Ag and Ag rarely cause MIC; however,
these bacteria are highly related to biofilm formation. The biofilm formation test involved a six-day
culture, which was twice the time period used in the previous experiment where Ag was shown
to inhibit biofilm formation [7]. Unfortunately, we could not procure sufficient DNA samples to
analyze the next generation in the previous three-day culture. Thus, we extended the culture period
for the current experiment and obtained sufficient DNA from both the biofilms of Ag and Non-Ag.
However, extending the culture period may affect the microbial composition on the biofilm of Ag, i.e.,
increased number of initial biofilms of Ag may comprise different bacteria.
Figure 3. Main bacterial orders detected in the seawater (Seawater), biofilms of silane-based coating
samples (Non-Ag) and biofilms of silver nanoparticles-dispersed silane-based coating samples (Ag).
Unassigned and archaeal OTUs were removed. When all samples showed orders with an abundance of
<1.0%, the orders were excluded from the bacterial percentages. 1: Acidimicrobiales; 2: Flavobacteriales;
3: Rhodothermales; 4: Cryptophyta; 5: Stramenopiles; 6: Synechococcales; 7: unknown order of Pla3;
8: unknown order of Alphaproteobacteria; 9: Rhodobacterales; 10: Rickettsiales; 11: Burkholderiales;
12: Rhodocyclales; 13: Sva0853; 14: Campylobacterales; 15: Alteromonadales; 16: Oceanospirillales;
17: Pseudomonadales; 18: Vibrionales; 19: Arctic96B-7; 20: unknown order of Pedosphaerae.
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It is still unclear as to whether the biofilms of Ag and Non-Ag comprise similar biofilm-forming
bacteria. In order to estimate the presence of biofilm-forming bacteria in this experiment, three abundant,
order-level bacterial groups were summarized (Tables 2–4). On the biofilms of both Non-Ag and Ag,
Anaerospora of Rhodobacteraceae was the dominant genus, followed by Marinomonas of Oceanospirillaceae
and an unknown genus of the Vibrionaceae of Vibrionales (not Vibrio). Marinomonas is an aerobic
bacterial genus; Vibrionaceae is a facultative aerobic bacterial family; and Anaerospora is an anaerobic
bacterial genus, although only Anaerospora hongkongensis is registered as a member of Anaerospora [23,24].
When considering the oxygen requirement of bacteria, anaerobic bacteria would be more abundant than
aerobic bacteria on the biofilms of Non-Ag and Ag. Extracted DNA from the biofilms was derived from
living bacterial cells and extracellular DNA [25], which can be released from either living or dead cells
that may no longer be present on the biofilms. Hence, we assumed that OTUs would help determine
the history of biofilm-related bacteria. Our current biofilm formation test was performed in a closed
LBR where dissolved oxygen concentration was estimated to be high during the early culture period,
but very poor during the late culture period because stored seawater was used and no additional oxygen
was supplied. Based on the presence of Oceanospirillales in the young biofilms, Marinomonas were
considered to be the dominant biofilm-forming bacteria in early-stage biofilm formation in the LBR.
Later, Anaerospora dominated as the main biofilm-forming bacteria as the dissolved oxygen concentration
decreased during the culture period. In the bacterial phylum section, we considered that MIC might occur
in either Non-Ag or Ag because abundant bacteria of biofilms of Non-Ag and Ag were Proteobacteria
comprising many MIC-related bacteria such as Pseudomonas, sulfate-reducing bacteria, Acidithiobacillus
and Gallionella. Indeed, the abundant members of Proteobacteria of biofilms of Non-Ag and Ag were
Anaerospora and Marinomonas, which were biofilm-forming bacteria, but not reported for MIC. On the other
hand, sulfate-reducing bacteria such as Desulfovibrio, Acidithiobacillus and Gallionella had undetectable
levels there; however, Pseudomonas was slightly detected in the biofilm of Ag (OTU, 0.01% and 0.99%).
These results show that both Non-Ag and Ag had biofilms formed on the surface, but they rarely
progressed to MIC.
Table 2. Percentage abundance of operational taxonomic units of Rhodobacterales. -: unknown.
Seawater-1 Seawater-2 Non-Ag-1 Non-Ag-2 Ag-1 Ag-2 Families Genera
5.29 3.79 4.77 4.51 3.86 3.30
Rhodobacteraceae
Other
5.50 4.11 3.32 2.53 3.67 1.66 -
0.29 0 0 0 0 0 Amaricoccus
6.15 4.33 34.86 44.79 47.15 40.30 Anaerospora
0.06 0.04 0 0.01 0.01 0 Loktanella
0 0.02 0 0 0 0 Octadecabacter
0.01 0.01 0.02 0.42 0.01 0.03 Paracoccus
0.89 1.18 4.42 3.31 0.46 6.05 Pseudoruegeria
0.03 0.02 0.01 0 0 0 Rhodobacter
0 0 0.01 0.01 0.01 0.01 Rhodovulum
0.01 0 0 0.01 0.01 0.01 Roseivivax
0.86 0.59 0 0 0 0 Rhodospirillaceae -
0.04 0 0 0 0 0 Magnetospirillum
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Table 3. Percentage abundance of operational taxonomic units of Oceanospirillales. -: unknown.
Seawater-1 Seawater-2 Non-Ag-1 Non-Ag-2 Ag-1 Ag-2 Families Genera
0 0 1.80 0.65 0.81 1.09
Oceanospirillaceae
Other
1.72 1.70 1.89 2.58 3.72 3.92 -
0 0 0 0.26 0 0.15 Amphritea
0.28 0.32 21.76 19.56 18.97 19.60 Marinomonas
0 0 0 0 0 0.27 Neptunomonas
0 0.01 0 0 0 0 Oceanospirillum
0 0 0.64 0.30 2.40 0.06 Oleispira
0 0 0 0.31 0.56 0.41 -
0.01 0.02 0 0 0 0 SUP05 -
Table 4. Percentage abundance of operational taxonomic units of Vibrionales. -: unknown.
Seawater-1 Seawater-2 Non-Ag-1 Non-Ag-2 Ag-1 Ag-2 Families Genera
0 0 0 0.01 0 0.01
Pseudoalteromonadaceae
-
0.03 0.04 1.21 1.68 0.24 0.90 Pseudoalteromonas
0.41 0.43 7.30 9.47 3.27 9.17
Vibrionaceae
Other
0 0 0.01 0.02 0 0.01 -
0.07 0.01 0.05 0 1.45 0 Photobacterium
0.01 0.02 0.21 0.03 0.01 0.08 Vibrio
We have already reported that the amount of biofilm of Ag was significantly less than that of
Non-Ag [7]; however, what kinds of bacteria formed biofilm was unclear. Therefore, we approached
revealing the microbiota of biofilms of Ag and Non-Ag. Comparing the OTU percentages of the biofilm
of Ag with that of the biofilm of Non-Ag, Figures 2 and 3 demonstrate that the microbiota composition
of biofilm of Ag was almost the same as that of the biofilm of Non-Ag. Therefore, we presumed that
the microbiota composition of biofilms formed on silane-based coating did not change whether silver
nanoparticles were dispersed in the coating or not; whereas, silver particles in the silane-based coating
would control the attachment, growth and quorum sensing of bacteria on the surface, resulting in
a small amount of biofilm.
4. Conclusions
In our previous study, we found that a silver nanoparticle-dispersed silane-based coating
effectively inhibited biofilm formation. Here, we attempted the analysis of microbiomes on biofilms
formed on the coatings using an NGS technique. No archaea phyla were detected on the biofilms of Ag,
whereas only one archaea phylum was detected on the biofilms of Non-Ag. Proteobacteria were the
dominant bacterial phylum on the biofilms of both Non-Ag and Ag. Comparing OTUs of the biofilms
on Ag with those of the biofilms on Non-Ag, no distinct difference was noted in bacterial orders,
but biofilm-forming bacterial orders and a biocorrosion-protective bacterial order were found to be
present in both biofilms. In addition, members of Marinomonas were the main biofilm-forming bacteria
under aerobic conditions, but were replaced by those of Anaerospora under anaerobic conditions.
Moreover, the addition of silver nanoparticles did not affect the microbiome of biofilms on silane-based
coating, while it decreased the amount of biofilm on it.
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Abstract: Multidrug-resistant bacteria (MDRB) are extremely dangerous and bring a serious threat
to health care systems as they can survive an attack from almost any drug. The bacteria’s adaptive
way of living with the use of antimicrobials and antibiotics caused them to modify and prevail in
hostile conditions by creating resistance to known antibiotics or their combinations. The emergence
of nanomaterials as new antimicrobials introduces a new paradigm for antibiotic use in various
fields. For example, silver nanoparticles (AgNPs) are the oldest nanomaterial used for bactericide
and bacteriostatic purposes. However, for just a few decades these have been produced in a biogenic
or bio-based fashion. This review brings the latest reports on biogenic AgNPs in the combat against
MDRB. Some antimicrobial mechanisms and possible silver resistance traits acquired by bacteria
are also presented. Hopefully, novel AgNPs-containing products might be designed against MDR
bacterial infections.
Keywords: silver nanoparticles; biological synthesis; multidrug-resistant bacteria
1. Introduction
Antimicrobial resistance refers to the evolutionary capacity developed by microorganisms such
as bacteria, fungi, viruses, and parasites to fight and neutralize an antimicrobial agent. According to
the World Health Organization (WHO) [1], the intensive use and misuse of antimicrobials has led to
an expansion of the number and types of resistant organisms. Moreover, the use of sub-therapeutic
antibiotic doses to prevent diseases in animal breeding to improve animal growth can select resistant
microorganisms, which can possibly disseminate to humans [2].
The number of pathogens presenting multidrug resistance has had an exponential increase in
recent times and is considered an important problem for public health [3]. A wide number of bacteria
have been reported as multidrug-resistant (MDR), and they present a high cost of management,
including medicines, staff capacity, isolation materials [4], and productivity loss [5]. For instance,
in the USA, the cost of conventional tuberculosis treatment for the drug-susceptible bacterium is
$17,000 and up to $482,000 for the treatment of the MDR bacterium [5]. In 2017, WHO published the
first list of antibiotic-resistant pathogens offering risk to human health and, as such, the development
of new drugs is crucial. Priority 1 (critical) microorganisms are carbapenem-resistant Acinetobacter
baumannii; carbapenem-resistant Pseudomonas aeruginosa; and carbapenem-resistant, ESBL-producing
Enterobacteriaceae. Accounting for priority 2 (high) are vancomycin-resistant Enterococcus faecium;
methicillin-resistant, vancomycin-intermediate and resistant Staphylococcus aureus; clarithromycin-
resistant Helicobacter pylori; fluoroquinolone-resistant Campylobacter spp.; fluoroquinolone-resistant
Salmonellae; and cephalosporin-resistant, fluoroquinolone-resistant Neisseria gonorrhoeae. In priority 3
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(medium) are penicillin-non-susceptible Streptococcus pneumoniae, ampicillin-resistant Haemophilus
influenzae, and fluoroquinolone-resistant Shigella spp. [6].
The use of drugs combinations, two or more antimicrobial drugs to combat MDRB [7], is already
employed in cancer therapy [8], HIV-patients [9], and malaria patients [10]. On the other hand, research
groups around the globe are suggesting innovative solutions to treat resistant organisms. Xiao et al. [11]
synthesized the block copolymer poly (4-piperidine lactone-b-ω-pentadecalactone) with high antibacterial
activity against E. coli and S. aureus, and low toxicity to NIH-3T3 cells, and suggested that cationic block
copolymer biomaterials can be employed in medicine and implants. Zoriasatein et al. [12] showed that a
derivative peptide from the snake (Naja naja) has an antimicrobial effect against S. aureus, B. subtilis, E. coli,
and P. aeruginosa. Al-Gbouri and Hamzah [13] reported that an alcoholic extract of Phyllanthus emblica
exhibits antimicrobial activity against E. coli, S. aureus, and P. aeruginosa and it inhibits biofilm formation of
P. aeruginosa. Naqvi et al. [14] suggested the combined use of biologically synthesized silver nanoparticles
(AgNPs) and antibiotics to combat the MDRB.
The increasing utilization and in-depth studies of nanomaterials have brought new perspectives
towards new antimicrobial materials and nanocomposites that could add-in to the MDRB pandemic
that we are currently facing. Nanoparticles and nanocomposites comprising zinc oxide [15], copper
oxide [16], iron oxide [17], and, especially, silver, have been widely used in textiles [18,19], dental
care [20], packaging [21], paints [22], and in a whole myriad of applications. Silver nanoparticles are one
of the most exploited nanomaterials for this end, as they have been used for over a century in the healing
of wounds and burns. Although chemical methods were successfully employed for AgNPs synthesis,
with the need to use sustainable and non-toxic methods in chemistry, a biocompatible modality
of AgNPs synthesis came about by using biological routes for nanoparticle synthesis (Figure 1).
Biosynthesis or bio-based synthesis of AgNPs may occur through three routes: fungal, bacterial,
or by plants, for the reduction of Ag+ to Ag0. The saturation of Ag0 monomers in suspension eventually
leads to a burst-nucleation process [23] in which nanoclusters of metallic silver are produced and
stabilized by biomolecules from the biological extracts.
 
Figure 1. Biological extracts may be prepared from any part of plant material, or via extracellular/
intracellular processes using fungi and bacteria cultures. The extracts are rich in biomolecules such as
sugars, proteins, nucleic acids, and metabolites that either have a stabilizing potential or reducing and
stabilizing potential for the formation of silver nanoparticles.
The demand of products for the combat of MDR bacterial strains such as Pseudomonas aeruginosa,
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA),
erythromycin-resistant Streptococcus pyogenes, and ampicillin-resistant Escherichia coli [24] has led to the
design of powerful antimicrobial materials that are reinforced with silver nanoparticles [25]. Today,
in medicinal practice, there are wound dressings, contraceptive devices, surgical instruments, bone
prostheses, and dental implants which are coated or embedded with nanosilver [26–31]. In daily life,
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consumers may find nanosilver in room sprays, laundry detergents, water purification devices and
paints [26,32,33]. In the final part of this review, some of the recent advances in patented technologies
containing AgNPs that establish viable grounds for the development of biogenic AgNPs-containing
products for MDRB eradication purposes are cited and discussed.
2. Antibiotics
Antibiotics gained popularity because of their effectiveness or activities against microorganisms,
as described by Selman Waksman [34], and refers to an application, and not a class of compound
or its function [35]. The first compound with antibacterial activity discovered was arsphenamine,
synthesized in 1907 by Alfred Bertheim in Paul Ehrlich’s laboratory, with antisyphilitic activity
identified in 1909 by Sahachiro Hata [36,37]. Classically, the golden era of antibiotics refers to the
period between the 50s and 70s, when the discovery of different classes of antibiotics took place [38].
For a more detailed review of antibiotics and antibacterial drugs, see Bbosa et al., 2014 [39]. Figure 2
illustrates the main antibiotic classes and examples of compounds, with corresponding dates of
discovery and resistance as first reported.
Figure 2. Illustration of different classes of antibiotics. Antibiotics that act as bactericidal agents, i.e.,
cause cell death, are shown in rectangles with orange borders; antibiotics that act as bacteriostatic
agents, i.e., restrict growth and reproduction, are shown in rectangles with dashed line orange borders.
Years shown in blue indicate when the antibiotic class was discovered (the first number), and when
resistance was first reported (the second number). The structure and years of discovery and resistance
refer to the first antibiotic from each class [35,40–46].
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3. The Emerging of Antimicrobial Resistance
One of the most famous antibiotics, Penicillin, was discovered in 1928 by Alexander Fleming.
In 1940, before its public use, the same group identified a bacterial penicillinase [47], an enzyme
able to degrade penicillin. This fact can now be related to the number of antibiotic genes that are
naturally present in microbial populations [48]. In Japan, during the 50s, genetically transferable
antibiotic resistance was identified. This discovery introduced the concept that antibiotic genes could
spread among a population of bacterial pathogens using bacterial conjugation [49,50]. This horizontal
gene transfer is important throughout genome evolution and currently presents a serious threat [51].
The bacterial genetic elasticity prompts the acquisition of genetic material, mutational adaptations,
or changes in gene expression, leading to the survival of the fittest organism and the generation of
resistance to antibiotics [52]. For more details regarding antibiotic resistance development, mechanisms,
emergence, and spread see further references [52–58].
Currently, we face a deficiency in the development of new antibiotics to face the growing
antimicrobial resistance. The constant increment in the emergence of resistant strains has not been
balanced by the availability of new therapeutic agents for many reasons [59,60]. Firstly, policy-makers
want to avoid the use of new antibiotics until they are indispensable, because of the resistance
development. On the other hand, society needs the pharmaceutical industry to design and develop
new drugs, which should not be used. Moreover, antibiotics are used in the short-term, which does not
help companies to make a sustained profit. Also, the excessive cost of development and the regulatory
onus makes it difficult to attend a demand for cheap antibiotics [61]. Looking at this alarming scenario
the design of new therapeutics and/or new approaches is imperative.
4. Biogenic AgNPs as a Weapon against Multidrug-Resistant Bacteria (MDRB)
Traditionally, the synthesis of AgNPs using chemical approaches has been the most explored for a
better size and shape control, preparation of nanocomposites and elucidation of electronic properties.
However, the necessity of applying the well-known antibacterial activity of AgNPs in biological
systems propelled the development of a new synthesis approach. The biological, biogenic, or bio-based
methods for AgNPs synthesis present four main advantages: (1) increased biocompatibility, once
AgNPs are produced in water and capped with biomolecules such as proteins, sugars or metabolites;
(2) diminished toxicity, as the reducing agents are natural compounds that usually have mild reducing
strength; (3) easy production, such as preparation of an extract from fungi, bacteria or plants, followed
by the addition of a silver salt (typically, silver nitrate); and (4) low cost [62]. Despite positive
aspects, the lack of control of shape and size of the nanoparticles is still a challenge for biogenic
synthesis methods.
Because every biological synthesis is different from another as a consequence of using distinct
species, the capping agents on the surface of the nanoparticles may differ. The concept of “protein
corona” [63], for instance, describes the existence and dynamics of a protein shell surrounding
nanoparticles in a biological environment or after a biological synthesis [64]. The interaction of
biologically synthesized AgNPs with a bacterial cell will inherently involve the contact with the
microorganism and the outer biomolecule shell. Thus, this interaction is unique as new joint effects
(between biomolecules and the silver itself) can arise and improve the antibacterial action due to a
change in toxicity, cell uptake, and bio-distribution [65].
In the case of MDRB, the mechanism of action of AgNPs is distinct from the mechanism by which
traditional antibiotics act, and thus resistance does not pose an obstacle that cannot be overcome in
most cases. In the following sections, each type of biological synthesis is detailed along with a literature
review of biogenic AgNPs being used against MDRB. In most of the papers reviewed, the bacterial
strains used for susceptibility and antibacterial tests were clinical isolates from hospital patients,
however the list of antibiotics to which the strain is resistant is not always described. Also, in many
cases the strain used is standardized (ATCC strains, for example), but no details on the drug resistance
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capacity are provided. Here, we emphasize the examples where the provenience and description of
the bacterial strain are well detailed, along with a robust antibacterial testing methodology.
4.1. Fungal AgNPs against MDRB
The synthesis of AgNPs using fungal cells may be performed outside the cells (extracellular synthesis)
or inside the cells (intracellular synthesis) [66]. The former is the most recurrent in the literature, in which a
fungal filtrate is obtained after the cultivation of the microorganism and a silver salt solution is added to
it. Advantages of extracellular synthesis include ease of purification (as nanoparticles are not inside or
attached to the fungus), facilitated downstream processing, and improved size control [67]. Despite usually
having high reproducibility, fungal syntheses are time-consuming, as the fungi grow at a slower rate when
compared to bacteria or the preparation of a plant extract. Moreover, the reduction of silver ions is also a
gradual process, taking up to 96 h for completion. Fusarium oxysporum is perhaps the most studied species
for AgNPs biosynthesis [19,68]; the mechanism of nanoparticle formation involves the reduction of silver(I)
by a nitrate reductase and a shuttle quinone [69]. Scandorieiro et al. [70] demonstrated the synergistic
effect of F. oxysporum produced AgNPs with oregano essential oil against a range of antibiotic-resistant
bacterial strains, including MRSA and beta-lactamase producing strains. Naqvi et al. [14] also showed the
effectiveness of a synergistic approach by combining Aspergillus flavus produced AgNPs with well-known
commercial antibiotics resulting in an increase of up to 7-fold in the area of inhibition against bacterial
strains resistant to the same antibiotics. In fact, a combinational therapy is highly desirable taking into
consideration the development of AgNPs tolerance in bacteria via genetic evolution [71]. Chowdhury et al.
studied the effect of AgNPs synthesized by Macrophomina phaseolina against ampicillin and chloramphenicol
resistant E. coli and noted plasmid fragmentation and a decrease of supercoiled plasmid content upon
incubation of the circular DNA with nanoparticles [72]. On the other hand, nanoparticle attachment to
the cell wall and leakage of cell components induced by Penicillium polinicum-produced AgNPs were
observed in transmission micrographs by Neethu et al. [73], which confirms that more than one antibacterial
mechanism is possible (this theme is further explored in Section 4.4). Table 1 brings a summary of fungal
AgNPs and their activity against MDR bacterial strains.
Table 1. Fungi-mediated AgNPs biosynthesis and their activity against (MDRB).
Fungus AgNPs Size (nm) Target MDR Microorganism Test Type a Test Result b Reference
Aspergillus flavus 5–30
E. coli ZI 15 ± 1.5 mm
[14]
S. aureus ZI 16 ± 2 mm
M. luteus ZI 14 ± 1 mm
P. aeruginosa ZI 14 ± 1.5 mm
E. faecalis ZI 15 ± 1.5 mm
A. baumanii ZI 15 ± 1 mm
K. pneumoniae ZI 14 ± 0.6 mm
Bacillus spp. ZI 15 ± 1.5 mm
Fusarium oxysporum NGD 16.3–70
Enterobacter sp. ZI 31 mm
[74]
P. aeruginosa ZI 20 mm
K. pneumoniae ZI 19 mm
E. coli ZI 2 mm
Trichoderma viride 5–40
E. coli ZI 16–28 mm (*)
[75]
S. typhi ZI 19–36 mm (*)
S. aureus ZI 10–19 mm (*)
M. luteus ZI 9–17 mm (*)
Aspergillus niger 30–40
S. aureus ZI 15 ± 0.23 mm
[76]
B. cereus ZI 16 ± 0.32 mm
P. vulgaris ZI 14 ± 0.26 mm
E. coli ZI 14 ± 0.44 mm
V. cholerae ZI 13 ± 0.51 mm
Tricholoma crassum 5–50
E. coli (DH5 α) ZI 17.5 ± 0.5 (**)
[77]A. tumifaciens (LBA4404) ZI 20.0 ± 0.5 (**)
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Table 1. Cont.
Fungus AgNPs Size (nm) Target MDR Microorganism Test Type a Test Result b Reference
Agaricus bisporus -
E. coli ZI 14 mm
[78]
Klebsiella sp. ZI 15 mm
Pseudomonas sp. ZI -
Enterobacter sp. ZI 18 mm
Proteus sp. ZI 20 mm
S. aureus ZI 17 mm
S. typhi ZI 22 mm
S. paratyphi ZI 17 mm
Aspergillus clavatus 550–650 (AFM) S. aureus ZI 20.5 mm [79]S. epidermidis ZI 19 mm
Penicilium polonicum 10–15 A. baumanii MIC, MBC, ZI
15.62 μg mL−1 (MIC),
31.24 μg mL−1 (MBC),
21.2 ± 0.4 mm (ZI)
[73]
Cryphonectria sp. 30–70
S. aureus (ATCC-25923) ZI 16 ± 0.69 mm
[80]S. typhi (ATCC-51812) ZI 12 ± 0.29 mm
E. coli (ATCC-39403) ZI 13 ± 1.54 mm
Rhizoppus spp. 27–50 E. coli ZI 15–22 mm (***) [81]
Fusarium oxysporum 77.68
S. aureus (MRSA 101) MIC, MBC 250 μM (MIC),500 μM (MBC)
[70]
S. aureus (MRSA 107) MIC, MBC 250 μM (MIC),500 μM (MBC)
E. coli (ESBL 167) MIC, MBC 125 μM (MIC),125 μM (MBC)
E. coli (ESBL 169) MIC, MBC 125 μM (MIC),125 μM (MBC)
E. coli (ESBL 176) MIC, MBC 125 μM (MIC),125 μM (MBC)
E. coli (ESBL 192) MIC, MBC 125 μM (MIC),125 μM (MBC)
E. coli (KPC 131) MIC, MBC 125 μM (MIC),125 μM (MBC)
E. coli (KPC 133) MIC, MBC 125 μM (MIC),125 μM (MBC)
A. baumannii (CR 01) MIC, MBC 125 μM (MIC),125 μM (MBC)
Aspergillus flavus 5–30
E. coli ZI 15 ± 1.5 mm
[14]
S. aureus ZI 16 ± 2 mm
M. luteus ZI 14 ± 1 mm
P. aeruginosa ZI 14 ± 1.5 mm
E. faecalis ZI 15 ± 1.5 mm
A. baumannii ZI 15 ± 1 mm
K. pneumoniae ZI 14 ± 0.6 mm
Bacillus spp. ZI 15 ± 1.5 mm
Macrophomina phaseolina 5–40
E. coli (DH5α-MDR) ZI 3.0 ± 0.2 mm (**)
[72]A. tumefaciens (LBA4404-MDR) ZI 3.3 ± 0.2 mm (**)
a ZI = zone of inhibition; MIC = Minimum Inhibitory Concentration; MBC = Minimum Bactericidal Concentration.;
b For tests in which more than one concentration of AgNPs was used, the best results are shown; (*) Values related to
a synergistic effect with distinct antibiotics; (**) Values estimated from graphs; (***) More than one bacterial isolate
was used.
4.2. Bacterial AgNPs against MDRB
Similarly to fungal biosynthesis, bacterial AgNPs biosynthesis may also be performed extra- or
intracellularly [82]. The former can be done by using the cell biomass, where the reducing agents are
secreted by the cells and the nanoparticles formed might be attached to the bacterial wall (which can
possibly extend the purification process). In contrast, using a bacterial supernatant/cell-free extract has
the advantage of facilitating the downstream process and purification procedures by utilizing a sterile
biomolecule-rich mixture to synthesize the nanoparticles, often with the aid of microwave [83] or light
irradiation [84]. Conversely, the intracellular AgNPs synthesis takes place inside the cell, often in the
periplasmic space [85]. This mechanism requires a certain metal resistance from the bacteria [86] or
exposure to very low concentrations of the silver salt, as the Ag+ ion must be imported without causing
any major damage. The biggest disadvantage of this method is the purification as the nanoparticles
must be removed from the interior of the cells. Ultrasonication is usually the most common method
used for this end [87].
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Singh et al. [88] prepared AgNPs from the culture supernatant of Aeromonas sp. THG-FG1.2
extracted from soil and obtained inhibition of several bacterial strains otherwise completely insensitive
to erythromycin, lincomycin, novobiocin, penicillin G, vancomycin, and oleandomycin. Desai et al. [89]
reported a hydrothermal biosynthesis of AgNPs using a cell-free extract of Streptomyces sp. GUT 21
by autoclaving the bacterial extract along with a silver salt solution. The nanoparticles were between
20–50 nm in size and active towards MDRB up to a concentration of 10 μg mL−1. Sunlight exposure
is also a good methodology for AgNPs biosynthesis, as demonstrated by Manikprabhu et al. [90].
Nanoparticles were produced from Sinomonas mesophila MPKL 26 cell supernatant in contact with
silver nitrate upon up to 20 min of sun exposure. Specific secreted extracellular compounds can also
be used for AgNPs synthesis. Santos et al. [91] attribute the formation of AgNPs smaller than 10 nm
to xanthan gum produced during the growth of Xanthomonas spp. The nanoparticles could inhibit,
to a certain extent, the growth of MDR Acinetobacter baumannii and Pseudomonas aeruginosa. Table 2
brings a summary of AgNPs produced by bacteria with activity against MDRB.
Table 2. Bacteria-mediated AgNPs biosynthesis and their activity against MDRB.
Bacteria AgNPs Size (nm) Target MDR Microorganism Test Type a Test Result b Reference
Streptomyces 20–70
K. pneumoniae (ATCC 100603) MIC 4 μg mL−1
[92]K. pneumoniae MIC 1.4 μg mL
−1
E. coli MIC 2 μg mL−1
Citrobacter MIC 2 μg mL−1
Bacillus sp. 14–42
S. epidermidis strain 73 (pus) ZI 15 mm
[93]
S. epidermidis strain 145
(catheter tips) ZI 19 mm
S. epidermidis strain 152 (blood) ZI 19 mm
S. aureus (MTCC 87) ZI 18 mm
S. typhi ZI 13 mm
S. paratyphi ZI 15 mm
V. cholerae (MTCC 3906) ZI 18 mm
Bacillus cereus 24–46
E. coli MIC, ZI 6.25 μg mL
−1 (MIC),
16 ± 1 mm (ZI)
[94]
S. aureus MIC, ZI 12.5 μg mL
−1 (MIC),
14 ± 1 (ZI)
K. pneumoniae MIC, ZI >3.12 μg mL
−1 (MIC),
17 ± 1 mm (ZI)
P. aeruginosa MIC, ZI 3.12 μg mL
−1 (MIC),
23 ± 1 mm (ZI)
Bacillus safensis (LAU 13) 5–95
E. coli ZI 11–19 mm
[95]
K. granulomatis ZI 11–19 mm
P. vulgaris ZI 11–19 mm
P. aeruginosa ZI 11–19 mm
S. aureus ZI 11–19 mm
Aeromonas sp.
THG-FG1.2 8–16
B. cereus (ATCC 14579) ZI 13.5 ± 0.5 mm
[88]
B. subtilis (KACC 14741) ZI 13 ± 1.0 mm
S. aureus (ATCC 6538) ZI 15.5 ± 0.5 mm
E. coli (ATCC 10798) ZI 13 ± 0.2 mm
P. aeruginosa (ATCC 6538) ZI 16 ± 0.1 mm
V. parahaemolyticus
(ATCC 33844) ZI 16 ± 0.1 mm
S. enterica (ATCC 13076) ZI 11 ± 0.2 mm
C. albicans (KACC 30062) ZI 20 ± 0.1 mm
C. tropicalis (KCTC 7909) ZI 15 ± 0.5 mm
Bacillus thuringiensis 15
E. coli ZI 12 ± 1 mm (*)
[96]P. aeruginosa ZI 16 ± 1 mm (*)
S. aureus ZI 9 ± 1 mm (*)
Anabaena diololum
10–50 K. pneumoniaeDF12SA (HQ114261) ZI 36 ± 0.82 mm
[97]10–50 E. coli DF39TA (HQ163793) ZI 33 ± 1.63 mm
10–50 S. aureus DF8TA (JN642261) ZI 34 ± 0.81 mm
Streptomyces sp. GUT 21 23–48
E. coli (MTCC 9537) MIC, ZI 14 μg mL
−1 (MIC),
27.05 ± 3.20 mm (ZI)
[89]
K. pneumoniae (MTCC 109) MIC, ZI 12 μg mL
−1 (MIC),
28.50 ± 2.60 mm (ZI)
S. aureus (MTCC 96) MIC, ZI 15 μg mL
−1 (MIC),
24.25 ± 2.09 mm (ZI)
P. aeruginosa (MTCC 1688) MIC, ZI 10 μg mL
−1 (MIC),
10.05 ± 3.60 mm (ZI)
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Table 2. Cont.
Bacteria AgNPs Size (nm) Target MDR Microorganism Test Type a Test Result b Reference
Bacillus megaterium 80–98.56 (AFM) S. pneumoniae ZI 21 mm [98]S. typhi ZI 18 mm
Xanthomonas spp. 5–40
P. aeruginosa ZI 10.0 ± 1.0 mm
[91]baumannii ZI 10.6 ± 0.6 mm
Sinomonas mesophila
MPKL 26 4–50 S. aureus ZI 12 mm [90]
Bacillus flexus 12–65
E. coli ZI 11.55 mm
[99]
P. aeruginosa ZI 11.05 mm
S. pyogenes ZI 11.65 mm
subtilis ZI 11.55 mm
Bacillus brevis
(NCIM 2533) 41–68
S. aureus ZI 19 mm
[100]S. typhi ZI 7.5 mm
a ZI = zone of inhibition; MIC = Minimum Inhibitory Concentration; MBC = Minimum Bactericidal Concentration;
b For tests in which more than one concentration of AgNPs was used, the best results are shown; (*) Values estimated
from graphs.
4.3. AgNPs from Plants against MDRB
Production of AgNPs using plant extracts is perhaps the most explored method in biogenic
synthesis, probably due to the easiness of the procedure and wide availability of species to work
with [101]. The whole plant, the stem, pod, seeds, fruit, flowers, and, most frequently, leaves are used
to prepare an extract, which may be done in cold or hot solvent and almost always utilizes water
(despite the fact that organic solvent extracts have also been used). The abundance of components such
as reducing sugars, ascorbic acid [102], citric acid [103], alkaloids and amino acids [104], along with
slightly soluble terpenoids [105], flavonoids [106], and other metabolites in various parts of the plant
may easily act as reducing agents, converting Ag+ to AgNPs in shorter times (when compared to fungal
or bacterial syntheses). Due to the lower protein content in most plants, the capping biomolecule
shell often has a significant contribution of polysaccharides [107] and other molecules. Most reports
on plant biosynthesis are studies of plant species found in the surroundings of the university or city
where the laboratory is located, however, in vitro-derived culture of plants can also be used for these
purposes [108].
Ma et al. [107] reported on the biosynthesis of 60 nm AgNPs using polysaccharide-rich root
extract of Astragalus membranaceus and compared the bacterial inhibition against reference strains of
E. coli, P. aeruginosa, S. aureus, and S. epidermidis with clinically isolated MDR strains of these bacteria.
Interestingly, the nanoparticles were slightly more active toward the resistant strains.
The nanoparticle size is known to play an important role in antibacterial activity [24], and this
is no different for MDR strains. AgNPs synthesized by Caesalpinia coriaria leaf extract, which were
50–53 nm were shown to be more active towards MDR bacterial clinical isolates when compared to
79–99 nm AgNPs [109].
Despite the common belief that biological synthesis implies a lack of control for Ag+ reduction
and poor shape control, Jinu et al. [110] demonstrated the synthesis of cubic and triangular shaped
20 nm AgNPs using Solanum nigrum leaf extract. The nanoparticles had a contributing effect along with
the antimicrobial plant extract towards six MDRB strains. Moreover, these AgNPs showed antibiofilm
activity against P. aeruginosa and S. epidermidis. Prasannaraj et al. [111] reported an extensive study
using ten different plant species for AgNPs biosynthesis, yielding spherical, cubic, and fiber-like
nanoparticles. All of them inhibited bacterial growth of clinically isolated MDR pathogens and some
also displayed antibiofilm activity against P. aeruginosa and S. epidermidis. The authors correlate the
results with the 3 to 4-fold increase in reactive oxygen species (ROS) by AgNPs.
Intracellular ROS production was also observed by flow cytometry for Ocimum gratissimum
leaf extract-produced AgNPs [112]; the authors suggest that the membrane damage caused by the
nanoparticles could prevent efficient electronic transport in the respiratory chain. This was confirmed
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by micrographs of MDR E. coli and S. aureus cells treated with AgNPs, which showed leakage of
intracellular content and pits in the membrane.
The antibacterial properties of silver can also be delivered by silver chloride nanoparticles
(AgCl-NPs), as shown by Gopinath et al. [113]. AgNPs and AgCl-NPs were produced from Cissus
quadrangularis leaf extract and were active towards both Gram-negative and Gram-positive MDR
strains. In this case, chloride ions were identified in the extract and attributed to the formation of
AgCl nanocrystals.
Table 3 presents the gathered data on plant biosynthesis of AgNPs with the corresponding activity
against MDRB.




Target MDR Microorganism Test Type a Test Result b Reference
Olive leaf 20–25
S. aureus ZI 2.4 ± 0.2 cm (*)
[114]P. aeruginosa ZI 2.4 ± 0.2 cm (*)
E. coli ZI 1.8 ± 0.2 cm (*)
Phyllanthus
amarus Whole plant 24 ± 8 P. aeruginosa MIC, ZI
6.25–12.5 μg mL−1 (MIC),
10 ± 0.53 to 21 ± 0.11 mm (ZI) [115]
Corchorus
capsularis leaf 5–45
P. aeruginosa ZI 17 mm
[116]S. aureus ZI 21 mm
Coagulase




S. pyogens ZI 10 mm
[117]
E. coli ZI 10.75 mm
P. aeruginosa ZI 9.25 mm
B. subtilis ZI 9.25 mm
S. aureus ZI 9.75 mm
Garcinia
mangostana leaf 35
E. coli ZI 15 mm





B. fusiformis ZI 2.90 cm




E. coli ZI 12.0 ± 0.50 mm
[109]
P. aeruginosa ZI 18.3 ± 0.80 mm
K. pneumonia ZI 14.6 ± 1.20 mm
S. aureus ZI 10.3 ± 1.20 mm
78–98
E. coli ZI 9.6 ± 0.80 mm
[109]
P. aeruginosa ZI 18.3 ± 1.20 mm
K. pneumonia ZI 13.3 ± 0.30 mm
S. aureus ZI 11.0 ± 0.00 mm
Mimusops
elengi leaf 55–83
K. pneumoniae ZI 18 mm
[120]S. aureus ZI 10 mm
M. luteus ZI 11 mm
Ocimum
gratissimum leaf 16 ± 2
E. coli (MC-2) MIC, MBC, ZI
4 μg mL−1 (MIC),
8 μg mL−1 (MBC),
12 ± 0.6 mm (ZI)
[112]
S. aureus (MMC-20) MIC, MBC, ZI
8 μg mL−1 (MIC),
16 μg mL−1 (MBC),
16 ± 1.0 mm (ZI)
Hydrocotyle
sibthorpioides Whole plant 13.37 ± 10
K. pneumonia ZI 3.0 ± 0.17 mm
[121]P. aeruginosa ZI 2.7 ± 0.32 mm
S. aureus ZI 3.6 ± 0.57 mm
Vaccinium
corymbosum leaf 10–30
E. coli (ATCC 25922) MIC, MBC, ZI 11.22 ± 0.29 mm
[122]
S. aureus (ATCC 25923) MIC, MBC, ZI 13.1 ± 1.1 mm
P. aeruginosa (ATCC 27853) MIC, MBC, ZI 11.6 ± 0.32 mm
B. subtilis (ATCC 21332) MIC, MBC, ZI 12.4 ± 0.40 mm
Prosopis
farcta leaf 10.8 ± 3.54
S. aureus (PTCC 1431) ZI 9.5 mm
[123]
B. subtilis (PTCC 1420) ZI 9 mm
E. coli (PTCC 1399) ZI 9.5 mm
P. aeruginosa (PTCC 1074) ZI 9.5 mm
Sesbania
gradiflora leaf 10–25
S. enterica ZI 15.67 ± 0.09 mm
[124]S. aureus ZI 10.54 ± 0.23 mm
Solanum
nigrum leaf 20
K. pneumoniae ZI 21.5 mm
[110]
P. aeruginosa ZI 21.3 mm
S. epidermidis ZI 19.6 mm
E. coli ZI 15.3 mm
P. vulgaris ZI 13.3 mm
S. aureus ZI 9.6 mm
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S. pyogens MIC, ZI 4 μg mL
−1 (MIC),
7.77 ± 0.25 mm (ZI)
[113]
S. aureus MIC, ZI 3 μg mL
−1 (MIC),
8.83 ± 0.26 mm (ZI)
E. coli MIC, ZI 5 μg mL
−1 (MIC),
7.9 ± 0.31 mm (ZI)
P. vulgaris MIC, ZI 7 μg mL
−1 (MIC),
8.4 ± 0.40 mm (ZI)
Cola nitida pod 12–80
E. coli ZI 19 ± 0.9 mm
[125]K. granulomatis ZI 11 ± 0.8 mm
P. aeruginosa ZI 28 ± 0.1 mm
Strychnos
potatorum leaf 28
S. aureus ZI 8 mm




E. coli ZI 10.0 ± 2.8 mm
[111]
P. aeruginosa ZI 8.0 ± 1.4 mm
K. pneumoniae ZI 11.0 ± 1.0 mm
S. aureus ZI 10.0 ± 3.0 mm
P. vulgaris ZI 8.3 ± 0.6 mm
S. epidermidis ZI 10.6 ± 1.2 mm
Andrographis
paniculata leaf 70
E. coli ZI 8.0 ± 1.4 mm
[111]
P. aeruginosa ZI 6.7 ± 0.7 mm
K. pneumoniae ZI 9.3 ± 0.6 mm
S. aureus ZI 8.0 ± 1.0 mm
P. vulgaris ZI 8.3 ± 0.6 mm




E. coli ZI 11.0 ± 2.8 mm
[111]
P. aeruginosa ZI 9.0 ± 1.4 mm
K. pneumoniae ZI 9.3 ± 1.6 mm
S. aureus ZI 9.7 ± 1.5 mm
P. vulgaris ZI 9.7 ± 0.6 mm




E. coli ZI 12.7 ± 0.7 mm
[111]
P. aeruginosa ZI 8.0 ± 1.4 mm
K. pneumoniae ZI 12.0 ± 1.0 mm
S. aureus ZI 13.0 ± 2.0 mm
P. vulgaris ZI 9.7 ± 0.6 mm
S. epidermidis ZI 14.0 ± 1.0 mm
Eclipta
prostrata leaf 70
E. coli ZI 10.0 ± 4.0 mm
[111]
P. aeruginosa ZI 8.3 ± 2.5 mm
K. pneumoniae ZI 10.0 ± 5.2 mm
S. aureus ZI 12.6 ± 4.9 mm
P. vulgaris ZI 6.6 ± 0.5 mm
S. epidermidis ZI 8.0 ± 0.0 mm
Moringa
oleifera leaf 50
E. coli ZI 7.7 ± 0.6 mm
[111]
P. aeruginosa ZI 8.0 ± 1.7 mm
K. pneumoniae ZI 7.0 ± 1.0 mm
S. aureus ZI 9.0 ± 2.6 mm
P. vulgaris ZI 7.0 ± 2.0 mm
S. epidermidis ZI 7.0 ± 0.0 mm
Thespesia
populnea bark 70
E. coli ZI 9.0 ± 1.7 mm
[111]
P. aeruginosa ZI 10.3 ± 2.1 mm
K. pneumoniae ZI 11.3 ± 1.2 mm
S. aureus ZI 9.3 ± 2.4 mm
P. vulgaris ZI 8.6 ± 1.2 mm
S. epidermidis ZI 8.6 ± 0.7 mm
Terminalia
arjuna bark 70
E. coli ZI 8.0 ± 0.7 mm
[111]
P. aeruginosa ZI 9.0 ± 2.0 mm
K. pneumoniae ZI 14.0 ± 1.0 mm
S. aureus ZI 12.7 ± 1.1 mm
P. vulgaris ZI 8.3 ± 0.6 mm
S. epidermidis ZI 9.0 ± 2.0 mm
Plumbago
zeylanica Root bark 90
E. coli ZI 8.0 ± 1.4 mm
[111]
P. aeruginosa ZI 14.7 ± 0.7 mm
K. pneumoniae ZI 8.3 ± 0.8 mm
S. aureus ZI 7.7 ± 0.6 mm
P. vulgaris ZI 8.3 ± 0.6 mm




E. coli ZI 10.0 ± 2.0 mm
[111]
P. aeruginosa ZI 9.3 ± 1.5 mm
K. pneumoniae ZI 10.0 ± 1.0 mm
S. aureus ZI 7.7 ± 1.1 mm
P. vulgaris ZI 8.3 ± 0.6 mm
S. epidermidis ZI 9.3 ± 1.5 mm
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Acinetobacter sp. ZI 22 mm
[127]K. pneumoniae ZI 19 mm
P. aeruginosa ZI 20 mm
Phyllanthus
amarus Whole plant 24 ± 8 P. aeruginosa (***) MIC, ZI
6.25–12.5 μg mL−1 (MIC),
21 ± 0.11 mm (ZI) [115]
Ricinodendron
heudelotti Seed kernel 89.0 E. coli MIC, MBC
1.68 μg mL−1 (MIC),
6.75 μg mL−1 (MBC) [128]
Gnetum
bucholzianum leaf 67.4 E. coli MIC, MBC
1.687 μg mL−1 (MIC),




44.2 (AgCl) E. coli MIC, MBC
0.515 μg mL−1 (MIC),




37.9 (AgCl) E. coli MIC, MBC
8.25 μg mL−1 (MIC),




37.9 (AgCl) E. coli MIC, MBC
5.3 μg mL−1 (MIC),
5.3 μg mL−1 (MBC) [129]
Areca catechu leaf 22–40
E. coli ZI 20 mm
[129]
P. aeruginosa ZI 24 mm
S. typhi ZI 19 mm
P. vulgaris ZI 23 mm
K. pneumoniae ZI 26 mm
Cocoa bean 8.96–54.22
S. aureus ZI 12 mm (*)
[130]
K. pneumoniae (wound) ZI 12 mm (*)
K. pneumoniae (urine) ZI 13 mm (*)
E. coli ZI 14 mm (*)
Cocoa Pod husk 4–32
K. pneumoniae ZI 10–14 mm




E. coli (ATCC 15224) ZI 13.2 ± 0.12
[108]S. aureus (ATCC 6538) ZI 11.1 ± 0.10
K. pneumoniae (ATCC 4619) ZI 10.3 ± 0.11
Momordica
cymbalaria fruit 15.5
E. coli ZI 24.0 ± 1.0
[132]
M. luteus ZI 20.0 ± 1.4
B. cereus ZI 22.0 ± 1.0
K. pneumoniae ZI 26.0 ± 1.4
S. pneumoniae ZI 26.0 ± 1.7
Astragalus
membranaceus root 65.08
S. aureus (MRSA) MIC, ZI 0.063 mg mL
−1 (MIC),
12.83 ± 1.04 mm (ZI)
[107]
S. epidermidis (MRSE) MIC, ZI 0.063 mg mL
−1 (MIC),
12.33 ± 0.29 mm (ZI)
P. aeruginosa MIC, ZI 0.032 mg mL
−1 (MIC),
15.17 ± 0.76 mm (ZI)
E. coli MIC, ZI 0.032 mg mL
−1 (MIC),
14.67 ± 0.76 mm (ZI)
a ZI = zone of inhibition; MIC = Minimum Inhibitory Concentration; MBC = Minimum Bactericidal Concentration;
b For tests in which more than one concentration of AgNPs was used, the best results are shown; (*) Values estimated
from graphs; (**) Silver chloride nanoparticles; (***) 15 strains were tested
4.4. Modes of Action of AgNPs against Bacteria
As stated in previous reviews on the subject [24,133–137], the antibacterial action of silver
nanoparticles involves a complex mechanism in which more than one factor can act simultaneously
to contribute to an overall effect. Moreover, one must consider the existence of more than one silver
species, these being the Ag0 in the form of nanoparticles and the Ag+ which is released from the
surface of the nanoparticles as they are slowly oxidized.
Proteomic analysis of E. coli proteins expressed after exposure to AgNPs and Ag+ revealed that
both have a similar mode of action, such as overexpressing envelope and heat shock proteins. However,
the nanoparticles were effective at inhibiting bacteria in the nanomolar concentration, whereas the
Ag+ ions were effective only in the micromolar range [138]. On the other hand, further reports point
to the opposite direction. Ag+ release depends on oxidation of metallic silver by oxygen in the air;
in a study where E. coli was exposed to AgNPs in anaerobic conditions, no bactericidal activity was
observed, while in aerobic conditions the usual antimicrobial activity was noticed [139]. This effect can
be partially explained by a strong interaction of Ag+ with the cell membrane and cell wall components
such as proteins, phospholipids, and thiol-containing groups, as well as by a proton leakage that can
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induce cell disintegration [140]. As much as the affinity of Ag+ for thiol groups has been known for
decades [141], just recently Liao et al. [142] demonstrated how Ag+ can deplete intracellular thiol
content of S. aureus and bind to cysteine residues of thioredoxin reductase’s catalytic site. This enzyme
is one of the most important ones related to the antioxidant mechanism and reactive oxygen species
(ROS) levels regulation in bacteria. Binding to respiratory chain enzymes is also a factor for intracellular
ROS increase [143]. It is worth noting, however, that the protein corona that involves AgNPs has a
significant effect on silver ions release. According to a study performed by Wen et al. [144], the binding
of cytoskeletal proteins to AgNPs led to a decrease in Ag+ leakage, which could suggest that, similarly,
biogenic AgNPs that are capped by biomolecules also have a diminished Ag+ release and thus their
antimicrobial action would rely much less on this species.
Regarding the action of the nanoparticles, their size, shape and capping molecules may play
significant roles when binding to the cell wall, membrane, and their internalization. In a study
performed with silver nanospheres, nanocubes, and nanowires, the latter resulted in diminished
antimicrobial activity when compared to the first two due to a smaller effective contact area with the
cell membrane [145]. The same explanation applies for truncated octahedral AgNPs outperforming
spherical AgNPs [146]. Truncated triangular shaped AgNPs had a better performance than all the other
shapes in a study conducted against E. coli [147]. Acharya et al. [148] recently reported a study on silver
nanospheres and silver nanorods acting against K. pneumoniae and attributed the antibacterial activity
to the {111} plane shapes, which contain the highest atomic density. Smaller sizes of nanoparticles also
lead to an enhanced bactericidal effect [149,150]. This effect is due to a greater surface area in contact
with the bacteria that facilitate membrane rupture and internalization [151].
Perhaps one of the most accepted antibacterial mechanisms involves the association of nanoparticles
with the cell wall followed by the formation of “pits” [152] and leakage of cellular contents [153].
This corroborates with the fact that AgNPs are usually more active towards Gram-negative bacteria [154],
as Gram-positive bacteria have a thicker peptidoglycan cell wall, which could act as an additional physical
barrier. Once inside the bacterial cell (a process that is facilitated by sizes smaller than 5 nm [155]),
small nanoparticles are able to interfere with the respiratory chain dehydrogenases [156] and also induce
generation of intracellular ROS [112,157], which have the ability to cleave DNA [158] and diminish bacterial
life. It must be also pointed out that the interaction of AgNPs with the media which they are suspended
in has a great influence on AgNPs physicochemical properties and their action on bacterial cells [159].
Figure 3 illustrates all the major mechanisms by which AgNPs display their antibacterial action.
Figure 3. Summary of the factors affecting the antimicrobial capacity of AgNPs and main antibacterial
mechanisms. Size, shape and capping agents have a significant influence on the activity against
bacterial cells, which are susceptible to nanoparticles because of a strong affinity of the metal with
the cell wall and membrane, as well as due to interference in the respiratory chain and generation of
reactive oxygen species (ROS).
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4.5. Bacterial Resistance to Silver
The increasing application of silver nanomaterials in dressings, packages, and textiles has raised
concerns about the development of bacterial resistance to nanosilver, despite the good performance
of AgNPs against a range of bacterial strains, as already described. In fact, one of the first reports on
resistance to silver was published in 1975, when a strain of Salmonella typhimurium resistant to silver
nitrate, mercuric chloride, and a range of common antibiotics was identified in three patients in a burn
unit [160]. Decades later, this exogenous type of resistance was unveiled by Gupta et al. [161] through
the isolation of the plasmid pMG101. This plasmid was identified as the carrier of a silver resistance
gene silE, which encodes a 143-amino-acid periplasmic Ag+-specific protein. Upstream of silE, a series
of genes from the Sil system encode silver efflux-related proteins, such as a protein/cation antiporter
system and a P-type cation ATPase (Figure 4). Resistance to silver attributed to sil genes was also
recently reported for clinical isolates of Klebsiella pneumonia and Enterobacter cloacae [162]. Endogenous
(mutational) silver resistance may also be observed, as reported by Li et al. [163], who observed silver
resistance induced in E. coli cells by selectively culturing bacterial cells in increasing concentrations of
silver nitrate. In this case, mutant cells were deficient in major porins (OmpF and OmpC). Silver efflux
is also mediated through a CusCFBA efflux pump system, which has a high amino acid sequence
similarity with the Sil system, in spite of being an endogenous type of resistance [164]. Crystal
structures of proteins of the CusCFBA system suggest a methionine shuttle efflux mechanism, in which
Ag+ ions are ejected from the bacterial periplasm [165,166]. Nuclear magnetic resonance (NMR) and
inductively coupled plasma mass spectrometry (ICP-MS) studies have demonstrated that silver ions
may induce a histidine kinase (CuS) dimerization and this conformational change may have a reflex
on the upregulation of genes encoding the CusCFBA transport system [167]. The E. coli gene ybdE
belonging to the K38 chromosome was also pointed out as related exclusively to Ag+ resistance since
its deletion in silver-resistant mutant strains had no effect on Cu+ resistance [168]. Graves et al. [71]
recently performed an extensive study using a non-resistant E. coli strain for an evolutionary analysis
focused on mutations acquired upon exposure to silver nitrate and silver nanoparticles. After 300
generations, the Minimum Inhibitory Concentration (MIC) (using more than one type of AgNPs) of
treated bacteria was already between 1.40 and 4.70 times the MIC of control bacteria. Three main
mutations were observed: (1) in the cuS gene, which encodes the already mentioned histidine kinase
which functions as a sensor for the CusCFBA efflux pump; (2) in the purL gene, which encodes for an
enzyme involved in de novo purine nucleotide biosynthesis; and (3) in the rpoB gene, responsible for an
RNA polymerase beta subunit.
Figure 4. Silver efflux system found in Gram-negative silver-resistant bacteria. SilE is a periplasmic,
histidine-rich Ag+ binding protein; SilS belongs to a two-component (SilRS) transcription regulation
system; SilA, SilB, and SilC comprise a three-component chemiosmotic bacterial proton/cation antiporter.
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It is worth noting, however, that most of the studies cited are related to exogenous and endogenous
Ag+ resistance. The release of Ag+ ions by AgNPs is only one of the forms by which AgNPs might be
antimicrobial, as explained in Section 4.4. Few studies have looked at resistance to silver nanoparticles.
For instance, Panacek et al. [169] have observed E. coli resistance to 28 nm AgNPs in sub-MIC
concentrations without any genetic changes noted in E. coli. Only a phenotypic change in production
of flagellin was noted. Flagellin, an adhesive protein of the flagellum, related to biofilm formation
and motility, was found to readily induce nanoparticle aggregation and attenuate their antimicrobial
capacity. There is still much to be researched and discovered on outer membrane–metal interactions,
especially what accounts for different capping agents, topography, and morphology of AgNPs. Also,
other bacterial species and strains must be studied as to map genetic and/or phenotype modifications
induced by AgNPs.
5. Nanosilver Applications in Antimicrobial Products
The well-documented antimicrobial activities of AgNPs have attracted great attention from
researchers and companies and caused manufacturing of many products which are in everyday use.
For instance, dressings, biomedical equipment, paints, packaging materials, and gels containing
nanosilver formulations are widely used. However, the number of AgNPs-containing products that
are focused on or have been tested against MDRB is still unexpressive and modest. This is even
surprisingly true when it comes to biogenically or bio-based synthesized AgNPs. Nevertheless, among
many patents of products containing nanosilver, there are some possible applications of patented
formulations in the combat against resistant bacteria, which are summarized in Table 4.
Table 4. Patents of AgNPs-based products tested against resistant bacterial strains.
Patent Number Application Resistant Bacteria Reference
WO2006074117A2 Hydrogel E. cloacae, K. pneumoniae, E. coli, P. aeruginosa, A. Acinetobacter [170]
WO2018010403A1 Pharmaceuticals E. cloacae, K. pneumoniae, E. coli, P. aeruginosa, A. Acinetobacter [171]
US20100003296A1 Textiles Methicillin-resistant S. aureus (MRSA) [172]
KR200384433Y1 Apron, perfume Methicillin-resistant S. aureus (MRSA) [173]
KR100933736B1 Detergent additive E. coli [174]
CN105412940A General Vancomycin-resistant Enterococcus faecalis [175]
WO2005120173A2 General P. aeruginosa [176]
US7135195B2 General Methicillin-resistant S. aureus (MRSA) [177]
Despite the controversy that involves the oral use of silver nanoparticles, a recent patent has
established a preparation involving AgNPs active towards MDRB suggesting many possible forms
of administration, including oral, topical, and intravenous [171]. An invention communicated by
Holladay et al. [170] postulates compositions containing AgNPs that may be introduced into a hydrogel
for the treatment of various types of infections and inflammations, with activity against MDR E. cloacae,
K. pneumoniae, E. coli, P. aeruginosa, and A. Acinetobacter. In fact, the well-known wound healing
capacity of nanosilver is often exploited in dressings and plasters. Liang et al. [178] developed an
AgNPs/chitosan composite with amphiphilic properties—a hydrophobic and waterproof surface and
a hydrophilic one with a capacity to interact with water and inhibit the growth of the drugs resistant
S. aureus, E. coli, and P. aeruginosa. It is important to point out that these types of dressings with
asymmetric wettability properties also enhance re-epithelization and collagen deposition and might be
very helpful for wound healing not just because of their antiseptic properties.
Nanocrystalline silver coatings are already available commercially, for example, ACTICOAT™ has
been used against MDR P. aeruginosa in burn wound infections in rat models [179]. This dressing has
also been proven to be effective against methicillin-resistant S. aureus, by inhibiting bacterial growth in
burn wounds. But it also decreases the secretion and swelling of the damaged tissue areas [180], which
speeds up processes of wound healing.
An invention deposited by Paknikar (2006) [176] claims the production of biologically stabilized
AgNPs, which were produced from various plants parts, and their incorporation into a variety of
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possible carriers, such as ointments, sprays, membranes, plasters. The nanoparticles were shown to
successfully inhibit MDR strains of P. aeruginosa and other highly resistant bacterial strains: E. coli
ATCC 117, P. aeruginosa ATCC 9027, S. abony NCTC 6017, S. typhimurium ATCC 23564, K. aerogenes
ATCC 1950, P. vulgaris NCBI 4157, S. aureus ATCC 6538P, B. subtilis ATCC 6633., and C. albicans, and,
interestingly, were non-cytotoxic towards human leukemic cells (K562), carcinoma cells (HEPG2), and
mouse fibroblasts (L929) in the concentrations used against cited MRDB.
Also, there are some reports on materials that contain AgNPs, such as a multipurpose
nanocomposite comprising silver nanotriangles and silicon dioxide, which was developed and tested
against vancomycin-resistant bacteria E. Faecalis (ATCC 51299) [173]. There is a nanocomposite of silver
and silver oxide active towards methicillin-resistant S. aureus and a broad spectrum of pathogenic
bacteria associated with common infections and inflammations in humans [177].
Common household objects can also be enriched with AgNPs to enhance their antimicrobial
potential; for example, nanosilver has been used as a detergent additive to enhance the antibiotic
effect of the surfactant while not inducing any decrease in the detergent capability of a product [174].
The detergent can be used to disinfect resistant E. coli strains. Enhanced hygiene and diminished
contamination were also achieved by reinforcing aprons with AgNPs; the material was successful in
inhibiting methicillin-resistant S. aureus. Cheng and Yan [172] reported and patented the invention on
antimicrobial plant fibers enriched with AgNPs that showed strong antimicrobial activity. This material
may be applied in various types of linings, clothing, and even for fabricating laboratory or medical
coats with improved disinfection properties and thus avoid bacterial contamination.
As stated, there are still much to be discovered and researched until novel fabrics, commodities,
and/or pharmaceuticals based on biogenic or bio-based silver nanoparticles became suitable for
everyday applications.
6. Conclusions
Some of the main reasons for observing the multidrug resistance in bacteria were discussed along
with an introduction of biogenic silver nanoparticles as an alternative or combined technology to
overcome this growing health problem. Even though bio-based silver containing nanomaterials are
usually not ingested as known antibiotics, mainly due to a lack of understanding of the nanotoxicology
associated with nanosilver in the bloodstream or in organs, AgNPs may be incorporated in products
such as dressings, sprays, textiles, and paints for MDRB combat to a certain extent. Topical use of
ointments and wound dressings have become quite common, as AgNPs not only inhibit bacteria
growth but also stimulate epithelial growth and reduce swelling and secretion. Bacterial resistance to
silver is a concerning perspective; however, application of bio-based AgNPs may at least postpone
it because the extracts used for their synthesis might have natural antimicrobial effects that can act
synergistically with the nanosilver. Moreover, combined therapies based on biogenic AgNPs and
known antibiotics might be even more effective than the use of only one of them.
The development of biogenic AgNPs-containing products, which are active against MDRB,
finds its main obstacle in discovering a systematic, easy to reproduce, and scaled-up process for
the production of the uniform nanoparticles with desirable properties that do not vary, which is
extremely hard to achieve considering the biological provenience of the extracts. By the time these
processes become viable, controlled, and understood, the incorporation of the biologically synthesized
nanomaterials as novel biopharmaceuticals or their use as commercial products should find many
opportunities in various fields.
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Abstract: Silver nanoparticles (Ag NPs) were synthesized using Juglans regia (J. regia) leaf extract,
as both reducing and stabilizing agents through microwave irradiation method. The effects of a 1%
(w/v) amount of leaf extract (0.1–0.9 mL) and an amount of 1 mM AgNO3 solution (15–25 mL)
on the broad emission peak (λmax) and concentration of the synthesized Ag NPs solution were
investigated using response surface methodology (RSM). Fourier transform infrared analysis
indicated the main functional groups existing in the J. regia leaf extract. Dynamic light scattering,
UV-Vis spectroscopy and transmission electron microscopy were used to characterize the synthesized
Ag NPs. Fabricated Ag NPs with the mean particle size and polydispersity index and maximum
concentration and zeta potential of 168 nm, 0.419, 135.16 ppm and −15.6 mV, respectively,
were obtained using 0.1 mL of J. regia leaf extract and 15 mL of AgNO3. The antibacterial activity
of the fabricated Ag NPs was assessed against both Gram negative (Escherichia coli) and positive
(Staphylococcus aureus) bacteria and was found to possess high bactericidal effects.
Keywords: green synthesis; silver nanoparticles; microwave irradiation; Juglans regia; antibacterial
activity
1. Introduction
Silver is known as strong antimicrobial agent due to its toxicity against most microorganisms
including bacteria, fungi, and viruses [1]. As compared to the silver element in bulk state,
silver nanoparticles (Ag NPs) exhibit unusual physico-chemical and antimicrobial properties due to
their lower particle size (less than 100 nm) and higher surface area to volume ratio, which increase the
proportion of high-energy surface atoms [1–3]. Because of the marvelous antimicrobial properties of Ag
NPs, they have been widely utilized in numerous fields such as medicine, electronics, biotechnology,
water disinfection, air treatment, and packaging [3].
Green chemistry is the use of chemistry principles to reduce or eliminate the use of toxic reagents,
leading to lower amounts of undesirable residues, which in turn are harmful to human health or
the environment [4,5]. Incorporation of green chemistry and nanotechnology is of great interest and
has gained much attention over the past decade. Green synthesis of Ag NPs, using plants and their
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derivative extracts as an alternative method for the conventional physical and chemical NP fabrication
methods, has attracted considerable attention in recent years [1,6]. In fact, various metabolites existing
in the plants including sugars, alkaloids, phenolic acids, terpenoids, polyphenols, and proteins play an
important role in the bioreduction of silver ions to Ag NPs and their stabilization [7]. Several studies
have been completed on green synthesis of Ag NPs using Aloe vera and Pelargonium zonali leaf extract
and chitosan [8–10].
Walnut belongs to Juglandaceae family and has the scientific name Juglans regia (J. regia).
Numerous health benefits of walnut for human have been reported, some of which are related
to the existence of its main bioactive compounds including polyphenolic compounds, flavonoids,
proteins, carotenoids, lipids, and alkaloids. Leaf of walnut contains malic acid, sucrose, α-tocopherol,
3-O-caffeoylquinic acids, and quercetin O-pentoside as the most abundant organic acids, disaccharide,
tocopherol isomer and phenolic compounds, respectively [11–13].
The present work focuses on (i) the potential of walnut leaf extract in the fabrication of Ag NPs;
(ii) Ag NPs synthesized parameter optimization using microwave irradiation to achieve Ag NPs
with more desirable physico-chemical properties and (iii) an antibacterial activity assessment of the
produced Ag NPs.
2. Results
2.1. Formation of Ag NPs
During the synthesis of Ag NPs, the color of the mixture solution containing silver salt and walnut
leaf extract changed from colorless into brown and dark. In fact, the synthesized Ag NPs, due to their
surface plasmon resonance (SPR), changed the color of the mixture solution and this color change
verified the formation of Ag NPs using walnut leaf extract and microwave irradiation (Figure 1).
As clearly observed in Table 1, λmax of the synthesized Ag NPs was varied 424–429 nm, which was in a
favorable range for Ag NPs [8,10]. The particle size of the synthesized Ag NPs could be correlated
with their broad emission peaks (λmax), where longer wavelengths in λmax of Ag NPs were associated
with bigger size [9]. This indicated that J. regia leaf extract successfully reduced silver ions and formed
Ag NPs.
Figure 1. Color and appearance changes during synthesis of silver nanoparticles (Ag NPs) using
J. regia leaf extract. J. regia leaf extract containing silver nitrate before (A) and after (B) exposure to
microwave irradiation.
Figure 2 shows the Fourier transform-infrared (FT-IR) spectrum of J. regia leaf extract which was
in the region range of 400–4000 cm−1. The IR spectrum of leaf extract absorption bands at 3454.87 and
2072.86 cm−1 represent the phenolic–OH and N=C groups. Absorption bands at 1637.48 cm−1 are
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related to the amino group, bending vibrations, and the –OH group. The obtained results indicated
that the phenolic compounds and proteins were the two main components of the J. regia leaf extract
which had key roles in the formation of the stabilized Ag NPs [11,12].
Table 1. Experimental runs according to the central composite design (CCD) and response variables






λmax (nm) Concentration (ppm)
Exp Pre Exp Pre
1 0.10 20.00 425 424.896 104.813 101.702
2 0.78 16.46 429 429.104 100.003 97.802
3 0.78 23.53 424 424.00 93.503 96.614
4 0.50 15.00 427 426.854 72.443 74.643
5 0.50 25.00 * * 48.393 43.081
6 0.50 20.00 426 427.250 56.453 61.835
7 0.50 20.00 426 427.250 56.453 61.835
8 0.217 23.53 426 426.043 50.343 55.654
9 0.50 20.00 428 427.250 66.073 61.835
10 0.90 20.00 427 426.957 * *
11 0.217 16.46 424 424.146 * *
12 0.50 20.00 429 427.250 66.723 61.835
13 0.50 20.00 * * 63.473 61.835
Exp, Experimental values of studied responses; Pre, Predicted values of studied responses. *, Out of range.
Figure 2. Fourier transform-infrared (FT-IR) spectrum of J. regia leaf extract.
2.2. Models Generation and Synthesis Conditions Optimization
Based on experimental runs, the values of broad emission peaks (λmax, nm) and concentration
(ppm) for the fabricated Ag NPs were achieved (Table 1) and according to these obtained data,
models were created. Table 2 shows coefficients of the model terms and models accuracy based on R
square and its adjusted (R2, R2-adj) and lack of fit. The high values of R2 (>77.80) and R2-adj (>85.61)
and lack of fit (p > 0.05) verified higher suitability of the generated models to predict the synthesis
response parameters. p-Values of the generated model terms are also described in Table 3. As can be
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seen, the interaction of the amounts of leaf extract and silver salt solution had significant (p < 0.05)
effects on λmax and concentration of the formed Ag NPs.
Table 2. Regression coefficients, R2, R2-adj, and probability values for the fitted models.
Regression Coefficient λmax (nm) Concentration (ppm)
β0 (constant) 386.44 249.7
β1 (main effect) −45,084 −513.04
β2 (main effect) 3.09 −3.68
β11 (quadratic effect) −8.27 336.8
β22 (quadratic effect) −0.061 −0.119
β12 (interaction effect) −1.75 10.56
R2 77.81% 95.25%
R2-adj 85.62% 90.49%
Lack of fit (p-value) 0.985 0.142
β0 is a constant, β1, β11 and β12 are the linear, quadratic, and interaction coefficients of the quadratic polynomial
equation, respectively.
Table 3. p-Values of the regression coefficients in the obtained models.
Main Effects
Main Effects Quadratic Effects Interacted Effect
X1 X2 X11 X22 X1 X2
λmax (nm) (p-value) 0.003 0.693 0.00 0.580 0.045
Concentration (ppm) (p-value) 0.018 0.153 0.224 0.247 0.030
Figure 3A,B indicates the effects of the amount of J. regia leaf extract and amount of AgNO3 on the
λmax of the synthesized Ag NPs. As clearly observed in Figure 3, the minimum λmax (particle size) was
obtained at both minimum amount of J. regia leaf extract and of AgNO3 solution and the maximum
amount of J. regia leaf extract and of AgNO3 solution. The experimental value of the concentration for
the synthesized Ag NPs ranged 19–80 ppm (Table 1). The effects of the amount of J. regia leaf extract
andof AgNO3 on the concentration of the fabricated Ag NPs are shown in Figure 4A,B.
As clearly observed in Figure 4, the maximum concentration of the synthesized Ag NPs was
obtained using the highest amount of the J. regia leaf extract. The obtained results were in line
with the findings of other research [8–10]. They found that by increasing the amount of plant
extract, the concentration of the bioreductants increased in the extract, which in turn increased the
concentration of the formed Ag NPs.
In the synthesis of Ag NPs, the main objective is formation of NPs with desirable physico-chemical
properties, including minimum particle size (λmax) and maximum concentration. This synthesis process
is known as optimized procedure. According to the generated models for the synthesis of Ag NPs,
an overlaid contour plot, as graphical optimization (Figure 5), was plotted to better visualize of
optimum area (white colored zone).
The result of a numerical optimization also demonstrated that by using 0.1 mL of J. regia leaf
extract and 15 mL of AgNO3, Ag NPs with minimum λmax of 421 nm and maximum concentration of
135.64 ppm were produced. A verification test using optimum synthesis parameters also indicated
insignificant (p > 0.05) differences between the values of predicted and experimental of λmax and
concentration of the fabricated Ag NPs and verified the suitability of the models.
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Figure 3. Response surface (A) and contour plots (B) for λmax of the synthesized Ag NP solution as
function of the amount of J. regia leaf extract and amount of AgNO3 solution.
Figure 4. Response surface (A) and contour plots (B) for the concentration of the synthesized Ag NP
solution as function of amount of J. regia leaf extract and amount of AgNO3 solution.
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Figure 5. Overlaid contour plot of Ag NPs λmax and concentration with acceptable levels as a function
of amount of J. regia leaf extract and amount of AgNO3 solution.
2.3. Physico-Chemical Characteristics of the Synthesized Ag NPs at Obtained Optimum Conditions
Formation of Ag NPs using J. regia leaf extract at obtained optimum conditions was confirmed by
changes in the color of the mixture solution. Dynamic light scattering (DLS) analysis also indicated
that the synthesized Ag NPs had particle size, polydispersity index (PDI), and zeta potential values of
168 nm, 0.419 and −15.6 mV, respectively. The particle size distributions (PSD) of the sample are also
shown in Figure 6.
Figure 6. Particle size distribution of synthesized Ag NPs at obtained optimum synthesis conditions
using J. regia leaf extract.
2.4. Antibacterial Activity
The antibacterial activity of synthesized Ag NPs on the growth of Gram-positive (S. aureus)
and Gram-negative (E. coli) bacteria during incubation indicated that the diameter of the clear
zone for synthesized Ag NPs in the plate containing S. aureus and E. coli were 16 and 10 mm,
respectively (Figure 7). The results also indicated that the mean diameter of formed clear zone around
the Ampicillin disc in the plates containing S. aureus and E. coli were 35 and 33 mm, respectively.
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Figure 7. Created zones of inhibition with S. aureus (A) and E. coli (B) incubated at 37 ◦C for 24 h for
synthesized Ag NPs using J. regia leaf extract.
The obtained results indicated that the fabricated Ag NPs had higher antibacterial activity
against Gram-positive bacteria compared to the Gram-negative bacteria. The obtained results
were in agreement with findings of Ahmadi et al., Mohammadlu et al., and Torabfam and
Jafarizadeh-Malmiri [8–10]. The main reason behind the bactericidal activity of the Ag NPs against the
bacteria strains is related to their effects on the permeability of the cell wall and membrane. In fact,
the released silver ions (Ag+) from the Ag NPs were attached into the anionic groups of the cell
wall, such as polycyclic aromatic hydrocarbon and teichoic acids. They also formed polyelectrolyte
complexes, which limited the transference of nutrients and provided metabolites into and outside
the cell [9]. Furthermore, caffeoylquinic acid is the main phenylpropanoids in J. regia leaf extract,
which has various bioactivities such as antioxidant, antibacterial, anticancer, antihistamic, and other
biological effects. The direct antimicrobial activity of caffeoylquinic acid implies an array of possibilities,
including effects in the cell envelope [13].
3. Materials and Methods
3.1. Materials
J. regia leaves were picked from walnut trees in Tabriz, Iran. AgNO3, as silver salt, was bought
from Dr. Mojallali (Dr. Mojallali Chemical Complex Co., Tehran, Iran). Standard solution of Ag NPs
(with particle size of 10 nm and concentration of 1000 ppm) was purchased from Tecnan-Nanomat
(Spain). Escherichia coli (PTCC 1270) and Staphylococcus aureus (PTCC 1112) were attained from
microbial Persian-type culture collection (PTCC, Tehran, Iran). There is no ATCC (American type
culture collection) number for E. coli and this bacteria is clinical isolate. However, the ATCC number of
S. aureus is 6538. Nutrient agar was bought from Biolife (Biolife Co., Milan, Italy).
3.2. Preparation of J. regia Leaf Extract
The J. regia leaf was washed, dried (in dark room), powdered, and 1 g of the prepared powder
was added into 100 mL of boiling distilled water for 5 min. After cooling the solution, it was filtered
(Whatman No. 1 filter paper) using a Buchner funnel under vacuum pressure and the clear walnut leaf
extract was stored at a cold temperature (4 ◦C).
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3.3. Ag NPs Synthesis Using J. regia Leaf Extract
The Ag NPs solution was obtained by a domestic microwave-assisted synthetic approach.
AgNO3 solution (1 mM) was made by dissolving 0.017 g of its powder in 100 mL of deionized
double-distilled water. In a typical synthesis, different amounts of AgNO3 solution (15–25 mL) were
mixed with different amounts of J. regia leaf extract (0.1–0.9 mL) and the mixture solutions were put
into a microwave oven (MG-2312W, LG Co., Seoul, Korea) at a constant power of 800 W and microwave
exposure time (180 s).
3.4. Physico-Chemical Assay
3.4.1. Fourier Transform-Infrared (FT-IR) Spectra Analysis
In order to identify the possible reducing and stabilizing biomolecules of J. regia leaf extract,
FT-IR measurements were carried out. The FT-IR spectrum of the extract was recorded on
a Bruker Tensor27 spectrometer (Bruker Co., Karlsruhe, Germany) using KBr pellets in the
4000–400 cm−1 region.
3.4.2. Surface Plasmon Resonance
Ag NPs, due to their SPR, have a strong absorption of light, which is shown as broad emission
peaks (λmax) in the wavelength ranging from 380 to 450 nm [8–10]. Therefore, formation of Ag
NPs using J. regia leaf extract can be confirmed by the absorption spectrum of the mixture solutions
containing fabricated Ag NPs by using a Jenway UV-Vis spectrophotometer 6705 (Cole-Parmer Co.,
Staffordshire, UK). Furthermore, by preparing several serial dilute Ag NPs solutions (10–1000 ppm)
and establishing standard curves based on the defined concentrations of the Ag NPs solutions and
their absorbance unit values, it is possible to determine the concentration of the formed Ag NPs using
J. regia leaf extract [10].
3.4.3. Particle Size, Particle Size Distribution, Polydispersity Index and Zeta Potential of the
Synthesized Ag NPs
In order to measure values of the mean particle size (nm), PDI (ranging 0–1) and zeta potential
(mV) of the fabricated Ag NPs and their PSD, a DLS particle size analyzer (Nanotrac Wave, Microtrac,
Montgomeryville, PA, USA) was utilized. The DLS technique scatters a laser light beam at the surface
of dispersed NPs, which results in the detection of the backscattered light. PDI is a dimensionless
value which shows that the uniformity of the synthesized NPs and their surface electric charge are
related to the PDI and zeta potential values of the synthesized NPs [14,15].
3.5. Antibacterial Assay
Bactericidal activity of the formed Ag NPs was evaluated using the well diffusion method. For this
reason, bacterial suspensions containing 1.5 × 108 colony-forming units of bacteria was prepared
based on a 0.5 McFarland standard and 0.1 mL of that amount was spread on the surface of solid
nutrient agar in the plates and a hole, 5 mm in diameter, was made in the solid agar. 10 μL of the
produced Ag NPs solution was then poured into the created well and put in incubator at 37 ◦C for 24 h.
The antibacterial activity of the synthesized Ag NPs correlated to the diameter of created clear zones
around the holes. An Ampicillin disc 5mm in diameter (Oxoid, 10 μg/disc) was used as a positive
control for both Gram-positive and Gram-negative bacteria strains and the antibacterial activity of the
synthesized Ag NPs was compared to the Ampicillin.
3.6. Experimental Design, Statistical Analysis and Optimization Procedure
The experiment was planned using a central composite design (CCD) and response surface
methodology (RSM) was used to evaluate the effects of two independent parameters, namely amount
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of leaf extract (X1) and amount of AgNO3 solution (X2), on the prepared Ag NPs. The studied response
variables were broad emission peak (λmax) (Y1, nm) and concentration (Y2, ppm) of the synthesized
Ag NPs. As clearly observed in Table 1, thirteen experimental treatments were assigned with five
different levels for each independent parameter using Minitab software (v.16 statistical package,
Minitab Inc., Pennsylvania State, PA, USA). In order to correlate the λmax (Y1) and concentration (Y2)
of the synthesized Ag NPs to the studied synthesis variables, a second order polynomial equation
(Equation (1)) was used. Where β0 is a constant, β1, β11, and β12 correspond to the linear, quadratic and
interaction effects, respectively [16]. The suitability of the model was studied, accounting for the
coefficient of determination (R2) and adjusted coefficient of determination (R2-adj) [17]. Analysis of
variance (ANOVA) was also used to provide the significance determinations of the resulted models in
terms of p-value. Small p-values (lower than 0.05) were considered as statistically significant [18].
Y = β0 + β1X1 + β2X2 + β11X12 + β22X22 + β12X1X2 (1)
Numerical optimization was carried out to determine exact amounts of silver salt and J. regia leaf
extract in the Ag NPs synthesis to produce NPs with minimum λmax (particle size) and maximum
concentration. Graphical optimization was also used to better visualize the effects of the synthesis
parameters on the response variables (λmax and concentration) [19]. Suitability and accuracy of the
generated models in predicting the response variables in the defined range of the Ag NPs synthesis
parameters were validated by synthesis of Ag NPs using obtained optimum synthesized conditions
and comparison of the experimental values of the response variables and their predicted values [20].
4. Conclusions
Fabricated Ag NPs using a rapid, one-step green approach, based on microwave irradiation
showed desirable physico-chemical properties with antibacterial activity against E. coli and S. aureus.
However, their antibacterial activity was significantly (p < 0.05) higher toward Gram-positive bacteria
strains. The synthesized Ag NPs using the rapid developed synthesis method can be used as a
favorable antibacterial agent in different areas such as medicine and food packaging.
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Abstract: The phytosynthesis of metal nanoparticles is nowadays attracting the increased attention of
researchers and is much needed given the worldwide matter related to environmental contamination.
The antimicrobial activity of colloidal and spray formulation of silver nanoparticles (AgNPs)
synthesized by pomegranate peel extract against Candida albicans and Staphylococcus aureus, and their
cytotoxicity in mammalian cells were tested in the present study. Dry matter, pH, total phenolics, and
ellagic acid in the extract were determined. Then, AgNPs were phytosynthesized and characterized
by X-ray diffraction, electron transmission microscopy, dynamic light scattering, zeta potential, and
Ag+ dosage. Spray formulations and respective chemical-AgNP controls were prepared and tested.
The peel extract reduced more than 99% of Ag+, and produced nanoparticles with irregular forms
and an 89-nm mean size. All AgNP presented antimicrobial activity, and the spray formulation
of green-AgNP increased by 255 and 4 times the effectiveness against S. aureus and C. albicans,
respectively. The cytotoxicity of colloidal and spray green-AgNP was expressively lower than the
respective chemical controls. Pomegranate peel extract produced stable AgNP with antimicrobial
action and low cytotoxicity, stimulating its use in the biomedical field.
Keywords: silver; nanoparticles; Candida albicans; Staphylococcus aureus; herbal medicine; Punicaceae
1. Introduction
Recently, a state of alert on a topic that affects people globally, antimicrobial resistance,
has received much attention. This has led to the deaths of more than 700,000 people a year worldwide
and this number has risen every year [1]. It is estimated that there will be a reduction in the world
population of 11–444 million people in 2050 if antimicrobial resistance is not bypassed [1].
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As an alternative against antimicrobial resistance, one approach gaining in strength is the use of
inorganic particles at the nanoscale. The most prominent metals in the group of inorganic nanoparticles
are copper, zinc, titanium, magnesium, gold, and silver [2–4]. In this context, silver nanoparticles have
been the most exploited as they have a wide range of toxicity against several microorganisms such as
Staphylococcus aureus, Escherichia coli, Candida albicans, and others [5].
The incorporation and use of silver nanoparticles has been observed in sundry sectors, for instance,
in the food industry as an attempt to produce packaging with antimicrobial activity [6]. Its use in the
area of cosmetics has also received prominence, as has its use in housecleaning, antiseptics, sunscreens,
soap, and shampoo [7–9] as well as in textile manufacturing [10].
Considering the synthesis of silver nanoparticles, many routes have been presented such
as electrochemical [11], radiation [12], photochemistry [13], and by biological methods [14].
Phytochemical synthesis has been noteworthy since the use of chemical compounds may result in
undesirable toxic effects not only for the human organism but also for the environment. Its effectiveness
in the production of silver nanoparticles has been demonstrated by the use of compounds of different
plants in the ion reduction, being characterized as rapid, low cost, and environmentally friendly
synthesis [15]. Furthermore, green-silver nanoparticles are usually less cytotoxic when compared to
those reduced by conventional chemical agents [16]. It is believed that silver nanoparticles reduced
by plant extracts do not carry on their surface chemical compounds used for the reduction and
stabilization of chemically produced silver nanoparticles that are toxic to human cells. It is still believed
that the phytochemicals present in the extracts are carried on the surface of the silver nanoparticles,
reducing their cytotoxic effect, aside from presenting different forms of chemically produced silver
nanoparticles [16]. Important aspects in green-synthesis should be taken into account including the
choice of plant to be used, being the plants which grow in different regions of the world more eligible
for this [16]. The previously known potential of the plant including antioxidant, anti-inflammatory,
and antimicrobial such as the case of Punica granatum (pomegranate) should also be considered [17–19].
Some studies have also used Punica granatum to reduce silver ions to silver nanoparticles [19–21]. Silver
nanoparticles were green-synthesized and showed significantly lower cytotoxicity when compared to
the silver nanoparticles synthesized by a chemical pathway. This fact has stimulated the search for
the use of reduced silver nanoparticles by means of plant extracts for biological purposes such as the
treatment of contagious infectious diseases, especially those in need of topical treatment.
Thus, taking together the benefits of pomegranate and the antimicrobial applicability of silver
nanoparticles, the present study aimed to synthesize silver nanoparticles using pomegranate peel
extract, and to produce spray formulations containing the previously green-synthesized silver
nanoparticles. Their antimicrobial activity against Staphylococcus aureus and Candida albicans, and their
cytotoxicity effect on fibroblast cells were investigated.
2. Results
2.1. Characterization of Peel Extract, Silver Nanoparticles and Formulations
The pH and the dry matter of the peel extract obtained by maceration followed by percolation
were 3.13 and 86.39 (±0.96) % w/w, and the total phenolics expressed in gallic acid and the ellagic acid
were 392.0 (±9) and 3.64 (±0.03) mg/g, respectively.
The formation of silver nanoparticles was confirmed by comparing the XRD patterns and the
corresponding standard patterns of cubic of silver nanoparticles (Figure 1), according to the diffraction
standard (JCPDS file No. 04-0783). The reflection peak (2 2 2) is characteristic of the substrate (Si),
where silver particles were deposited as a thin film. TEM images (Figure 2) showed different forms
and sizes of silver nanoparticles produced by green and conventional chemical routes as well as in
their respective formulations. In general, green-synthesis produced particles with a larger size than
those obtained by conventional synthesis. Dynamic Laser Scanning (DLS) analyses of the formulations
prepared with green or conventional silver nanoparticles demonstrated different particle sizes, being
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the mean values of 89 ± 21 and 19 ± 4 nm for the green and conventional formulation, respectively.
The values of zeta potential of green and conventional silver nanoparticles were lower than −30 mV
(−46.2 ± 6.06 mV green, and −67.5 ± 3.69 mV conventional), indicating the stability of both colloidal
silver nanoparticles.
Figure 1. X-ray diffraction (XRD) of the green and chemical silver nanoparticles.
Figure 2. Images of transmission electron microscopy (TEM): (A) Green silver nanoparticles;
(B) Silver nanoparticles green formulation; (C) Chemical silver nanoparticles; (D) Silver nanoparticles
chemical formulation.
Almost 100% of the Ag+ ions coming from AgNO3 were reduced by the pomegranate peel extract
(99.89%) and sodium citrate (99.51%). However, in the spray formulation containing chemical-silver
nanoparticles, the percentage of reduction was diminished to 68.18% although the formulation
maintained stable regarding Ag+ ions concentration for 28 days (Table 1). Zeta potential data confirmed
the stability of the spray formulations regardless of the method used to obtain the silver nanoparticles
(Table 2). The total phenolics in the spray formulations with or without silver nanoparticles were
quantified at 0, 7, 14, and 28 days after having been prepared (Figure 3), and it has been significantly
reduced in the green-synthesized silver nanoparticle formulation after 14 days with values ranging
from 0.405 to 0.295 mg/g.
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Table 1. Values of the silver ionic reduction and zeta potential for green and chemical silver nanoparticle
formulations in different periods.
Time
Silver Nanoparticles Green Formulation Silver Nanoparticles Chemical Formulation
μgAg+/mL % of Reduction Zeta Potential μgAg+/mL % of Reduction Zeta Potential
T0 0.249 99.93% −73.7 ± 6.49 1.769 68.15% −78.2 ± 3.06
T7 0.178 99.95% −68.3 ± 4.92 1.927 65.31% −72.9 ± 3.10
T14 0.220 99.94% −72.8 ± 6.49 1.543 72.22% −85.5 ± 3.36
T28 0.186 99.95% −68.6 ± 5.62 1.846 66.77% −76.5 ± 4.05
Table 2. Silver ion concentration (μgAg+/mL) and percentage of silver ions reduction after the reactions,
AgNP percentage, and values of minimum inhibitory concentration (MIC) of silver nanoparticles and







S. aureus C. albicans
Control * 10,303.26 95.52 4.48 4.13 4.59
Pomegranate peel extract - - - 391 781
Silver nanoparticles green 10.89 0.11 99.89 67.50 68.75
Silver nanoparticles chemical 130.40 1.21 98.79 0.50 0.25
Pomegranate peel extract formulation - - - 0.37 0.18
Silver nanoparticles green formulation 0.249 0.01 99.99 0.26 16.87
Silver nanoparticles chemical formulation 1.769 31.85 68.15 0.56 1.12
* Control = Carboxymethylcellulose, propylene glycol, silver nitrate.
Figure 3. Total phenolics concentration for the silver nanoparticles green formulation and pomegranate
peel extract formulation in different periods. Different capital letters denote significant difference
(p < 0.05; one-way ANOVA followed by Tukey’s multiple comparison test) among the groups.
2.2. Antimicrobial Activity
The antimicrobial activity expressed as MIC values of silver nanoparticles and pomegranate peel
extract (μg/mL) (Table 1) was, in general, considerably lower for the spray formulations than the
active inputs regardless of the microorganisms tested. MIC values against C. albicans for active inputs
and spray formulations were 781 and 0.18 for the peel extract, 68.75 and 16.87 for the green-, and 0.25
and 1.12 for the chemical-silver nanoparticles. While for S. aureus, the values were 391 and 0.37, 67.5,
and 0.26, and 0.5 and 0.56 for pomegranate peel extract, green-, and chemical-silver nanoparticles in the
active inputs and spray formulations, respectively. In addition, different conditions of humidity and
temperature did not affect the effectiveness of the spray formulations against both microorganisms.
2.3. Cytotoxicity
Figure 4 shows the fibroblast L929 cells viability in view of different concentrations of silver
nanoparticles (green and conventional route). Green silver nanoparticles presented lower cytotoxicity
than conventional ones. A dosage of 50 μg/mL was necessary to initiate the toxicity, but the
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cell viability was nearly 80%, while conventional-silver nanoparticles were quite toxic at very low
concentration (6.25 μg/mL) and was similar to the negative control (DMSO) with viability lower
than 20%. Furthermore, the addition of the reagents to prepare the formulations did not interfere
in the toxicity of the conventional-silver nanoparticles, whereas the cytotoxicity for the green-silver
nanoparticles formulation as well as for the extract formulation was considerably increased.
Figure 4. Cytotoxicity evaluation of respective active input (green and chemical silver nanoparticles
and pomegranate peel extract), their respective formulations, and the vehicle (compounds of
spray-formulation without the active inputs). (A) Silver nanoparticles green; (B) Silver nanoparticles
green formulation; (C) Silver nanoparticles chemical; (D) Silver nanoparticles chemical formulation;
(E) Pomegranate peel extract; (F) Pomegranate peel extract formulation and (G) Vehicle.
3. Discussion
For future reproducibility of the experiment, the extract obtained by maceration followed by
percolation was duly characterized in relation to dry matter, total phenolics content, ellagic acid,
and pH. Total phenolics were determined only in samples that contained the pomegranate peel
extract, and then the chemical formulation did not present any phenolic content in its composition.
Polyphenols are effective hydrogen donors and are correlated to the number and position of hydroxyl
groups and conjugations as well as the presence of donor electrons in the aromatic ring B, because
of the ability of this aromatic ring to withstand the electron depletion located in the π electron
system [22]. The antimicrobial activity of various polyphenols and plant extracts have been evaluated
in pharmaceutical and food studies [23,24]. Some phenolic compounds present in sage, rosemary,
thyme, hops, coriander, tea, cloves, and basil are known to exhibit antimicrobial effects against
foodborne pathogens. Their mechanisms of action need to be further elucidated, and might be due to
a plethora of phenolic compounds present in a very single plant extract. Furthermore, as the bioactive
compounds in the extract presented antioxidant and anti-inflammatory activities, the antimicrobial
potential of the pomegranate peel extract in the in vivo trials could show better results, and should be
strongly stimulated in further studies. Regarding the multi conceptual nature of the term antioxidant
and bringing it into the context of this study, some polyphenols present in low concentrations could
prevent or reduce the extent of oxidative damage in mammalian cells. Taken together, these natural
biomolecules could indirectly protect the cells and reduce the cytotoxicity of silver nanoparticles.
The correct selection of the plant and the standardization of the methods to obtain the extracts to
be used as reducing or capping agent in the nanosynthesis of metal particles should be preponderant
when the green process is elected for the production of products in large scale. Additionally, a plethora
of plants used in the phytosynthesis of metal nanoparticles [25–27] and the lack of information of the
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extraction techniques used in the articles has hindered the comparison of the present results with those
found in the literature. For instance, different values and methods of total phenolics quantification
can be observed in the literature as described by Kalaycioglu et al. (2017) [28]. Similarly, other factors
can interfere in the evaluation and comparisons of the extracts such as the chemical and genotypic
composition of the plant, the variety and the soil type, the place of the plant origin, the harvest season,
maturation method, aside from the solvent and the process used for the obtention of the pomegranate
extract, among others [29].
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images showed
the smallest particles obtained by conventional chemical synthesis, and DLS data confirmed these
findings with mean sizes of 89 and 19 nm for green and chemical nanoparticles, respectively. The fission
of colloidal particles of different sizes and shapes may be related to additives (salts, polymers), solvent
properties (boiling temperature, affinity with created surfaces), the addition of nucleation, among
others [30]. The reagents used in the chemical synthesis would produce particles with more predictable
characteristics than the several substances and compounds present in the plant extract and used in
the phytosynthesis route, which would interfere with the size and form of the nanoparticles and
make phytosynthesis a challenge in controlling the reaction process and the morphological aspects
of the particles. Moreover, the presence of different bioactive substances in the extract would reduce
only a fraction of the silver ions present in the solution. The remaining silver ions would form other
nuclei and further the growth of the previously formed silver nanoparticles [31]. This process is called
Ostwald Ripening, where the largest particles consume the smaller ones and grow larger, where the
dissolution of the smaller ones and deposition of ions on the surface of larger ones occur [32].
Almost 100% of ions reduction was observed for both synthesis routes. However, when the
chemical silver nanoparticles were added to the formulation, a dissociation of ions from nearly 30%
was observed when compared to chemical silver nanoparticles alone. This fact could be due to the
presence of the components as carboxymethylcellulose and propylene glycol in the spray formulation
which possibly favored the silver ion dissociation into the system [33]. The presence of oxygen or
ligands for Ag+ in the formulations may increase the dissolution rate of AgNP and lead to increased
dissolution through the formation of Ag+ complexes [34]. Ag+ in solution will interact with various
ions and molecules that are present in aqueous media. Important ligands to be considered for Ag+ are
sulfide and organic ligands such as the carboxylic acids group which are used as Ag coatings (e.g.,
citrate, lactate). Carboxyl ligands such as carboxymethylcellulose strongly bind Ag+, which may affect
the dissolution of AgNP and the bioavailability of Ag+ [35].
Furthermore, the size of the Ag in the NP affects the extent and kinetics of the AgNP dissolution as
the smallest nanoparticles dissolve faster and to a greater extent [36]. This would explain the difference
in the dissolution of the nanoparticles in the formulations. Their dissolution is of high relevance for the
possible toxic effects of AgNP as Ag+ appears in many cases to determine their toxicity [37]. This fact
was not observed when green-synthesis was carried out. This could be related to several compounds
present in the extract which would readily react with the released silver ions, or the encapsulation
of the silver nanoparticles promoted by those phytocompounds may have avoided the silver ions
dissociation from the silver nanoparticles and its release to the solution.
Zeta potential test demonstrated the stability of the silver nanoparticles, most notedly in the spray
formulations. Electrical charges on the surface of the nanoparticles prevent agglomeration, and thus
afford the stability of the nanoparticles [38,39]. Indeed, silver nanoparticles and spray formulations
presented a mean of 70 mV, which indicates their high stability of silver nanoparticles [40].
Antimicrobial results are also promising for the silver nanoparticles as well as the pomegranate
extract obtained. The formulations notably showed better results when compared with the input
active only. This fact could be explained for the proper dispersion of the active inputs (silver
nanoparticles and pomegranate peel extract) in the spray formulation. Additionally, a synergistic effect
could have occurred between those active inputs and the methylparaben present in the formulation.
In the literature, studies with an antimicrobial effect of pomegranate extract were conducted against
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Staphylococcus aureus, Enterobacter aerogene, Salmonella typhi, and Klebsiella pneumonia [41]. The MIC
values obtained in this study for pomegranate extract were in accordance with Bakkiyaraj et al.
(2013) [42] for both the microorganisms studied, and a difference was observed in C. albicans, but this
fact may be explained by the difference between the C. albicans strains used in the studies.
Chemical-silver nanoparticles, in formulation or not, produced MIC values against S. aureus about
10-fold lower than those produced by Prema et al. (2017) [33] (60 μg/mL), who also produced silver
nanoparticles stabilized with CMC. Indeed, the antimicrobial activity of chemical silver nanoparticles
was also determined by Monteiro et al. (2011) [43] with MIC values for C. albicans (0.5 μg/mL) in
accordance with this present study.
Noteworthy is the difference found in the present study in respect of cytotoxicity between the
chemical and green routes to obtain silver nanoparticles. Studies have shown that silver nanoparticles
produced with Protium serratum and Nyctanthes arbortristis extracts were biocompatible when tested
in L929 fibroblasts [44,45]. It is believed that what makes the silver nanoparticle toxic to human
cells is the type of reducing agent used such as sodium citrate or sodium borohydride [46]. Even in
conventional syntheses of silver nanoparticles, reagents are used that prevent the aggregation of these
nanoparticles [47], which may further favor their cytotoxicity.
In the case of phytosynthesis of metal nanoparticles, plant extracts, aside from acting as reducing
agents, would act to stabilize the particles against dissolution, hence reducing the toxicity of the
silver nanoparticles solution. Furthermore, it is possible that some compounds in the extracts may
have a synergistic effect with the silver nanoparticles [48], making them less toxic to human cells.
Furthermore, extracts of Punica granatum have exhibited antioxidant [49] and anti-inflammatory [50]
activity, and may have contributed to reducing the cytotoxicity of green- in comparison with
chemical-silver nanoparticles.
In general, the stability assay (silver ions dosage, zeta potential, and antimicrobial activity)
showed a high stabilizing capacity of the formulations. However, the spray formulations of green
silver nanoparticles and pomegranate peel extract showed a significant reduction in the content
of total phenolics in 14 and 28 days. The decrease in the content of total phenolics may have
occurred due to the temperature variations inherent in the stability test, as occurred in the study
of [51] where the temperature affected the total phenolics content in the roselle-mango juice blends.
Moreover, in formulations containing green-silver nanoparticles, the components of the extract may
have been degraded or associated with the nanoparticles, explaining the faster decrease of the total
phenolics content when compared to the pomegranate extract formulation. Interestingly, ion dosage,
zeta potential, and antimicrobial activity were not affected by different conditions of temperature, time,
and humidity of the stability test.
Altogether, the reported results suggest that the plant extract mediated syntheses of AgNP showed
a pronounced lower cytotoxic effect in mouse fibroblast cells (L929) than the syntheses of AgNP by the
chemical method. Of note is the implication that different sizes between the green- chemical-AgNP as
well as the expected impurities sedimented on both obtained nanoparticles could have had on their
toxicity. Although it is quite tricky to obtain AgNP with a well-defined form and size and prevent the
particles aggregation [52], it is of importance to complement and support our findings, then strongly
recommend an eco-friendly approach to producing green-AgNP and prototype wound-care sprays
containing these particles.
4. Materials and Methods
4.1. Plant Material and Preparation of Pomegranate Peel Extract
Pomegranate samples were collected from a crop cultivated in Eixo (21◦08′01′ ′ S, 51◦06′06′ ′ W),
Mirandópolis, São Paulo, Brazil, during May 2015. Pomegranate peels were separated and stove-dried
at 50 ◦C, ground, and sieved to a granulometry lower than 2 mm. Peels were submitted to alcohol
extraction using 70% ethanol by maceration, followed by the percolation process [53]. The extract was
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characterized in relation to pH, dry matter, and total phenolics expressed as gallic acid. The chemical
marker of pomegranate, ellagic acid, was also identified and quantified.
4.1.1. Determination of Total Phenolics, pH, and Dry Matter
To determine the total phenolics, an analytical curve of gallic acid (Sigma-Aldrich Chemical Co.,
St. Louis, MO, USA) was carried out [54]. All extracts obtained and the standard solution of gallic acid
were prepared in 50 mL volumetric flasks using water as the solvent. The samples were homogenized
and, the flasks were brought to the ultrasonic bath for 30 min. A 0.5 mL aliquot was transferred to
another 50 mL flask where 2.5 mL of Folin-Denis reagent (Qhemis-High Purity, Hexis, São Paulo,
Brazil) and 5.0 mL of 29% sodium carbonate (Cinética, São Paulo, Brazil) were added. The samples
were protected from light and the readings were performed after 30 min in a UV-Vis spectrophotometer
at 760 nm [53]. The pH was measured direct from a solution of 1% extract, using a pH kit (Merck
KGaA, Darmstadt, Germany) and dry matter was calculated after drying on a sample stove at 105 ◦C
and was expressed in percentage w/w. All data were analyzed in triplicate.
4.1.2. Determination of the Ellagic Acid Content
A Shimadzu liquid chromatograph and a Shimpack ODS C18 (Shimadzu Corporation, Kyoto,
Japan) reverse phase column (100 mm × 2.6 mm) were used to determine the ellagic acid content
by high performance liquid chromatography (HPLC). Analytical conditions were optimized based
on de Sousa et al. (2007) [55] with modifications. As the mobile phase, HPLC grade methanol and a
2% aqueous acetic acid solution with gradient elution (0–7 min, 20–72.5% v/v methanol, 7–7.5 min,
72.5–95% v/v methanol, 7.5–8.5 min 95% v/v methanol, 8.5–9 min 95–20% v/v methanol, 9–10 min
20% v/v methanol) were used. The flow rate was 1.0 mL/min, and the separation was achieved at
25 ◦C. The injection volume was 5 μL and the wavelength used was 254 nm. Peaks were determined
by comparison with an authenticated ellagic acid standard. Briefly, the sample was transferred to a
20 mL volumetric flask which was diluted with HPLC grade methanol. Extraction was undertaken
using a vortex for 5 min and ultrasonic bath for 1 h. For the extracts, samples were transferred to
volumetric flasks of 10 mL, using methanol HPLC as the solvent. All samples were vortexed for 5 min
and sonicated for 30 min. Samples were filtered through 0.45 μm filter. All samples were prepared
in triplicate.
4.2. Synthesis of Green-Silver Nanoparticles
The protocols described by Gorup et al. (2011) [56] and Das et al. 2015 [57] with modifications
were used to produce silver nanoparticles. Briefly, 3.5% of carboxymethylcellulose (CMC) (Labsynth,
Diadema, Brazil), 20% of propylene glycol (PG) (Labsynth, Diadema, Brazil), 100 mM of silver nitrate
(SN) (Merck KGaA, Darmstadt, Germany), pomegranate peel extract at 30 mg/mL, and water to make
up 100% of the samples were used. Silver nanoparticles were not purified relative to the excess reagents.
The reaction was carried out at 50 ◦C for 12 min, and it was selected based on previous results.
4.3. Synthesis of Chemical-Silver Nanoparticles
Chemical-silver nanoparticles were produced according to Gorup et al. [53]. AgNO3 (Merck
KGaA, Darmstadt, Hesse, Germany) was dissolved in water, and brought to boiling at 90 ◦C. After 2
min of boiling, an aqueous solution of sodium citrate (Na3C6H5O7) (Merck KGaA, Darmstadt, Hesse,
Germany) was added, and kept boiling for another 6 min until the solution reached a yellow amber
color. The stoichiometric ratio was 1:3, respectively for AgNO3 and Na3C6H5O7. Silver nanoparticles
were not purified relative to the excess reagents.
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4.4. Preparation of the Spray Formulations
The reagents used were CMC (Labsynth, Diadema, Brazil), PG (Labsynth, Diadema, Brazil),
and methylparaben (Labsynth, Diadema, Brazil) in a proportion of 0.1%, 7%, and 0.1%, respectively.
The active inputs (green- or chemical-silver nanoparticles and pomegranate peel extract) concentrations
were based on the minimum inhibitory concentration and cytotoxicity. Therefore, the final
concentrations of active inputs in the spray formulations were: 337.5 μg/mL of green-silver nanoparticles,
5.55 μg/mL chemical-silver nanoparticles, and 94 μg/mL of crude peel extract dry matter.
4.5. Characterization of the Silver Nanoparticles and the Spray Formulations
4.5.1. X-ray Diffraction (XRD), Dynamic Light Scattering (DLS), and Zeta Potential Analysis
A Shimadzu XRD diffractometer with a Cu Kα radiation operating at 30 kV and 30 mA and 2θ
range from 35◦ to 85◦ with step scan of 0.02◦ and scan speed 0.2◦·min−1 was used to perform XRD
analysis. To collect silver nanoparticles patterns, the nanoparticles were deposited on the surface of a
silicon substrate (Si) by dripping the aqueous colloidal dispersion on the substrate at room temperature
until the solvent had evaporated.
DLS experiments were performed at room temperature and at a fixed angle of 173◦ on a Zetasizer
Nano ZS (Malvern Instruments Ltd., Malvern, UK) equipped with 50 mW 533 nm laser and a digital
auto correlator. The number-average values obtained were compared to the size distributions of the
silver nanoparticles. For the zeta potential test a Zetasizer (Malvern instruments, Malvern, UK) with an
MPT-2 titrator was used. Aliquots from each test suspension were obtained to conduct zeta potential,
and mean values were obtained from three independent measurements.
4.5.2. TEM Analyzes
The nanocompounds morphology was characterized by TEM images in a Jeol JEM-100 CXII
(JEOL USA Inc., Peabody, St. Louis, MO, USA) microscope equipped with Hamamatsu ORCA-HR
digital camera.
4.6. Silver Ions Dosage
The dosages of free silver ions (Ag+) present in the compounds and spray formulations were
performed to observe if the total amount of Ag added in the synthesis reaction was successfully
reduced. A specific electrode 9616 BNWP (Thermo Scientific, Beverly, MA, USA) coupled to an ion
analyzer (Orion 720 A+, Thermo Scientific, Beverly, MA, USA) was used. A 1000 μg Ag/mL standard
was prepared by adding 1.57 g of AgNO3 to 1 L of deionized water. The combined electrode was
calibrated with standards containing 6.25 to 100 μg Ag/mL to achieve equivalent silver concentrations
in the compounds. A silver ionic strength adjuster solution (ISA, Cat. No. 940011) that provided a
constant background ionic strength was used (1 mL of each sample/standard: 0.02 mL ISA).
4.7. Stability Test of the Spray Formulations
The spray formulations were submitted to a stability test with controlled conditions of temperature
and time. This test was based on Anvisa protocols (Cosmetics stability guide ISBN 85-88233-15-0;
Copyright© Anvisa, 2005) and the guide to stability studies (Ordinance No. 593 of 25 August 2000).
Briefly, samples of each spray formulation were submitted to alternating cycles of temperature daily
ranging from 40 to −5 ◦C for 28 days. The tests selected to evaluate the stability of the samples were ion
dosage, total phenolics content, zeta potential, and minimal inhibitory concentration (MIC). All tests
were done in the same conditions as described before, and were carried out at 0, 7, 14, and 28 days.
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4.8. Antimicrobial Activity of the Silver Nanoparticles and the Spray Formulations
Minimal inhibitory concentration of the silver nanoparticles samples were determined following
the instructions of the Clinical Laboratory Standards Institute with some modifications. The samples
were first diluted in water and subsequently in culture medium specific for each microorganism,
Mueller Hinton broth (BD Difco, Franklin Lakes, USA) for Staphylococcus aureus (ATCC 25923),
and RPMI (Sigma-Aldrich, St. Louis, MO, USA) for Candida albicans SC 5314) [58]. The microorganisms
were adjusted to 5 × 105 cells/mL for S. aureus and 5 × 103 cells/mL for C. albicans, and the plates
were incubated for 24 h and 48 h in aerobiosis at 37 ◦C for S. aureus and C. albicans, respectively.
After incubation, the plates were visually read. The assays were performed in triplicate.
4.9. Cytotoxicity Analysis
For the evaluation of cytotoxicity, fibroblast cells of the L929 lineage were used. Cells were
cultured in DMEM culture supplemented with 10% fetal bovine serum (FBS), penicillin G (100 U/mL)
(Gibco®, Carlsbad, USA), streptomycin (100 μg/mL), amphotericin B (25 μg/mL) and incubated in
a stove at 37 ◦C with 5% CO2. Cells were subcultured (5–7 days), using 0.9% saline to wash them
and 0.25% trypsin to disintegrate them from the vial. After disruption, these cells were centrifuged at
1000 rpm for 10 min at 10 ◦C, resuspended in complete DMEM medium (supplemented with FBS),
and cell counted in a Neubauer’s chamber.
The sub-cultured third to eighth passage fibroblasts were inoculated into 96-well microplates
at a density of 0.5 × 105 cells/well. They were then incubated at 37 ◦C with 5% CO2. After 24 h,
20 μL of different dilutions of each sample were added to the wells of the plate containing the
cells in medium not supplemented with SBF (incomplete medium) and incubated. Twenty-four
hours post-treatment, the medium was withdrawn, cells were washed with saline and 20 μL of
resazurin (Sigma-Aldrich) 0.01% w/v in deionized H2O was added to each well containing 180 μL
of DMEM medium supplemented with 10% Of SFB. The plates were then incubated for 4 h at 37 ◦C
and fluorescence was measured at 540 and 590 nm for excitation and emission, respectively [59].
Cell viability was expressed as a percentage of viable cells when compared to the control group
without treatment.
4.10. Statistical Analysis
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was employed for the
statistical analysis with a confidence level of 95%. Parametric statistical analyses were conducted with
one-way ANOVA followed by Tukey’s multiple comparison test for total phenols and zeta potential.
For the ion test the statistical analyses was Dunn’s multiple comparison test.
5. Conclusions
In light of the results obtained and the limitations of the present study, it was concluded that the
use of pomegranate peel extract showed it to be an efficient reducing agent for the production of silver
nanoparticles. Moreover, the antimicrobial potential and the low cytotoxicity demonstrated by green-silver
nanoparticles have stimulated the search for improvements in the bio-nanotechnology field. Furthermore,
the anti-inflammatory and antioxidant properties of pomegranate have encouraged further studies to use
nanosystems with future application in prophylaxis or treatment of biofilm-dependent diseases.
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Abstract: Silver nanoparticles (AgNPs) are well-known for their antimicrobial effects and several
groups are proposing them as active agents to fight antimicrobial resistance. A wide variety of
methods is available for nanoparticle synthesis, affording a broad spectrum of chemical and physical
properties. In this work, we report on AgNPs produced by laser ablation synthesis in solution
(LASiS), discussing the major features of this approach. Laser ablation synthesis is one of the best
candidates, as compared to wet-chemical syntheses, for preparing Ag nano-antimicrobials. In fact,
this method allows the preparation of stable Ag colloids in pure solvents without using either capping
and stabilizing agents or reductants. LASiS produces AgNPs, which can be more suitable for medical
and food-related applications where it is important to use non-toxic chemicals and materials for
humans. In addition, laser ablation allows for achieving nanoparticles with different properties
according to experimental laser parameters, thus influencing antibacterial mechanisms. However,
the concentration obtained by laser-generated AgNP colloids is often low, and it is hard to implement
them on an industrial scale. To obtain interesting concentrations for final applications, it is necessary
to exploit high-energy lasers, which are quite expensive. In this review, we discuss the pros and
cons of the use of laser ablation synthesis for the production of Ag antimicrobial colloids, taking into
account applications in the food packaging field.
Keywords: silver nanoparticles; laser ablation synthesis in solution; nano-antimicrobials; food packaging
1. Introduction
Due to their unique properties [1], metal nanoparticles (NPs) have been used for applications
in several fields, such as medicine and the biomedical sciences [2,3], cosmetics [4,5], food and
agriculture [6–9], electronics [10], energy science [11], and catalysis [12], providing significant
improvements in each area. This review focuses on laser ablation synthesis in solution (LASiS)
nanotechnology and its specific potentialities in the food industry, with particular consideration to
food packaging.
The growing demand for ready-to-eat food products, along with requirement of easy and safe
transport, has led to the need to extend their shelf life, prevent foodborne diseases, minimize
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industrial processing, track them, and improve their preservation during storage. To this aim,
the use of antimicrobial metal nanoparticles is continuously increasing. They are used in agriculture
(e.g., pesticide and fertilizer delivery [13–16]), food processing (e.g., encapsulation of flavor or odor
enhancers, food textural or quality improvement), food packaging (e.g., limitation of pathogen
proliferation, gas sensors; UV protection, more impermeable polymer films), and nutrient supplements
(e.g., nutraceuticals with higher stability and bioavailability) [17–19].
Inorganic or organic nanoparticles can either be placed on the surface of polymeric matrices used
for food packaging or dispersed into their bulk [20]. The introduction of nanoparticles in a polymeric
matrix aims to improve the properties of traditional packaging, e.g., containment and protection (ease of
transportation and avoided leakage or break-up), foodstuffs preservation (protection against microbial
contaminants, extended shelf-life), convenience (consumer-friendly products), and marketing and
communication (real-time information about the quality of enclosed foodstuffs) [8]. In response to
required features, food packaging employs innovative materials, which can be categorized as follows:
(1) Improved nanomaterials (the presence of nanoparticles in the polymeric matrix improves the
mechanical and/or chemical properties of the packaging, but they are not in direct interaction
with food);
(2) Active nanomaterials (dispersed nanoparticles into polymeric bulk enable the packaging to
interact actively with environment and regulate the preservation of food);
(3) Intelligent nanomaterials (packaging is able to monitor and identify the state of the product,
because of the integration of nanosensors and devices) [8,21].
Nanoparticles, and specifically silver nanoparticles (AgNPs), can be widely used for active
packaging due to their antimicrobial properties [22]. Generally, organic antimicrobial materials are less
stable at high temperatures compared to inorganic ones, whereas metal and metal oxide nanoparticles
withstand harsher processing conditions [23].
The most common nanocomposites used as antimicrobial films for food packaging are based on
AgNPs, which are well-known for their efficacy towards a wide range of microorganisms, with high
temperature stability and low volatility [20].
Several reviews pick features and use common nanostructures employed in food
packaging [8,20,21,24–31]. In each of them, AgNPs are taken into account, but few papers are
exclusively focused on AgNPs in food packaging [23]. One of the earliest works on this specific
topic was proposed by Rhim and coworkers; they produced chitosan–AgNP nanocomposite films and
examined their bioactivity and mechanical properties [32].
In general, AgNP-based nanocomposites are stable and offer slow release of silver ions in the
surrounding medium, resulting in a long-lasting antimicrobial activity [8]. The released amount of
silver ions into the system is dependent not only on the properties of the nanoparticles themselves—for
example NP size, shape, structure, composition, etc.—but also relies on external factors, including the
properties of the surrounding medium: ionic strength, pH, composition, humidity, dissolved oxygen
content, temperature, etc. [26].
This review is focused on AgNPs to be used in food packaging, and particularly on a peculiar NP
synthesis approach. Special attention will be given to AgNPs synthetized by laser ablation, a method
proposed by several groups as a green route to high-purity nanomaterials. The pros and cons of this
technique for the production of Ag antimicrobial nanocolloids will be critically discussed.
2. Silver Nanoparticles
AgNPs are chemically stable [33,34] antimicrobial agents [35] providing strong activity towards a
wide range of pathogenic microorganisms, including bacteria, yeasts, viruses, fungi, and parasites, even
when low doses are used (full growth inhibition of bacteria can occur at a few mg/mL) [36]. Moreover,
AgNPs are non-toxic to the human body at low concentrations [37]. The Occupational Safety and
Health Administration (OSHA) and Mine Safety and Health Administration (MSHA) proposed that a
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permissible exposure limit (PEL) for metallic and most soluble Ag compounds should be 0.01 mg/m3.
Argentina, Bulgaria, Columbia, Jordan, Korea, New Zealand, Singapore, and Vietnam recognize the
American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit values (TLV) of
0.1 mg/m3 for metallic Ag, while Austria, Denmark, Germany, the Netherlands, Norway, Switzerland,
and Japan recognize 0.01 mg/m3 as the occupational exposure limit for all forms [38]. According
to the Registration, Evaluation and Authorization of Chemicals (REACH; Council of the European
Union for chemicals and nanomaterials regulation), 0.01 ppb of Ag (for medical products) is not
an environmental concern, even if this threshold cannot be interpreted as a safe concentration [39].
The European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources Added to
Food did provide upper limits of Ag migration from packaging. Recommended values should not
exceed 0.05 mg/L in water and 0.05 mg/kg in food. This implies that the evaluation of silver migration
profiles is needed to assure antimicrobial effectiveness while complying with the current legislation,
and that products for food packaging and food supplements containing AgNPs are not allowed in the
EU, unless authorized [23]. Toxicity of AgNPs also depends on their size, as it generally increases upon
decreasing size [40,41]. A smaller size results in the following characteristics: (1) greater tendency to
enter into organisms; (2) a larger number of surface atoms available for diverse reactions; (3) more
released Ag ions from the nanoparticles; and (4) more reactive oxygen species (ROS) production on
the surface, which eventually results in an increased toxicity [40]. However, there are many papers
that discuss in detail the properties and aspects connected to AgNP. toxicity, such as [38,42–49], to cite
a few.
2.1. Synthesis Methods
The synthesis of supported (which is beyond the scope of this review) and colloidal AgNPs
has been investigated extensively and, over the years, several techniques have been proposed for
the synthesis of AgNPs. For a detailed view of such literature, we recommend review works and
book chapters published in the last two years, such as [50–66], which deal with the synthesis of
colloidal materials. Figure 1 summarizes the main approaches to synthetize AgNPs, including
chemical reduction [67,68], photoreduction [69–71], microemulsion (reverse micelle) methods [72,73],
electrochemical methods [74–76], evaporation-condensation processes [77], laser ablation [18],
and biosynthesis [78,79].
 
Figure 1. Schematic representation of some of the main methods available for the synthesis of silver
nanoparticles (AgNPs). Reprinted from [61], with permission from Elsevier.
Chemical reduction is the most common method for the preparation of AgNPs as stable colloidal
dispersions. This method requires a reductant capable of transforming the silver salt into AgNPs,
which is usually also used as a stabilizing or capping agent to ensure stability of colloids. Commonly
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used reducing agents are ascorbic acid, sodium borohydride, sodium citrate, ferulic acid, poly(ethylene
glycol)-block copolymers, and hydrazine compounds [64,80–82]. Jokar et al. [83] prepared AgNPs for
low-density polyethylene (LDPE) nanocomposites via chemical reduction, using polyethylene glycol
(PEG) as a reducing agent, stabilizer, and solvent, with silver nitrate (AgNO3) as metal precursor.
To improve antibacterial activity of AgNPs, researchers usually use reductants and stabilizing agents
which possess additional antibacterial properties. Cao and coworkers, for example, proposed the
synthesis of AgNPs using AgNO3 as a metal precursor, ascorbic acid as reducing agent, and chitosan
as a stabilizer. Chitosan, which exhibits excellent biocompatibility, biodegradability, and antibacterial
and antifungal activities, was used to prepare silver nanoparticles in many studies [84–86]. Sometimes,
chemical reduction may be supported by microwave to achieve a more homogeneous heating process
and speed up the reaction rate [87].
Biological synthesis of metal nanoparticles using biological agents such as bacteria, fungi,
yeast, plant, and algal extracts is becoming more common due to the necessity to develop simple,
cost-effective, and eco-friendly processes. The fundamental mechanism is an ordinary chemical
reduction, with the difference that reductants are natural agents. Plants and their parts contain
carbohydrates, fats, proteins, nucleic acids, pigments, and several types of secondary metabolites which
can act as reducing agents to produce nanoparticles from metal salts without any toxic by-products [88].
Similarly, biomolecules such as enzymes, proteins and bio-surfactants present in microorganisms can
serve as reducing agents [64]. The major phytochemicals responsible for reducing silver ions into
AgNPs are terpenoids, glycosides, alkaloids, and phenolics (flavonoids, coumarins, ubiquinones,
tannins, lignin, etc.) [89]. There are countless organisms which can be used for the synthesis of
NPs. Bhoir and coworkers [89] used mint extract in the presence of silver nitrate as metal precursors
and polyvinyl alcohol (PVA) as a capping material. Moreover, they demonstrated the use of these
nanoparticles in food packaging: incorporating them in chitosan and gelatin blend they obtained
improved mechanical and barrier properties for the chitosan–gelatin films, as well as antimicrobial
activity for food packaging applications. Terenteva at al. [80] investigated the synthesis of AgNPs
under the influence of flavonoids as reductants, and they found that quercetin, dihydroquercetin, rutin,
and morin produced AgNPs better than chrysin, naringenin, and naringin.
Most of the synthetic techniques mentioned above may suffer from some drawbacks.
With chemical synthesis, metal precursor, reductant, and stabilizing/capping agents, which are
always needed to ensure stable chemical-synthetized colloids, are all present in the synthesis solution.
However, they (or their by-products) can be toxic and unsafe for human health. For this reason, adverse
products must be separated and removed from the final nanocolloids before their use in antibacterial,
biomedical, or catalytic applications.
In general, LASiS is a low environmental impact technique which does not need metal precursors
and reductants, and produces colloids of a relatively high purity as compared to chemical methods.
In particular, the possibility of fragmenting a metal target without making use of capping and reducing
agents intrinsically lowers the risk of contamination of the resulting colloid from unknown chemical
agents and provides NPs with unique surface characteristics [90]. In the field of nano-antimicrobials,
LASiS-generated NPs are expected to exhibit higher reactivity and antimicrobial effects in comparison
to their chemically synthesized homologous NPs, due to the absence of ligands and/or stabilizers on
the NP surface [91,92].
In addition, LASiS allows in situ conjugation of nanoparticles with biomolecules, which has
sometimes proved to be more efficient than the ex situ conjugation required for chemically synthetized
nanoparticles [93].
Hence, high-purity nanoparticles generated by laser ablation can be considered as a very
promising agent for antimicrobial applications, especially in food packaging.
However, in terms of other preparation methods, laser ablation presents some drawbacks
as well. Indeed, it incurs high investment costs because of the high price of laser system; to be
economically convenient, a large number of colloids should be prepared, and fairly often. Moreover,
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lasers need a considerable amount of energy (although many other synthesis routes need a high energy
consumption) [94], and the most diffused laser sources are not capable of producing nanomaterials
on an industrial scale. A great amount of energy is necessary to deliver a good ablation efficiency.
Ablation efficiency decreases with long ablation time because of significant number of NPs placed
along the laser beam. This inconvenience can be solved through a careful choice of fluidics, e.g.,
by removing the as-prepared NPs from the optical path by using a flow-through system [95].
Barcikowski and Gökce et al. have recently demonstrated the production of nanocolloids at
continuous multi-gram ablation rates (i.e., up to 4 g/h) for different metals and under tight composition
control. They exploited a 500 W picosecond laser source working at 10 MHz repetition rate fully
synchronized with a polygon scanner in order to reach a scanning speed up to 500 m/s [96,97]. Such a
technical solution allows to spatially bypassing the laser-induced cavitation bubbles that prevent
higher ablation rates at an MHz repetition rate due to the shielding effect. Therefore, we firmly
believe LASiS represents a very interesting and versatile way to produce technologically relevant
Ag nano-antimicrobials and in the following we will systematically discuss the aspects which make
invaluable this technique.
2.2. Bioactivity of AgNPs
Many studies have been performed on the mechanism of action of AgNPs and the complete
significance of AgNP bioactivity is still under investigation. A bird’s-eye view of some relevant review
works published in the last three years is provided in [36,52,66,98–113]. A variety of mechanisms
may be involved in the antimicrobial activity of silver against a broad spectrum of organisms
(Figure 2). Some of the commonly accepted mechanisms include silver–amino acid and silver–thiolate
group interactions, silver–DNA interactions, generation of reactive oxidative species, and direct cell
membrane damage [47,114].
 
Figure 2. Schematic representation of the known mechanisms of antibacterial action of silver
nanoparticles and silver ions. Reprinted from [108], with permission from Elsevier.
Zhang and his collaborators highlight that Ag+ is expected to show high affinity to the soft
base-like thiolate ligands, which are abundant in the bacterial membrane and subcellular structure
(e.g., sulfur-containing proteins and enzymes), leading to the inhibition of crucial biological cellular
functions [114]. It was found that intracellularly released Ag+ ions interact with thiol groups of
antioxidants such as glutathione (GSH), superoxide dismutase (SOD), and thioredoxin, leading to
increased lipid peroxidation, oxidative stress, DNA damage, and subsequent apoptotic cell death [100].
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Nomiya and coworkers found Ag+ bonded to the amino acids, forming weak Ag–N bonds which
replace biological bonds, resulting in the alteration of cell machinery [115]. AgNPs in the mitochondria
could potentiate mitochondrial membrane potential collapse, disruption of the respiratory chain,
oxidative stress, inhibition of ATP synthesis, and subsequent activation of the mitochondria-dependent
intrinsic pathway of apoptosis. NPs are able to attach to the bacterial membrane by electrostatic
interaction [100,114,116]. Lara et al. reported that the positive charge on the Ag+ ion is crucial
for its antimicrobial activity through the electrostatic attraction between the negatively-charged
cell membrane of the microorganism and the positively-charged inorganic agent. According to
these authors, one of the mechanisms of antibacterial action for AgNPs is the formation of pits
in the cell wall due to AgNP accumulation in the bacterial membrane, which disturbs membrane
permeability, resulting in membrane degradation and cell death [37]. Furthermore, AgNPs and Ag+
ions can work as catalysts and increase generation of reactive oxygen species (ROS). ROS are usually
present in cells in small amounts, but an excess can lead to oxidative stress [47,117]. Nanosilver
is also known to interact with DNA and cause DNA damage [118]. DNA is responsible for the
reproduction process. Any damage done to it will cause either mutation or death of the organism.
It was found that AgNPs specifically interact with the exocyclic nitrogen present in the adenine,
guanine, and cytosine bases, which leads to DNA changes [101]. Undoubtedly, both Ag+ ions and
AgNPs possess antimicrobial activity, but it is very hard to precisely discriminate between the effect
of ions and those of nanosilver [44]. Li et al. [119] reported on a similar mode of action of Ag+ ions
compared to that of AgNPs, although with stronger antibacterial activity. Navarro et al. [120] suggested
that AgNP toxicity could be explained by the release of Ag+ from the particles which damage cells.
AgNPs have been proved to be active against both Gram-positive and Gram-negative bacteria,
as briefly listed in Table 1, where effect of both silver ions and AgNPs has been described on several
microorganisms [103,121]. It is well accepted that AgNPs and Ag+ give rise to different cellular uptake
pathways (Figure 3) depending on whether Gram-positive or Gram-negative bacteria are considered,
as also shown in some recent papers [103,122].
 
Figure 3. Schematic diagram of bactericidal activity of AgNPs on Gram-positive and Gram-negative
bacteria. Reprinted from [105], an open access article distributed under the Creative Commons
Attribution License. ROS: reactive oxygen species.
AgNPs have also been proved to be active against multi-resistant bacteria like methicillin-
resistant Staphylococcus aureus (MRSA), as well as multidrug-resistant Pseudomonas aeruginosa,
ampicillin-resistant Escherichia coli O157:H7 and erythromycin-resistant Streptococcus pyogenes [37],
or other pathogenic organisms such as Bacillus subtilis, Vibrio cholera, and Syphilis typhus [64].
Pazos-Ortiz and colleagues showed antibacterial activity of AgNPs dispersed in polycaprolactone
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(PCL). They found that there is greater sensitivity towards Escherichia coli, Klebsiella pneumoniae,
Staphylococcus aureus, and Pseudomonas aeruginosa, and poor results for Bacillus subtilis and Streptococcus
mutans [123]. Gram-negative bacteria (e.g., Escherichia coli, Pseudomonas aeruginosa, and Klebsiella
pneumoniae) were found to be, in general, more sensitive to AgNPs than Gram-positive ones
(e.g., Staphylococcus aureus, Streptococcus mutans, and Bacillus subtilis), because of their negatively
charged external membrane together with the thinner peptidoglycan layer, which allows adherence
and the subsequent penetration of AgNPs [26,123].
Table 1. Activity of Ag+ and/or AgNPs against selected bacterial strains. Adapted from [124],
with permission from John Wiley and Sons.
Target Organism Different Form of Silver References
Staphylococcus aureus and Escherichia coli Silver ions [125]
Escherichiacoli Silver nanoparticles [126,127]
RNA viruses Silver ions [128]
Escherichia coli, Vibrio cholerae,
Pseudomonas aeruginosa, and Salmonella typhus Silver nanoparticles [129]
Escherichia coli Silver ions [130]
Escherichia coli, Salmonella typhi,
Staphylococcus epidermidis, Streptococcus Aureus Silver nanoparticles [131]
Phoma glomerata, Phoma herbarum,




and Pseudomonas aeruginosa Silver nanoparticles [133]
P. aeruginosa, S. aureus, pathogenic fungi
Aspergillus flavus and Aspergillus niger Silver nanoparticles [134]
S. aureus, E. coli, Klebsiella pneumoniae,
Bacillus subtilis, Enterococcus faecalis, P. aeruginosa Silver nanoparticles [135]
The biological activity of AgNPs depends on factors including surface chemistry and morphology,
size, shape, coating/capping agent, NP agglomeration and dissolution rate, particle reactivity in
solution, and efficiency of ion release [136–140]. According to Riaz Ahmed and colleagues [100],
smaller sized AgNPs (about <20 nm) with increased surface to volume ratio possess increased cell
permeation capacity and a higher rate of Ag+ ion release, thus increasing the potential for cytotoxicity
and cell injury. They proposed an empiric scale of AgNP bioactivity depending on size (Figure 4) and
they showed that cellular effects aggravate with size decrease. They also outlined how entity of DNA
damage is not dependent on AgNP diameter.
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Figure 4. Size-dependent effects of AgNPs in vitro. In general, adverse cellular effects are associated
with exposure to smaller AgNPs. One exception is DNA damage; the magnitude of response appears
to not depend on AgNP size. Reprinted from [100], with permission from Elsevier.
It has been observed that the shape of AgNPs also causes a critical impact on their antimicrobial
activity. Plate- and rod-shaped AgNPs showed higher antibacterial activity as compared to spherical
AgNPs and thus they could be used in lower concentrations. In fact, it was observed that the
bactericidal activity of plate- and rod-shaped AgNPs was favored by the presence of high atom density
facets {111}, whereas, due to predominance of {100} facets on spherical AgNPs, the latter showed
relatively lesser bactericidal activity [108,127]. The concentration of AgNPs is another important factor
affecting toxicity. It is critical to determine the minimum concentration level of NPs that induces
toxicity and its variation in different subjects. Table 2 summarizes a few works that discussed a
concentration-dependent AgNP bioactivity.
Table 2. Effects of Ag-NPs at different ranges of concentration on different cell lines. Adapted from
[52], with permission from Elsevier.
Concentration Range Effects of AgNPs References
25–75 μg/mL In rat alveolar macrophage cell line, cytotoxicity increases in aconcentration-dependent manner [141]
5, 15, 40, 125 μg/mL Cytotoxicity occurred through mitochondrial depolarization [142]
20–250 μg/mL Apoptosis and necrosis induced in an Hematopoietic stem cell(HSC) cell line [143]
1, 2, 4 μg/mL Cell viability decreased in a concentration-dependent manner [144]
0.4 and 0.8 μg/mL Arrest G1 phase in cell cycle in a Murine Macrophages cell line(#RAW 264.7) [145]
AgNPs produced by laser ablation ensure surface cleanliness and the absence of capping agents,
which could induce a potential shielding effect on the antimicrobial activity. Hence, we would expect
that the antimicrobial activity of laser-produced nanoparticles would be higher compared with the
bioactivity of colloids fabricated with other methods which result in NPs with a core-shell structure.
Furthermore, reaction by-products of AgNPs synthesis may have potential toxicity. This poses serious
issues for the authorization of use of these nanomaterials. However, there are only a few studies that
analyze the bactericidal properties of AgNPs produced by laser ablation, and a systematic assessment
of these aspects is still missing.
Perito and coworkers [146] tested the antimicrobial activity of AgNPs prepared either by
nanosecond (ns) or picosecond (ps) laser ablation using a 1064-nm ablation wavelength, in pure water
and in LiCl solution against two bacteria: E. coli, as a model for Gram-negative bacteria, and B. subtilis,
as a model for Gram-positive bacteria. They found that silver colloids ablated in chloride solution
exhibited higher antimicrobial activity compared to colloids ablated in pure water. They suggested
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that AgNPs are coated by a thin oxide layer which “activates” AgNP surface by the addition of a small
quantity of LiCl, increasing metal surface reactivity due to the presence of positively-charged active
sites. They also stated that bacterial growth inhibition is more effective with AgNPs having an average
diameter lower than 10 nm (i.e., prepared with ns pulses), and this is in agreement with the findings of
several other works [129,147–150]. As a general statement supported by different groups, it can be
inferred that the antibacterial activity of AgNPs decreases with increasing particle size [88].
The effect of the AgNP concentration on the final biocidal properties, while intuitive and
reasonable, is not obvious in the case of use of silver nano-antimicrobials because of the strict
solubility limits that Ag+ ions show in vivo, primarily due to the precipitation of insoluble salts
such as AgCl, which could lower bioactivity. Nevertheless, Korshed and coworkers studied
laser-generated AgNPs [151] and showed that the NP antibacterial effects against both Gram-negative
and Gram-positive bacteria displayed significant dose dependency on AgNP concentration when
investigating a range from 10 μg/mL to 50 μg/mL. Similar trends were observed by Pandey and
colleagues, investigating a concentration range from 40 μg/mL to 600 μg/mL [122].
Zafar et al. [152] reported a comparison between the bioactivity of AgNPs produced by laser
ablation and AgNPs produced by chemical reduction. The size of chemically synthesized nanoparticles
was in the range of 30–40 nm, while the size range of laser ablated nanoparticles was 20–30 nm.
Experiments were carried out at the same AgNP dose and laser-ablated nanoparticles provided
maximum inhibition against each pathogen (S. aureus, E. coli, Salmonella). The reduced bioactivity
of chemically synthesized NPs, as compared to laser-ablated ones, was interpreted as due to the
adsorption of chemical species on their surface, producing adverse effects on their antibacterial action.
However, NP size plays a key role in the antibacterial action, so the different bioactivity of laser-ablated
AgNPs and chemically synthetized-AgNPs shown in this paper could also be ascribed to different
NP sizes.
Based on the literature cited above, it is evident how both the effect of NP size and concentration
strictly depends on the single microorganism involved. As a general interpretation, it is possible to
state that, even though <10 nm NPs can perform a stronger antimicrobial action, it is better to maintain
a conservative approach towards potential nanotoxicological issues arising from the use of such small
materials. It is known, in fact, that risks related to NP penetration through main entrance pathways in
the human body reach a maximum for dimensions below a critical value of ~50 nm in diameter [153].
Hence, in a growing number of applications of NP-based materials in real-life products, the presence
of a (polymeric) matrix that immobilizes NPs appears to be extremely important. In fact, it can prevent
and/or limit human exposure to bare (and potentially dangerous) NPs [154].
3. Laser Ablation Synthesis in Solution
In the laser ablation process, an extremely high energy is concentrated at a specific point on a
solid target, to remove the material from surface. When a laser pulse irradiates the surface of a bulk
material, electromagnetic radiation is adsorbed by the target electrons and energy transfers to material
vibrational lattice. As a result, material is expelled from the surface in the form of a plasma plume
(in which nanoparticles are formed) [155]. The plasma plume is confined, due to the high pressure
exerted by the surrounding liquid, and the considerable temperature gradient between the plume and
the liquid. During the plasma decay, the energy is transferred to the surrounding liquid, producing a
layer of vapor with a volume approximately equal to that of the plasma, and shaping up a cavitation
bubble. Soon after, the cavitation bubble undergoes a periodic evolution of further expansion and
shrinkage until its collapse, after which nanoparticles are released into the environmental liquid [156].
The ablation rate is generally determined by laser parameters such as: wavelength, fluence,
pulse duration and repetition rate, light absorption efficiency of the target material, transmission,
and chemical composition of the liquid. Consequently, NP features depend on laser parameters as well
as on the liquid medium. Typical requirements for laser ablation are a wavelength from UV-Vis to near
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infrared (NIR-IR), a laser fluence approximately comprised between 0.1 and 100 J/cm2, pulse durations
from nanosecond (ns) to picosecond (ps) and femtosecond (fs) [92,95].
These laser parameters can be used to tune several NP features, such as size, shape, surface
properties, aggregation state, solubility, structure, and chemical composition [156,157]. As we have
previously discussed, these features may affect the NP antimicrobial activities: hence, it is important to
know how NP characteristics depend on some laser parameters.
3.1. Ablation Medium
Distilled or deionized water is the most frequently employed liquid medium for the LASiS
synthesis of metal nanoparticles, as shown by Mafuné et al. [19,158–161]. Using water as synthesis
medium could generate several oxide or hydroxide species because of reactions occurring between
the target material and dissolved oxygen, or oxidizing reactions caused by the plasma-induced
decomposition of water. Species (such as hydroxyl groups) can be adsorbed on the NP surface,
which can lead to highly-charged surfaces that contribute to the electrostatic stabilization of the
synthetized nanoparticles [156]. Water is a favorable medium in most ablation processes because it is
cheap, safe, exhibits a high heat capacity, and does not absorb laser light [162].
Organic solvents have been also investigated for laser ablation processes, and the most commonly
used ones are methanol, ethanol, isopropanol, acetonitrile, and ethylene glycol. When using organic
solvents, the higher dipole moment of the solvent has been reported to result in a higher ablation
efficiency and in smaller particles. This effect was attributed to the increased electrostatic interactions
resulting from the higher molecular dipolar moment of the solvent molecules, which generates a
stronger electric double layer at the NPs surface and enhances the repulsive force between NPs [156].
Comparing organic solvents with different viscosity and different dipole moment, it was found that
the smallest and most stable AgNPs, with the narrowest size distribution, were obtained in acetone
and 2-propanol. In fact, the former has high dipolar moment but low viscosity, while the latter has
high viscosity and low dipolar moment. Hence, factors like solvent dipolar moment and viscosity
play a fundamental role in avoiding NP agglomeration [163]. Furthermore, when using homologous
solvents, such as alcohols with different chain lengths, it has been shown that short-chain alcohols
(e.g., methanol and ethanol) result in unstable particles, whereas alcohols with chain lengths from C-3
to C-5 give rise to more stable and smaller particles as compared to those produced in alcohols with
chain lengths exceeding C-5 [164].
Moura et al. [165] showed that ethanol and acetone can be good stabilizing environments to
keep NPs free from precipitation and oxidation; however, organic environments resulted in a low
process yield and a larger mean NP size compared to water. Figure 5 displays TEM images of NPs
obtained by laser ablation of Au, Ag, and Fe bulk targets in different solvents with 9-ns pulses
at 1064 nm and 10 J cm−2 [166]. Moura and coworkers [165] hypothesized that, when acetone
molecules are adsorbed around the metal NP, a protective surface dipole layer is developed in the most
external plane, inducing a repulsive interaction between nanoparticles. NP aggregation in ethanol
can be more intense, since ethanol is a low-polarity solvent compared to acetone. However, it was
reported that ablation processes performed in ethanol environment had a low ablation efficiency [165].
This was attributed to the ethanol decomposition during ablation process, promoting the formation of
permanent gas bubbles. The latter, in combination with the ablated plasma plume and the as-formed
NPs, may act as obstacles within the laser path, thus reducing the energy reaching the target. Recently,
Kalus et al. [167] studied the effect of persistent microbubbles on nanoparticle productivity in laser
synthesis of colloids, finding that the highest productivity and monodisperse quality is achieved in
liquids with the lowest viscosities.
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Figure 5. Summary of the NMs obtained by laser ablation of Au, Ag, and Fe bulk targets in different
solvents with 9-ns pulses at 1064 nm and 10 J cm−2. Reprinted from [166], an open access article
distributed under the Creative Commons Attribution License.
Tajdidzadeh et al. [168] showed that NPs ablation efficiency in chitosan solution is higher than in
ethylene glycol (EG), and that it is higher in EG than in deionized water due to plasma confinement on
the Ag target (Figure 6). It is worth noting that the broad tail at high wavelength values in AgNP UV-Vis
spectra reported in the following is known to be ascribable to NP agglomeration [169]. Those who are
not familiar with the UV-vis spectra of nanoparticles should refer to [22] for fundamental information
on these phenomena.
 
Figure 6. UV-visible absorption spectra of AgNPs prepared for 30 min ablation times in ethylene glycol,
chitosan, and deionized water. Reprinted from [168], an open access article distributed under the
Creative Commons Attribution License.
In the same paper it is shown by TEM how chitosan solution, which has higher density and
viscosity than other liquids, produces a mean size decrement for AgNPs. The same authors also
assumed that the plasma generated on the target surface is confined, generating local high pressures
and thus etching the target surface. The process, called secondary ablation, can improve ablation
efficiency. Additionally, the obtained chitosan-functionalized NPs were shown to be quite stable
because the biopolymer acts as a capping agent.
165
Antibiotics 2018, 7, 67
Similar results was reported by Al-Azawi and coworkers [170], who synthetized AgNPs by
laser ablation in three different solvents: water, ethanol, and polyvinylpyrrolidone (PVP). Indeed,
the ablation efficiency for Ag colloids in ethanol was found to be the lowest, whereas in water it was
higher than in PVP solution, corroborating the evidence that the ablation yield of AgNPs in organic
solution is generally low. It was found that the efficiency of laser ablation increased, and the NP size
decreased for the solvent with higher density and viscosity, which is in agreement with the findings of
Moura and Tajdidzadeh.
Accordingly, also in Ganeev’s work [171] colloidal silver surface plasmon resonance (SPR)
absorbance in water and in ethanol noticeably decreased over time as compared with AgNPs in
ethylene glycol, which resulted more stable because of high solvent viscosity. This may be ascribed to
a higher solvent viscosity, which prevents NP flocculation.
Overall, we can state that the ablation efficiency is higher in an aqueous environment, but AgNPs
are generally more stable in organic environment. This is correlated to solvent physicochemical
properties, like the dipole moment and viscosity, which influence NP growth and stability. Higher
solvent viscosity prevents NP flocculation and improves ablation efficiency and higher molecular
dipolar moment of the solvent molecules generates a stronger electric double layer at the NP surface,
which improves the repulsive forces between NPs, increasing their stability.
3.2. Pulse Duration
The effects of the pulse duration are dependent on the electron cooling time (electron-phonon
coupling constant) of the material. For fs lasers, pulse duration is shorter than the electron cooling time;
thus, the electron-lattice (phonon) coupling is negligible, and the ablation process can be considered as
a solid–vapor transition. The ablation process associated with ns pulses is believed to be a thermal one,
involving laser heating and melting [166,172]. For these reasons, during fs laser ablation, craters are
clearer and more defined than during ns processes.
Tzuji et al. [173] reported a comparison between AgNPs ablated with ns and fs pulsed lasers.
They showed that fs ablation yield was lower than nanosecond one. Sizes of ns-prepared particles were
much dispersed, and they were irregularly shaped (Figure 7) as compared to fs-prepared particles.
  
(a) (b) 
Figure 7. TEM images and size distribution of silver colloids prepared by (a) 120-fs and (b) 8-ns laser
pulses. Reprinted from [173], with permission from Elsevier.
Barcikowski and colleagues [95] showed that fs pulses have an higher ablation rate than
picosecond ones, but the reported process yield was about three times higher for ps laser ablation when
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compared to fs ablation. At the same time, it was shown that both ps and fs ultrashort pulsed lasers
generated nanoparticles with comparable size distributions. A similar trend was found by Hamad [172],
who reported a comparison between AgNPs produced by ns, ps, and fs pulses, and showed a higher
ablation efficiency for fs pulses.
3.3. Laser Wavelength
According to the photon energy equation E = hc/λ, a shorter wavelength implies a greater energy.
For instance, at a wavelength of 532 nm, green laser pulses have higher photon energy (2.33 eV) in
comparison with those at a 1064-nm wavelength (1.16 eV). In general, the 532-nm wavelength is more
effective at producing smaller AgNPs than the 1064-nm one. This is because the lower energy of
1064-nm photons results in less fragmentation, thus producing larger nanoparticles with a higher
extinction coefficient in the near-infrared region. On the other hand, the fragmentation produced at
532 nm is higher not only because of the greater photon energy but also because this wavelength
is in the range of the SPR peak of AgNPs, thus leading to a reduction of NP size in the colloidal
solution [174].
The laser wavelength also determines the laser penetration into the metal target and, consequently,
the ablation depth. This parameter decreases with the laser wavelength, thus indicating that the ablated
mass per pulse may increase for longer wavelengths if reflectivity is the same [156].
However, it is important to highlight that the influence of the laser wavelength on NP properties
still depends on all the other laser parameters, e.g., pulse energy and duration, liquid media,
and radiation focus, above all. Solati and colleagues [175] investigated the effect of laser wavelength
on the production of AgNPs in acetone (Figure 8); they used nanosecond pulses at 532 nm and 1064 nm
and, for each wavelength, they worked at different laser fluences. Results showed that NP size was
smaller for a 532 nm than 1064 nm wavelength. They also showed that a surface plasmon resonance
(SPR) shift between colloids produced at different fluences is more evident at 1064 nm than at 532 nm.
  
(a) (b) 
Figure 8. Absorption spectra of Ag nanoparticles in acetone prepared at (a) 532 nm wavelength;
(b) 1064 nm wavelength at several fluences (samples 1 and 4: 14 J/cm2, samples 2 and 5: 18 14 J/cm2,
samples 3 and 6: 22 J/cm2). Reprinted from [175], with permission from Springer Nature.
The studies by Tsuji and coworkers [176,177] showed that ablation efficiency (evaluated by
measuring interband absorption at 250 nm) increases for shorter wavelengths when radiation is
unfocused with respect to the target, while it increases with the wavelength for tighter beam focusing
conditions (Figure 9). Authors hypothesized that ablation efficiency depends on the laser fluence,
which changed with beam focusing.
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Figure 9. Absorption spectra of Ag colloidal solution prepared with various wavelength laser lights.
(a) The laser beam was not focused and laser fluence was 900 mJ/cm2; (b) The laser beam was focused
and laser fluence was >12 J/cm2. Reprinted from [176], with permission from Elsevier.
3.4. Laser Fluence and Energy Pulse
Laser fluence is a crucial laser parameter that determines the ablation efficiency. NP production
yield is affected by the cavitation bubble. In general, the cavitation bubble lifetime increases with the
laser fluence [178]. As a result, when the time interval (determined by the repetition rate of pulsed
lasers) between two subsequent pulses spatially overlapping on the same spot onto the target is faster
than the bubble lifetime, the latter substantially shields and reflects the incoming pulse, thus reducing
the ablation rate [156].
Above the ablation threshold, increasing the laser fluence gradually increases the synthesis yield.
In fact, Moura et al. [165] observed that the absorption intensity tended to be higher at increasing laser
fluences, suggesting that AgNPs concentration increased. Dorranian and coworkers [179], for example,
showed the increase of ablated mass upon increasing the fluence (Figure 10).
 
Figure 10. Ablated mass versus laser pulse fluency. Reprinted from [179], an open access article
distributed under the Creative Commons Attribution License.
They also found that smaller average NP sizes were obtained by using higher laser fluence
values, as shown in STEM (scanning transmission electron microscope) micrographs of Figure 11.
This behavior was explained considering that, at high pulse energies, the ablation process is
accompanied by melting of the target surface, with less evaporation and NP auto-absorption of
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Figure 11. STEM images and corresponding histograms of silver colloidal nanoparticles prepared
by laser ablation at different laser fluences (a) 2122.2 J/cm2; (b) 3183.3 J/cm2 and (c) 4244.0 J/cm2.
Reprinted from [165], with permission from Elsevier.
This trend was also found in other papers [175,179–181]. However, Nikolov et al. [182]
demonstrated that the average particle size remained unchanged with the laser fluence at its
fundamental wavelength (λ = 1064 nm), but it increased strongly with increasing laser fluence at
the second harmonic wavelength (λ = 532 nm). On the contrary, Al-Azawi [170] found that the ablation
efficiency increased (while the particle size decreased) when laser fluence reached its maximum;
subsequently, the ablation efficiency rapidly decreased with increasing the laser fluence. This behavior
was ascribed to the occurrence of auto-absorption processes leading to fragmentation of larger particles.
Ablation efficiency generally increases with increasing of pulse energy, as was shown by
Valverde-Alva et al. [183] who found an increase of the SPR peak intensity when higher laser pulse
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energies were used. This result was attributed to the more concentrated AgNP colloids produced with
higher pulse energies.
Syntheses of AgNPs using a 1064-nm wavelength Nd:YAG laser, with pulse frequency of 20 Hz
and 4 ns of pulse duration, were also carried out by our group. We observed that, at a fixed ablation
time of 20′, ablation rate increased with pulse energy. Moreover, AgNPs average size decreased with
the energy. Moreover, we found that ablation rate grew with pulse energy for longer ablation times.
This effect was attributed to the increasing concentration of AgNPs lying on the laser beam path,
which caused an attenuation of the incident radiation owing to scattering phenomena.
3.5. Repetition Rate
The repetition rate (RR) is defined as the number of output laser pulses per unit time. Therefore,
for a given laser power, reducing the repetition rate results in an increase of the pulse energy,
thus yielding a higher ablation rate per pulse (and larger cavitation bubbles) because of the increased
laser fluence [156]. In general, ablation efficiency and concentration of AgNPs increases with the
repetition rate. To explain this phenomenon, Valverde-Alva measured the transmission of laser pulses
through colloidal solutions and showed that it increased with the RR. Zamiri and coworkers [184]
obtained a similar trend. They also investigated the variation of average AgNP size and showed
that it increased with increasing RR, in contrast to the trends obtained by Menéndez-Manjón and
Barcikowski [185]. However, in this last case, significantly higher repetition rates, spanning in a broad
range from 100 to 5000 Hz, were used compared to the very limited range of RR from 10 to 40 Hz
explored by Zamiri. For RR exceeding tens of kHz or even approaching the MHz regime, the pulse
energy must be decreased to reduce the size and lifetime of the cavitation bubble, which otherwise
would shield the laser radiation, thus reducing the ablation yield [97].
4. AgNPs in Food Packaging
AgNPs are a valid antimicrobial additive to control the microbial population in commercialized
foodstuff. They have been proved to reduce, delay, or inhibit the growth of spoilage microorganisms,
thus improving food shelf life.
Some recent reviews and book chapters discuss the use of AgNPs for this specific
application [8,20,21,23–31,186,187]. These references highlight the antimicrobial activity of AgNPs,
the mechanism of action against microorganisms, and the correlations existing between bioactivity
and AgNP features such as size, shape, and concentration. In most of the literature in this field, AgNPs
are embedded in packaging films and tested against foodborne microorganisms, or directly used to
package fruit and vegetables, meat, and dairy products. For example, Costa and coworkers [188]
prepared and used silver-montmorillonite (Ag-MMT) in packaging for freshly-sliced fruit salads,
and found inhibition of microbial growth and increased shelf life. In another interesting work,
Sivakumar and colleagues [189] showed a new method to produce nontoxic silver nanorods from dairy
industry waste. They used them to control bacterial growth in milk during processing and storage,
thus demonstrating extension of milk shelf-life. The most cited reviews and book chapters include
many other examples of real-life use of AgNPs. Table 3 summarizes some of the aforementioned
applications of AgNPs in food packaging.
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Table 3. Applications of AgNPs in food industry. Adapted from [25], with permission from Elsevier.
Nanomaterial Product Packaging Manufacturer Country NP Size References
Nano-silver salad bowl Changmin Chemicals Korea not reported [190]
Nano silver baby mug cup and nurser Baby Dream® Co., Ltd. Korea not reported [191]
Fresh Box® food storage containers BlueMoonGoods™ USA not reported [190]
FresherLonger™ containers and bags SharperImage® USA 25 nm and 1–100 nm [192]
Nano-silver storage box Quan Zhou Hu Zeng NanoTechnology® Co., Ltd. China not reported [190]
Plastic food containers and water bottle A-Do Global Korea not reported [191]
Fresh food containers Oso Fresh USA 40–60 nm [193]
Smartwist food storage with nano-silver Kinetic Go Green USA 10–20 nm [193]
The antimicrobial properties of packaging materials are based on the migration of antimicrobial
substances from the packaging to the food, and/or to the headspace surrounding the food product.
Thus, the migration of an active compound from the substrate is an intentional process, which is
needed to exert the antimicrobial and protective action against undesirable food contaminants [194].
For these reasons, the efficiency of antimicrobial packaging is largely determined by a controlled release
of the antimicrobial agent from the active material. A slow and gradual migration of these substances
allows for maintaining an effective antimicrobial concentration on the product over time [194,195].
Nerin and colleagues [194] highlighted that antimicrobials needed to reach bacterial cells to exert their
action, while other substances such as antioxidants can exert their action even without being in direct
contact with foodstuffs and without releasing any agents. It is worth pointing out that other toxic
substances can be released unintentionally into food. AgNP safety limits, both for the environment and
human health, are different according to the various legislative authorities in Europe, the USA, Japan,
and Australia [196]. For instance, in the United States and in Japan, only silver nitrate is regulated
by law in the food and drinks sector, with a maximum allowed limit of 0.017 mg/kg for foodstuffs
and 0.1 mg/kg for drinking water, respectively. As for nanosilver, colloidal solutions are accepted in
the United States and commercialized as nutrition supplements (e.g., Mesosilver), with the claim of
being highly beneficial for human health. In the medical field, different wound dressings containing
nanocrystalline silver or silver ion-releasing systems are widely spread as well as indwelling devices,
like prostheses or catheters [196]. To date, the European Union does not recommend silver for medicinal
use, because of the lack of reliable information with respect to health-risk assessment. The European
Food Safety Authority (EFSA) restricted food migration to a maximum of 0.05 mg/kg [196,197].
Besides silver ions, excessive release of entire silver nanoparticles from packaging can be
dangerous to human health. Food and beverages produced with AgNPs added in their packaging are
considered as the main source of exposure to nanoparticles through ingestion [198]. After ingestion,
these nanoparticles undergo various chemical reactions, including agglomeration, adsorption,
or binding with other food components, and reactions with acids and digestive enzymes. Internal
systemic exposure to NPs can be hazardous since these particles are able to cross biological barriers
and reach internal body tissues [154]. As a consequence, AgNPs may accumulate in tissues, resulting
in changes in body nutrient profiles. In additions, nanoparticles may introduce toxic agents or viruses
adsorbed on their surfaces, or induce production of oxyradicals at the cellular level [198,199]. Therefore,
regulation is very important to minimize harmful consequences deriving from the use of nanoparticles,
although there are still no internationally recognized research protocols or standards [198].
5. Conclusions
In this review, we focused on AgNPs, a very useful nanomaterial for active food packaging,
paying particular attention to AgNPs synthetized by LASiS. After brief overviews of bioactivity
pathways of AgNPs and of synthesis methods to produce silver nanocolloids, we focused on the LASiS
method, describing in detail its working principles and the influence of the main laser parameters
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on the production yield and quality. A short overview of the use of AgNPs in food packaging was
also proposed. Laser ablation is a green technique to produce stable Ag nanocolloids in a wide
variety of dispersing media without using metal precursors and reductants. Highly pure colloids are
produced with unique surface characteristics and without any by-products. These features, in principle,
make AgNPs produced by LASiS some of the best candidates for antimicrobial applications. However,
to date, the productivity is insufficient for direct use in the industrial sector. The current world
record for LASiS NP productivity is 4 g/h; this value, although appealing, needs to be improved for
LASiS to be used in the industrial sector. Methods to increase this productivity level are currently
under development, exploiting high scanning speeds. This way, laser-induced cavitation bubbles
are spatially bypassed at high repetition rates, and continuous multi-gram ablation rates have been
already demonstrated for platinum, gold, silver, aluminum, copper, and titanium. LASiS requires
a great amount of energy, and its scaling-up at the industrial production level is approaching the
efficiency required for real-life applications, although there is still a need of for further technological
improvement, mostly with regard to the technological laser solutions.
Author Contributions: M.C.S. and M.I. performed bibliographic research and wrote the first draft of the paper.
A.V., M.C., R.A.P., A.A., P.M.L., G.P., and N.C. took part in scientific discussions and contributed to different
sections of this review. A.A. and N.C. coordinated and revised the study.
Funding: This research was partially funded by: by Italian MIUR Project, grant number #PONa3 00369.
Acknowledgments: The authors gratefully acknowledge the Apulian Region and the Italian Ministry of Education,
University and Research for having supported this research activity within the projects MICROTRONIC
(Lab Network cod. 71) and “Reti di Laboratori Pubblici di Ricerca” (Lab Network cod. 56).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Lue, J.T. Physical Properties of Nanomaterials. In Encyclopedia of Nanoscience and Nanotechnology;
Nalwa, H.S., Ed.; American Scientific Publishers: Valencia, CA, USA, 2007; Volume 10, pp. 1–46. ISBN
1-58883-058-6.
2. Daraee, H.; Eatemadi, A.; Abbasi, E.; Aval, S.F.; Kouhi, M.; Akbarzadeh, A. Application of gold nanoparticles
in biomedical and drug delivery. Artif. Cells Nanomed. Biotechnol. 2016, 44, 410–422. [CrossRef] [PubMed]
3. Sun, H.; Jia, J.; Jiang, C.; Zhai, S. Gold Nanoparticle-Induced Cell Death and Potential Applications
in Nanomedicine. Int. J. Mol. Sci. 2018, 19, 754. [CrossRef] [PubMed]
4. Yacoot, S.M.; Salem, N.F. A Sonochemical-assisted Simple and Green Synthesis of Silver Nanoparticles and
its Use in Cosmetics. Int. J. Pharmacol. 2016, 12, 572–575. [CrossRef]
5. Jiménez-Pérez, Z.E.; Singh, P.; Kim, Y.-J.; Mathiyalagan, R.; Kim, D.-H.; Lee, M.H.; Yang, D.C. Applications of
Panax ginseng leaves-mediated gold nanoparticles in cosmetics relation to antioxidant, moisture retention,
and whitening effect on B16BL6 cells. J. Ginseng Res. 2018, 42, 327–333. [CrossRef] [PubMed]
6. Syed, B.; Tatiana, V.; Prudnikova, S.V.; Satish, S.; Prasad, N. Nanoagroparticles emerging trends and future
prospect in modern agriculture system. Environ. Toxicol. Pharmacol. 2017, 53, 10–17. [CrossRef]
7. Kaphle, A.; Navya, P.N.; Umapathi, A.; Daima, H.K. Nanomaterials for agriculture, food and environment:
Applications, toxicity and regulation. Environ. Chem. Lett. 2018, 16, 43–58. [CrossRef]
8. Sharma, C.; Dhiman, R.; Rokana, N.; Panwar, H. Nanotechnology: An Untapped Resource for Food
Packaging. Front. Microbiol. 2017, 8, 1735. [CrossRef] [PubMed]
9. Srivastava, A.K.; Dev, A.; Karmakar, S. Nanosensors and nanobiosensors in food and agriculture.
Environ. Chem. Lett. 2018, 16, 161–182. [CrossRef]
10. Ko, S.H. Low temperature thermal engineering of nanoparticle ink for flexible electronics applications.
Semicond. Sci. Technol. 2016, 31, 073003. [CrossRef]
11. Liu, X.; Iocozzia, J.; Wang, Y.; Cui, X.; Chen, Y.; Zhao, S.; Li, Z.; Lin, Z. Noble metal-metal oxide
nanohybrids with tailored nanostructures for efficient solar energy conversion, photocatalysis and
environmental remediation. Energy Environ. Sci. 2017, 10, 402–434. [CrossRef]
172
Antibiotics 2018, 7, 67
12. Akbari, A.; Amini, M.; Tarassoli, A.; Eftekhari-Sis, B.; Ghasemian, N.; Jabbari, E. Transition metal oxide
nanoparticles as efficient catalysts in oxidation reactions. Nano-Struct. Nano-Objects 2018, 14, 19–48.
[CrossRef]
13. Baker, S.; Volova, T.; Prudnikova, S.V.; Satish, S.; Prasad, N. Nanoagroparticles emerging trends and future
prospect in modern agriculture system. Environ. Toxicol. Pharmacol. 2017, 53, 10–17. [CrossRef] [PubMed]
14. Duhan, J.S.; Kumar, R.; Kumar, N.; Kaur, P.; Nehra, K.; Duhan, S. Nanotechnology: The new perspective in
precision agriculture. Biotechnol. Rep. 2017, 15, 11–23. [CrossRef] [PubMed]
15. Ammar, A.S. Nanotechnologies associated to floral resources in agri-food sector. Acta Agron. 2018, 67,
146–159. [CrossRef]
16. Bhagat, Y.; Gangadhara, K.; Rabinal, C.; Chaudhari, G.; Ugale, P. Nanotechnology in agriculture: A review.
J. Pure Appl. Microbiol. 2015, 9, 737–747.
17. Duncan, T.V. Applications of nanotechnology in food packaging and food safety: Barrier materials,
antimicrobials and sensors. J. Colloid Interface Sci. 2011, 363, 1–24. [CrossRef] [PubMed]
18. Picca, R.A.; Di Maria, A.; Riháková, L.; Volpe, A.; Sportelli, M.C.; Lugarà, P.M.; Ancona, A.;
Cioffi, N. Laser ablation synthesis of hybrid copper/silver Nanocolloids for prospective application as
Nanoantimicrobial agents for food packaging. MRS Adv. 2016, 1, 3735–3740. [CrossRef]
19. Sportelli, M.C.; Volpe, A.; Picca, R.A.; Trapani, A.; Palazzo, C.; Ancona, A.; Lugarà, P.M.; Trapani, G.; Cioffi, N.
Spectroscopic characterization of copper-chitosan Nanoantimicrobials prepared by laser ablation synthesis
in aqueous solutions. Nanomaterials 2017, 7, 6. [CrossRef] [PubMed]
20. De Azeredo, H.M. Nanocomposites for food packaging applications. Food Res. Int. 2009, 42, 1240–1253.
[CrossRef]
21. Ahmad, N.; Bhatnagar, S.; Dubey, S.D.; Saxena, R.; Sharma, S.; Dutta, R. Nanopackaging in Food and
Electronics. In Nanoscience in Food and Agriculture 4; Sustainable Agriculture Reviews; Springer: Cham,
Switzerland, 2017; pp. 45–97. ISBN 978-3-319-53111-3.
22. Sportelli, M.C.; Picca, R.A.; Cioffi, N. Nano-antimicrobials based on metals. In Novel Antimicrobial Agents and
Strategies; Phoenix, D.A., Harris, F., Dennison, S.R., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim,
Germany, 2014; pp. 181–218. ISBN 978-3-527-67613-2.
23. Carbone, M.; Donia, D.T.; Sabbatella, G.; Antiochia, R. Silver nanoparticles in polymeric matrices for fresh
food packaging. J. King Saud Univ. Sci. 2016, 28, 273–279. [CrossRef]
24. Farhoodi, M. Nanocomposite materials for food packaging applications: Characterization and safety evaluation.
Food Eng. Rev. 2016, 8, 35–51. [CrossRef]
25. Hannon, J.C.; Kerry, J.; Cruz-Romero, M.; Morris, M.; Cummins, E. Advances and challenges for the use of
engineered nanoparticles in food contact materials. Trends Food Sci. Technol. 2015, 43, 43–62. [CrossRef]
26. Hoseinnejad, M.; Jafari, S.M.; Katouzian, I. Inorganic and metal nanoparticles and their antimicrobial activity
in food packaging applications. Crit. Rev. Microbiol. 2018, 44, 161–181. [CrossRef] [PubMed]
27. Kuswandi, B. Environmental friendly food nano-packaging. Environ. Chem. Lett. 2017, 15, 205–221. [CrossRef]
28. Llorens, A.; Lloret, E.; Picouet, P.A.; Trbojevich, R.; Fernandez, A. Metallic-based micro and nanocomposites
in food contact materials and active food packaging. Trends Food Sci. Technol. 2012, 24, 19–29. [CrossRef]
29. Narayan, R.J.; Adiga, S.P.; Pellin, M.J.; Curtiss, L.A.; Stafslien, S.; Chisholm, B.; Monteiro-Riviere, N.A.;
Brigmon, R.L.; Elam, J.W. Atomic layer deposition of nanoporous biomaterials. Mater. Today 2010, 13, 60–64.
[CrossRef]
30. Piperigkou, Z.; Karamanou, K.; Engin, A.B.; Gialeli, C.; Docea, A.O.; Vynios, D.H.; Pavão, M.S.G.;
Golokhvast, K.S.; Shtilman, M.I.; Argiris, A.; et al. Emerging aspects of nanotoxicology in health and
disease: From agriculture and food sector to cancer therapeutics. Food Chem. Toxicol. 2016, 91, 42–57.
[CrossRef] [PubMed]
31. De Azeredo, H.M. Antimicrobial nanostructures in food packaging. Trends Food Sci. Technol. 2013, 30, 56–69.
[CrossRef]
32. Rhim, J.-W.; Hong, S.-I.; Park, H.-M.; Ng, P.K.W. Preparation and characterization of chitosan-based
nanocomposite films with antimicrobial activity. J. Agric. Food Chem. 2006, 54, 5814–5822. [CrossRef]
[PubMed]
33. Novikov, S.M.; Popok, V.N.; Evlyukhin, A.B.; Hanif, M.; Morgen, P.; Fiutowski, J.; Beermann, J.;
Rubahn, H.-G.; Bozhevolnyi, S.I. Highly stable monocrystalline silver clusters for plasmonic applications.
Langmuir 2017, 33, 6062–6070. [CrossRef] [PubMed]
173
Antibiotics 2018, 7, 67
34. Pugazhendhi, S.; Palanisamy, P.K.; Jayavel, R. Synthesis of highly stable silver nanoparticles through a novel
green method using Mirabillis jalapa for antibacterial, nonlinear optical applications. Opt. Mater. 2018, 79,
457–463. [CrossRef]
35. Franci, G.; Falanga, A.; Galdiero, S.; Palomba, L.; Rai, M.; Morelli, G.; Galdiero, M. Silver nanoparticles as
potential antibacterial agents. Molecules 2015, 20, 8856–8874. [CrossRef] [PubMed]
36. Le Ouay, B.; Stellacci, F. Antibacterial activity of silver nanoparticles: A surface science insight. Nano Today
2015, 10, 339–354. [CrossRef]
37. Lara, H.H.; Garza-Treviño, E.N.; Ixtepan-Turrent, L.; Singh, D.K. Silver nanoparticles are broad-spectrum
bactericidal and virucidal compounds. J. Nanobiotechnol. 2011, 9, 30. [CrossRef] [PubMed]
38. Miyayama, T.; Arai, Y.; Hirano, S. Health Effects of Silver Nanoparticles and Silver Ions. In Biological Effects
of Fibrous and Particulate Substances; Current Topics in Environmental Health and Preventive Medicine;
Springer: Tokyo, Japan, 2016; pp. 137–147. ISBN 978-4-431-55731-9.
39. Hansen, S.F.; Baun, A. European regulation affecting nanomaterials—Review of limitations and future
recommendations. Dose-Response 2011, 10, 364–383. [CrossRef] [PubMed]
40. Zhou, Q.; Liu, W.; Long, Y.; Sun, C.; Jiang, G. Toxicological effects and mechanisms of silver nanoparticles.
In Silver Nanoparticles in the Environment; Springer: Berlin/Heidelberg, Germany, 2015; pp. 109–138. ISBN
978-3-662-46069-6.
41. Rai, M.; Yadav, A.; Cioffi, N. Silver Nanoparticles as Nano-antimicrobials: Bioactivity, benefits and
bottlenecks. In Nano-Antimicrobials; Springer: Berlin/Heidelberg, Germany, 2012; pp. 211–224. ISBN
978-3-642-24427-8.
42. El-Ansary, A.; Al-Daihan, S. On the Toxicity of Therapeutically Used Nanoparticles: An Overview. Available
online: https://www.hindawi.com/journals/jt/2009/754810/ (accessed on 23 June 2018).
43. Gaillet, S.; Rouanet, J.-M. Silver nanoparticles: Their potential toxic effects after oral exposure and underlying
mechanisms—A review. Food Chem. Toxicol. 2015, 77, 58–63. [CrossRef] [PubMed]
44. Gupta, I.; Duran, N.; Rai, M. Nano-silver toxicity: Emerging concerns and consequences in human health.
In Nano-Antimicrobials; Springer: Berlin/Heidelberg, Germany, 2012; pp. 525–548. ISBN 978-3-642-24427-8.
45. Jamuna, B.A.; Ravishankar, R.V. Environmental risk, human health, and toxic effects of nanoparticles.
In Nanomaterials for Environmental Protection; Wiley-Blackwell: Hoboken, NJ, USA, 2014; pp. 523–535. ISBN
978-1-118-84553-0.
46. Levard, C.; Hotze, E.M.; Lowry, G.V.; Brown, G.E. Environmental transformations of silver nanoparticles:
Impact on stability and toxicity. Environ. Sci. Technol. 2012, 46, 6900–6914. [CrossRef] [PubMed]
47. Marambio-Jones, C.; Hoek, E.M.V. A review of the antibacterial effects of silver nanomaterials and potential
implications for human health and the environment. J. Nanopart. Res. 2010, 12, 1531–1551. [CrossRef]
48. Santos, C.A.D.; Seckler, M.M.; Ingle, A.P.; Gupta, I.; Galdiero, S.; Galdiero, M.; Gade, A.; Rai, M.
Silver Nanoparticles: Therapeutical Uses, Toxicity, and Safety Issues. J. Pharm. Sci. 2014, 103, 1931–1944.
[CrossRef] [PubMed]
49. Gonzalez, C.; Rosas-Hernandez, H.; Ramirez-Lee, M.A.; Salazar-García, S.; Ali, S.F. Role of silver
nanoparticles (AgNPs) on the cardiovascular system. Arch. Toxicol. 2016, 90, 493–511. [CrossRef] [PubMed]
50. Abbasi, E.; Milani, M.; Aval, S.F.; Kouhi, M.; Akbarzadeh, A.; Nasrabadi, H.T.; Nikasa, P.; Joo, S.W.;
Hanifehpour, Y.; Nejati-Koshki, K.; et al. Silver nanoparticles: Synthesis methods, bio-applications and
properties. Crit. Rev. Microbiol. 2016, 42, 173–180. [CrossRef] [PubMed]
51. Abdelghany, T.M.; Al-Rajhi, A.M.H.; Abboud, M.A.A.; Alawlaqi, M.M.; Magdah, A.G.; Helmy, E.A.M.;
Mabrouk, A.S. Recent advances in green synthesis of silver nanoparticles and their applications: About
future directions. A review. BioNanoScience 2018, 8, 5–16. [CrossRef]
52. Akter, M.; Sikder, M.T.; Rahman, M.M.; Ullah, A.K.M.A.; Hossain, K.F.B.; Banik, S.; Hosokawa, T.; Saito, T.;
Kurasaki, M. A systematic review on silver nanoparticles-induced cytotoxicity: Physicochemical properties
and perspectives. J. Adv. Res. 2018, 9, 1–16. [CrossRef] [PubMed]
53. Beyene, H.D.; Werkneh, A.A.; Bezabh, H.K.; Ambaye, T.G. Synthesis paradigm and applications of silver
nanoparticles (AgNPs), a review. Sustain. Mater. Technol. 2017, 13, 18–23. [CrossRef]
54. Calderón-Jiménez, B.; Johnson, M.E.; Montoro Bustos, A.R.; Murphy, K.E.; Winchester, M.R.; Vega Baudrit, J.R.
Silver Nanoparticles: Technological advances, societal impacts, and metrological challenges. Front. Chem.
2017, 5, 6. [CrossRef] [PubMed]
174
Antibiotics 2018, 7, 67
55. De Matteis, V.; Cascione, M.; Toma, C.C.; Leporatti, S. Silver Nanoparticles: Synthetic Routes, In vitro toxicity
and theranostic applications for cancer disease. Nanomaterials 2018, 8, 319. [CrossRef] [PubMed]
56. Javaid, A.; Oloketuyi, S.F.; Khan, M.M.; Khan, F. Diversity of Bacterial Synthesis of Silver Nanoparticles.
BioNanoScience 2018, 8, 43–59. [CrossRef]
57. Khan, A.U.; Malik, N.; Khan, M.; Cho, M.H.; Khan, M.M. Fungi-assisted silver nanoparticle synthesis and
their applications. Bioprocess Biosyst. Eng. 2018, 41, 1–20. [CrossRef] [PubMed]
58. Khatoon, U.T.; Rao, G.V.S.N.; Mantravadi, K.M.; Oztekin, Y. Strategies to synthesize various nanostructures
of silver and their applications—A review. RSC Adv. 2018, 8, 19739–19753. [CrossRef]
59. Malik, B.; Pirzadah, T.B.; Kumar, M.; Rehman, R.U. Biosynthesis of nanoparticles and their application in
pharmaceutical industry. In Nanotechnology; Springer: Singapore, 2017; pp. 235–252. ISBN 978-981-10-4677-3.
60. Pandiarajan, J.; Krishnan, M. Properties, synthesis and toxicity of silver nanoparticles. Environ. Chem. Lett.
2017, 15, 387–397. [CrossRef]
61. Pinto, R.J.B.; Nasirpour, M.; Carrola, J.; Oliveira, H.; Freire, C.S.R.; Duarte, I.F. Antimicrobial properties and
therapeutic applications of silver nanoparticles and nanocomposites. In Antimicrobial Nanoarchitectonics;
Grumezescu, A.M., Ed.; Elsevier: New York, NY, USA, 2017; Chapter 9; pp. 223–259. ISBN 978-0-323-52733-0.
62. Rafique, M.; Sadaf, I.; Rafique, M.S.; Tahir, M.B. A review on green synthesis of silver nanoparticles and their
applications. Artif. Cells Nanomed. Biotechnol. 2017, 45, 1272–1291. [CrossRef] [PubMed]
63. Ramanathan, S.; Gopinath, S.C.B. Potentials in synthesizing nanostructured silver particles. Microsyst. Technol.
2017, 23, 4345–4357. [CrossRef]
64. Siddiqi, K.S.; Husen, A.; Rao, R.A.K. A review on biosynthesis of silver nanoparticles and their biocidal properties.
J. Nanobiotechnol. 2018, 16, 14. [CrossRef] [PubMed]
65. Syafiuddin, A.; Salmiati; Salim, M.R.; Kueh, A.B.H.; Hadibarata, T.; Nur, H. A Review of silver nanoparticles:
Research trends, global consumption, synthesis, properties, and future challenges. J. Chin. Chem. Soc. 2017,
64, 732–756. [CrossRef]
66. Khan, S.U.; Saleh, T.A.; Wahab, A.; Khan, M.H.U.; Khan, D.; Khan, W.U.; Rahim, A.;
Kamal, S.; Khan, F.U.; Fahad, S. Nanosilver: New Ageless and Versatile Biomedical Therapeutic
Scaffold. Available online: https://www.dovepress.com/nanosilver-new-ageless-and-versatile-biomedical-
therapeutic-scaffold-peer-reviewed-fulltext-article-IJN (accessed on 23 June 2018).
67. Li, Z.; Wang, Y.; Yu, Q. Significant parameters in the optimization of synthesis of silver nanoparticles by
chemical reduction method. J. Mater. Eng. Perform. 2010, 19, 252–256. [CrossRef]
68. Ajitha, B.; Divya, A.; Kumar, K.S.; Reddy, P.S. Synthesis of silver nanoparticles by soft chemical method: Effect
of reducing agent concentration. In Proceedings of the International Conference on Advanced Nanomaterials
Emerging Engineering Technologies, Chennai, India, 24–26 July 2013; pp. 7–10.
69. Xu, G.; Qiao, X.; Qiu, X.; Chen, J. Preparation and characterization of stable monodisperse silver nanoparticles
via photoreduction. Colloids Surf. A Physicochem. Eng. Asp. 2008, 320, 222–226. [CrossRef]
70. Afify, T.A.; Saleh, H.H.; Ali, Z.I. Structural and morphological study of gamma-irradiation synthesized silver
nanoparticles. Polym. Compos. 2017, 38, 2687–2694. [CrossRef]
71. Eid, M.; Araby, E. Bactericidal effect of poly(acrylamide/itaconic acid)–silver nanoparticles synthesized
by gamma irradiation against pseudomonas aeruginosa. Appl. Biochem. Biotechnol. 2013, 171, 469–487.
[CrossRef] [PubMed]
72. Fatema, U.K.; Rahman, M.M.; Islam, M.R.; Mollah, M.Y.A.; Susan, M.A.B.H. Silver/poly(vinyl alcohol)
nanocomposite film prepared using water in oil microemulsion for antibacterial applications. J. Colloid
Interface Sci. 2018, 514, 648–655. [CrossRef] [PubMed]
73. An, J.; Luo, Q.; Li, M.; Wang, D.; Li, X.; Yin, R. A facile synthesis of high antibacterial polymer nanocomposite
containing uniformly dispersed silver nanoparticles. Colloid Polym. Sci. 2015, 293, 1997–2008. [CrossRef]
74. Thuc, D.T.; Huy, T.Q.; Hoang, L.H.; Tien, B.C.; Van Chung, P.; Thuy, N.T.; Le, A.-T. Green synthesis of
colloidal silver nanoparticles through electrochemical method and their antibacterial activity. Mater. Lett.
2016, 181, 173–177. [CrossRef]
75. Yin, B.; Ma, H.; Wang, S.; Chen, S. Electrochemical Synthesis of silver nanoparticles under protection of
poly(N-vinylpyrrolidone). J. Phys. Chem. B 2003, 107, 8898–8904. [CrossRef]
76. Cioffi, N.; Colaianni, L.; Pilolli, R.; Calvano, C.; Palmisano, F.; Zambonin, P. Silver nanofractals:
Electrochemical synthesis, XPS characterization and application in LDI-MS. Anal. Bioanal. Chem. 2009,
394, 1375–1383. [CrossRef] [PubMed]
175
Antibiotics 2018, 7, 67
77. Baker, C.; Pradhan, A.; Pakstis, L.; Pochan, D.J.; Shah, S.I. Synthesis and antibacterial properties of silver
nanoparticles. J. Nanosci. Nanotechnol. 2005, 5, 244–249. [CrossRef] [PubMed]
78. Velmurugan, P.; Iydroose, M.; Mohideen, M.H.A.K.; Mohan, T.S.; Cho, M.; Oh, B.-T. Biosynthesis of silver
nanoparticles using Bacillus subtilis EWP-46 cell-free extract and evaluation of its antibacterial activity.
Bioprocess Biosyst. Eng. 2014, 37, 1527–1534. [CrossRef] [PubMed]
79. Rajeshkumar, S.; Bharath, L.V. Mechanism of plant-mediated synthesis of silver nanoparticles—A review on
biomolecules involved, characterisation and antibacterial activity. Chemico-Biol. Interact. 2017, 273, 219–227.
[CrossRef] [PubMed]
80. Terenteva, E.A.; Apyari, V.V.; Dmitrienko, S.G.; Zolotov, Y.A. Formation of plasmonic silver nanoparticles
by flavonoid reduction: A comparative study and application for determination of these substances.
Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2015, 151, 89–95. [CrossRef] [PubMed]
81. Abou El-Nour, K.M.M.; Eftaiha, A.; Al-Warthan, A.; Ammar, R.A.A. Synthesis and applications of
silver nanoparticles. Arab. J. Chem. 2010, 3, 135–140. [CrossRef]
82. Iravani, S.; Korbekandi, H.; Mirmohammadi, S.V.; Zolfaghari, B. Synthesis of silver nanoparticles: Chemical,
physical and biological methods. Res. Pharm. Sci. 2014, 9, 385–406. [PubMed]
83. Jokar, M.; Rahman, R.A. Study of silver ion migration from melt-blended and layered-deposited silver
polyethylene nanocomposite into food simulants and apple juice. Food Addit. Contamin. Part A 2014, 31,
734–742. [CrossRef] [PubMed]
84. Cao, X.L.; Cheng, C.; Ma, Y.L.; Zhao, C.S. Preparation of silver nanoparticles with antimicrobial activities
and the researches of their biocompatibilities. J. Mater. Sci. 2010, 21, 2861–2868. [CrossRef] [PubMed]
85. Rehan, M.; El-Naggar, M.E.; Mashaly, H.M.; Wilken, R. Nanocomposites based on chitosan/silver/clay
for durable multi-functional properties of cotton fabrics. Carbohydr. Polym. 2018, 182, 29–41. [CrossRef]
[PubMed]
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Abstract: Healthcare-associated infections and the rise of drug-resistant bacteria pose significant
challenges to existing antibiotic therapies. Silver nanocomposites are a promising solution to
the current crisis, however their therapeutic application requires improved understanding of
underpinning structure-function relationships. A family of chemically and structurally modified
mesoporous SBA-15 silicas were synthesized as porous host matrices to tune the physicochemical
properties of silver nanoparticles. Physicochemical characterization by transmission electron
microscopy (TEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), X-ray absorption
near-edge spectroscopy (XANES) and porosimetry demonstrate that functionalization by a titania
monolayer and the incorporation of macroporosity both increase silver nanoparticle dispersion
throughout the silica matrix, thereby promoting Ag2CO3 formation and the release of ionic silver in
simulated tissue fluid. The Ag2CO3 concentration within functionalized porous architectures is a
strong predictor for antibacterial efficacy against a broad spectrum of pathogens, including C. difficile
and methicillin-resistant Staphylococcus aureus (MRSA).
Keywords: silver; antibacterial; titania; mesoporous; macroporous; surface functionalization
1. Introduction
Healthcare-associated infections (HCAIs) impact on millions of patients annually, and hundreds
of thousands of deaths worldwide [1–4]. Current models predict that global mortality rates will
approach 10 million annual deaths as a direct result of HCAIs by 2050 [5]. Approximately one-third
of all such HCAIs are preventable [6], and while recent improvements in hygiene standards across
the medical sector have for example significantly reduced the number of HCAIs per year in the UK,
certain groups remain at very high risk of infection during hospital visits, and infection rates for some
bacteria such as Escherichia coli have even increased [7–9].
The rise of drug-resistant bacteria which are disproportionately responsible for HCAIs,
such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamases
(ESBL)-producing Enterobacteriaceae [2], has prompted a resurgence in the search for broad-spectrum
antibiotics to tackle HCAIs. Silver is one such broad spectrum antibiotic, effective against Gram-positive
(e.g., MRSA, B. subtilis) and Gram-negative bacteria (e.g., E. coli, P. aeruginosa) [10], and is consequently
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the subject of commercial [11] and academic interest for the treatment of existing HCAIs and
drug-resistant organisms through its incorporation in surface coatings [12], nanotechnology [13–16],
and pharmaceuticals [17–19].
A major advantage of nanoparticulate silver (and silver-based solid compounds) compared with
salts or complexes is that oxidative dissolution is confined to exposed surfaces, offering a potential
route to regulate the release of biologically active (commonly held to be Ag+) [20] species permitting
the design of long lasting antimicrobial therapies [15,21–23]. Control over silver dissolution kinetics in
Ag-nanoparticle-(NP) based systems has been investigated through tuning particle size [23–26], the use
of inert coatings to retard release [26], or control of silver speciation in nanocomposite to accelerate
dissolution and hence antibacterial activity [13,14]. Silver has also shown recent promise as a promoter
of conventional antibiotic therapies [27].
Here we explore the use of high surface area and porous metal oxide frameworks to control
the dispersion and subsequent dissolution of surface silver. The impact of framework porosity and
oxide termination on silver speciation, dissolution, and antibacterical efficacy, was studied using
ordered mesoporous and hierarchical macroporous-mesoporous SBA-15 silicas [28,29], and titania
functionalized analogues. Conformal titania surface coatings, and hierarchically porous architectures
promote silver NP dissolution and activity against Gram-positive (Staphylococcus aureus) and
Gram-negative (Pseudomonas aeruginosa) bacteria.
2. Results and Discussion
2.1. Materials Synthesis and Characterisation
Three families of ordered porous frameworks were prepared using soft or hard-soft dual
templating approaches and subsequent titania functionalization (Figure 1). Mesoporous and
macroporous-mesoporous (MM) SBA-15 silicas were prepared using a Pluronic 123 (P123) surfactant
either alone or in conjunction with 400 nm colloidal polystyrene nanospheres respectively, according to
literature methods. Titania modified variants were subsequently prepared adapting the procedure of
Landau et al. [30] to preactivate surface silanols before the self-limited grafting of titanium isopropoxide
under anhydrous conditions, and calcination. Repeated grafting cycles were used to create conformal
TiO2 monolayers encapsulating the silica supports. Silver nanoparticles were introduced to either
the parent SBA-15, or TiO2-grafted SBA-15 and TiO2-grafted MM-SBA-15, frameworks by wet
impregnation with varying silver nitrate concentrations.
Figure 1. Synthesis of Ag-doped mesoporous silica and titania-functionalized mesoporous and
mesoporous-macroporous silica materials.
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Textural properties of the parent SBA-15 and MM-SBA-15 supports, before and after titania
functionalization, were first characterized by transmission electronic microscopy (TEM), N2
porosimetry, X-ray diffraction (XRD), and X-ray photoelectron spectroscopy (XPS). The expected
hexagonally close-packed channels of the SBA-15 mesopore network were observed in all cases,
with surface areas and mesopore diameters decreasing with successive TiO2 grafting cycle (Figure 2 and
Figure S1), reflecting pore narrowing and partial blockage of micropores in the silica framework [31].
Uniform mesopores of 6.3 nm diameter were in accordance with previous reports [29]. No titania
crystallites were visible by TEM following grafting, indicating the formation of highly dispersed phase.
Assuming a TiO2 monolayer thickness of 0.355 nm [32], mesopore shrinkage across three grafting
cycles from 6.3 to 5.3 nm for SBA-15 was consistent with deposition of a 1.4 monolayer (ML) titania
coating, and from 6 to 5.2 nm for MM-SBA-15 consistent with 1.1 ML titania.
 
Figure 2. Bright-field transmission electron microscopy (TEM) images of (a) TiO2/SBA-15 (3rd cycle
grafting), and (b) TiO2/MM-SBA-15 (3rd cycle grafting) highlighting ordered hexagonally close-packed
mesopores and uniform macropores, and the evolution of textural properties and calculated TiO2
monolayer thickness as a function of grafting cycle for (c) TiO2/SBA-15 and (d) TiO2/MM-SBA-15.
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Low-angle X-ray diffraction (XRD) (Figure 3) confirmed that titania-functionalized frameworks
retained the P6mm symmetry of the parent SBA-15 mesopore network. Wide angle XRD (Figure S2)
showed no evidence for crystalline titania phases, consistent with TEM and the formation of conformal
monolayers over the SBA-15 template. The surface chemical environment of Ti atoms within the
monolayer coatings was examined by XPS, which reveals the presence of Ti-O-Si (associated with the
silica-titania interface) and Ti-O-Ti species over both SBA-15 and MM-SBA-15 with Ti 2p5/2 binding
energies of 459.9 eV and 458.5 eV respectively. The shift to higher binding energy for Ti coordinated
to Si (through a bridging oxygen) reflects the higher electronegativity of the latter, and hence higher
induced initial charge on the former. We attribute the small shift between the Ti-O-Ti environments in
P25 and the titania monolayers to quantum size (initial and/or final state) effects.
θ
Figure 3. (a) Low angle X-ray diffraction (XRD), and (b) fitted Ti 2p XP spectra of TiO2/SBA-15 and
TiO2/MM-SBA-15, alongside pure silica (SBA-15) and titania (P25) references.
Silver was subsequently deposited over the unfunctionalized SBA-15, and TiO2/SBA-15 and
TiO2/MM-SBA-15 at three different nominal loadings spanning 0.3–3 wt% (see the Supplementary
Materials (Table S1); elemental analysis revealed almost identical bulk loadings for the mesoporous
materials, but systematically lower loadings for the hierarchical material. Surface and bulk silver
loadings were generally in good agreement for all materials (see the Supplementary Materials Table S1),
indicating a homogenous distribution throughout the porous frameworks. Physicochemical properties
of the resulting silver species were determined by TEM, XPS, XRD, and X-ray absorption near edge
spectroscopy (XANES). Only fcc metallic silver (JCPDS no. 04-0783) reflections were observed by XRD,
which sharpened with increasing loading (see the Supplementary Materials Figure S3), indicative of
crystallite growth. Volume averaged silver NP sizes were smaller for MM-SBA-15 (3.5–6.5 nm) than
SBA-15 (4.5–8.5 nm) at comparable loadings (~0.3 wt%), evidencing higher metal dispersion over
the hierarchically porous framework, and indeed fell below the threshold of detection for the lowest
0.25 wt% Ag/TiO2/MM-SBA-15. Ag NPs were directly visualized by TEM (see the Supplementary
Materials Figures S4–S6), which revealed a relatively broad size distribution spanning 1–20 nm over
all three supports. The mean particle size increased (and size distribution narrowed) with Ag loading
(see the Supplementary Materials Figure S7), with the smallest NPs observed over the hierarchical
support in all cases, in accordance with XRD. Ag 3d XP spectra showed the existence of two distinct
chemical environments with 3d5/2 spin-orbit split component binding energies of 368.0 eV and 370.5 eV
consistent with Ag0 and possibly a surface Ag2CO3 respectively (see the Supplementary Materials
Figure S8) [33].
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Note that discrimination of silver oxides and carbonate by XPS alone is complicated due to
their similar core-level binding energies, and anomalous negative binding energy shift of the oxides
relative to the metal [14,34,35] and therefore requires careful fitting to well-defined standards (difficult
to guarantee due to the tendency of Ag2O to oxidise, and of both oxides to adsorb atmospheric
CO2 and form surface carbonates [36]), or Auger parameter analysis employing the Ag M4,5NN
Auger transition in conjunction with 3d5/2 core-level spectra [13]. Silver speciation as metal, oxide,
or carbonate was therefore examined by linear combination fitting of Ag K-edge X-ray absorption
near-edge spectroscopy (XANES, see the Supplementary Materials Figures S9–S11). In all cases, good
spectral fits could only be obtained using Ag and Ag2CO3 components. Nanoparticle growth is
accompanied by a continuous decrease in the proportion of surface and bulk silver carbonate for all
frameworks (Figure 4). This switchover from electron deficient to metallic silver with particle size
likely reflects the higher surface energy of the latter [37], which is thus favoured for larger particles.
The bulk Ag2CO3 content determined by XANES was systematically higher than that of the surface
determined by XPS, likely reflecting the distribution of particle sizes present in all materials; XPS is
expected to more sensitive to larger (more metallic) particles preferentially located on the external
surface. AgO and Ag2O could not be detected by linear combination fitting of the XANES data.
Figure 4. Surface (XPS) and bulk (XANES) silver speciation as Ag2CO3 of Ag/SBA-15, Ag/TiO2/SBA-15,
and Ag/TiO2/MM-SBA-15 as a function of Ag loading.
2.2. Materials Performance Assaying
The release rate of ionic silver (Ag+) from the preceding SBA-15 and MM-SBA-15 frameworks
in a 0.5 M NaNO3 solution at 37 ◦C was subsequently determined by ICP-MS analysis (Figure 5).
Dissolution rates normalised to the mass of silver were inversely proportional to particle size (loading)
for all frameworks, as reported for citrate stabilized silver metal nanoparticles [23] and core-shell
silver-silica nanoparticles [26] indicating that the release of ionic silver occurred by a common
mechanism, being solely dependent on the geometric surface area of the silver nanoparticles. Coating
of the mesoporous SBA-15 by a conformal titania monolayer slightly decreased the average particle size
over the bare silica framework, and hence increased the rate of silver dissolution, a phenomenon further
enhanced by the introduction of macropores. The rate constant for Ag+ dissolution was determined
as 5244 μmol·h−1·nm−1·g1Ag by fitting the data (see the Supplementary Materials Figure S12) in
accordance with the method of Zhang et al. [23] This is significantly higher than that found for
Ag@SiO2 core-shell nanoparticles (14.7 μmol·h−1·nm−1·g−1Ag) [26], while the absolute release rate
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of the 0.3 wt% Ag/TiO2/MM-SBA-15 is consistent with that previously observed for 0.05 wt% high
surface area Ag-hydroxyapatite nanoparticles [14].
Figure 5. Ag+ dissolution rates normalized to mass of Ag determined by XANES for Ag/SBA-15,
Ag/TiO2/SBA-15 and Ag/TiO2/MM-SBA-15.
Antibacterial activity was subsequently assessed against a range of bacteria (Pseudomonas
aeruginosa, Staphylococcus aureus, Clostridium difficile, Escherichia coli, Bacillus subtilis and MRSA) by
zone plate inhibition (ZoI) (Figure 6) using simulated body fluid (SBF), in which the antimicrobial
efficacy is proportional to the size of the colony-free zone surrounding the silver functionalized porous
frameworks. None of the parent (silver-free) materials exhibited bactericidal properties. In all cases the
ZoI values normalized to the mass of silver were inversely proportional to silver loading, mirroring the
ionic silver release rates, and superior to those reported for hydroxyapatite (HA) supported Ag3PO4
composites or Ag@SiO2 core-shell nanocomposites. For example, for S. aureus Ag/TiO2/MM-SBA-15
achieved 70 mm·gAg−1 versus 40–60 mm·gAg−1 for a high area Ag-HA [14] or 23 mm·gAg−1 for 4.5 nm
Ag nanoparticles encapsulated by a 10.5 nm mesoporous silica shell) [26]. The zone size (antibacterial
performance) decreased in the sequence Ag/TiO2/MM-SBA-15 > Ag/TiO2/SBA-15 > Ag/SBA-15.
The logarithmic reduction method was also employed to obtain a more quantitative evaluation
of antibacterial activity for representative Gram-positive and Gram-negative bacteria (Staphylococcus
aureus and Pseudomonas aeruginosa respectively). Experiments were performed in the absence
of light to eliminate any possible influence from photogenerated reactive oxygen species by the
semiconducting titania coating. All three frameworks were inactive in the absence of silver (see
the Supplementary Materials Figure S13). Corresponding decimal reduction times (D-values),
i.e., the time to kill 90% of the bacteria, normalised to the mass of silver, also evidenced an inverse
relationship with silver loading for all frameworks (Figure 7) consistent with their Ag+ release rates.
(Figures S14–S15). As for the ZoI assays, antibacterial activity followed the order Ag/TiO2/MM-SBA-15
> Ag/TiO2/SBA-15 > Ag/SBA-15, i.e., titania functionalization, and the introduction of macroporosity,
both enhanced the potency of silver nanoparticles dispersed throughout an SBA-15 framework.
Ag/MM-TiO2/SBA-15 outperformed Ag/SBA-15 by ~105% against Staphylococcus aureus and
~103% against Pseudomonas aeruginosa. The present observations are consistent with previous reports
of augmented antimicrobial efficacy arising from the preferential formation of highly soluble silver
carbonate versus silver metal over γ-alumina supports [13].
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Figure 6. Zone of inhibition plots, normalized to mass of Ag, against a range of Gram-positive and
Gram-negative bacteria for (a) Ag/SBA-15, (b) Ag/TiO2/SBA-15 and (c) Ag/TiO2/MM-SBA-15.
Figure 7. Decimal reduction times for Ag/TiO2/MM-SBA-15, Ag/TiO2/SBA-15 and Ag/SBA-15
against (a) Staphylococcus aureus, and (b) Pseudomonas aeruginosa.
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3. Conclusions
Families of silver functionalized porous frameworks based around surfactant templated SBA-15
mesoporous silica were synthesized to investigate the impact of surface chemistry and pore architecture
on antibacterial performance. Silver nanoparticles introduced by wet impregnation of AgNO3 and
subsequent thermal processing comprised mixed metal and carbonate phases, with the concentration of
silver carbonate (and dissolution rate for ionic Ag+) inversely proportional to particle size independent
of the framework. The introduction of a conformal titania monolayer coating of SBA-15 improved
the dispersion of silver nanoparticles, corresponding bulk and surface carbonate content, and hence
ionic silver release kinetics. This observation likely reflects the ability of defective reducible metal
oxides to act as nucleation centers for metals [38–40], thereby increasing the density of small
nanoparticles, and amphoteric nature of titania and ability to capture atmospheric CO2 [41] which can
subsequently react with (weakly basic) silver oxides [42,43] at the nanoparticle interface. Additional
rate enhancements for ionic silver were observed for hierarchical microporous-mesoporous SBA-15
frameworks, presumably due to their stabilization of even smaller silver nanoparticles and hence
higher carbonate concentrations. Silver release rates from the porous frameworks directly correlated
with broad spectrum antibacterial activity, with a 16–38% decrease in decimal reduction times
for Staphylococcus aureus and Pseudomonas aeruginosa observed following titania functionalization,
and a further 65–89% reduction following the introduction of macroporosity. The quantitative
structure-function relationship identified between the concentration of Ag2CO3 and antibacterial
efficacy will guide the development of future nanocomposite architectures, notably optimization of
the reducible metal oxide coatings and pore networks to further promote ionic silver release.
4. Materials and Methods
Polystyrene bead templates were synthesized using a method developed by Vaudreuil et al. [44]
in which styrene, divinyl benzene (comonomer, Sigma Aldrich, 80%) and potassium persulphate
(initiator, Sigma Aldrich, >99%) were the reagents. The reaction was performed on a large scale in
a 2-liter jacketed Radleys Reactor-Ready system at 90 ◦C. Deionized water (1.5 L) was introduced
to the reactor, along with a Leibig condenser, thermocouple, and a nitrogen line at 1.5 bar pressure.
The reactor was stirred at 300 rpm overnight to outgas the solution. Styrene (140 mL, Sigma Aldrich,
>99%) and divinylbenzene (27 mL) were washed with NaOH (0.1 M) three times in separate separating
funnels and added to the reaction vessel. Potassium persulfate (Sigma Aldrich, 0.35 g) was dissolved
in deionized water (20 mL) at 80 ◦C. After 30 min of stirring (300 rpm) in the reactor at 90 ◦C,
the potassium persulfate solution was added. After stirring for 3 h, the solid particles were recovered
as a concentrated solution and stored in a freezer overnight, then the product was allowed to warm
before being filtered, washed with ethanol and the beads dried at 80 ◦C overnight.
SBA-15 was prepared using a cooperative self-assembly method [29], in which a 2.6 wt% solution
of Pluronic P123 triblock copolymer (poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene
glycol) (Sigma Aldrich), in 1.6-M HCl solution was stirred (500 rpm) at 35 ◦C. Tetraethyl orthoxysilicate
(Sigma Aldrich, 98%) was then added to the mixture, at a molar ratio of 60:1 [TEOS]:[P-123].
The mixture was aged at 80 ◦C for 24 h without stirring in a sealed container in an oven. The resultant
solid material was filtered, then washed with ethanol before drying in air at 100 ◦C overnight. Removal
of the P123 framework was performed by calcination at 500 ◦C in a muffle furnace for 6 h with a
ramp rate of 1 ◦C/min. Macropores were introduced by the addition of polystyrene beads to the SBA
synthesis (2.3.1) at a weight ratio of 5.3:1 [PS beads]:[TEOS] in the initial mixture.
The grafting of titania onto the surface of the prepared silica materials was done using a modified
procedure by Landau et al. [30] in which triethylamine is used to activate the surface silanols on
the silica and allow the reaction to proceed at lower temperatures. To ensure a uniform coating of
TiO2, the reaction must be performed under completely dry conditions, due to the facile hydrolysis
of the titania precursor, which will readily form large titania particles in the presence of water.
The synthetic procedure involves mixing titanium isopropoxide (Sigma Aldrich,) in anhydrous toluene
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(Aldrich, water content <0.002%), adding triethylamine (Sigma Aldrich, >99%) and MM-SBA-15 or
SBA-15 material whilst stirring at 85 ◦C for 6 h under nitrogen flow. The concentration of titanium
isopropoxide was 145 g/L, the molar ratio between titanium isopropoxide and SBA-15 was fixed at
3.5 and the triethylamine: SBA-15 weight ratio at 1.5 on a scale of 5 g of SBA-15/MM-SBA-15. After the
reaction, the solid was separated by filtration, washed with toluene (300 mL) and inserted in a 0.5 wt%
water-ethanol solution (500 mL) under stirring for 24 h. The resultant solid was washed with ethanol,
dried in air in an oven at 90 ◦C for 24 h, then calcined for 1 h at 250 ◦C, 1 h 400 ◦C and finally for 4 h at
500 ◦C all at 1 ◦C/min.
Ag NPs were deposited via wet impregnation using a solution of aqueous silver nitrate (99.9%,
Sigma-Aldrich). A slurry of the silver precursor and support (10 mL of 5–25 μM + 1 g support) was
stirred for 18 h at room temperature before heating to 50 ◦C. After 5 h, agitation was ceased and the
solid aged at 50 ◦C for a further 24 h to yield a dry powder. Dried samples were calcined at 500 ◦C
(ramp rate 1 ◦C/min) in static air for 3 h.
XRD patterns were recorded on either a PANalytical X’pertPro diffractometer fitted with an
X’celerator detector and Cu Kα (1.54 Å) source or a Bruker D8 Advance diffractometer fitted with
a LynxEye high-speed strip detector and Cu Kα (1.54 Å) source. Both instruments were calibrated
against either Si (PANalytical, Malvern, UK) or SiO2 (Bruker, Billerica, MA, USA) standards. Low angle
patterns were recorded for 2θ = 0.3–8◦ with a step size of 0.01◦. Wide angle patterns were recorded for
2θ = 10–80◦ with a step size of 0.02◦.
N2 adsorption isotherms were recorded using a Nova 4000 porosimeter (Quantachrome, Boynton
Beach, FL, USA), before which the samples were thoroughly degassed under vacuum at 120 ◦C for
2 h. T-plot analysis was used to calculate microporosity. Data was analyzed using NOVAWin version
11 (Quantachrome, Boynton Beach, FL, USA).
XPS analysis was recorded using a Kratos Axis Hsi X-ray photoelectron spectrometer (Kratos
Analytical Ltd., Manchester, UK) using a monochromated Al Kα (1486.6 eV) anode. Data was charge
corrected to adventitious carbon at 284.6 eV and analyzed using CASAXPS version 2.3.15. Ag 3D peaks
were fitted using a Doniach-Sunjic modified Gaussian-Lorentz peak shape and a doublet separation of
6 eV.
TEM analysis was performed using a JEOL 2100 microscope (JEOL Ltd., Tokyo, Japan) with a
LaB6 source and HT of 180 kV. Particle sizing was performed using ImageJ 1.46r software (open source).
Samples were prepared using a drop casting method in ethanol onto continuous carbon grids.
Dissolution rates were determined by stirring 10 mg of composite in 25 mL of 0.5 M NaNO3
at 37 ◦C with periodic aliquots of the analyte solution measured for silver content using an Agilent
6130B single Quad (ESI) ICP-MS (Agilent Technologies, Santa Clara, CA, USA) calibrated against
a range of silver concentrations made by serial dilution of a 1000 ppm Ag in 1% HNO3 standard
from Sigma-Aldrich.
The antibacterial performance of all materials was evaluated against Staphylococcus aureus ATCC
6538, MRSA ATCC 33591, Escherichia coli NCTC 10418, Bacillus subtilis NCTC 8236, Pseudomonas
aeruginosa ATCC 15442 and Clostridium difficile ATCC 9689, which are representative Gram-positive
and Gram-negative problematic organisms found in hospital environments. Zone of inhibition (ZoI)
tests were performed by inoculating the surface of a nutrient agar plate (Oxoid, Basingstoke, UK) with
an excess volume (3 mL) of nutrient broth which had previously been inoculated and incubated to
a cell density of ~108 colony-forming units (cfu)/mL as determined spectrophotometrically using
a Perkin-Elmer Lambda 10 UV-Vis spectrophotometer. The liquid was manipulated by agitation to
provide a confluent inoculum and the excess fluid removed to waste using a sterile pipette. Using a
sterilized boring tool, 5 mm holes were then bored into the agar, and 100 μL of a solution of 10 mg of
Ag nanocomposite in 5 mL of simulated body fluid (SBF, see the Supplementary Materials Table S2)
dispensed into the borehole using a calibrated micropipette. SBF was prepared according to a method
from Kokubo et al. [45] 750 mL of deionized water was stabilized at 37 ◦C with stirring, to this the
following ions were added: NaCl (7.996 g, Sigma Aldrich >99%), NaHCO3 (0.35 g, Sigma Aldrich
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>99%), KCl (0.224 g, Sigma Aldrich >99%), K2HPO4·3H2O (0.228 g, Sigma Aldrich >99%), MgCl2
(0.305 g, Sigma Aldrich >99%), HCl (40 mL, 1 kmol/L, Fisher scientific 37%), CaCl2 (0.278 g, Sigma
Aldrich >99%), Na2SO4 (0.071 g, Sigma Aldrich >99%) and (CH2OH)3CNH2 (6.057 g, Sigma Aldrich
99%). Finally, the pH was adjusted to 7.35 using HCl solution (1 kmol/L, Fisher scientific 37%).
Plates were then incubated at 37 ◦C overnight, photographed, and calibrated zone areas determined
using ImageJ software (open source).
Quantitative antimicrobial activity was determined by logarithmic reduction [13,14]. Here, 5 mg of
Ag nanocomposite material was added to an Eppendorf tube kept in dark conditions containing 1 mL
of either S. aureus or P. aeruginosa in a nutrient broth at concentrations of 107 cfu·mL−1. 100 μL aliquots
of the resulting suspensions were subsequently removed at 0, 60, 240 min and 24 h, and added to a
1 mL solution of Tween 20 (Fisher, 1%), sodium dodecyl sulphate (Sigma-Aldrich, 0.4%) and sodium
chloride (Sigma-Aldrich, 0.85%) in deionized water to neutralise any soluble silver species [13,14].
Each of the resulting neutralized solutions was serially diluted with phosphate buffered saline
(PBS) prior to plating onto agar and incubation at 37 ◦C for 24 h. The experiments were all run
with positive and negative controls of silver nitrate and without any nanocomposite respectively.
After incubation, the number of colonies present on the agar was counted by visual inspection,
and normalized relative to the initial colony count in the negative control at time t = 0 min to determine
the logarithmic reduction of bacteria. All experiments were performed in triplicate, with mean values
and standard deviations reported.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/7/3/55/s1,
Figure S1: (left) N2 adsorption-desorption isotherms, and BJH pore size distributions for parent SBA-15,
TiO2/SBA-15 and TiO2/MM-SBA-15. Type-IV isotherms with H1 hysteresis is characteristic of mesoporous SBA-15,
Table S1: Elemental analysis of Ag/SBA-15, Ag/TiO2/SBA-15 and Ag/TiO2/MM-SBA-15, Figure S2: XRD patterns
for the three prepared support materials, SBA-15, TiO2/SBA-15 and TiO2/MM-SBA-15, Figure S3: XRD patterns for
(a) Ag/SBA-15; (b) Ag/TiO2/SBA-15; and (c) Ag/TiO2/MM-SBA-15 as a function of silver loading. All reflections
associated with fcc silver metal., Figure S4: Particle size distributions from TEM for (a) 0.3 wt%; (b) 0.95 wt% and
(c) 2.4 wt% Ag nanoparticles deposited on SBA-15, Figure S5: Particle size distributions from TEM (a) 0.3 wt%;
(b) 0.9 wt% and (c) 2.4 wt% Ag nanoparticles deposited on TiO2/SBA-15, Figure S6: Particle size distributions
from TEM (a) 0.25 wt%; (b) 0.75 wt% and (c) 1.2 wt% Ag nanoparticles deposited on TiO2/MM-SBA-15, Figure S6:
Particle size distributions from TEM (a) 0.25 wt%, (b) 0.75 wt% and (c) 1.2 wt% Ag nanoparticles deposited on
TiO2/MM-SBA-15, Figure S7: Mean particle size and standard deviation for Ag/SBA-15, Ag/TiO2/SBA-15,
and Ag/TiO2/MM-SBA-15 as a function of bulk silver loading, Figure S8: Fitted Ag 3d XP spectra of
(a) Ag/SBA-15; (b) Ag/TiO2/SBA-15; and (c) Ag/TiO2/MM-SBA-15 as a function of Ag loading. All spectra
fitted to carbonate and metal spin-orbit doublets possessing common lineshapes and fixed binding energies,
Figure S9: XANES profiles for (a) 0.3 wt%; (b) 0.95 wt% and (c) 2.4 wt% Ag/SBA-15, Figure S10: XANES profiles for
(a) 0.3 wt%; (b) 0.9 wt% and (c) 2.4 wt% Ag/TiO2/SBA-15, Figure S11: XANES profiles for (a) 0.25 wt%; (b) 0.75 wt%
and (c) 1.2 wt% Ag/TiO2/MM-SBA-15, Figure S12: Fitted dissolution kinetics for Ag/SBA-15, Ag/TiO2/SBA-15,
and Ag/TiO2/MM-SBA-15 as a function of particle size, Figure S13: Zone of Inhibition assays for Staphylococcus
aureus, MRSA, Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa and Clostridium difficile normalized
to the mass of silver for (a) Ag/SBA-15; (b) Ag/TiO2/SBA-15; and (c) Ag/TiO2/MM-SBA-15, Figure S14:
Logarithmic reductions for SBA-15, Ag/TiO2/SBA-15, and Ag/TiO2/MM-SBA-15 against (a) Staphylococcus aureus
and (b) Pseudomonas aeruginosa after 24 h incubation, Figure S15: Logarithmic reductions for (a) Ag/SBA-15;
(b) Ag/TiO2/SBA-15; and (c) Ag/TiO2/MM-SBA-15 against Staphylococcus aureus and Pseudomonas aeruginosa,
Figure S16: Logarithmic colony forming units of (a) S. aureus; and (b) P. aeruginosa as a function of time for
SBA-15, TiO2/SBA-15, and TiO2/MM-SBA-15, Table S1: Elemental analysis of Ag/SBA-15, Ag/TiO2/SBA-15 and
Ag/TiO2/MM-SBA-15, Table S2: Ion concentrations in SBF solution.
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Abstract: In this article, a series of silver-containing dressings are prepared by metal-vapor
synthesis (MVS), and their antibacterial properties are investigated. The antibacterial activity of the
dressings containing silver nanoparticles (AgNPs) against some Gram-positive, and Gram-negative
microorganisms (Staphylococcus aureus, Staphylococcus haemolyticus, Pseudomonas aeruginosa, Klebsiella
pneumoniae, Escherichia coli, Moraxella spp.) has been determined. Based on the plasmon resonance
frequency of these nanoparticles, the frequency of laser irradiation of the dressing was chosen. The gauze
bandage examined showed pronounced antibacterial properties, especially to Staphylococcus aureus
strain. When 470 nm laser radiation, with a power of 5 mW, was applied for 5 min, 4 h after inoculating
the Petri dish, and placing a bandage containing silver nanoparticles on it, the antibacterial effect of
the latter significantly increased—both against Gram-positive and Gram-negative microorganisms.
The structure and chemical composition of the silver-containing nanocomposite were studied by
transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS) and extended X-ray
absorption fine structure (EXAFS). The synthesized AgNPs demonstrate narrow and monomodal
particle size distribution with an average size of 1.75 nm. Atoms of metal in Ag/bandage system are
mainly in Ag0 state, and the oxidized atoms are in the form of Ag-Ag-O groups.
Keywords: antibacterial effect; laser irradiation; metal-vapour method; silver nanoparticles; TEM;
XPS; EXAFS
1. Introduction
The widespread use of antibiotics for the treatment and prevention of bacterial diseases leads to
a significant increase in the antibacterial resistance of microorganisms through its acquisition either
through exogenous resistance genes or chromosomal mutations [1]. This stimulates not only the search
for new antibacterial drugs, but also possible alternatives to the latter [2,3]. The scientists are tasked to
find substances that effectively act simultaneously on Gram-positive, Gram-negative microorganisms
and fungi, which are independent of the antibiotic resistance of the microorganism.
Silver and its compounds have been used in medicine since ancient times. Mass application of
silver preparations began in the seventies of the 19th century [4,5]. Since then, numerous confirmations
of antiviral, antibacterial, and immunomodulating activity of silver preparations have been received [6].
With the invention of antibiotics, which have more pronounced antibacterial properties, interest in
the therapeutic properties of silver dramatically decreased. However, widespread use of antibiotics
revealed by the end of the 20th century a number of their shortcomings and silver preparations were
again actively studied and used [7].
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The mechanism of antimicrobial effect of silver was carefully studied previously. It has now
been established that silver ions are selectively toxic with respect to prokaryotic microorganisms with
a weak effect on eukaryotic cells [6], including comparatively minimal toxicity to mammalian cells [8].
This is due to the fact that the concentration of silver ions or silver nanoparticles necessary for the
death of prokaryotic cells (bacteria) is much lower than the concentration that causes the death of
eukaryotic cells, including cells of the human body [9].
It should be noted that new prospects for the use of silver in medicine are opened in connection
with the development of nanotechnology, an interdisciplinary field of science that deals with the
creation, production and application of structures, devices and systems ranging in size from 1 to
1000 nm, although in practice they use the sizes ranging from 1 to 100 nm more often [10]. It is proved
that the metal nanoparticles have unique properties, often differing from that of the solid metal [10].
This is due to the fact that the surface/bulk energy ratio of nanoparticles is much larger than that of
compact metal [11].
As applied to medicine, this means that the nature of the interaction of a nanoparticle with
a bacterium or fungus is significantly different from the impact of a compact metal on them and
probably enhances their bactericidal or fungicidal activity [10].
Localized surface plasmon resonance is an optical phenomenon that is generated when light
interacts with conductive nanoparticles that are smaller than the incident wavelength [12]. From the
point of view of antibacterial properties of (silver nanoparticles) AgNPs, it is interesting to study how
these properties change when plasmon resonance effect occurs.
One of the ecological and effective methods for producing mono- and bi-metallic nanoparticles
and materials based on them is the metal-vapor synthesis (MVS). The method was used for preparation
of silver-containing composite materials for medical applications [13]. It is assumed that MVS will
be effective for the modification of wound dressings prepared from natural or synthetic materials
with AgNPs.
In this regard, the wide introduction of dressings containing AgNPs correctly combined with the
plasmon resonance effect can play a significant role in improving treatment of purulent wounds in the
era of increasing antibiotic resistance of microorganisms.
The aim of this research is to study the antibacterial effect of a new dressing material, based on
gauze bandage containing AgNPs prepared by MVS, and changing this effect under the influence of
laser radiation.
2. Results
The structure and chemical composition of the silver-containing nanocomposite were studied by
transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS) and extended X-ray
absorption fine structure (EXAFS).
The TEM micrograph of the cotton fibre is shown in Figure 1. The photograph shows amorphous
extended structure with a diameter in the range of 16–25 nm, and dark crystalline nanostructures,
the density of which is higher than that of cotton. The enlarged image of the regions of ordered atoms
on a surface marked with a square in Figure 1 is shown in Figure 2.
The EDS spectra obtained from dark nanostructures (not shown) contain the characteristic line
AgLα = 2.98 keV, which allows attribute dark nanostructures to AgNPs. Most of AgNPs are in the
form of chains and agglomerates, which is a characteristic feature of the systems prepared by MVS.
The particle size distribution is narrow and monomodal. The average particle size is 1.75 ± 0.25 nm.
Simulation of the electron diffraction for the group of the atoms selected in Figure 2 is shown in
Figure 3. It is seen from Figures 2 and 3 that groups of atoms form faces with interplanar distances
d1 and d2. Calculating the ratio d1/d2 gives a value of 1.09. The angle between d1 and d2 is 52◦.
The values 1.09 and 52◦ indicate the presence of faces (111) and (200) of a face-centered cubic (fcc)
structure in silver particles (for an ideal fcc structure: d(111)/d (200) = 1.15, the angle is 55◦).
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Figure 1. Transmission electron microscopy (TEM) micrograph of Ag-cotton system.
Based on the synthesis method and sample storage conditions, three models of the chemical
composition of the particle surface can be proposed: Ag0, Ag+, and Ag0 + Ag+. With a high degree
of probability, the mixed composition in crystalline form can be excluded from the consideration.
Otherwise, “double reflexes” should be observed in Figure 3. The fcc lattice constants (a) for Ag0 and
Ag2O are 4.08 Å and 4.76 Å, respectively. Calculation of a by the formula a = d(hkl) × (h2 + k2 + l2)1/2,
where h = 1, k = 1, l = 1; d (hkl) = 2.3 Å, gives a value of 3.98 Å. Consequently, there is reason to believe
that the surface of the crystalline particles consists of metallic silver. However, presence of Ag+ state in
amorphous form cannot be excluded.
Figure 4 shows the survey spectrum of Ag black. Along with the peaks characteristic of silver
atoms there are peaks of impurity carbon and oxygen atoms.
The determination of the chemical state of silver atoms in nanoparticles by the XPS method is
a complex task. This is due to the fact that the spectral characteristics of the metal particles and the
oxide particles are fairly close. According to NIST XPS Database [14] the binding energies of the Ag
3d5/2 peak for Ag, Ag2O and AgO are in the ranges 367.9–368.4, 367.7–368.4, and 367.3–368.1 eV,
respectively. One of the solutions to this problem is the use of the Auger parameter. However, as a rule,
the concentration of silver nanoparticles in materials is low, whereas the registration of the Auger
spectrum requires a significantly longer time than the recording of the photoelectron spectrum, which
can lead to the reduction of silver from oxides under the action of X-ray irradiation [15].
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Figure 2. An enlarged image of the regions of ordered atoms on a surface, marked with a square in
Figure 1.
Another approach may be based on controlled differential charging, in which separation of signals
from regions with good and poor conductivity is possible. If the region has a metallic conductivity
and is in good electrical contact with the sample holder, then it does not accumulate a charge due
to the emission of secondary electrons. In contrast, in a region with poor conductivity, a positive
charge is usually accumulated, the value of which depends on the secondary emission coefficient and
conductivity, and it leads to the displacement of photoelectron peaks in the region of high binding
energies. When a positive bias voltage Ub is applied, the stray electrons flow to the sample surface
is increased and contributes to the compensation of the surface charge. In this case, narrowing of
the photoelectron peaks and their shift toward higher binding energies are observed. Photoelectron
peaks corresponding to regions with good conductivity should be shifted by Ub the amount of applied
bias voltage, while from areas with a worse conductivity by a smaller amount. With a negative bias
voltage, the flux stray electrons decreases, it leads to increase in charging on non-conducting regions
and an increase in the interval between peaks corresponding to signals from the conducting and
non-conducting regions. In this case, the signal from the conductive region must also be shifted by Ub.
Taking into account the difference in the electrical conductivity of metallic silver and its oxides, we
attempted to separate signals from regions containing silver atoms in a metal state and other chemical
states by controlled differential charging, changing the potential on the sample holder. This approach
is widely used to determine the presence of different phases in a sample [16–21].
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Figure 3. Simulation of the electron diffraction pattern for the group of atoms circled in Figure 2 and
assignment for face-centered cubic (fcc) structure.
Figure 4. X-ray photoelectron spectroscopy (XPS) survey spectrum of Ag black.
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To discriminate regions with different conductivities, or other words with different chemical
states, a bias voltage Ub = ±7 V was supplied to the sample holder. Figure 5 shows the Ag 3d spectra
of the Ag black measured at different bias voltage Ub applied to the sample holder. It is seen that
binding energy of the Ag 3d5/2 and Ag 3d3/2 peaks is slightly depends on Ub. Table 1 presents the
characterization of the Ag 3d spectra. The full widths at high maximum (FWHM) are rather different
as well. Both the binding energies of the Ag 3d peaks and their FWHM values indicate that the spectra
contain some states with different conductivities. Considering that the recording the Ag2O and AgO
spectra is accompanied by the surface charging [22,23], one can assume the presence of the Ag+ and/or
Ag2+ state in the Ag black. To determine the characteristics of the Agδ+ state a subtraction of the
spectrum measured at Ub = 7 V from the spectrum measured at Ub = −7 V was performed under the
condition of their best coincidence in the high-energy region. The difference spectrum is presented in
Figure 5. The binding energies of the Ag 3d5/2 and Ag 3d3/2 peaks 367.73 and 373.71 eV correspond to
Ag2O state [22]. The relative intensity of this state is no less than 0.27. This estimate is based on the
fact that the spectrum measured at Ub = 7 V may contain Ag2O state.
Figure 5. The Ag 3d photoelectron spectra of Ag black measured at different Ub = +7 (1), −7 (2), 0 V (3),
ant difference spectrum (2)–(1). The spectra are corrected for Ub.
Table 1. Binding energies and full widths at high maximum (FWHMs) measured by XPS.
Ub Ag 3d5/2, eV Ag 3d3/2, eV Ag 3d5/2 FWHM, eV
0 V 368.17 374.17 1.3
−7 V 368.09 374.11 1.4
+7 V 368.21 374.21 1.5
(−7 V)–(+7 V) 367.73 373.71 1.3
The C 1s and O 1s spectra of Ag black show a strong dependence on Ub (Figure 6) which indicate
that a large part of carbon and oxygen is has low conductivity. It should be noted that binding energy
of the main C 1s peak measured at Ub = +7 V is 284.77 eV, and corresponds to that used for charge
reference [14].
It follows that some of the carbon atoms have good conductivity, or in other words, is in close
contact with silver atoms. To estimate this value, we use the fitting the C 1s spectrum measured
at Ub = −7 V, when the best separation of the electron emission from regions with good and poor
conductivity is realized. When the spectrum was fitted with some components, two restrictions were
imposed: The width of the low-energy peak should describe the low-energy side by the best way, and
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the energy interval between the low-energy peak and the next should not be less than that at Ub = +7 V.
The second restriction is imposed because of the possible manifestation of differential charging for
regions containing C-O groups. The fraction of such carbon atoms is 0.47. A similar value of 0.48 was
obtained for the spectrum measured at Ub = 0 V, whereas for the spectrum measured at Ub = +7 V it
is 0.77. This is due to conductivity induced with the stray electrons, which make conducting regions
that are not in direct contact with silver nanoparticles. Figure 7 shows fitting the corresponding C 1s
spectra, and Table 2 contains corresponding data.
Figure 6. The C 1s and O 1s photoelectron spectra of Ag black measured at different Ub = +7 (1), −7 (2),
0 V (3).
Figure 7. Fitting the C 1s photoelectron spectra of Ag black measured at Ub = −7, 0 and 7 V.
Table 2. Binding energies (Eb), peak widths (W) and relative intensities of the peaks deconvoluted in
the C 1s and O 1s spectra of Ag black.
Ub












Eb 284.7 286.2 287.6 289.8 530.6 532.5 533.5 534.7
W 1.45 1.50 1.51 1.58 1.42 1.65 1.80 1.85
Irel 0.48 0.35 0.10 0.07 0.18 0.21 0.35 0.26
−7 V
Eb 284.6 286.2 287.4 289.8 530.9 533.2 534.9 536.7
W 1.48 1.50 1.76 3.05 1.76 1.90 1.90 1.90
Irel 0.47 0.17 0.23 0.13 0.24 0.27 0.38 0.00 0.10
+7 V
Eb 284.8 286.3 287.7 288.8 530.7 532.4 532.5 531.8 533.8
W 1.43 1.43 1.43 1.43 1.42 1.42 1.55 1.42 1.55
Irel 0.77 0.13 0.03 0.07 0.18 0.09 0.37 0.18 0.18
203
Antibiotics 2018, 7, 80
It should be noted that the fitting the C 1s spectra with some components measured at Ub = −7
and 0 V, presented in Figure 7 is largely conditional and do not reflect the real relative concentrations
of COx groups. At the same time, applying a positive bias voltage Ub = +7 V practically compensates
the surface charging, and Figure 7 (+7 V) reflects the real relative concentrations of COx groups.
It was found that the peaks in the low-energy region of the O 1s spectra, measured at Ub = −7
and 0 V (Figure 8), have close binding energies and intensities. Based on the reference data [21,22],
the binding energy of these peaks of about 530.8 eV cannot be attributed to C-O bonds. Therefore, they
should be attributed to the Ag-O bonds. And from the weak dependence of Eb and Irel on Ub, one can
assign binding energies of 530.6 and 530.9 eV to Ag-Ag-O state. The Irel of this state, determined from
the fitting the O 1s spectra measured at Ub = −7, 0 and 7 V, are 0.24, 0.18 and 0.18, respectively.
It should be stressed that relative intensities of CO groups in the O 1s spectrum measured at
Ub = 7 V correspond those obtained from the relative C 1s spectrum. It means that the bias voltage of
Ub = 7 V neutralize the surface charging.
Figure 8. Fitting the O 1s photoelectron spectrum of Ag black measured at Ub = −7, 0 and 7 V.
Figure 9 shows the survey spectrum of the Ag/bandage system. Along with the peaks characteristic
of silver, carbon and oxygen there are peaks of impurity silicon atoms.
Figure 9. Survey spectrum of the Ag/bandage system.
In case of the Ag/bandage system the charge referencing was done using the C 1s spectrum
of cellulose. The latter was simulated using the reference data [24] by considering the difference in
peak resolution. The binding energy of 286.7 eV was assigned to C-OH state of cellulose. Figure 10
shows the C 1s spectrum of the Ag/bandage sample fitted with four Gaussian peaks at 286.7, 288.1,
284.8 and 283.13 eV. The first and the second peaks are assigned to cellulose [24]. The third peak is
assigned to adventitious carbon, while the origin of the peak at 283.1 eV is not clear because it does
not correspond to reference data for polymers [24]. However, it may be resulted either of differential
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charging or low-molecular weight species. Similar C 1s spectrum was recorded for Au/bandage
system. It slightly differs in relative concentration of C-C/C-H peak and peak at 283.1 eV. The O 1s
spectra of Ag/bandage and Au/bandage systems are practically indistinguishable. It means that the
peak at 283.1 eV may be assigned to C-C/C-H state as well.
Figure 10. The C 1s photoelectron spectra of Ag/bandage and Au/bandage systems.
Figure 11 shows the C 1s spectra of Ag black and Ag/bandage system. It is clearly seen that the
spectra are strongly different. The C 1s peak of the Ag/bandage system shifted to high binding energy
region by 0.66 eV and its FWHM is 1 eV more than that of Ag black. These differences may be assigned
to the size effect in photoelectron spectra which induces both energy shift to high binding energy and
the peak broadening [25,26]. The transition from AgNPs in the Ag black, to their dispersion in the
bandage followed with fairy large changes in size of AgNPs, and an increase of the proportion of the
Ag0 state was observed. Apparently, there was a partial reduction of silver and its stabilization by
a modified layer of cellulose. However, as follows from a comparison of the O 1s spectra of the Ag
black and Ag/bandage system (Figure 12), the low-energy side of the latter might be assigned to the
Ag-Ag-O group.
Figure 11. The C 1s photoelectron spectra of Ag black (1) and Ag/bandage system (2).
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Figure 12. The O 1s photoelectron spectra of Ag black (1), Ag/bandage (2), and Au/bandage
systems (3).
But, given the almost complete coincidence of the O 1s spectra of Ag/bandage and Au/bandage
systems, this conclusion should be rejected. Thus, one can conclude that the basic state of Ag atoms
in Ag/bandage system is Ag0 state, whereas the oxidized silver is in the form of Ag-Ag-O groups,
and, as follows from Figure 12 the proportion of oxidized state is small. This is in accordance with
EXAFS and TEM data which indicate that silver atoms are mainly in Ag0 state. It should be noted that
EXAFS is not a surface-sensitive method as XPS and electron diffraction may be recorded only from
the ordered regions.
Table 3 shows the number of colony-forming units (CFU) of the studied microbes along the
perimeter of the bandage at a distance equal to the diameter of one colony on both sides of the edge
in the form Me (Q1; Q3), together with the level of statistical significance, where Me is the median,
Q1—lower quartile, Q3—upper quartile.
Table 3. The number of colony-forming units (CFU) of the studied microorganisms along the edge of
the bandage at a distance to both sides of the edge equal to the diameter of one colony (Me (Q1; Q3))
and the level of statistical significance (p) between control groups and gauze with AgNPs.
Strain of Microorganism Control (Normal Bandage) AgNPs-Containing Bandage p
Staphylococcus aureus 7.0 (6.0; 8.0) 0.0 (0.0; 1.0) <0.001
Staphylococcus haemolyticus 11.0 (7.5; 14.5) 7.5 (6.0; 8.0) 0.049
Pseudomonas aeruginosa 5.0 (5.0; 6.0) 2.0 (1.0; 3.0) <0.001
Klebsiella pneumoniae 6.5 (6.0; 7.0) 2.0 (1.0; 3.0) <0.001
Escherichia coli 16.0 (13.5; 17.5) 6.0 (4.0; 7.0) <0.001
Moraxella spp. 8.0 (5.0; 8.5) 3.0 (2.5; 4.0) 0.002
Due to the fact that the data of the control groups of different strains differ, in order to compare
the antibacterial effect of the AgNPs-containing bandage with respect to different microorganisms, we
calculated the percentage reduction factor. Table 4 presents the results of the study of the percentage
reduction of CFU.
The results of the change in the antibacterial properties of the ordinary medical gauze bandage
under the influence of laser irradiation are presented in Table 5, in the form Me (Q1; Q3), where Me is
the median, Q1 is the lower quartile, Q3 is the upper quartile.
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Table 4. Percentage reduction in the number of CFU towards control.







Table 5. The number of CFU of the investigated microorganisms along the edge of the ordinary medical
gauze bandage (Me (Q1; Q3)) and p—the level of statistical significance between groups.
Strain of Microorganism
Control (Normal Bandage)









Staphylococcus aureus 6.0 (5.5; 7.0) 6.5 (5.0; 9.0) 0.682 6.5 (6.0; 8.0) 0.325
Staphylococcus haemolyticus 6.5 (5.5; 8.0) 7.0 (6.0; 8.0) 0.681 6.0 (4.0; 9.5) 0.620
Pseudomonas aeruginosa 14.0 (11.5; 15.5) 14.0 (13.0; 15.5) 0.861 14.5 (13.0; 16.5) 0.620
Klebsiella pneumoniae 5.0 (3.0; 5.0) 5.0 (4.0; 7.0) 0.223 4.0 (4.0; 5.0) 0.862
Escherichia coli 10.0 (9.0; 10.5) 10.0 (8.0; 12.0) 0.861 11.0 (8.5; 11.5) 0.380
Moraxella spp. 7.0 (4.0; 8.0) 6.5 (4.5; 8.0) 0.930 6.0 (5.0; 8.5) 0.838
p1 = the level of statistical significance between groups 1 and 2, and p2 = the level of statistical significance between
groups 1 and 3.
Based on the data presented in Table 5, no statistically significant changes in the indices of the
number of CFUs when using an ordinary medical gauze bandage without or in conjunction with laser
irradiation have been identified. This indicates the absence of an antibacterial effect in laser radiation
at a wavelength of 470 nm (blue region of the spectrum), a 5 mW power, and with exposure time of
5 min.
Table 6 shows the results of the change in the antimicrobial properties of the medical gauze
bandage containing AgNPs, depending on the presence or absence of exposure to the laser and the
time through which it was performed.
Table 6. The number of CFU of the investigated microorganisms along the edge of the medical













Staphylococcus aureus 5.0 (3.5; 5.5) 5.0 (4.0; 5.0) 0.904 4.0 (2.0; 5.0) 0.043
Staphylococcus haemolyticus 5.0 (4.0; 6.0) 5.5 (2.5; 6.5) 0.861 4.0 (2.5; 4.5) 0.011
Pseudomonas aeruginosa 7.0 (5.5; 8.0) 6.0 (5.0; 7.5) 0.250 4.0 (2.5; 5.0) <0.001
Klebsiella pneumoniae 2.0 (1.5; 3.0) 2.0 (1.0; 3.0) 0.903 1.0 (1.0; 1.5) 0.016
Escherichia coli 6.5 (6.0; 7.0) 7.0 (5.5; 8.0) 0.727 5.0 (4.5; 6.0) 0.024
Moraxella spp. 3.5 (2.0; 4.0) 3.0 (2.0; 4.0) 0.723 2.0 (1.0; 3.0) 0.039
p1 = the level of statistical significance between groups 4 and 5, and p2 = the level of statistical significance between
groups 4 and 6.
According to the data presented in Table 6, laser radiation in the blue region of the spectrum did
not have a statistically significant increase in the antibacterial effect of AgNPs when applied two hours
after inoculating the Petri dish and placing a bandage on it. However, when the laser treatment was
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used four hours after the seeding an increase in the antibacterial effect of this bandage was observed
with respect to all studied microorganisms. The phenomenon is statistically significant in all groups of
microorganisms. The difference can be observed in Table 7.
According to the data, presented in Table 7, there is no significant diversity between difference
in percentage reduction of CFU of Gram-positive and Gram-negative microorganisms. Considering
the fact that they differ in the structure of the cell wall, it can be concluded that the mechanism for
increasing the antibacterial effect of the AgNPs-containing bandage cannot be explained solely by the
effect on it. As follows from Table 7, laser radiation, when exposed four hours after inoculating the
Petri dish and the application of a AgNPs-containing bandage on it allows to increase the antibacterial
properties of the bandage by 15–24%, depending on the strain of the microorganism.
Table 7. Difference in percentage reduction of CFU between the groups of the AgNPs-containing
bandage without laser irradiation and with laser irradiation four hours after inoculating the Petri dish
and placing the bandage.








It is believed that the antibacterial effect of silver ions is due primarily to the high affinity of the
latter to sulfur or phosphorus [27]. Namely, it depends on the silver cations (Ag+), which bind firmly
to groups of electron donors in biological molecules containing silver, oxygen or nitrogen. Due to the
large number of sulfur-containing proteins on the surface of the bacterial cell, AgNPs can interact
with sulfur-containing proteins inside or outside the cell membrane, which affect the viability of the
bacterial cell [27]. Silver ions act by replacing other necessary metal ions, such as Ca2+ or Zn+ [28].
Simultaneously, it was suggested that silver ions (especially Ag+) liberated from AgNPs can
interact with phosphorus moieties in DNA, leading to inactivation of DNA replication [27] or react
with sulfhydryl groups of metabolic enzymes of the chain of bacterial transport of electrons, causing
their inactivation [29].
The release of silver ions is only one of the mechanisms of AgNPs action. AgNPs themselves have
different physical, chemical and other properties than the solid silver from which they were obtained.
A number of authors suggest that the antibacterial effect of silver nanoparticles is due to
the electrostatic interaction between negatively charged bacterial cells and positively charged
nanoparticles [30].
Analysis of the electronic state of AgNPs showed that the core of the particles is zero-valent, while
the shell is oxidized by interaction with the functional groups of the bandage and the surrounding
medium. Earlier, analysis of the O 1s and valence band spectra showed the existence of four states
of oxygen atoms on the Ag surface, which reflect the different states of silver atoms as well [31].
The discrimination of these in the Ag 3d spectrum is practically impossible because of insufficient
overall energy resolution of electron energy analyzers. The surface atoms of nanoparticles, which,
as a rule, are positively charged, should play the main role in interaction with the bacterial membranes.
The Ag 3d spectra shoe that a large fraction (0.27) of the Ag atoms is in the Ag+ state, which determines
the antimicrobial effect. It is possible that laser radiation in the surface plasmon resonance mode
changes the electronic state of AgNPs, which increases the antibacterial activity of the system as
a whole.
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The wavelength of laser radiation used in the study was chosen by considering the plasmon
resonance effect. When the frequency of the external field coincides with the frequency of the localized
surface plasmon, a resonance arises, leading to a sharp increase in the field on the surface of the particle
and an increase in the absorption cross section [32].
Apparently, the statistically significant effect of enhancing the antibacterial properties of
the medical gauze bandage containing AgNPs observed in the present study is caused by laser
photothermolysis of bacteria when exposed to laser radiation.
Probably, AgNPs, when irradiated with a laser, absorb energy, which is transformed into
heat. The resulting hyperthermia of AgNPs can lead to both local damage of the bacterial cell and
intensification of metabolic processes around the heated AgNPs with the subsequent acceleration of
silver ionization processes, which in turn leads to the death of the microbial cell.
4. Materials and Methods
The ordinary medical gauze bandage was used in the study, produced in the Republic of
Belarus (State Standard 1172–93) both as a control and for the production of medical gauze bandages
containing AgNPs.
The metal vapor technique was used for the preparation of Ag-bearing bandage (Scheme 1).
Scheme 1. Synthesis of silver-containing nanocomposite.
The silver nanoparticles were obtained by the MVS from pieces of silver (99.99%) using
an apparatus described elsewhere [33–36]. In the preparation of silver organosol, isopropanol was
used as the organic dispersion medium, which was degassed in the vacuum prior to synthesis by
alternating freeze-thaw cycles. Isopropanol (Fluka, 99.8%) was dried over zeolites 4 Å, and distilled
under argon.
Silver was evaporated by resistive heating from a tantalum boat. During the synthesis, a vacuum
of no more than 10−2 Pa was maintained in a 5-L quartz glass reactor with using a high-vacuum post.
In a typical experiment, 120–150 mL of organic reagent was used in the synthesis and 0.1–0.12 grams of
metal were evaporated. The supply of the organic reagent was adjusted with a fine adjustment valve.
Before the synthesis, the glass reactor flask was evacuated, immersed in a vessel with liquid nitrogen,
and then an organic reagent isopropanol was fed, which was condensed on the cooled walls of the
reactor together with the metal vapors for about 1.5 h.
After the synthesis was completed, the cooling was stopped; the reactor was cut off from the
vacuum post with a slide gate. Argon was fed to the reactor; the co-condensate of metal and organics
was heated to the melting point. The obtained colloidal silver solution in isopropanol was impregnated
with a bandage, which was before modification in a vacuum flask. The excess organosol was removed
by drying in a vacuum of 1 Pa at a temperature of 80 ◦C.
Four strains of Gram-negative microbes (Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia
coli, Moraxella spp.) and two strains of Gram-positive bacteria (Staphylococcus aureus, Staphylococcus
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haemolyticus) were used. The strains were sowed from purulent wounds of patients of surgical
departments in Grodno (Belarus).
The sampling for microbiological testing was performed in patients with purulent wounds using
standard disposable sterile tampons by Heinz Herenz company, within an hour the material was
delivered to a microbiological laboratory where a pure microbial culture was isolated and identified
with a BioMerieux Vitek apparatus, antibiotic susceptibility of each microorganism was defined.
The bacteria sensitivity to the six most commonly used antibiotics in surgical hospitals in
Belarus (amoxicillin (ACC), cephalexin (CFL), gentamicin (GEN), ciprofloxacin (CIP), cefazolin (CZ),
erythromycin (ERI)) is presented in Table 8. Definition of antibacterial sensitivity was performed by
diffusion into agar using discs.
Table 8. Antibacterial sensitivity of the strains of microbes used in the study.
Microbial Strain
Antibiotics
ACC CZ CFL CIP GEN ERI
Staphylococcus aureus S S S S S R
Staphylococcus haemolyticus R S R S S S
Pseudomonas aeruginosa R R R R R R
Klebsiella pneumoniae R R R R R R
Escherichia coli R S S S S R
Moraxella spp. R R R R R I
S = the microorganism is sensitive to this antibiotic, I = moderate resistance of the microorganism to the antibiotic
presented, R = the microorganism is resistant to this antibiotic. ACC = amoxicillin, CFL = cephalexin, GEN =
gentamicin, CIP = ciprofloxacin, CZ = cefazolin, ERI = erythromycin.
Then, the isolated culture of the microbe was inoculated on sloping beef-extract agar, after 24 h
cultivation, a sterile 0.85% solution of NaCl (5 mL) was flushed and diluted to the desired concentration
with the same solution by successive inoculation into Petri dishes with agar of different concentrations
of the microorganism. The desired concentration corresponded to the formation, after seeding, with
a pipette, of 0.1 mL of the microbe suspension and placing the Petri dish in a 24 h thermostat for about
100 CFU. The following concentrations were used in the study: 0.5 × 10−6 for Staphylococcus aureus,
0.5 × 10−5 for Staphylococcus haemolyticus, Klebsiella pneumoniae and Escherichia coli, for Pseudomonas
aeruginosa 1 × 10−7 and for Moraxella spp. 1 × 10−6.
The obtained suspension of microorganisms (0.1 mL) was seeded on a Petri dish with beef-extract
agar. Then, two bands of medical gauze bandage were placed on each cup, measuring 1.5 × 4 cm.
A standard medical gauze bandage was used as a control, medical gauze bandage containing AgNPs
was used in the experimental groups. After that, all Petri dishes were placed in a thermostat at
a temperature of 37.0 ◦C on 1 day for cultivation. After 24 h, CFU were counted on both sides of the
edge of the bandage at a distance from the edge equal to the diameter of one colony ad oculus and
using a binocular magnifier glass.
In addition, the percentage decrease in the number of CFU was calculated by the Formula (1):
Percentage reduction of CFU (%) = 100 × (A − B)/A (1)
where A is the average value of the number of CFU along the edge of the bandage in the control
groups; and B is the average value of the number of CFU in the groups with medical gauze bandage
containing AgNPs.
Microbial strains were cultivated on the Pronadisa beef-extract agar manufactured by Laboratorios
Conda, S.A., which was prepared and sterilized according to the instructions of the manufacturer.
Sterilization of the experimental and control samples of the bandage was carried out by
autoclaving at 121 ◦C during 16 min with a Cliniklav-25 vacuum autoclave.
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Laser irradiation was performed by a Rodnik-1 therapeutic laser apparatus, a wavelength of
470 ± 30 nm (blue region of the spectrum), with a power of 5 mW, for 5 min. Laser irradiation was
performed 2 and 4 h after inoculating the Petri dish and placing the dressing on it.
The schematic view of the irradiation experiment is shown on the Figure 12.
Figure 13 shows a Petri dish with agar, and two pieces of bandage placed on it irradiated with
a laser.
 
Figure 13. The scheme of the laser experiment; 1—laser and 2—two pieces of the bandage.
The frequency selected in the study is determined by the frequency of plasmon resonance of
AgNPs, the power and time of the exposure are determined experimentally.
Statistical processing of the results was carried out using the program Statistica 10.0. The difference
between the groups was estimated using the nonparametric Mann-Whitney U-test at a given 5%
significance level.
To assess the degree of increase in the antibacterial effect, the difference between the percentage
decrease in the number of CFUs in the group where a AgNPs-containing bandage without laser
irradiation was used and the percentage reduction in the group with laser irradiation was calculated
4 h after seeding the Petri dish and placing the bandage on it using the Formula (2):
Difference in the percentage reduction of CFU (%) = 100 × (A − B)/A = 100 × (A − C)/A (2)
where A is the average value of the number of CFU along the edge of the bandage in the control group
(ordinary medical gauze bandage without laser irradiation); B is the average value of the CFU in the
band with medical gauze bandage containing AgNPs with laser irradiation four hours after seeding
the Petri dish and placing the bandage on it; and C is the average value of the number of CFUs in the
group with medical gauze bandage containing AgNPs without laser irradiation.
Micrographs of the Ag-cotton sample were obtained by transmission electron microscopy (TEM)
using a JEOL JEM 2100F/UHR instrument with a resolution of 0.1 nm. Prior to the test, 0.1 g of the
sample was placed in 30 mL of isopropanol and sonicated for 300 s. A drop of the resulting mixture was
placed on a carbon-coated copper TEM grid and dried for 1 h. The size of the Ag-containing particles
was determined as the maximum linear dimension. To construct a histogram of the particle size
distribution, the TEM data on 192 particles were processed. Identification of the chemical composition
of the particles and the surface of the samples was carried out using an energy dispersive analysis
(EDA) on a JED-2300 instrument. The interplanar distances in structures visible in high resolution
TEM photographs were calculated using the electron diffraction patterns obtained with the fast Fourier
transform in the ImajeJ 1.4 code. To assign the electron diffraction patterns to the crystallographic faces
of the silver compounds, a crystallographic JCPDS database was used.
The X-ray photoelectron spectra were recorded using a XSAM-800 spectrometer (Kratos,
Manchester, UK) with Mg Kα radiation at an operating power of 90 W of the X-ray tube in the
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fixed analyzer transmission mode at ~20 ◦C and a pressure in the analytical chamber of ~10−8 Pa.
Survey and high-resolution spectra of appropriate core levels were recorded with step sizes of 1 and
0.1 eV, respectively. The photoelectron spectra were approximated by Gauss function or the sum of
Gauss functions, and the background caused by secondary electrons and photoelectrons that lost
energy, was approximated by the straight line. The energy scale of spectrometer was calibrated
according to the standard procedure, while considering the following binding energies: 932.7, 368.3,
and 84.0 eV for Cu2p3/2, Ag3d5/2, and Au4f7/2, respectively. Quantification was performed using
atomic sensitivity factors included in the software of the spectrometer. The samples were fixed to
the sample holder by double-sided conductive adhesive tape. Sample charging was corrected by
referencing to the C-C/C-H state deconvoluted in the C ls spectrum (284.8 eV).
5. Conclusions
1. The Ag-cotton nanocomposites synthesized via MVS has a pronounced antimicrobial activity
against some Gram-positive and Gram-negative bacteria.
2. Antibacterial properties of medical gauze bandage containing AgNPs significantly increase when
exposed to laser radiation. The effect of enhancing the antibacterial properties of the nanocomposite
apparently associated with the effect of localized plasmon resonance of AgNPs.
3. TEM data indicate that the particle size distribution is narrow and monomodal with average
particle size of 1.75 nm. EDA shows that interplanar distances correspond to metallic nanoparticles.
XPS and EXAFS demonstrate that Ag atoms in Ag/bandage system is Ag0, the oxidized silver is in the
form of Ag-Ag-O groups.
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Abstract: Nanobiomaterials combining remineralization and antimicrobial abilities would bring
important benefits to control dental caries. This study aimed to produce nanocompounds containing
calcium glycerophosphate (CaGP) and silver nanoparticles (AgNP) by varying the reducing agent
of silver nitrate (sodium borohydride (B) or sodium citrate (C)), the concentration of silver (1% or
10%), and the CaGP forms (nano or commercial), and analyze its characterization and antimicrobial
activity against ATCC Candida albicans (10231) and Streptococcus mutans (25175) by the microdilution
method. Controls of AgNP were produced and silver ions (Ag+) were quantified in all of the samples.
X-ray diffraction, UV-Vis, and scanning electron microscopy (SEM) analysis demonstrated AgNP
associated with CaGP. Ag+ ions were considerably higher in AgCaGP/C. C. albicans was susceptible to
nanocompounds produced with both reducing agents, regardless of Ag concentration and CaGP form,
being Ag10%CaGP-N/C the most effective compound (19.5–39.0 μg Ag mL−1). While for S. mutans,
the effectiveness was observed only for AgCaGP reduced by citrate, also presenting Ag10%CaGP-N
the highest effectiveness (156.2–312.5 μg Ag mL−1). Notably, CaGP enhanced the silver antimicrobial
potential in about two- and eight-fold against C. albicans and S. mutans when compared with the
AgNP controls (from 7.8 to 3.9 and from 250 to 31.2 μg Ag mL−1, respectively). The synthesis that
was used in this study promoted the formation of AgNP associated with CaGP, and although the use
of sodium borohydride (B) resulted in a pronounced reduction of Ag+, the composite AgCaGP/B
was less effective against the microorganisms that were tested.
Keywords: silver; calcium glycerophosphate; nanoparticles; Candida albicans; Streptococcus mutans
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1. Introduction
The synthesis and study of properties of new biomaterials has been emphasized lately with the
improvement of nanotechnology. In this context, the development of nanomaterials has been the focus
of many areas of chemistry, physics, and materials science because of the promising characteristics
that these materials exhibit [1].
Nanotechnology aims to manipulate particles by creating new structures with favorable properties
in many areas, such as medicine and dentistry [2], and new alternatives of treatment for oral pathologies
are emerging. Metallic nanoparticles, in particular silver nanoparticles (AgNP), have been studied
as an alternative antimicrobial agent against a broad spectrum of species in the control of oral
biofilms [3–5]. Although there are several studies where AgNP are used as antimicrobial agents,
their mechanism of action is not completely understood. Kim et al. [6] and Besinis et al. [4] related
their antimicrobial action to the toxicity resulting from free metal ions dissolution from the surface of
the AgNP. In addition, AgNP would lead to oxidative stress through the generation of reactive oxygen
species (ROS), interacting with cytoplasmic and nucleic acid components by inhibiting enzymes of the
respiratory chain and changing the permeability of the cytoplasmatic bacterial membrane [7–11].
Among oral pathologies, dental caries is one of the most common diseases in humans that
relates to genetics, saliva, and diet of the host [9]. Streptococcus mutans is the main cariogenic
microorganism owing to its ability to produce acids and glucans from sugar metabolism, which
exceed the buffering capacity of saliva [9–11] and leads by a localized and irreversible destruction
of the tooth structure [9,12]. However, recent evidence indicates the presence of C. albicans and
S. mutans in oral biofilms, suggesting that the interaction between them can lead to the development
of caries [9,13,14]. C. albicans colonization depends on the presence of the bacteria, which, besides
promoting adhesion sites, act as a carbon source for yeast growth. On the other hand, yeasts reduce
the levels of oxygen for streptococci [9]. Studies have shown the resistance of many microorganisms to
antimicrobial agents currently used [15,16].
Studies since the 1930s [17] have reported the importance of using calcium phosphate derivatives
for favouring the remineralization process in dental caries. Calcium glycerophosphate (CaGP) is
an organic phosphate salt with anti-caries properties being demonstrated in studies carried out in
monkeys [18] and in rats [19]. It is action in dental biofilms may be related to the increase of calcium and
phosphate levels [20], buffering capacity [18], and reduction of the mass of the biofilms [21]. Becauses
that it seems to interact with dental tissues [22], CaGP has been incorporated in dentifrices [23,24].
Do Amaral et al. [25] and Zaze et al. [26], when associating CaGP (0.25%) in toothpastes with fluoride
at low concentrations, found the same efficacy against caries in enamel when compared to dentifrices
that were supplemented with a higher concentration of fluoride demonstrating CaGP be an good
option for oral products to both prevent caries and avoid fluorose in dental tissues.
The use of a biomaterial containing both an antimicrobial and a compound acting as a source
of calcium phosphate for dental remineralization would have a great impact on the prevention and
control of dental caries. Therefore, this study aimed to produce nanocompounds containing calcium
glycerophosphate (CaGP) and silver nanoparticles (AgNP) by varying the reducing agent of silver
nitrate (sodium borohydride or sodium citrate), the concentration of silver (1% or 10%), and the CaGP
forms (nano or microparticulated), and analyze its characterization and antimicrobial activity against
ATCC strains of Candida albicans and Streptococcus mutans.
2. Results
2.1. Synthesis and Characterization of Ag-CaGP Nanocomposites
UV-Vis absorption spectroscopy (UV-Vis) showed that Ag-CaGP nanocomposites presented silver
in nanosized dimensions in all of the nanocomposites synthesized, regardless of the reducing agent
used. It was demonstrated by the presence of an intense absorption peak, denominated plasmonic
band, which occurred between 420 and 450 nm (Figure 1a, Figure S1). It characterizes noble metal
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nanoparticles, with strong absorption band being observed in the visible region [27]. The CaGP did
not exhibit absorption peak in the visible region of the electromagnetic spectrum.
X-ray diffraction (XRD) pattern indicated that all of the Ag-CaGP nanocomposites were composed
of AgNP and CaGP for confirming the presence of silver in Ag-CaGP nanocomposites through
comparison of the nanoparticles and CaGP. The typical powder XRD pattern of the prepared CaGP
showed diffraction peaks at 2θ = 6.30◦, 12.3◦, 26.4◦, 41.1◦, and 44.2◦ (Figure 1b, Figure S2), and the
corresponding crystallographic form (PDF No. 1-17) [28]. The typical powder XRD pattern of the
silver nanoparticles showed (Figure 1b) diffraction peaks at 2θ = 38.2◦, 44.4◦, 64.6◦, 77.5◦, and 81.7◦,
which can be indexed to (111), (200), (220), (311), and (222) planes of pure silver with face-centered
cubic system (PDF No. 04-0783).
Figure 1. (a) UV-Vis (b) XRD pattern of Ag-CaGP (B4 group) nanocomposite, silver nanoparticles,
and CaGP.
Nanostructured materials that exhibit a pattern of small nanoparticles scattered on a larger surface,
similar to glass bead embellishments on a Christmas tree, are generally classified as a decorated
material. The scanning electron microscopy (SEM) images of Figure 2 show this typical pattern, with
spherical silver nanoparticles (indicated by arrows) decorating the surface of the CaGP microparticles
in all synthesized nanocomposites containing 10% Ag (B4; B8; C4). In addition, transmission electron
microscopy (TEM) was performed for the nanocomposite B4 (Figure S3).
Figure 2. SEM images of the Ag-CaGP nanocomposites: B4 (a,b), C4 (c,d), and B8 (e,f) at different
magnifications. The arrows indicate silver nanoparticles on the surface of CaGP in B4 and in the bulk
of CaGP in C4 and B8.
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The energy-dispersive X-ray sprectroscopy (EDS) clearly showed the outline of Ag-CaGP
nanocomposites in all micrographs. Also, Figure 3 (B4), Figure 4 (C4) and Figures S4–S6,
the two-dimensional (2D) images were constructed by analyzing the energy released from the issuance
Si Kα, O Kα, P Kα, Ca Kα, and Ag Kα, indicating the distribution of these elements on the demarcated
area in the micrograph.
Figure 3. SEM and EDS mapped in 2D elements issuance Si Kα, O Kα, P Kα, Ca Kα, and Ag Kα false
color. Analysis of the distribution of silver nanoparticles on the Ag-CaGP for sample B4: (a) SEM
image; (b) chemical mapping of silicon element present in the substrate, where the electron beam was
focused directly on the substrate and is showed in green color, and the dark regions the beam was
focused in Ag-CaGP nanocomposite B4; (c–f) oxygen, calcium, phosphorus, and silver, respectively,
demonstrating they are constituents of the Ag-CaGP.
 
Figure 4. SEM and EDS mapped in 2D elements issuance Si Kα, O Kα, P Kα, Ca Kα, and Ag Kα false
color. Analysis of the distribution of silver nanoparticles on the Ag-CaGP for sample C4: (a) SEM
image; (b) chemical mapping of silicon element present in the substrate, where the electron beam
was focused directly on the substrate and is showed in green color, and the dark regions the beam
was focused in Ag-CaGP nanocomposite C4; and, (c–f) oxygen, calcium, phosphorus, and silver,
respectively, demonstrating they are constituents of the Ag-CaGP.
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2.2. Minimum Inhibitory Concentration
The results showed that the MIC values were related to the synthesis process and the Ag
concentration used (Table 1). Nanocomposites that were obtained using Na3C6H5O7 as reducing agent
showed the most effective antimicrobial activity against C. albicans and S. mutans. In these composites,
the lowest MIC values were observed for those containing 10% of Ag (C3 and C4), being between 19.05
and 39.05 μg/mL for C. albicans and 156.2 and 625 μg/mL for S. mutans. The nanocomposites that
were synthesized using NaBH4 as reducing agent and isopropanol as solvent showed fungicidal effect
varying between 100 and 1600 μg/mL, whilst no effect against S. mutans was observed. While the
nanocomposites synthesized using the same reducing agent and deionized water as solvent did not
show any effect against both microorganisms. In addition to the MICs found for the synthesized
compounds, it was carried out the microdilution assay to find the MIC values for the solutions
containing only AgNP or CaGP diluted in deionized water, besides the other compounds used in the
synthesis reaction as reducing and surfactant agents. These data are showed in Table 2.
Table 1. Values of minimum inhibitory concentration (MIC) of the nanocompounds based on μg of
AgCaGP mL−1 and on μg of Ag mL−1 in each ones, synthesized using sodium borohydride (Group B)





MIC (μg AgCaGP mL−1/μg Ag mL−1)
μg Ag+/mL
C. albicans S. mutans
B1 1/M I >1600/>16 >1600/>16 2.83
B2 1/N I 400–1600/0.40–16 >1600/>16 4.46
B3 10/M I 400–800/40–80 >1600/>16 10.81
B4 10/N I 100–200/10–20 >1600/>16 63.34
B5 1/M W >1600/>16 >1600/>16 0.44
B6 1/N W >1600/>16 >1600/>16 2.76
B7 10/M W >1600/>16 >1600/>16 5.97
B8 10/N W >1600/>16 >1600/>16 15.63
C1 1/M W 156.2–312.5/1.56–3.12 1250/12.5 305.43
C2 1/N W 156.2–312.5/1.56–3.12 1250/12.5 168.14
C3 10/M W 39.0/3.9 312.5–625/31.2–62.5 506.73
C4 10/N W 19.5–39.0/1.9–3.9 156.2–312.5/15.6–31.2 487.95
Table 2. Values of minimum inhibitory concentrations (MIC) (μg/mL) and silver ions (Ag+)
(μg Ag+/mL) of the control solutions: AgNP reduced by sodium citrate (Na3C6H5O7), and by
sodium borohydride (NaBH4); silver nitrate (AgNO3); nanoparticulated CaGP (CaGP-nano), and CaGP
in commercial form (CaGP-commercial); sodium citrate and surfactant (Na3C6H5O7+NH-PM),




C. albicans S. mutans
AgNP (Na3C6H5O7) 7.8 250 107.2
AgNP (NaBH4) 62.5 125 576.2
AgNO3 5.3 21.2 -
CaGP-nano >5000 >5000 -
CaGP-commercial >5000 >5000 -
Na3C6H5O7+NH-PM >400 >400 -
NaBH4+NH-PM >1500 >1500 -
2.3. Determination of Ag+ Concentration
The Ag+ concentration of all the nanocomposites containing Ag (AgNP and Ag-CaGP) is showed
in Table 1. For samples that were obtained through NaBH4 route (B1–B8), a reduction of ionic silver
higher than 98% was observed, when considering the total amount of ionic silver added to the reaction
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was 500 μg Ag+/mL for B1, B2, B5, B6, and 5000 μg Ag+/mL for B3, B4, B7, and B8. While for the
compounds that were synthesized using Na3C6H5O7 as reducing agent, the ionic silver remaining was
higher and reached about 10% in those samples that were produced using initially 5000 μg Ag+/mL in
the reaction process (C3 and C4). C1 and C2 presented 61.1% and 33.3%, respectively, of ionic silver in
samples as the total Ag+ added in the reaction was 500 μg Ag+/mL. For AgNP with no CaGP added to
the reaction (Table 2) obtained by Na3C6H5O7 route (nanoAg(Na3C6H5O7)) the Ag+ concentration was
107.25 μg/mL, whereas for AgNP produced through NaBH4 (nanoAg(NaBH4)) the Ag+ concentration
was 576.19 μg/mL.
3. Discussion
In the present study, both of the synthesis methods proposed using sodium citrate or sodium
borohydride as reducing agents, led to the anchorage between the silver nanoparticles and calcium
glycerophosphate (Figure 2). Besides, in general, the nanocomposites (AgCaGP) were effective against
reference strains of Candida albicans and Streptococcus mutans. Notably, CaGP substantively increased
the antimicrobial effectiveness of silver in the AgCaGP, reducing up to a quarter their minimum
inhibitory concentration when compared to the respective AgNP controls (Tables 1 and 2).
Although the CaGP has been previously nanoparticulated before the Ag-CaGP synthesis, in our
study it was not characterized as being in nanoparticulated form when associated with silver. It might
be happen due to the poor solubility of calcium at pH = 7 [29], even when using the same dispersant
(NH-PM), as preconized by Miranda et al., whom synthesized AgNP with hydroxyapatite. A pastier
bulk was particularly noted in micrographics of Ag-CaGP when water was used as solvent instead of
isopropanol (Figure 2c–f), regardless of the reducing agent that was used in the reaction. Although
there has not been difference between micro and nanoparticulated-CaGP in the SEM images, its form
influenced the amount of silver ions in the compounds (Table 1). In addition, our results showed the
antimicrobial effectiveness against C. albicans and S. mutans for the samples of group C, and it could be
explained by the highest amount of silver ions that are present in those compounds [4,30–35].
This expressive difference in the quantity of silver ions between groups B and C would be related
to the characteristics of the reducing agents used, being sodium borohydride considered a stronger
reducing agent than sodium citrate [33]. Although silver ions are effective to kill several pathogenic
microorganisms, they are easily dispersed, which quickly decreases its local concentration to levels
of low effectivity. Moreover, ambient light reduces ionic silver forming typical black spots on skin or
on any surface of contact [36]. This process causes aesthetic problems and it has potential to injure
healthy living tissues. Silver nanoparticles, contrary to ionic silver, induce the production of reactive
oxygen species (ROS), which is the primary antimicrobial mechanism [37]. However, AgNP tend to
form aggregates in the absence of any support, reducing their efficacy. Therefore, substrates decorated
with immobilized AgNP exhibits enhanced antimicrobial activity for longer periods, reducing the
undesirable secondary effects that are associated to free ionic silver [38]. Although the difficult to
separate the impact of free ionic silver from the AgNP antimicrobial action, differences that were
observed in minimum inhibitory concentrations (MIC), as shown in Table 1, for C. albicans and
S. mutans suggests the influence of their respective metabolism on the efficacy of silver against
each microorganism.
Furthermore, other factors may influence the antimicrobial potential of AgNP [34]. For instance,
how the compound containing silver interacts with the microorganisms would dependent on the
characteristics of the AgNP formed, as well as the chemical and physical changes that may occur
when they are added to the medium of interest [33]. In general, for the synthesis of AgNP, AgNO3
is used as source of silver, water or ethanol as solvent, and sodium borohydride or sodium citrate as
reducing agent [39]. Fabricated under similar conditions, the AgNP would have a negative surface
charge [33,40], and this fact is noteworthy to elucidate the lower effectiveness of the compounds against
S. mutans. Bacteria have a negative outer membrane charge [41] and the electrostatic attraction may
have been hampered, and hence the action of the AgNP associated or not with CaGP on the S. mutans
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was diminished. On the other hand, apart from fungi present a neutral surface charge [41] and might
enhance the attraction of AgNP, the presence of phospholipid components, which contain phosphate
groups, may have improved the antimicrobial activity of silver by targeting these sites [42,43]. Indeed,
the control of AgNP reduced by sodium citrate showed a lower amount of ions (107.2 μg Ag+/mL)
than the control that was produced using sodium borohydride (576.2 μg Ag+/mL), and it was more
effective against C. albicans, suggesting an antifungal potential of AgNP by itself, which may have
afforded the disruption of the C. albicans cell membrane by damaging the inner layers of the cell wall,
increasing their permeabilization and then allowing for the passage of these particles to into the cell.
On the contrary, against S. mutans plaktonic cells, Ag+ may have played a preponderant role,
particularly in view of the MIC values that are found for AgNO3 (21.2 μg/mL) when compared to those
for AgNP, regardless of the reducing agent that is used in the reaction (250 and 125 μg/mL, respectively,
for AgNP (Na3C6H5O7) and AgNP (NaBH4)). Noteworthy was the effect that was produced against
S. mutans when CaGP was associated with AgNP (Table 1). CaGP afforded an increment in the
silver activity and it could be related to the acidogenic and acidic characteristic of S. mutans, acting
CaGP probably as a buffer, and hence might have prevented the proliferation of the cells in the
medium [44–46]. So that, the CaGP buffer activity and the highest amount of Ag+ ions could account
for the better effectiveness of the samples of C group against that gram positive bacteria tested.
4. Materials and Methods
4.1. Synthesis of Silver-Calcium Glycerophosphate (Ag/CaGP) Nanocomposites
Ag/CaGP nanocomposites were synthesized at the Interdisciplinary Laboratory of Electrochemistry
and Ceramics of the Chemistry Department in Federal University of São Carlos. Initially,
the commercial form of calcium glycerophosphate (80% β-isomer and 20% rac-α-isomer, CAS
58409-70-4, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) was acquired and was nanoparticulated
using a ball mill for 24 h at 120 rpm, obtaining nanoparticles of approximately 10 nm. Then, two
chemistry methods were employed for the synthesis. The first method was employed using sodium
borohydride as reducing agent (NaBH4, Sigma-Aldrich Chemical Co., St. Louis, MO, USA) and
was based on the methodology that was proposed by Miranda et al. [29]. The synthesis was carried
out in an alcoholic medium (isopropanol) or deionized water. For this, suspensions containing 5 g
of CaGP and silver nitrate (AgNO3 Merck KGaA, Darmstadt, Hessen, Germany) at 0.85 or 0.085 g
were prepared in the presence of 0.5 mL of a surfactant (ammonium salt of polymethacrylic acid
(NH-PM), Polysciences Inc., Warrington, PA, USA) (Table 1). Then, NaBH4 (0.015 g) was added to each
suspension, which caused the reduction of Ag+ to metallic silver nanoparticles in the presence of CaGP.
The molar stoichiometric ratio between Ag+ and NaBH4 was 1:1.26, respectively. The second method
was based on that proposed by Turkevich et al. [47] and Gorup et al. [48] (2011, p. 355). The reducing
agent of AgNO3 was sodium citrate (Na3C6H5O7, Merck KGaA) and the stoichiometric ratio of each
compound was, respectively, 1:3. Thus, in a flask containing 100 mL of deionized H2O 5 g of CaGP was
added following of 0.5 mL NH-PM and 1.4 g of Na3C6H5O7. This mixture was kept under magnetic
stirring and heating. After reaching 95 ◦C temperature, AgNO3 was added and this suspension was
maintained stirring for 30 min until occurring the color change, which qualitatively indicated the
formation of AgNP. Controls containing only the reducing agents and surfactant, and AgNP produced
by both reducing were also prepared.
4.2. Characterization of Ag-CaGP Nanocomposites
In order to demonstrate the presence of AgNP and CaGP in the compounds, the UV-Vis absorption
spectroscopy was employed. The measure is based on the phenomenon of plasmon resonance band,
as observed in metallic nanoparticles. Thus, UV-Vis spectra of Ag-CaGP nanocomposites were obtained
from aqueous solutions poured out in a commercial quartz cuvette with 1 cm optical path using
a spectrophotometer (Shimadzu MultSpec-1501 spectrophotometer; Shimadzu Corporation, Tokyo,
Japan) at 300 to 800 nm. Water was used as blank.
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After a drying step, the resulting powder, Ag-CaGP, was subjected to X-ray diffraction (XRD)
phase characterization using Cu Kα radiation (λ = 1.5406 Å), generated at a voltage of 30 kV and
a current of 30 mA with continuous sweep in the range of 5◦ < 2θ < 80◦, at a scan rate of 2◦/min
(Diffractometer Rigaku DMax-2000PC, Rigaku Corporation, Tokyo, Japan). The particles morphology
was also characterized by scanning electron microscopy (SEM) on a Zeiss Supra 35VP microscope
(S-360 Microscope, Leo, Cambridge, MA, USA), with field emission gun electron effect (FEG-SEM)
operating at 10 kV. A drop of each sample were added with a micropipette and deposited on silicon
metal plate (111) and dried at 40 ◦C for 2 h. With this technique, we can identify in the synthesized
biomaterials the presence of silver, oxygen, silicon, phosphate, and calcium, which were artificially
colored (Figures 3 and 4).
4.3. Minimum Inhibitory Concentration (MIC)
The MIC values for each sample were determined through the microdilution method and followed
the Clinical Laboratory Standards Institute guidelines (CLSI, documents M27-A2 and M07-A9).
Candida albicans (ATCC 10231) was cultivated on Sabouraud Dextrose Agar (SDA, Difco, Le Pont
de Claix, France) and S. mutans (ATCC 25175) on Brain Heart Infusion Agar (BHI, Difco, Le Pont
de Claix, France). Inocula from 24 h cultures on the respective media were adjusted to a turbidity
equivalent to a 0.5 McFarland standard in saline solution (0.85% NaCl). This suspension was diluted
(1:5) in saline solution, and afterwards diluted (1:20) in RPMI 1640 or BHI. Initially, the Ag-CaGP
nanocomposite was diluted in deionized water in a geometric progression, from 2 to 1024 times.
Afterwards, each Ag-CaGP nanocomposite concentration obtained previously was diluted (1:5) in
RPMI 1640 medium (Sigma-Aldrich) for C. albicans and in BHI for S. mutans. The final concentrations
of Ag-CaGP nanocomposite in the dispersion ranged from 5 to 0.01 mg/mL. Each inoculum (100 μL)
was added to the respective well of microtiter plates containing 100 μL of each specific concentration
of the Ag-CaGP nanocomposite solution. The microtiter plates were incubated at 37 ◦C, and the MIC
values were determined visually as the lowest concentration of Ag-CaGP with no microorganism
growth after 48 h for C. albicans and 24 h for S. mutans. All of the assays were repeated in triplicate on
three different occasions.
4.4. Determination of Ag+ Concentration
The evaluation of Ag+ concentration in Ag-CaGP and AgNP, as obtained by both reducing agents,
was determined by a specific electrode 9616 BNWP (Thermo Scientific, Beverly, MA, USA) coupled to
an ion analyzer (Orion 720 A+, Thermo Scientific, Beverly, MA, USA). A 1000 μg/mL silver standard
was prepared placing 1.57 g of dried AgNO3 into a 1 L volumetric flask containing deionized water.
This solution was stored in an opaque bottle in a dark location and diluted in deionized water at the
moment of dosage in order to achieve the standard concentrations used. Thus, the combined electrode
was calibrated with standards containing 6.25 to 100 μg Ag/mL at the same conditions of samples.
A silver ionic strength adjuster solution (ISA, Cat. No. 940011) that provides a constant background
ionic strength was used (1 mL of each sample/standard: 0.02 mL ISA).
5. Conclusions
In conclusion, the synthesis that is proposed in this study promoted the anchorage of AgNP with
the CaGP, and the nanocomposites produced using sodium citrate as reducing agent were effective
against both of the microorganisms tested. Also, the highlight of our study was that the addition of
CaGP to AgNP expressively reduced the MIC values when it was compared with the MIC values
of AgNP by itself. These promising results strongly encourage further studies with the purpose of
producing biomaterials with antimicrobial and remineralizing functions in the near future, particularly
in the dental field.
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false color. Analysis of the distribution of silver in the Ag-CaGP nanocomposites B5, B6 and B7, Figure S6: SEM
images and EDS mapping in 2D elements issuance Si Kα, O Kα, P Kα,Ca Kα and Ag Kα false color. Analysis of
the distribution of silver nanoparticles in the Ag-CaGP nanocomposites C1, C2 and C3.
Author Contributions: G.L.F., D.B.B., A.C.B.D. conceived and designed the experiments; G.L.F., R.A.F., J.G.d.A.,
J.A.S.S. performed the experiments; G.L.F., D.B.B., A.C.B.D., D.R.M. analyzed the data; F.N.d.S.N., L.F.G., E.R.C.
contributed reagents/materials/analysis tools; G.L.F., D.B.B., A.M.A.H. wrote the paper.
Funding: This study was supported by: São Paulo Research Foundation (FAPESP, Processes 2013/24200-9 and
2014/08648-2), Brazil; and Coordination for the Improvement of Higher Education Personnel (Capes, Process
88881.030445/2013-01), Brazil.
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study in the role on the design of the study in the collection, analyses, or interpretation of data; in the
writing of the manuscript, and in the decision to publish the results.
References
1. De Oliveira, J.F.; Cardoso, M.B. Partial aggregation of silver nanoparticles induced by capping and reducing
agents competition. Langmuir ACS J. Surf. Colloids 2014, 30, 4879–4886. [CrossRef] [PubMed]
2. Zandparsa, R. Latest biomaterials and technology in dentistry. Dent. Clin. N. Am. 2014, 58, 113–134.
[CrossRef] [PubMed]
3. Perez-Diaz, M.A.; Boegli, L.; James, G.; Velasquillo, C.; Sanchez-Sanchez, R.; Martinez-Martinez, R.E.;
Martinez-Castanon, G.A.; Martinez-Gutierrez, F. Silver nanoparticles with antimicrobial activities against
Streptococcus mutans and their cytotoxic effect. Mater. Sci. Eng. C Mater. Biol. Appl. 2015, 55, 360–366.
[CrossRef] [PubMed]
4. Besinis, A.; De Peralta, T.; Handy, R.D. The antibacterial effects of silver, titanium dioxide and silica dioxide
nanoparticles compared to the dental disinfectant chlorhexidine on Streptococcus mutans using a suite of
bioassays. Nanotoxicology 2014, 8, 1–16. [CrossRef] [PubMed]
5. Li, Q.; Mahendra, S.; Lyon, D.Y.; Brunet, L.; Liga, M.V.; Li, D.; Alvarez, P.J. Antimicrobial nanomaterials
for water disinfection and microbial control: Potential applications and implications. Water Res. 2008, 42,
4591–4602. [CrossRef] [PubMed]
6. Kim, K.J.; Sung, W.S.; Suh, B.K.; Moon, S.K.; Choi, J.S.; Kim, J.G.; Lee, D.G. Antifungal activity and mode of
action of silver nano-particles on Candida albicans. Biomet. Int. J. Role Met. Ions Biol. Biochem. Med. 2009, 22,
235–242. [CrossRef] [PubMed]
7. Kim, J.S.; Kuk, E.; Yu, K.N.; Kim, J.H.; Park, S.J.; Lee, H.J.; Kim, S.H.; Park, Y.K.; Park, Y.H.; Hwang, C.Y.;
et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3, 95–101. [CrossRef] [PubMed]
8. Monteiro, D.R.; Silva, S.; Negri, M.; Gorup, L.F.; de Camargo, E.R.; Oliveira, R.; Barbosa, D.B.; Henriques, M.
Silver nanoparticles: Influence of stabilizing agent and diameter on antifungal activity against Candida
albicans and Candida glabrata biofilms. Lett. Appl. Microbiol. 2012, 54, 383–391. [CrossRef] [PubMed]
9. Metwalli, K.H.; Khan, S.A.; Krom, B.P.; Jabra-Rizk, M.A. Streptococcus mutans, Candida albicans, and the
human mouth: A sticky situation. PLoS Pathog. 2013, 9, e1003616. [CrossRef] [PubMed]
10. Lemos, J.A.; Quivey, R.G., Jr.; Koo, H.; Abranches, J. Streptococcus mutans: A new Gram-positive paradigm?
Microbiology 2013, 159, 436–445. [CrossRef] [PubMed]
11. Falsetta, M.L.; Klein, M.I.; Lemos, J.A.; Silva, B.B.; Agidi, S.; Scott-Anne, K.K.; Koo, H. Novel antibiofilm
chemotherapy targets exopolysaccharide synthesis and stress tolerance in Streptococcus mutans to modulate
virulence expression in vivo. Antimicrob. Agents Chemother. 2012, 56, 6201–6211. [CrossRef] [PubMed]
12. Rouabhia, M.; Chmielewski, W. Diseases Associated with Oral Polymicrobial Biofilms. Open Mycol. J. 2012,
6, 27–32.
13. Barbieri, D.S.V.; Vicente, V.A.; Fraiz, F.C.; Lavoranti, O.J.; Svidzinski, T.I.E.; Pinheiro, R.L. Analysis of
the in vitro adherence of Streptococcus mutans and Candida albicans. Braz. J. Microbiol. 2007, 38, 624–631.
[CrossRef]
223
Antibiotics 2018, 7, 52
14. Jarosz, L.M.; Deng, D.M.; van der Mei, H.C.; Crielaard, W.; Krom, B.P. Streptococcus mutans
competence-stimulating peptide inhibits Candida albicans hypha formation. Eukaryot. Cell 2009, 8, 1658–1664.
[CrossRef] [PubMed]
15. Monteiro, D.R.; Gorup, L.F.; Silva, S.; Negri, M.; de Camargo, E.R.; Oliveira, R.; Barbosa, D.B.; Henriques, M.
Silver colloidal nanoparticles: Antifungal effect against adhered cells and biofilms of Candida albicans and
Candida glabrata. Biofouling 2011, 27, 711–719. [CrossRef] [PubMed]
16. Monteiro, D.R.; Gorup, L.F.; Takamiya, A.S.; Ruvollo-Filho, A.C.; de Camargo, E.R.; Barbosa, D.B.
The growing importance of materials that prevent microbial adhesion: Antimicrobial effect of medical
devices containing silver. Int. J. Antimicrob. Agents 2009, 34, 103–110. [CrossRef] [PubMed]
17. Lynch, R.J.; ten Cate, J.M. Effect of calcium glycerophosphate on demineralization in an in vitro biofilm
model. Caries Res. 2006, 40, 142–147. [CrossRef] [PubMed]
18. Bowen, W.H. The cariostatic effect of calcium glycerophosphate in monkeys. Caries Res. 1972, 6, 43–51.
[CrossRef] [PubMed]
19. Grenby, T.H. Trials of 3 organic phosphorus-containing compounds as protective agents against dental caries
in rats. J. Dent. Res. 1973, 52, 454–461. [CrossRef] [PubMed]
20. Duke, S.A.; Rees, D.A.; Forward, G.C. Increased plaque calcium and phosphorus concentrations after using
a calcium carbonate toothpaste containing calcium glycerophosphate and sodium monofluorophosphate.
Pilot study. Caries Res. 1979, 13, 57–59. [CrossRef] [PubMed]
21. Nordbo, H.; Rolla, G. Desorption of salivary proteins from hydroxyapatite by phytic acid and
glycerophosphate and the plaque-inhibiting effect of the two compounds in vivo. J. Dent. Res. 1972, 51,
800–811. [CrossRef] [PubMed]
22. Grenby, T.H.; Bull, J.M. Use of high-performance liquid chromatography techniques to study the protection
of hydroxylapatite by fluoride and glycerophosphate against demineralization in vitro. Caries Res. 1980, 14,
221–232. [CrossRef] [PubMed]
23. Naylor, M.N.; Glass, R.L. A three-year clinical trial of a calcium carbonate dentifrice containing calcium
glycerophosphate and sodium monofluorophosphate. Caries Res. 1979, 13, 39–46. [CrossRef] [PubMed]
24. Mainwaring, P.J.; Naylor, M.N. A four-year clinical study to determine the caries-inhibiting effect of
calcium glycerophosphate and sodium fluoride in calcium carbonate base dentifrices containing sodium
monofluorophosphate. Caries Res. 1983, 17, 267–276. [CrossRef] [PubMed]
25. do Amaral, J.G.; Sassaki, K.T.; Martinhon, C.C.; Delbem, A.C. Effect of low-fluoride dentifrices supplemented
with calcium glycerophosphate on enamel demineralization in situ. Am. J. Dent. 2013, 26, 75–80. [PubMed]
26. Zaze, A.C.; Dias, A.P.; Amaral, J.G.; Miyasaki, M.L.; Sassaki, K.T.; Delbem, A.C. In situ evaluation of
low-fluoride toothpastes associated to calcium glycerophosphate on enamel remineralization. J. Dent. 2014,
42, 1621–1625. [CrossRef] [PubMed]
27. Ghosh, S.K.; Pal, T. Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles:
From theory to applications. Chem. Rev. 2007, 107, 4797–4862. [CrossRef] [PubMed]
28. Inoue, M.; In, Y.; Ishida, T. Calcium binding to phospholipid: Structural study of calcium glycerophosphate.
J. Lipid Res. 1992, 33, 985–994. [PubMed]
29. Miranda, M.; Fernandez, A.; Lopez-Esteban, S.; Malpartida, F.; Moya, J.S.; Torrecillas, R. Ceramic/metal
biocidal nanocomposites for bone-related applications. J. Mater. Sci. Mater. Med. 2012, 23, 1655–1662.
[CrossRef] [PubMed]
30. Pal, S.; Tak, Y.K.; Song, J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the
nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol. 2007, 73,
1712–1720. [CrossRef] [PubMed]
31. Bradford, A.; Handy, R.D.; Readman, J.W.; Atfield, A.; Mühling, M. Impact of silver nanoparticle
contamination on the genetic diversity of natural bacterial assemblages in estuarine sediments.
Environ. Sci. Technol. 2009, 43, 4530–4536. [CrossRef] [PubMed]
32. Duran, N.; Duran, M.; de Jesus, M.B.; Seabra, A.B.; Favaro, W.J.; Nakazato, G. Silver nanoparticles: A new
view on mechanistic aspects on antimicrobial activity. Nanomedicine 2016, 12, 789–799. [CrossRef] [PubMed]
33. Le Ouay, B.; Stellacci, F. Antibacterial activity of silver nanoparticles: A surface science insight. Nanotoday
2015, 10, 339–354. [CrossRef]
224
Antibiotics 2018, 7, 52
34. Lok, C.N.; Zou, T.; Zhang, J.J.; Lin, I.W.; Che, C.M. Controlled-release systems for metal-based nanomedicine:
Encapsulated/self-assembled nanoparticles of anticancer gold(III)/platinum(II) complexes and antimicrobial
silver nanoparticles. Adv. Mater. 2014, 26, 5550–5557. [CrossRef] [PubMed]
35. Lok, C.N.; Ho, C.M.; Chen, R.; He, Q.Y.; Yu, W.Y.; Sun, H.; Tam, P.K.; Chiu, J.F.; Che, C.M. Proteomic analysis
of the mode of antibacterial action of silver nanoparticles. J. Proteom. Res. 2006, 5, 916–924. [CrossRef]
[PubMed]
36. Hou, W.C.; Stuart, B.; Howes, R.; Zepp, R.G. Sunlight-driven reduction of silver ions by natural organic
matter: Formation and transformation of silver nanoparticles. Environ. Sci. Technol. 2013, 47, 7713–7721.
[CrossRef] [PubMed]
37. Onodera, A.; Nishiumi, F.; Kakiguchi, K.; Tanaka, A.; Tanabe, N.; Honma, A.; Yayama, K.; Yoshioka, Y.;
Nakahira, K.; Yonemura, S.; et al. Short-term changes in intracellular ROS localisation after the silver
nanoparticles exposure depending on particle size. Toxicol. Rep. 2015, 2, 574–579. [CrossRef] [PubMed]
38. Agnihotri, S.; Mukherji, S.; Mukherji, S. Immobilized silver nanoparticles enhance contact killing and show
highest efficacy: Elucidation of the mechanism of bactericidal action of silver. Nanoscale 2013, 5, 7328–7340.
[CrossRef] [PubMed]
39. Tolaymat, T.M.; El Badawy, A.M.; Genaidy, A.; Scheckel, K.G.; Luxton, T.P.; Suidan, M. An evidence-based
environmental perspective of manufactured silver nanoparticle in syntheses and applications: A systematic
review and critical appraisal of peer-reviewed scientific papers. Sci. Total Environ. 2010, 408, 999–1006.
[CrossRef] [PubMed]
40. Solomon, S.D.; Bahadory, M.; Jeyarajasingam, A.V.; Rutkowsky, S.A.; Boritz, C. Synthesis and Study of Silver
Nanoparticles. J. Chem. Educ. 2007, 84, 322–325.
41. Malanovic, N.; Lohner, K. Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial
peptides. Biochim. Biophys. Acta 2016, 1858, 936–946. [CrossRef] [PubMed]
42. Loffler, J.; Einsele, H.; Hebart, H.; Schumacher, U.; Hrastnik, C.; Daum, G. Phospholipid and sterol analysis
of plasma membranes of azole-resistant Candida albicans strains. FEMS Microbiol. Lett. 2000, 185, 59–63.
[CrossRef]
43. Lara, H.H.; Romero-Urbina, D.G.; Pierce, C.; Lopez-Ribot, J.L.; Arellano-Jimenez, M.J.; Jose-Yacaman, M.
Effect of silver nanoparticles on Candida albicans biofilms: An ultrastructural study. J. Nanobiotechnol. 2015,
13, 91. [CrossRef] [PubMed]
44. Stoimenov, P.K.; Klinger, R.L.; Marchin, G.L.; Klabunde, K.J. Metal Oxide Nanoparticles as Bactericidal
Agents. Langmuir ACS J. Surf. Colloids 2002, 18, 6679–6686. [CrossRef]
45. Hamouda, T.; Baker, J.R., Jr. Antimicrobial mechanism of action of surfactant lipid preparations in enteric
Gram-negative bacilli. J. Appl. Microbiol. 2000, 89, 397–403. [CrossRef] [PubMed]
46. Lynch, R.J. Calcium glycerophosphate and caries: A review of the literature. Int. Dent. J. 2004, 54, 310–314.
[CrossRef] [PubMed]
47. Turkevich, J.; Stevenson, P.C.; Hillier, J. A study of the nucleation and growth processes in the synthesis of
colloidal gold. Discuss. Faraday Soc. 1951, 11, 55–75. [CrossRef]
48. Gorup, L.F.; Longo, E.; Leite, E.R.; Camargo, E.R. Moderating effect of ammonia on particle growth
and stability of quasi-monodisperse silver nanoparticles synthesized by the Turkevich method. J. Colloid
Interface Sci. 2011, 360, 355–358. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Antimicrobial Silver in Medicinal and Consumer
Applications: A Patent Review of the Past Decade
(2007–2017)
Wilson Sim 1, Ross T. Barnard 1,2, M.A.T. Blaskovich 3 and Zyta M. Ziora 3,*
1 School of Chemistry & Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia;
wilson.sim@uq.net.au (W.S.); rossbarnard@uq.edu.au (R.T.B.)
2 ARC Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane,
QLD 4072, Australia
3 Institute of Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia;
m.blaskovich@imb.uq.edu.au
* Correspondence: z.ziora@imb.uq.edu.au; Tel.: +61-733-462-101
Received: 20 August 2018; Accepted: 16 October 2018; Published: 26 October 2018
Abstract: The use of silver to control infections was common in ancient civilizations. In recent
years, this material has resurfaced as a therapeutic option due to the increasing prevalence of
bacterial resistance to antimicrobials. This renewed interest has prompted researchers to investigate
how the antimicrobial properties of silver might be enhanced, thus broadening the possibilities for
antimicrobial applications. This review presents a compilation of patented products utilizing any
forms of silver for its bactericidal actions in the decade 2007–2017. It analyses the trends in patent
applications related to different forms of silver and their use for antimicrobial purposes. Based on the
retrospective view of registered patents, statements of prognosis are also presented with a view to
heightening awareness of potential industrial and health care applications.
Keywords: antibiotic resistance; antimicrobial activity; medicinal silver; patents; silver; silver
nanoparticles; synergism
1. Introduction
Silver is a soft and shiny transition metal which is known to have the highest reflectivity of all
metals [1]. Among its many useful properties, silver it recognized to have antimicrobial activity. Silver
is known to be biologically active when it is dispersed into its monoatomic ionic state (Ag+), when it is
soluble in aqueous environments [2]. This is the same form which appears in ionic silver compounds
such as silver nitrate and silver sulfadiazine, which have been frequently used to treat wounds [3].
Another form of silver is its native nanocrystalline form (Ag0). The metallic (Ag0) and ionic forms
can also appear loosely associated with other elements such as oxygen or other metals and can form
covalent bonds or coordination complexes [3].
To date, there are three known mechanisms by which silver acts on microbes. Firstly, silver cations
can form pores and puncture the bacterial cell wall by reacting with the peptidoglycan component [4].
Secondly, silver ions can enter into the bacterial cell, both inhibiting cellular respiration and disrupting
metabolic pathways resulting in generation of reactive oxygen species [5]. Lastly, once in the cell
silver can also disrupt DNA and its replication cycle [6] (Figure 1). A recently published review
includes more details about the bactericidal mechanisms of silver, along with methods of silver
nanoparticle preparation [7]. Throughout history, silver has consistently been used to restrict the
spread of human disease by incorporation into articles used in daily life. The earliest recorded use of
silver for therapeutic purposes dates back to the Han Dynasty in China circa. 1500 B.C.E [8]. Silver
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vessels and plates were frequently used during the Phoenician, Macedonian, and Persian empires [9].
Families of the higher socioeconomic classes during the middle-ages were so acquainted with the
usage of silver that they developed bluish skin discolorations known as argyria, an affliction which may
have led to the term ‘blue blood’ to describe members of the aristocracy [10]. Modern medicine utilizes
medical grade forms of silver, such as silver nitrate, silver sulfadiazine, and colloidal silver [11].
Figure 1. Silver’s action on a bacterial cell. 1. Silver can perforate the peptidoglycan cell wall. 2. Silver
inhibits the cell respiration cycle. 3. Metabolic pathways are also inhibited when in contact with silver.
4. Replication cycle of the cell is disrupted by silver particles via interaction with DNA.
The discovery of antibiotics in the early 20th century led to a cessation in the development
of silver as an antimicrobial agent. However, the development of increasing levels of bacterial
resistance to most antibiotics in recent years has led to reexamination of the potential of this
ancient remedy [7,12] including studies with patients using colloidal silver and antibiotics [13].
This review aims to demonstrate the wide and ever-expanding applications of silver in medicine,
health care, and other daily life activities, with a focus on the patents registered during the past
decade. A similar patent review was published in Expert Opinion on Therapeutic Patents in
2005 [14], covering patents compiled from 2001–2004. The current review extends to the years
2007–2017. An analysis of the growth of patents describing antimicrobial silver applications is
presented throughout this review, along with commentary of selected examples demonstrating some of
the more interesting applications. Our analysis has separated these discussions of the use of silver into
four general categories: Medical applications, personal care products, domestic household products,
and agricultural/industrial applications.
2. Discussion
2.1. Antimicrobial Silver for Clinical and Medical Usage
This section presents a selection of some of the most interesting and unique patented products
which utilize silver for their bactericidal action in the medical field, including therapies based on
silver’s antimicrobial properties. The product numbers referred to in this section correspond to those
listed in Table 1.
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Table 1. List of patented medical grade products and medically related products containing silver as
an antimicrobial agent.
No. Patent Title Brief Product Description Patent Number Filing Date Ref.
1
Ready to use medical
device with instant
antimicrobial effect
A medical apparatus packaging
designed to activate a bioactive
silver coating and other bactericidal
elements upon opening of package.






The method of coating medical
implants with various forms of
silver for infection prevention.





Surgical needles coated with silver
nanoparticles for the prevention of
infection.





A method to coat invasive medical
instruments with silver
nanoparticles.





The coating of the internal structure
of a vascular portal device and the
interior of its applicator.






A specially designed bone implant
which allows surgeons to control
the release of silver ions.







A biliary duct implant bracket
made from plastic coated uniformly
with silver nanoparticles to prevent
biofilm formation at site of implant.
CN102485184A 3 December 2010 [21]
8a Antimicrobial coatings
on building surfaces
A coating with antimicrobial silver
applied to the interior surface of a
building’s exterior wall.
US7641912B1 5 January 2010 [22]
8b US8282951B2 9 October 2012 [23]
9a Silver nanoparticle
dispersion formulation
A topical gel to treat dermal
infections with 1% w/w silver
nanoparticles as active ingredient.
WO2007017901A2 16 February 2007 [24]




for the treatment of
burns and wounds
An aqueous gel with a range of
silver salt as its active ingredient
made for the treatment of wounds
specifically caused by burns.
WO20120282348A1 5 May 2011 [26]
11 Polysaccharide fibersfor wound dressings
The method of coating wound
dressing with a gel matrix where
silver can be immobilized and
applied to a wound to aid healing.






Wound dressing capable of
releasing silver ions to aid healing
upon contact with fluids from the
wound.
US20070286895A1 24 August 2007 [28]
13 Nano-silver wounddressing
A wound dressing with enhanced
antimicrobial properties for
improved scarring.
US20070293799A1 9 December 2008 [29]
14a Metal containing
materials
Silver containing materials for
treatment of bacterial conditions.
US8425880B1 23 April 2013 [30]
14b US7255881B2 14 August 2007 [31]
15 Dental Uses of SilverHydrosol
Silver suspended in aqueous gel
used to reduce infection risks of
dental procedures.






Denture material made with the
addition of silver nanoparticles for
additional antimicrobial effect.






Silver coating with antimicrobial,
antifouling and deodorant
properties
US20180245278A1 30 August 2018 [34]
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Surface coatings incorporating silver are a common application. One new approach is a method
for producing ready packed medical apparatus which sterilizes itself upon the opening of the package,
by creating a vapor that activates a silver-containing hydrophilic surface coating (Product No. 1).
The antimicrobial properties of silver have been highly valued in medical application where implanted
devices are coated with silver nanoparticles for the antimicrobial effects, but manufacturers need to be
aware that this application is claimed in a patent application (Product No. 2) with a very broad claim 1:
“An article that is implantable in an animal, the article comprising a microparticulate silver-containing
antimicrobial layer stably adhered upon at least one surface of the article.” However, the application
does not appear to have progressed towards granting. Invasive surgical tools such as medical grade
needles (Product No. 3) can also be coated with silver nanoparticles as described in its related patent
(Product No. 4). Medical devices that are directly introduced into the human body that contain silver
include vascular catheters (Product No. 5), bone implants (Product No. 6), and biliary duct brackets
(Product No. 7). Another topical application of antimicrobial silver has incorporated it into coatings
applied to the interior surface of a building's exterior wall (Products No. 8a and 8b).
Another general use is for topical treatments. Numerous topical gels with different formulations
of silver have been patented. Silver was first used to treat burn wounds in the form of 0.5% silver nitrate
solution and silver sulfadiazine cream in 1960 [35]. However, this was impractical as the dressings
required rehydration every couple of hours. To overcome this limitation silver nanoparticle-based gels
and silver salt-based gels have been developed (Products No. 9a, 9b and 10), with all approaches still
considered novel.
Silver based wound dressings have greatly improved in efficacy compared to standard dressings,
and more complex dressings have been developed. New knowledge in burn wound management
led to the discovery of a method to immobilize silver nanoparticles on a gel-support matrix which is
attached to a wound dressing (Product No. 11). A recently commercialized wound dressing allows a
prolonged use of the dressing for up to 7 days or until saturation, without reapplication (Figure 2).
It is made possible through its design, which slowly releases silver ions upon contact with wound
exudates. Its highly absorbent padding is also coated with a layer of silicone which is aimed to reduce
pain during removal and reapplication of the dressing. (Product No. 12). The use of silver with
wound dressings is known to reduce scarring and such formulations are widely used (Product No.13).
Silver-based wound dressings are available under brand names with different compositions, such as
Mepilex® Ag, Acticoat™, Aquacel®, Flaminal®, Allevyn® Ag, and Biatain® Ag, SILVERCEL™. Other
products containing a silver component, not specifically developed for wound healing, have been
patented for treatment of bacterial infection (Products No. 14a and 14b).
Figure 2. Mepilex® Ag with instructions for application. Images used with permission of Mölnlycke
Health care, Sweden.
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Silver has also been applied across the dental field. Silver has been the key component in dental
amalgam fillings for more than one hundred years. However, its antimicrobial properties were not
patented. Silver is used in the prevention of infection during and after dental surgery (Product No. 15).
Dental support fixtures made out of silver and denture materials, and other body restoration objects,
having silver nanoparticles as additives can reduce bacterial infections, especially during first few
months of installation (Products No. 16 and 17).
2.2. Antimicrobial Silver in Personal Care Products
This section presents grooming products and devices which utilize silver for its sanitizing
effects, summarized in Table 2. Hygiene and grooming products such as shavers (Product No. 18),
toothbrushes (Product No. 19) and sanitary pads (Product No. 20) are frequently employed under
adverse conditions where they encounter the bacteria microbiome, but are relied upon to be sanitary.
One example of such usage is by the German public company “Beiersdorf AG” which has products
incorporating silver for its added antimicrobial properties. They have applied silver over a wide range
of products from shower gels and deodorants to first aid bandages (Figure 3).
Table 2. List of patented personal-care products containing silver as an antimicrobial agent.
No. Patent Title Brief Product Description Patent Number Filing Date Ref.
18
Cosmetic and /or medical
device for antimicrobial
treatment of human skin with
silver particles
Technology in which shaving devices
can deposit silver ions unto skin in
place of traditional antiseptic medium.




and preparation method for
antimicrobial thermoplastic
polyurethane
Addition of silver nanoparticles into
plastic materials which are used to
manufacture bristles of tooth brushes.
CN103254401A 28 April 2013 [37]
20
Sanitary towel capable of
removing peculiar smell and
manufacturing
method thereof
Infusion of silver nanoparticles into
fibers of sanitary pads which prevents
the growth of odor causing microbes on
menstrual discharges.
CN102961778A 21 November2012 [38]
21
Solid oil cosmetics containing
antimicrobial Ag zeolites and
aluminum chlorohydrate
Deodorants and topical creams for the








The invention of a cosmetic lotion
preservative consisting of silver
nanoparticles.
JP2010059132A 18 March 2010 [40]
23 Functional cosmetic includingnano silver
Addition of silver nanoparticles into
manufactured cosmetics for its
antimicrobial effect which aids in the
prevention of acne and pimples.
KR20070119971A 21 December2007 [41]
24
Antimicrobial contact lenses
and methods for their
production
Contact lenses manufactured from
materials infused with silver
nanoparticles for antimicrobial effects.




Textile material manufactured from
fibers embedded with silver
nanoparticles.
US20050037057A1 17 February 2005 [43]
25b US7754625B2 13 July 2010 [44]
25c WO2018160708 7 September 2018 [45]
26 Breast pump assemblieshaving an antimicrobial agent
Suction cup segment of device coated
with silver ion exchange resin to
prevent possible microbial
contamination into breast milk.





Hair colorant having additional silver
nanoparticles as preservatives. CN104224617A 27 August 2014 [47]
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Figure 3. Commercial utilization of silver in consumer product lines, including Elastoplast (First aid
bandages) and NIVEA (Shower gels and deodorants) for enhanced antimicrobial properties. Images
used with permission of Beiersdorf AG, Germany.
Since using silver to treat skin infections is common, researchers in dermatology frequently resort
to silver for treating conditions related to bacterial colonization, such as body odors (Product No. 21),
acne outbreaks (Product No. 22), eczema and rash (Product No. 23).
A range of other personal health products have also added silver to improve their hygienic
capacities, including contact lenses (Product No. 24), antimicrobial fabric garments (Products No. 25a,
25b and 25c), breast pump assemblies (Product No. 26), and hair dye (Product No. 27).
Most cosmetic products come in the form of cream, aqueous lotions, or hydrogel medium. It is
observed that most manufacturers favor the incorporation of silver colloids into their products as
they do not precipitate and separate, with the added benefit of acting as a preservative. Colloidal
silver is defined as a mixture of silver ions and silver nanoparticles suspended in an aqueous medium.
They are usually synthesized by electrolysis using a set of silver cathodes [48]. Colloidal silver was
first used in 1891 by a surgeon named B.C Crede to sterilize wounds [9]. The use of silver grew in
popularity between 1900 to the 1940s. Subsequently, antibiotics supplanted the use of silver [9]. Today,
many products are offered not only as colloidal silver solutions, but also as personal devices suitable
for home use, that synthesize colloidal silver. However, the commercialization of colloidal silver has
been accompanied by inconsistencies in colloidal silver production and properties, as well as cases
of unexpected side effects. Therefore, the Food and Drug Administration (FDA) has excluded any
commercialized colloidal silver that claims health benefits without scientific evidence [49]. Similar
action has been taken by the Therapeutic Goods Administration (TGA) in Australia [49] and the
European Commission (EC) [50]. The commercial sales of colloidal silver are not banned, but claims of
health benefits without scientific support are not permitted.
2.3. Antimicrobial Silver in Domestic Products
The antimicrobial applications of silver started in ancient times in domestic products like silver
plates and pitchers [9]. With that in mind, there continue to be domestic applications of silver, particular
for surface treatments (Table 3).
Silver is widely incorporated into surface coatings of electrical goods such as automated bathtubs
(Product No. 28), laundry washing machines (Product No. 29), air purifiers with silver filters (Product
No. 30) and refrigerators (Product No. 31), to produce ‘bacteria-free’ products. Application of silver
nanoparticles to other household objects with frequent handling such as keyboards (Product No. 32),
bath safety aids (Product No. 33), and bathroom safety handles (Product No. 34). Special stand-alone
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products such as containers for meat or water/wine/milk storage (Products No. 35a and 35b) are
useful applications where bacterial contamination may present a health issue.
Table 3. List of patented home-use products containing silver as an antimicrobial agent.
No. Patent Title Brief Product Description Patent Number Filing Date Ref.
28 Automatic cleaning systemfor bathtub or piping
A cleaning system attached to a Silver ion
generator which flows through hot water
inlet pipe which sanitizes bathtubs as a
self-cleaning function.
JP2009268576A 19 November2009 [51]
29 Clothes washing machine
Laundry washing machine consisting of a
silver ion generator which will be released
during each wash cycle.
US20080041117A1 21 February 2008 [52]
30 Air purifier, useful forneutralizing bad smells
An electronic air cleaning device which
draws unclean air through an immobilized
silver filter killing any airborne odor
causing bacteria.
DE102007040742A1 3 March 2009 [53]
31
Antibiotic method for parts
of refrigerator using
antibiotic substance
Distribute silver ions within the fridge to
slow the spoilage of food spoilage. US7781497B2 24 March 2010 [54]
32 Submersible keyboard
A waterproof and washable keyboard with
key caps made from plastic embedded with
silver ions.





Bath safety aids made from silver
impregnated polymers for long lasting
antimicrobial effects.
US20130029029A1 31 January 2013 [56]
34 Bacteria-resistant grab bar
Disability support bar paddings made out
of silicone rubber impregnated with silver
nanoparticles as antimicrobial additives.
US20100148395A1 17 December2008 [57]
35a Antimicrobial reusable
plastic or glass container
Collapsible food storage containers mainly
for meat or water/wine/ milk storage in
kitchen composing of an antimicrobial
silver fabric as its bottom inner layer.
US20070189932A1 10 February 2006 [58]
35b WO2018137725A1 2 August 2018 [59]
36 Nano-silver antibacterialgloves
Domestic latex gloves impregnated with
silver nanoparticles and other antimicrobial
elements.
CN202738872U 20 February 2013 [60]
37 Natural silver disinfectantcompositions
General surface cleaner containing soluble




with polypectate and EDTA
Laundry liquid having aqueous suspension
of colloidal silver as additive for its
antimicrobial properties.
US7311927B2 25 December2007 [62]
Despite the many beneficial innovations in the use of silver as an antimicrobial agent, its
application in cleaning products and disposable tools such as gloves (Product No. 36), disinfectant
wipes (Product No. 37), and cleaning detergent (Product No. 38) may have negative environmental
impacts. Cleaning products, once used, usually end up in sewage treatment systems, and eventually the
environment. This is a concern for silver nanoparticles, as there are currently no effective methods for
filtering out silver nanoparticles. The release of large amount of silver products into the environment
may lead to disturbances of the microbiological ecosystem, and potentially lead to bacterial resistance
to silver [63]. Consequently, alternative methods of sanitization should be considered such as the
application of alcohol or bleach which are sufficient for domestic purposes, or employing ‘fixed’ silver
containing surfaces that reduce the risk of environmental release.
Apart from being a threat to beneficial environmental bacteria, another issue to be addressed is
the possible longer-term reduction of the potency of silver in killing microbes. Since the discovery
of antibiotics, the efficacy of antibiotics has been compromised by over-prescription and over-usage,
leading to the current antibiotic crisis. The presence of low levels of antibiotics in the environment
fosters the generation of multiple drug resistant strains [64]. Silver is not immune to the generation
of bacterial resistance, with several reports in recent years [65,66]. This history suggests a need
for a systemic reassessment of the usage of silver in domestic products, so that it is not used too
extravagantly, or released haphazardly.
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2.4. Antimicrobial Silver in Agricultural and Industrial Products
Silver has also been used for a variety of agricultural and industrial products. In industry,
large scale water purification can be made cost effective by using colloidal silver for purification
as it is needed only in small quantities and can purify large quantities of water, though potential
environmental risk needs to be considered [67]. For agriculture use, silver has been incorporated
in nylon ropes that are used to tie down plants, cover them with netting, and for various other
applications. These ropes normally decay after time due to bacterial biofilm formation, so the silver
prevents this decomposition [68]. Agricultural use of silver products must be carefully assessed to
avoid any impact on the microbial flora and symbiosis. The growth of healthy crop plants relies
heavily upon the formation of symbiotic microbes around the roots such as nitrifying bacteria and
mycorrhiza [69]. Studies have shown that the contact of bioactive silver to nitrifying bacteria impedes
the formation of symbiotic channels [70].
Table 4 presents patented industry and agricultural related products utilizing silver as an
antimicrobial agent. An example of agricultural use is Product No. 39 which uses Ag (I) and Ag
(II) to treat infections in plants, while Products No. 40 and 41 with coating of a single rope strand
with silver to prolong resistance to biofilm formation. Silver coatings can be beneficial in industrial
machines which require a completely sterile environment to manufacture food or medical grade
products, employing silver in the parts that come in direct contact with the products (Product No. 42).
Machinery parts are usually designed for prolonged periods and incorporating silver particles into
these materials provides an effective means of isolation and retention of silver so that it is not released
into the environment easily.
Table 4. List of patented industry and agricultural related products utilizing silver as an antimicrobial agent.






Method of applying high valency
silver to treat infection in plants of
the Rosaceae family.
US20120219638A1 21 November2011 [71]
40
Silver yarn, plied yarn
silver yarn, functional
fabric using same, and
method for producing
Strong weather resistant rope for
agricultural purposes made with
polyester and silver-plated fiber
yarn to prevent growth of biofilms.






The method and manufacture of
industrialized antimicrobial fabric
woven from nylon fibers
impregnated with silver.








Industry scale food grade rollers
made from silver impregnated
plastic for better hygiene and
disease prevention.
JP2005201385A 28 July 2005 [73]
43 An antimicrobial foodpackage
Food grade polymer containers
with interiors coated with silver
nanoparticles to prolong food
freshness.







Industry scale plastic garbage
container interiorly lined with silver
nanoparticles for improved waste
treatment.
US20080185311A1 7 August 2008 [75]
45a Sustained silver release
composition for water
purification
Water filtration unit containing
immobilized silver nanoparticles for
water purification purposes.
WO2012140520A8 23 March 2012 [76]





An industry cleaning liquid having
silver nanoparticles as its active
ingredients.
JP2007161649A 28 June 2007 [78]
234
Antibiotics 2018, 7, 93
Polymers are extremely versatile and when impregnated with silver nanoparticles, they can be
used for numerous applications, such as mass-produced food storage containers (Product No. 43) and
industrial scale waste bins (Product No. 44). Sterility in the food and therapeutics industry is crucial,
so the incorporation of silver into manufacturing equipment in contact with consumer products can be
regarded as an appropriate usage. However, in the case of daily used food containers, frequent usage
of silver may not be ideal as there is a risk of accumulation in the human body if the silver leaches,
potentially leading to similar side effects as were observed in the middle ages when silver utensils
were frequently used [9].
Products No. 45a and 45b describes a water filtration unit containing immobilized silver
nanoparticles for water purification purposes. The invention and manufacture of industrial cleaning
solutions containing silver (Product No. 46) is a potentially widespread application, as there is a need
for instant effective sanitization to prevent bacterial transmission. However, precautions must be
observed to prevent environmental release.
2.5. Overview of Patent Literature from 2007–2017
In the previous sections, applications of antibacterial silver in a variety of fields were discussed.
This section presents an overview of silver-related patents on a global level for the purpose of
understanding the trends, major applications as well as major contributors. Methods by which
the data sets were obtained are reported in Section 3.
Tracking the number of patents disclosing antimicrobial applications of silver for each year over
the past decade, as summarized in Figure 4, shows that there has been a steady upward trajectory in
the number of silver patent applications in recent years. The increase may have reached a plateau in
2016/17, but it will be necessary to consider data from 2018 and onwards to confirm this hypothesis.
Figure 4. Trend analysis of yearly number of patent registrations involving antimicrobial silver
applications over the past decade.
The data obtained from Figure 4 can be further dissected to reveal patents registered under
each language, as shown in Figure 5. This can be linked to a deduction of the country of origin
of these patents. This analysis demonstrates that patents claiming antimicrobial silver products
are predominantly contributed by Asian countries, with China (55%), Korea (7%), and Japan (8%)
comprising 70% of the chart. Patents registered in English compose 25% while another 5% are various
European language patent registrations. It has been speculated that since the FDA and EMA have
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reduced influence in the Asian countries [49], this opens up opportunities in Asia for innovations
with antimicrobial silver. Indeed, there is some basis for this speculation given the large number of
silver related patents being registered in Asian languages, but additional research will be needed to
establish the causes of this phenomenon. One of the potential reasons explaining the more substantial
contribution of Asian countries in patented silver related innovations and consumer products is the
fast-track approval pathway for new drugs in China, supported by consumer trials that are significantly
cheaper than in other countries, which can be performed on higher number of participants. There
is also a Chinese government strategy to commercialize non-Chinese ideas in China and financially
support innovators who are willing to patent their ideas in China, with a preference to procure products
whose IP is owned or registered in China. Finally, the database search may produce multiple results
for a single patent that are particularly difficult to detect for Chinese applications because Chinese
individuals’ names typically have only three or two characters [79].
Figure 5. Analysis of language of patent registrations involving antimicrobial silver over the past
decade with major contribution of Chinese (55%), English (25%), Korean (7%), Japanese (8%), and
others (5%).
We have also assessed the application of silver according to its field of use. Based on the analysis
from Figure 6, only about 20% of the patents in each year claimed medical uses of silver. This could
mean that approximately about 80% of the patented silver applications are for other usages, such as
domestic, agricultural and industrial usage. If this trend continues, there is potential for damage to the
ecosystem if the non-medical uses result in release to the environment. This could lead to a worrisome
situation where bacteria evolve resistance to silver, one of few promising alternatives to current classes
of antibiotics.
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Figure 6. Total patents registered globally for silver used in the medical field compared to all
other applications.
3. Materials and Methods
The patent analysis data and trend chart were generated through search results obtained from the
scientific publication database, SciFinder® by the American Chemical Society. It was accessed through
the University of Queensland Library portal. Results generated were accurate as of 15 June 2018.
3.1. Dataset 1—Application of Antibacterial Silver from the Global Perspective
The keywords used to generate this search were “antibacterial + silver” and “silver + medical”
that narrowed down the number of silver related patents to those presenting the word “silver” in
the title and describing only silver components. Therefore, patents with the general terms such as
“metal nanoparticles” covering all nanomaterials with potential antibacterial applications like silver,
platinum, gold, palladium, copper, zinc, and other metals, are not included here. Result limiters used
were publication years (2007–2017) and document type (Patent). Search results yielded 5054 hits of
exact words and concepts related to its words. No duplicates were found throughout the result set.
The full result was analyzed by publication year and was sorted out by natural order to reflect results
in yearly order. Obtained results were used to generate a bar chart as Figure 5 by using Microsoft
Word chart sketching function.
3.2. Dataset 2—Application of Antibacterial Silver from a Regional Perspective
The keywords used to generate this search were as for Dataset 1, “antibacterial + silver”. Result
limiters used were publication years (2007–2017) and document type (Patent). Search results yielded
5054 hits of exact words and concepts related to its words. No duplicates were found throughout
the result set. The full result was analyzed by language and was sorted out by frequency of region.
Results obtained were used to generate the pie chart (Figure 6) by using the Microsoft Word chart
sketching function.
3.3. Dataset 3—Application of Antibacterial Silver in the Medical Field
The keywords used to generate this search were “silver + medical”. Result limiters used were
publication years (2007–2017) and document type (Patent). Search results yielded 1310 hits of exact
words and concept related to its words. No duplicates were found throughout the result set. The full
result was analyzed by publication year and was sorted out by natural order to reflect results in yearly
order. Results obtained were tabulated against dataset 1 to in order to obtain a 100% stacked bar chart
presented at Figure 6 by using Microsoft Word chart sketching function.
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4. Conclusions
The use of silver for its antimicrobial properties is increasing in numerous fields, including
the medical, consumer, agricultural and industrial sectors. In just over 10 years, nearly 5000 new
applications have been registered. The majority of the patents are from Asian countries, with Chinese
language applications representing more than 50% of the global total, followed by Korean and Japanese
language filings. Only about 20% of patents are registered in English.
While the potential benefits of silver are attracting increased attention, a number of publications
have pointed out potential adverse effects from the overuse of silver, such as ecosystem disturbance [80],
and bacterial resistance to silver [81]. Since our “armory” of antibiotics has been depleted by the rise
in antimicrobial resistance, silver represents a new hope, but mindful use must be considered at an
early stage to prevent a repetition of past mistakes.
We suggest that the application and commercialization of silver related products should be
critically reassessed to avoid, or at least minimize, these adverse effects. In particular, while
incorporation of silver products in an enclosed environment is justifiable, products which are expected
to release silver into the environment should be avoided. There is ample evidence [82] that there can
be adverse long-term effects from consumption or exposure to silver, so silver products should only
be used in circumstances where (1) there is an absolute need for it, such as a medical intervention,
and (2) in modes where silver is immobilized and containable.
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